CA2363605A1 - Androgen-induced suppressor of cell proliferation and uses thereof - Google Patents
Androgen-induced suppressor of cell proliferation and uses thereof Download PDFInfo
- Publication number
- CA2363605A1 CA2363605A1 CA002363605A CA2363605A CA2363605A1 CA 2363605 A1 CA2363605 A1 CA 2363605A1 CA 002363605 A CA002363605 A CA 002363605A CA 2363605 A CA2363605 A CA 2363605A CA 2363605 A1 CA2363605 A1 CA 2363605A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- polypeptide
- cell
- protein
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 71
- 239000003098 androgen Substances 0.000 title claims description 76
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 263
- 238000000034 method Methods 0.000 claims abstract description 193
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 135
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 126
- 229920001184 polypeptide Polymers 0.000 claims abstract description 120
- 150000001875 compounds Chemical class 0.000 claims abstract description 108
- 108090000623 proteins and genes Proteins 0.000 claims description 460
- 102000039446 nucleic acids Human genes 0.000 claims description 249
- 108020004707 nucleic acids Proteins 0.000 claims description 249
- 230000014509 gene expression Effects 0.000 claims description 139
- 230000000694 effects Effects 0.000 claims description 121
- 108020004414 DNA Proteins 0.000 claims description 115
- 125000003729 nucleotide group Chemical group 0.000 claims description 113
- 239000002773 nucleotide Substances 0.000 claims description 112
- 101000609926 Homo sapiens Sister chromatid cohesion protein PDS5 homolog B Proteins 0.000 claims description 100
- 239000000523 sample Substances 0.000 claims description 92
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 72
- 239000013598 vector Substances 0.000 claims description 69
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 65
- 108020004999 messenger RNA Proteins 0.000 claims description 57
- 241001465754 Metazoa Species 0.000 claims description 56
- 201000010099 disease Diseases 0.000 claims description 52
- 239000012634 fragment Substances 0.000 claims description 51
- 230000035772 mutation Effects 0.000 claims description 49
- 239000013604 expression vector Substances 0.000 claims description 44
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 42
- 206010060862 Prostate cancer Diseases 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 39
- 241000282414 Homo sapiens Species 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 38
- 229940088597 hormone Drugs 0.000 claims description 38
- 239000005556 hormone Substances 0.000 claims description 38
- 238000012360 testing method Methods 0.000 claims description 37
- 239000013615 primer Substances 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 125000000539 amino acid group Chemical group 0.000 claims description 33
- 230000001965 increasing effect Effects 0.000 claims description 33
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 239000012472 biological sample Substances 0.000 claims description 30
- 230000002062 proliferating effect Effects 0.000 claims description 30
- 108700019146 Transgenes Proteins 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 28
- 238000003752 polymerase chain reaction Methods 0.000 claims description 27
- 230000009261 transgenic effect Effects 0.000 claims description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 23
- 230000004075 alteration Effects 0.000 claims description 22
- 102000054686 human PDS5B Human genes 0.000 claims description 21
- 230000004044 response Effects 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 230000004071 biological effect Effects 0.000 claims description 13
- 230000035755 proliferation Effects 0.000 claims description 13
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 11
- 229940030486 androgens Drugs 0.000 claims description 11
- 239000002853 nucleic acid probe Substances 0.000 claims description 11
- 239000002987 primer (paints) Substances 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 9
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 108700008625 Reporter Genes Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 239000003155 DNA primer Substances 0.000 claims description 5
- 230000001747 exhibiting effect Effects 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 238000004393 prognosis Methods 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 27
- 238000002560 therapeutic procedure Methods 0.000 abstract description 11
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 description 316
- 235000018102 proteins Nutrition 0.000 description 304
- 210000004027 cell Anatomy 0.000 description 245
- 239000003795 chemical substances by application Substances 0.000 description 68
- 230000000692 anti-sense effect Effects 0.000 description 56
- 238000003556 assay Methods 0.000 description 46
- 239000002299 complementary DNA Substances 0.000 description 45
- 239000003814 drug Substances 0.000 description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 description 41
- 229940079593 drug Drugs 0.000 description 39
- 102000037865 fusion proteins Human genes 0.000 description 39
- 108020001507 fusion proteins Proteins 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 35
- 238000009396 hybridization Methods 0.000 description 31
- 230000001105 regulatory effect Effects 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 28
- 108091034117 Oligonucleotide Proteins 0.000 description 22
- 241000282326 Felis catus Species 0.000 description 21
- 230000027455 binding Effects 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 20
- 230000001594 aberrant effect Effects 0.000 description 19
- 238000003199 nucleic acid amplification method Methods 0.000 description 19
- 239000004098 Tetracycline Substances 0.000 description 18
- 230000003321 amplification Effects 0.000 description 18
- 238000001514 detection method Methods 0.000 description 18
- 230000004927 fusion Effects 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 229960002180 tetracycline Drugs 0.000 description 18
- 229930101283 tetracycline Natural products 0.000 description 18
- 235000019364 tetracycline Nutrition 0.000 description 18
- 150000003522 tetracyclines Chemical class 0.000 description 18
- 230000000875 corresponding effect Effects 0.000 description 17
- 108091026890 Coding region Proteins 0.000 description 16
- 238000001794 hormone therapy Methods 0.000 description 16
- 210000002307 prostate Anatomy 0.000 description 16
- 238000007423 screening assay Methods 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 108091000080 Phosphotransferase Proteins 0.000 description 15
- 102000020233 phosphotransferase Human genes 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 108091023040 Transcription factor Proteins 0.000 description 14
- -1 e.g. Chemical group 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 238000002744 homologous recombination Methods 0.000 description 14
- 230000006801 homologous recombination Effects 0.000 description 14
- 238000003259 recombinant expression Methods 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 14
- 102000040945 Transcription factor Human genes 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- 102000053602 DNA Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 230000002974 pharmacogenomic effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 11
- 108010034529 leucyl-lysine Proteins 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 108010073969 valyllysine Proteins 0.000 description 10
- 101150008921 Brca2 gene Proteins 0.000 description 9
- 108090000994 Catalytic RNA Proteins 0.000 description 9
- 102000053642 Catalytic RNA Human genes 0.000 description 9
- 108091033380 Coding strand Proteins 0.000 description 9
- 230000004568 DNA-binding Effects 0.000 description 9
- 108010070675 Glutathione transferase Proteins 0.000 description 9
- 102000005720 Glutathione transferase Human genes 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 239000012707 chemical precursor Substances 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000000069 prophylactic effect Effects 0.000 description 9
- 108091092562 ribozyme Proteins 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 8
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 8
- 102100038358 Prostate-specific antigen Human genes 0.000 description 8
- 102000001253 Protein Kinase Human genes 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 201000000050 myeloid neoplasm Diseases 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 108700020462 BRCA2 Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 102000054765 polymorphisms of proteins Human genes 0.000 description 7
- 108060006633 protein kinase Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 102000052609 BRCA2 Human genes 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 108700024394 Exon Proteins 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108010038633 aspartylglutamate Proteins 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000005772 leucine Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 5
- 108091092724 Noncoding DNA Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 108010091086 Recombinases Proteins 0.000 description 5
- 102000018120 Recombinases Human genes 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 108010044940 alanylglutamine Proteins 0.000 description 5
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 5
- 230000002280 anti-androgenic effect Effects 0.000 description 5
- 239000000051 antiandrogen Substances 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 108091008324 binding proteins Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 5
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 108010027338 isoleucylcysteine Proteins 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 210000005267 prostate cell Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- CCCIJQPRIXGQOE-XWSJACJDSA-N 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 4
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 4
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108091060211 Expressed sequence tag Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- CKRJBQJIGOEKMC-SRVKXCTJSA-N His-Lys-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O CKRJBQJIGOEKMC-SRVKXCTJSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- HNDWYLYAYNBWMP-AJNGGQMLSA-N Leu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N HNDWYLYAYNBWMP-AJNGGQMLSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- LRZLZIUXQBIWTB-KATARQTJSA-N Ser-Lys-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRZLZIUXQBIWTB-KATARQTJSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- MTEQZJFSEMXXRK-CFMVVWHZSA-N Tyr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N MTEQZJFSEMXXRK-CFMVVWHZSA-N 0.000 description 4
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 108010092854 aspartyllysine Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 229950004398 broxuridine Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000004077 genetic alteration Effects 0.000 description 4
- 231100000118 genetic alteration Toxicity 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 4
- 239000000816 peptidomimetic Substances 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 201000001514 prostate carcinoma Diseases 0.000 description 4
- 230000004952 protein activity Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 108010026333 seryl-proline Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 3
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 3
- SYFHFLGAROUHNT-VEVYYDQMSA-N Arg-Thr-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SYFHFLGAROUHNT-VEVYYDQMSA-N 0.000 description 3
- KHBLRHKVXICFMY-GUBZILKMSA-N Asp-Glu-Lys Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O KHBLRHKVXICFMY-GUBZILKMSA-N 0.000 description 3
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 3
- PYXXJFRXIYAESU-PCBIJLKTSA-N Asp-Ile-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PYXXJFRXIYAESU-PCBIJLKTSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 3
- LOEANKRDMMVOGZ-YUMQZZPRSA-N Gly-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O LOEANKRDMMVOGZ-YUMQZZPRSA-N 0.000 description 3
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 3
- DGTOKVBDZXJHNZ-WZLNRYEVSA-N Ile-Thr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N DGTOKVBDZXJHNZ-WZLNRYEVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 3
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 3
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 3
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 3
- YCJCEMKOZOYBEF-OEAJRASXSA-N Lys-Thr-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YCJCEMKOZOYBEF-OEAJRASXSA-N 0.000 description 3
- MUYQDMBLDFEVRJ-LSJOCFKGSA-N Met-Ala-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 MUYQDMBLDFEVRJ-LSJOCFKGSA-N 0.000 description 3
- FBQMBZLJHOQAIH-GUBZILKMSA-N Met-Asp-Met Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O FBQMBZLJHOQAIH-GUBZILKMSA-N 0.000 description 3
- IQJMEDDVOGMTKT-SRVKXCTJSA-N Met-Val-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IQJMEDDVOGMTKT-SRVKXCTJSA-N 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 3
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 3
- BSXKBOUZDAZXHE-CIUDSAMLSA-N Ser-Pro-Glu Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O BSXKBOUZDAZXHE-CIUDSAMLSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GKWNLDNXMMLRMC-GLLZPBPUSA-N Thr-Glu-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O GKWNLDNXMMLRMC-GLLZPBPUSA-N 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 3
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000000368 destabilizing effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 108010079547 glutamylmethionine Proteins 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 108010003700 lysyl aspartic acid Proteins 0.000 description 3
- 108010009298 lysylglutamic acid Proteins 0.000 description 3
- 108010017391 lysylvaline Proteins 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 108010051242 phenylalanylserine Proteins 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108010090894 prolylleucine Proteins 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 2
- CWFMWBHMIMNZLN-NAKRPEOUSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CWFMWBHMIMNZLN-NAKRPEOUSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 2
- WXERCAHAIKMTKX-ZLUOBGJFSA-N Ala-Asp-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O WXERCAHAIKMTKX-ZLUOBGJFSA-N 0.000 description 2
- CXZFXHGJJPVUJE-CIUDSAMLSA-N Ala-Cys-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)N CXZFXHGJJPVUJE-CIUDSAMLSA-N 0.000 description 2
- NKJBKNVQHBZUIX-ACZMJKKPSA-N Ala-Gln-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKJBKNVQHBZUIX-ACZMJKKPSA-N 0.000 description 2
- ZODMADSIQZZBSQ-FXQIFTODSA-N Ala-Gln-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZODMADSIQZZBSQ-FXQIFTODSA-N 0.000 description 2
- SHKGHIFSEAGTNL-DLOVCJGASA-N Ala-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 SHKGHIFSEAGTNL-DLOVCJGASA-N 0.000 description 2
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 2
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 description 2
- QUIGLPSHIFPEOV-CIUDSAMLSA-N Ala-Lys-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O QUIGLPSHIFPEOV-CIUDSAMLSA-N 0.000 description 2
- SDZRIBWEVVRDQI-CIUDSAMLSA-N Ala-Lys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O SDZRIBWEVVRDQI-CIUDSAMLSA-N 0.000 description 2
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 2
- RMAWDDRDTRSZIR-ZLUOBGJFSA-N Ala-Ser-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RMAWDDRDTRSZIR-ZLUOBGJFSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- NTAZNGWBXRVEDJ-FXQIFTODSA-N Arg-Asp-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NTAZNGWBXRVEDJ-FXQIFTODSA-N 0.000 description 2
- QKSAZKCRVQYYGS-UWVGGRQHSA-N Arg-Gly-His Chemical compound N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O QKSAZKCRVQYYGS-UWVGGRQHSA-N 0.000 description 2
- FNXCAFKDGBROCU-STECZYCISA-N Arg-Ile-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FNXCAFKDGBROCU-STECZYCISA-N 0.000 description 2
- RIIVUOJDDQXHRV-SRVKXCTJSA-N Arg-Lys-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O RIIVUOJDDQXHRV-SRVKXCTJSA-N 0.000 description 2
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 2
- RYQSYXFGFOTJDJ-RHYQMDGZSA-N Arg-Thr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RYQSYXFGFOTJDJ-RHYQMDGZSA-N 0.000 description 2
- ZMUQQMGITUJQTI-CIUDSAMLSA-N Asn-Leu-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZMUQQMGITUJQTI-CIUDSAMLSA-N 0.000 description 2
- IIQIOFVDFOLCHP-UHFFFAOYSA-N Asn-Pro-Ser-Ser Chemical compound NC(=O)CC(N)C(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(O)=O IIQIOFVDFOLCHP-UHFFFAOYSA-N 0.000 description 2
- FMNBYVSGRCXWEK-FOHZUACHSA-N Asn-Thr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O FMNBYVSGRCXWEK-FOHZUACHSA-N 0.000 description 2
- ZELQAFZSJOBEQS-ACZMJKKPSA-N Asp-Asn-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZELQAFZSJOBEQS-ACZMJKKPSA-N 0.000 description 2
- BKXPJCBEHWFSTF-ACZMJKKPSA-N Asp-Gln-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O BKXPJCBEHWFSTF-ACZMJKKPSA-N 0.000 description 2
- OEUQMKNNOWJREN-AVGNSLFASA-N Asp-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N OEUQMKNNOWJREN-AVGNSLFASA-N 0.000 description 2
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 2
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 2
- RQHLMGCXCZUOGT-ZPFDUUQYSA-N Asp-Leu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RQHLMGCXCZUOGT-ZPFDUUQYSA-N 0.000 description 2
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 2
- GKWFMNNNYZHJHV-SRVKXCTJSA-N Asp-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O GKWFMNNNYZHJHV-SRVKXCTJSA-N 0.000 description 2
- DINOVZWPTMGSRF-QXEWZRGKSA-N Asp-Pro-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O DINOVZWPTMGSRF-QXEWZRGKSA-N 0.000 description 2
- NBKLEMWHDLAUEM-CIUDSAMLSA-N Asp-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N NBKLEMWHDLAUEM-CIUDSAMLSA-N 0.000 description 2
- GWWSUMLEWKQHLR-NUMRIWBASA-N Asp-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O GWWSUMLEWKQHLR-NUMRIWBASA-N 0.000 description 2
- NAAAPCLFJPURAM-HJGDQZAQSA-N Asp-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O NAAAPCLFJPURAM-HJGDQZAQSA-N 0.000 description 2
- ITGFVUYOLWBPQW-KKHAAJSZSA-N Asp-Thr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O ITGFVUYOLWBPQW-KKHAAJSZSA-N 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- 108700010154 BRCA2 Genes Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- UXUSHQYYQCZWET-WDSKDSINSA-N Cys-Glu-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O UXUSHQYYQCZWET-WDSKDSINSA-N 0.000 description 2
- KXUKWRVYDYIPSQ-CIUDSAMLSA-N Cys-Leu-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O KXUKWRVYDYIPSQ-CIUDSAMLSA-N 0.000 description 2
- OZSBRCONEMXYOJ-AVGNSLFASA-N Cys-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N OZSBRCONEMXYOJ-AVGNSLFASA-N 0.000 description 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 208000025499 G6PD deficiency Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- AAOBFSKXAVIORT-GUBZILKMSA-N Gln-Asn-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O AAOBFSKXAVIORT-GUBZILKMSA-N 0.000 description 2
- HHQCBFGKQDMWSP-GUBZILKMSA-N Gln-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HHQCBFGKQDMWSP-GUBZILKMSA-N 0.000 description 2
- QKCZZAZNMMVICF-DCAQKATOSA-N Gln-Leu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O QKCZZAZNMMVICF-DCAQKATOSA-N 0.000 description 2
- IULKWYSYZSURJK-AVGNSLFASA-N Gln-Leu-Lys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O IULKWYSYZSURJK-AVGNSLFASA-N 0.000 description 2
- HSHCEAUPUPJPTE-JYJNAYRXSA-N Gln-Leu-Tyr Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HSHCEAUPUPJPTE-JYJNAYRXSA-N 0.000 description 2
- QKWBEMCLYTYBNI-GVXVVHGQSA-N Gln-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O QKWBEMCLYTYBNI-GVXVVHGQSA-N 0.000 description 2
- MFORDNZDKAVNSR-SRVKXCTJSA-N Gln-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O MFORDNZDKAVNSR-SRVKXCTJSA-N 0.000 description 2
- ICRKQMRFXYDYMK-LAEOZQHASA-N Gln-Val-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ICRKQMRFXYDYMK-LAEOZQHASA-N 0.000 description 2
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 2
- MKRDNSWGJWTBKZ-GVXVVHGQSA-N Gln-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MKRDNSWGJWTBKZ-GVXVVHGQSA-N 0.000 description 2
- YYOBUPFZLKQUAX-FXQIFTODSA-N Glu-Asn-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YYOBUPFZLKQUAX-FXQIFTODSA-N 0.000 description 2
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 2
- XHWLNISLUFEWNS-CIUDSAMLSA-N Glu-Gln-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O XHWLNISLUFEWNS-CIUDSAMLSA-N 0.000 description 2
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 2
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 2
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 2
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 2
- QJCKNLPMTPXXEM-AUTRQRHGSA-N Glu-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O QJCKNLPMTPXXEM-AUTRQRHGSA-N 0.000 description 2
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 2
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 2
- MRWYPDWDZSLWJM-ACZMJKKPSA-N Glu-Ser-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O MRWYPDWDZSLWJM-ACZMJKKPSA-N 0.000 description 2
- DLISPGXMKZTWQG-IFFSRLJSSA-N Glu-Thr-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O DLISPGXMKZTWQG-IFFSRLJSSA-N 0.000 description 2
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 2
- VXKCPBPQEKKERH-IUCAKERBSA-N Gly-Arg-Pro Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O VXKCPBPQEKKERH-IUCAKERBSA-N 0.000 description 2
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 2
- AYBKPDHHVADEDA-YUMQZZPRSA-N Gly-His-Asn Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O AYBKPDHHVADEDA-YUMQZZPRSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- HQKADFMLECZIQJ-HVTMNAMFSA-N His-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N HQKADFMLECZIQJ-HVTMNAMFSA-N 0.000 description 2
- CMMBEMZGNGYJRJ-IHRRRGAJSA-N His-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N CMMBEMZGNGYJRJ-IHRRRGAJSA-N 0.000 description 2
- STGQSBKUYSPPIG-CIUDSAMLSA-N His-Ser-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 STGQSBKUYSPPIG-CIUDSAMLSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- WZPIKDWQVRTATP-SYWGBEHUSA-N Ile-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 WZPIKDWQVRTATP-SYWGBEHUSA-N 0.000 description 2
- TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 2
- LRAUKBMYHHNADU-DKIMLUQUSA-N Ile-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)CC)CC1=CC=CC=C1 LRAUKBMYHHNADU-DKIMLUQUSA-N 0.000 description 2
- VEPIBPGLTLPBDW-URLPEUOOSA-N Ile-Phe-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N VEPIBPGLTLPBDW-URLPEUOOSA-N 0.000 description 2
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 2
- KBDIBHQICWDGDL-PPCPHDFISA-N Ile-Thr-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N KBDIBHQICWDGDL-PPCPHDFISA-N 0.000 description 2
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 2
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 2
- FJUKMPUELVROGK-IHRRRGAJSA-N Leu-Arg-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N FJUKMPUELVROGK-IHRRRGAJSA-N 0.000 description 2
- MMEDVBWCMGRKKC-GARJFASQSA-N Leu-Asp-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N MMEDVBWCMGRKKC-GARJFASQSA-N 0.000 description 2
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 2
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 2
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 2
- HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 description 2
- QPXBPQUGXHURGP-UWVGGRQHSA-N Leu-Gly-Met Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N QPXBPQUGXHURGP-UWVGGRQHSA-N 0.000 description 2
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 2
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 2
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 2
- HDHQQEDVWQGBEE-DCAQKATOSA-N Leu-Met-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O HDHQQEDVWQGBEE-DCAQKATOSA-N 0.000 description 2
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 2
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 2
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 2
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 2
- DFXQCCBKGUNYGG-GUBZILKMSA-N Lys-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN DFXQCCBKGUNYGG-GUBZILKMSA-N 0.000 description 2
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 2
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 2
- GNLJXWBNLAIPEP-MELADBBJSA-N Lys-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCCN)N)C(=O)O GNLJXWBNLAIPEP-MELADBBJSA-N 0.000 description 2
- OJDFAABAHBPVTH-MNXVOIDGSA-N Lys-Ile-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OJDFAABAHBPVTH-MNXVOIDGSA-N 0.000 description 2
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 2
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 2
- GZGWILAQHOVXTD-DCAQKATOSA-N Lys-Met-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O GZGWILAQHOVXTD-DCAQKATOSA-N 0.000 description 2
- AFLBTVGQCQLOFJ-AVGNSLFASA-N Lys-Pro-Arg Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-AVGNSLFASA-N 0.000 description 2
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 2
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 2
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 2
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 description 2
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 2
- OVTOTTGZBWXLFU-QXEWZRGKSA-N Met-Val-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O OVTOTTGZBWXLFU-QXEWZRGKSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- DOXQMJCSSYZSNM-BZSNNMDCSA-N Phe-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O DOXQMJCSSYZSNM-BZSNNMDCSA-N 0.000 description 2
- AXIOGMQCDYVTNY-ACRUOGEOSA-N Phe-Phe-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 AXIOGMQCDYVTNY-ACRUOGEOSA-N 0.000 description 2
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 2
- BSTPNLNKHKBONJ-HTUGSXCWSA-N Phe-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O BSTPNLNKHKBONJ-HTUGSXCWSA-N 0.000 description 2
- ZYNBEWGJFXTBDU-ACRUOGEOSA-N Phe-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N ZYNBEWGJFXTBDU-ACRUOGEOSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- YKQNVTOIYFQMLW-IHRRRGAJSA-N Pro-Cys-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 YKQNVTOIYFQMLW-IHRRRGAJSA-N 0.000 description 2
- PTLOFJZJADCNCD-DCAQKATOSA-N Pro-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1 PTLOFJZJADCNCD-DCAQKATOSA-N 0.000 description 2
- BFXZQMWKTYWGCF-PYJNHQTQSA-N Pro-His-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BFXZQMWKTYWGCF-PYJNHQTQSA-N 0.000 description 2
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 2
- MDAWMJUZHBQTBO-XGEHTFHBSA-N Pro-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1)O MDAWMJUZHBQTBO-XGEHTFHBSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000012515 Protein kinase domains Human genes 0.000 description 2
- 108050002122 Protein kinase domains Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 2
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 2
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 description 2
- XVAUJOAYHWWNQF-ZLUOBGJFSA-N Ser-Asn-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O XVAUJOAYHWWNQF-ZLUOBGJFSA-N 0.000 description 2
- ZXLUWXWISXIFIX-ACZMJKKPSA-N Ser-Asn-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZXLUWXWISXIFIX-ACZMJKKPSA-N 0.000 description 2
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 2
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 2
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 2
- KMWFXJCGRXBQAC-CIUDSAMLSA-N Ser-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N KMWFXJCGRXBQAC-CIUDSAMLSA-N 0.000 description 2
- HBTCFCHYALPXME-HTFCKZLJSA-N Ser-Ile-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HBTCFCHYALPXME-HTFCKZLJSA-N 0.000 description 2
- LRWBCWGEUCKDTN-BJDJZHNGSA-N Ser-Lys-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LRWBCWGEUCKDTN-BJDJZHNGSA-N 0.000 description 2
- WNDUPCKKKGSKIQ-CIUDSAMLSA-N Ser-Pro-Gln Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O WNDUPCKKKGSKIQ-CIUDSAMLSA-N 0.000 description 2
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 2
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 2
- LMMDEZPNUTZJAY-GCJQMDKQSA-N Thr-Asp-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O LMMDEZPNUTZJAY-GCJQMDKQSA-N 0.000 description 2
- ADPHPKGWVDHWML-PPCPHDFISA-N Thr-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N ADPHPKGWVDHWML-PPCPHDFISA-N 0.000 description 2
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 2
- GUHLYMZJVXUIPO-RCWTZXSCSA-N Thr-Met-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GUHLYMZJVXUIPO-RCWTZXSCSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- CFMGQWYCEJDTDG-XIRDDKMYSA-N Trp-Lys-Cys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(O)=O)=CNC2=C1 CFMGQWYCEJDTDG-XIRDDKMYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- RCLOWEZASFJFEX-KKUMJFAQSA-N Tyr-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RCLOWEZASFJFEX-KKUMJFAQSA-N 0.000 description 2
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- WOCYUGQDXPTQPY-FXQIFTODSA-N Val-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N WOCYUGQDXPTQPY-FXQIFTODSA-N 0.000 description 2
- YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 2
- DLMNFMXSNGTSNJ-PYJNHQTQSA-N Val-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N DLMNFMXSNGTSNJ-PYJNHQTQSA-N 0.000 description 2
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 2
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 2
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 2
- JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 2
- 108010041407 alanylaspartic acid Proteins 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 108010070783 alanyltyrosine Proteins 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 108010038850 arginyl-isoleucyl-tyrosine Proteins 0.000 description 2
- 108010066119 arginyl-leucyl-aspartyl-serine Proteins 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 108010093581 aspartyl-proline Proteins 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000003200 chromosome mapping Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000002742 combinatorial mutagenesis Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 108010004073 cysteinylcysteine Proteins 0.000 description 2
- 108010069495 cysteinyltyrosine Proteins 0.000 description 2
- 108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 description 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 108010028295 histidylhistidine Proteins 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 108010053037 kyotorphin Proteins 0.000 description 2
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 2
- 108010000761 leucylarginine Proteins 0.000 description 2
- 108010012058 leucyltyrosine Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 108010024607 phenylalanylalanine Proteins 0.000 description 2
- 108010012581 phenylalanylglutamate Proteins 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- XWTNPSHCJMZAHQ-QMMMGPOBSA-N 2-[[2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(=O)NCC(O)=O XWTNPSHCJMZAHQ-QMMMGPOBSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- XTPUXCVIDQFHIT-UHFFFAOYSA-N 8-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(N)=C2NC(CCC(C)=C)=NC2=N1 XTPUXCVIDQFHIT-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 102000021527 ATP binding proteins Human genes 0.000 description 1
- 108091011108 ATP binding proteins Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- QDRGPQWIVZNJQD-CIUDSAMLSA-N Ala-Arg-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O QDRGPQWIVZNJQD-CIUDSAMLSA-N 0.000 description 1
- YWWATNIVMOCSAV-UBHSHLNASA-N Ala-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YWWATNIVMOCSAV-UBHSHLNASA-N 0.000 description 1
- RXTBLQVXNIECFP-FXQIFTODSA-N Ala-Gln-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RXTBLQVXNIECFP-FXQIFTODSA-N 0.000 description 1
- FVSOUJZKYWEFOB-KBIXCLLPSA-N Ala-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N FVSOUJZKYWEFOB-KBIXCLLPSA-N 0.000 description 1
- ZDYNWWQXFRUOEO-XDTLVQLUSA-N Ala-Gln-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDYNWWQXFRUOEO-XDTLVQLUSA-N 0.000 description 1
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- BLIMFWGRQKRCGT-YUMQZZPRSA-N Ala-Gly-Lys Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN BLIMFWGRQKRCGT-YUMQZZPRSA-N 0.000 description 1
- FDAZDMAFZYTHGS-XVYDVKMFSA-N Ala-His-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O FDAZDMAFZYTHGS-XVYDVKMFSA-N 0.000 description 1
- NYDBKUNVSALYPX-NAKRPEOUSA-N Ala-Ile-Arg Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NYDBKUNVSALYPX-NAKRPEOUSA-N 0.000 description 1
- IFKQPMZRDQZSHI-GHCJXIJMSA-N Ala-Ile-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O IFKQPMZRDQZSHI-GHCJXIJMSA-N 0.000 description 1
- CKLDHDOIYBVUNP-KBIXCLLPSA-N Ala-Ile-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O CKLDHDOIYBVUNP-KBIXCLLPSA-N 0.000 description 1
- NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 1
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 1
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 1
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- FUKFQILQFQKHLE-DCAQKATOSA-N Ala-Lys-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O FUKFQILQFQKHLE-DCAQKATOSA-N 0.000 description 1
- KQESEZXHYOUIIM-CQDKDKBSSA-N Ala-Lys-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KQESEZXHYOUIIM-CQDKDKBSSA-N 0.000 description 1
- RAAWHFXHAACDFT-FXQIFTODSA-N Ala-Met-Asn Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(O)=O RAAWHFXHAACDFT-FXQIFTODSA-N 0.000 description 1
- VEAPAYQQLSEKEM-GUBZILKMSA-N Ala-Met-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(O)=O VEAPAYQQLSEKEM-GUBZILKMSA-N 0.000 description 1
- CQJHFKKGZXKZBC-BPNCWPANSA-N Ala-Pro-Tyr Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CQJHFKKGZXKZBC-BPNCWPANSA-N 0.000 description 1
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 1
- XSLGWYYNOSUMRM-ZKWXMUAHSA-N Ala-Val-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XSLGWYYNOSUMRM-ZKWXMUAHSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- YFWTXMRJJDNTLM-LSJOCFKGSA-N Arg-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YFWTXMRJJDNTLM-LSJOCFKGSA-N 0.000 description 1
- BVBKBQRPOJFCQM-DCAQKATOSA-N Arg-Asn-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BVBKBQRPOJFCQM-DCAQKATOSA-N 0.000 description 1
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 1
- LMPKCSXZJSXBBL-NHCYSSNCSA-N Arg-Gln-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O LMPKCSXZJSXBBL-NHCYSSNCSA-N 0.000 description 1
- OHYQKYUTLIPFOX-ZPFDUUQYSA-N Arg-Glu-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OHYQKYUTLIPFOX-ZPFDUUQYSA-N 0.000 description 1
- JAYIQMNQDMOBFY-KKUMJFAQSA-N Arg-Glu-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JAYIQMNQDMOBFY-KKUMJFAQSA-N 0.000 description 1
- LKDHUGLXOHYINY-XUXIUFHCSA-N Arg-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LKDHUGLXOHYINY-XUXIUFHCSA-N 0.000 description 1
- OFIYLHVAAJYRBC-HJWJTTGWSA-N Arg-Ile-Phe Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O OFIYLHVAAJYRBC-HJWJTTGWSA-N 0.000 description 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
- GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 1
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
- CVXXSWQORBZAAA-SRVKXCTJSA-N Arg-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N CVXXSWQORBZAAA-SRVKXCTJSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- NYDIVDKTULRINZ-AVGNSLFASA-N Arg-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NYDIVDKTULRINZ-AVGNSLFASA-N 0.000 description 1
- YTMKMRSYXHBGER-IHRRRGAJSA-N Arg-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YTMKMRSYXHBGER-IHRRRGAJSA-N 0.000 description 1
- MNBHKGYCLBUIBC-UFYCRDLUSA-N Arg-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MNBHKGYCLBUIBC-UFYCRDLUSA-N 0.000 description 1
- ASQKVGRCKOFKIU-KZVJFYERSA-N Arg-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ASQKVGRCKOFKIU-KZVJFYERSA-N 0.000 description 1
- YHZQOSXDTFRZKU-WDSOQIARSA-N Arg-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N)=CNC2=C1 YHZQOSXDTFRZKU-WDSOQIARSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108020005224 Arylamine N-acetyltransferase Proteins 0.000 description 1
- 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 1
- QEYJFBMTSMLPKZ-ZKWXMUAHSA-N Asn-Ala-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QEYJFBMTSMLPKZ-ZKWXMUAHSA-N 0.000 description 1
- DNYRZPOWBTYFAF-IHRRRGAJSA-N Asn-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N)O DNYRZPOWBTYFAF-IHRRRGAJSA-N 0.000 description 1
- LDSFSKFATNBTBV-UHFFFAOYSA-N Asn-Asn-Gly-His Chemical compound NC(=O)CC(N)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NC(C(O)=O)CC1=CN=CN1 LDSFSKFATNBTBV-UHFFFAOYSA-N 0.000 description 1
- WVCJSDCHTUTONA-FXQIFTODSA-N Asn-Asp-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WVCJSDCHTUTONA-FXQIFTODSA-N 0.000 description 1
- QNJIRRVTOXNGMH-GUBZILKMSA-N Asn-Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(N)=O QNJIRRVTOXNGMH-GUBZILKMSA-N 0.000 description 1
- MSBDSTRUMZFSEU-PEFMBERDSA-N Asn-Glu-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MSBDSTRUMZFSEU-PEFMBERDSA-N 0.000 description 1
- ASCGFDYEKSRNPL-CIUDSAMLSA-N Asn-Glu-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O ASCGFDYEKSRNPL-CIUDSAMLSA-N 0.000 description 1
- AITGTTNYKAWKDR-CIUDSAMLSA-N Asn-His-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O AITGTTNYKAWKDR-CIUDSAMLSA-N 0.000 description 1
- NKLRWRRVYGQNIH-GHCJXIJMSA-N Asn-Ile-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O NKLRWRRVYGQNIH-GHCJXIJMSA-N 0.000 description 1
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 1
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
- GIQCDTKOIPUDSG-GARJFASQSA-N Asn-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N)C(=O)O GIQCDTKOIPUDSG-GARJFASQSA-N 0.000 description 1
- SZNGQSBRHFMZLT-IHRRRGAJSA-N Asn-Pro-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SZNGQSBRHFMZLT-IHRRRGAJSA-N 0.000 description 1
- NPZJLGMWMDNQDD-GHCJXIJMSA-N Asn-Ser-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NPZJLGMWMDNQDD-GHCJXIJMSA-N 0.000 description 1
- HPNDKUOLNRVRAY-BIIVOSGPSA-N Asn-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N)C(=O)O HPNDKUOLNRVRAY-BIIVOSGPSA-N 0.000 description 1
- XLDMSQYOYXINSZ-QXEWZRGKSA-N Asn-Val-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N XLDMSQYOYXINSZ-QXEWZRGKSA-N 0.000 description 1
- CBHVAFXKOYAHOY-NHCYSSNCSA-N Asn-Val-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O CBHVAFXKOYAHOY-NHCYSSNCSA-N 0.000 description 1
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 1
- NAPNAGZWHQHZLG-ZLUOBGJFSA-N Asp-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N NAPNAGZWHQHZLG-ZLUOBGJFSA-N 0.000 description 1
- JGDBHIVECJGXJA-FXQIFTODSA-N Asp-Asp-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JGDBHIVECJGXJA-FXQIFTODSA-N 0.000 description 1
- NYQHSUGFEWDWPD-ACZMJKKPSA-N Asp-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N NYQHSUGFEWDWPD-ACZMJKKPSA-N 0.000 description 1
- RATOMFTUDRYMKX-ACZMJKKPSA-N Asp-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N RATOMFTUDRYMKX-ACZMJKKPSA-N 0.000 description 1
- HSWYMWGDMPLTTH-FXQIFTODSA-N Asp-Glu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HSWYMWGDMPLTTH-FXQIFTODSA-N 0.000 description 1
- WSXDIZFNQYTUJB-SRVKXCTJSA-N Asp-His-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O WSXDIZFNQYTUJB-SRVKXCTJSA-N 0.000 description 1
- ICZWAZVKLACMKR-CIUDSAMLSA-N Asp-His-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CN=CN1 ICZWAZVKLACMKR-CIUDSAMLSA-N 0.000 description 1
- MFTVXYMXSAQZNL-DJFWLOJKSA-N Asp-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)O)N MFTVXYMXSAQZNL-DJFWLOJKSA-N 0.000 description 1
- KFAFUJMGHVVYRC-DCAQKATOSA-N Asp-Leu-Met Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O KFAFUJMGHVVYRC-DCAQKATOSA-N 0.000 description 1
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 1
- ORRJQLIATJDMQM-HJGDQZAQSA-N Asp-Leu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O ORRJQLIATJDMQM-HJGDQZAQSA-N 0.000 description 1
- UZFHNLYQWMGUHU-DCAQKATOSA-N Asp-Lys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UZFHNLYQWMGUHU-DCAQKATOSA-N 0.000 description 1
- XWSIYTYNLKCLJB-CIUDSAMLSA-N Asp-Lys-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O XWSIYTYNLKCLJB-CIUDSAMLSA-N 0.000 description 1
- IOXWDLNHXZOXQP-FXQIFTODSA-N Asp-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N IOXWDLNHXZOXQP-FXQIFTODSA-N 0.000 description 1
- LIQNMKIBMPEOOP-IHRRRGAJSA-N Asp-Phe-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)N LIQNMKIBMPEOOP-IHRRRGAJSA-N 0.000 description 1
- BRRPVTUFESPTCP-ACZMJKKPSA-N Asp-Ser-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O BRRPVTUFESPTCP-ACZMJKKPSA-N 0.000 description 1
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
- BPAUXFVCSYQDQX-JRQIVUDYSA-N Asp-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)O)N)O BPAUXFVCSYQDQX-JRQIVUDYSA-N 0.000 description 1
- UXRVDHVARNBOIO-QSFUFRPTSA-N Asp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)N UXRVDHVARNBOIO-QSFUFRPTSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150010738 CYP2D6 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- NOCCABSVTRONIN-CIUDSAMLSA-N Cys-Ala-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CS)N NOCCABSVTRONIN-CIUDSAMLSA-N 0.000 description 1
- DCJNIJAWIRPPBB-CIUDSAMLSA-N Cys-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N DCJNIJAWIRPPBB-CIUDSAMLSA-N 0.000 description 1
- WXKWQSDHEXKKNC-ZKWXMUAHSA-N Cys-Asp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N WXKWQSDHEXKKNC-ZKWXMUAHSA-N 0.000 description 1
- PRHGYQOSEHLDRW-VGDYDELISA-N Cys-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CS)N PRHGYQOSEHLDRW-VGDYDELISA-N 0.000 description 1
- JXVFJOMFOLFPMP-KKUMJFAQSA-N Cys-Leu-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JXVFJOMFOLFPMP-KKUMJFAQSA-N 0.000 description 1
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 1
- MHYHLWUGWUBUHF-GUBZILKMSA-N Cys-Val-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N MHYHLWUGWUBUHF-GUBZILKMSA-N 0.000 description 1
- YQEHNIKPAOPBNH-DCAQKATOSA-N Cys-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N YQEHNIKPAOPBNH-DCAQKATOSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020001738 DNA Glycosylase Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000028381 DNA glycosylase Human genes 0.000 description 1
- 102000004214 DNA polymerase A Human genes 0.000 description 1
- 108090000725 DNA polymerase A Proteins 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108700005088 Fungal Genes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- RZSLYUUFFVHFRQ-FXQIFTODSA-N Gln-Ala-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O RZSLYUUFFVHFRQ-FXQIFTODSA-N 0.000 description 1
- LKUWAWGNJYJODH-KBIXCLLPSA-N Gln-Ala-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LKUWAWGNJYJODH-KBIXCLLPSA-N 0.000 description 1
- MLZRSFQRBDNJON-GUBZILKMSA-N Gln-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MLZRSFQRBDNJON-GUBZILKMSA-N 0.000 description 1
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 1
- ZQPOVSJFBBETHQ-CIUDSAMLSA-N Gln-Glu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZQPOVSJFBBETHQ-CIUDSAMLSA-N 0.000 description 1
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 1
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 1
- XSBGUANSZDGULP-IUCAKERBSA-N Gln-Gly-Lys Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O XSBGUANSZDGULP-IUCAKERBSA-N 0.000 description 1
- NSORZJXKUQFEKL-JGVFFNPUSA-N Gln-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)N)N)C(=O)O NSORZJXKUQFEKL-JGVFFNPUSA-N 0.000 description 1
- HDUDGCZEOZEFOA-KBIXCLLPSA-N Gln-Ile-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HDUDGCZEOZEFOA-KBIXCLLPSA-N 0.000 description 1
- MWERYIXRDZDXOA-QEWYBTABSA-N Gln-Ile-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MWERYIXRDZDXOA-QEWYBTABSA-N 0.000 description 1
- JKGHMESJHRTHIC-SIUGBPQLSA-N Gln-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JKGHMESJHRTHIC-SIUGBPQLSA-N 0.000 description 1
- JNVGVECJCOZHCN-DRZSPHRISA-N Gln-Phe-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O JNVGVECJCOZHCN-DRZSPHRISA-N 0.000 description 1
- AQPZYBSRDRZBAG-AVGNSLFASA-N Gln-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N AQPZYBSRDRZBAG-AVGNSLFASA-N 0.000 description 1
- UWMDGPFFTKDUIY-HJGDQZAQSA-N Gln-Pro-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWMDGPFFTKDUIY-HJGDQZAQSA-N 0.000 description 1
- LGWNISYVKDNJRP-FXQIFTODSA-N Gln-Ser-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGWNISYVKDNJRP-FXQIFTODSA-N 0.000 description 1
- OUBUHIODTNUUTC-WDCWCFNPSA-N Gln-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O OUBUHIODTNUUTC-WDCWCFNPSA-N 0.000 description 1
- SOEXCCGNHQBFPV-DLOVCJGASA-N Gln-Val-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SOEXCCGNHQBFPV-DLOVCJGASA-N 0.000 description 1
- RCCDHXSRMWCOOY-GUBZILKMSA-N Glu-Arg-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCCDHXSRMWCOOY-GUBZILKMSA-N 0.000 description 1
- KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 description 1
- KEBACWCLVOXFNC-DCAQKATOSA-N Glu-Arg-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O KEBACWCLVOXFNC-DCAQKATOSA-N 0.000 description 1
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 1
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 description 1
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 1
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 1
- SBCYJMOOHUDWDA-NUMRIWBASA-N Glu-Asp-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SBCYJMOOHUDWDA-NUMRIWBASA-N 0.000 description 1
- CYHBMLHCQXXCCT-AVGNSLFASA-N Glu-Asp-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CYHBMLHCQXXCCT-AVGNSLFASA-N 0.000 description 1
- PVBBEKPHARMPHX-DCAQKATOSA-N Glu-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O PVBBEKPHARMPHX-DCAQKATOSA-N 0.000 description 1
- LVCHEMOPBORRLB-DCAQKATOSA-N Glu-Gln-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O LVCHEMOPBORRLB-DCAQKATOSA-N 0.000 description 1
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 1
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 1
- KUTPGXNAAOQSPD-LPEHRKFASA-N Glu-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O KUTPGXNAAOQSPD-LPEHRKFASA-N 0.000 description 1
- ZPASCJBSSCRWMC-GVXVVHGQSA-N Glu-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N ZPASCJBSSCRWMC-GVXVVHGQSA-N 0.000 description 1
- ZSWGJYOZWBHROQ-RWRJDSDZSA-N Glu-Ile-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSWGJYOZWBHROQ-RWRJDSDZSA-N 0.000 description 1
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- IOUQWHIEQYQVFD-JYJNAYRXSA-N Glu-Leu-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IOUQWHIEQYQVFD-JYJNAYRXSA-N 0.000 description 1
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 1
- BCYGDJXHAGZNPQ-DCAQKATOSA-N Glu-Lys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O BCYGDJXHAGZNPQ-DCAQKATOSA-N 0.000 description 1
- YKBUCXNNBYZYAY-MNXVOIDGSA-N Glu-Lys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YKBUCXNNBYZYAY-MNXVOIDGSA-N 0.000 description 1
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 description 1
- ZWMYUDZLXAQHCK-CIUDSAMLSA-N Glu-Met-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O ZWMYUDZLXAQHCK-CIUDSAMLSA-N 0.000 description 1
- LKOAAMXDJGEYMS-ZPFDUUQYSA-N Glu-Met-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LKOAAMXDJGEYMS-ZPFDUUQYSA-N 0.000 description 1
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 1
- ARIORLIIMJACKZ-KKUMJFAQSA-N Glu-Pro-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ARIORLIIMJACKZ-KKUMJFAQSA-N 0.000 description 1
- CQGBSALYGOXQPE-HTUGSXCWSA-N Glu-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O CQGBSALYGOXQPE-HTUGSXCWSA-N 0.000 description 1
- CAQXJMUDOLSBPF-SUSMZKCASA-N Glu-Thr-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAQXJMUDOLSBPF-SUSMZKCASA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 1
- KFMBRBPXHVMDFN-UWVGGRQHSA-N Gly-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCNC(N)=N KFMBRBPXHVMDFN-UWVGGRQHSA-N 0.000 description 1
- XRTDOIOIBMAXCT-NKWVEPMBSA-N Gly-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)CN)C(=O)O XRTDOIOIBMAXCT-NKWVEPMBSA-N 0.000 description 1
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 1
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 1
- PEZZSFLFXXFUQD-XPUUQOCRSA-N Gly-Cys-Val Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O PEZZSFLFXXFUQD-XPUUQOCRSA-N 0.000 description 1
- HHSOPSCKAZKQHQ-PEXQALLHSA-N Gly-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN HHSOPSCKAZKQHQ-PEXQALLHSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 1
- CLNSYANKYVMZNM-UWVGGRQHSA-N Gly-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CLNSYANKYVMZNM-UWVGGRQHSA-N 0.000 description 1
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 1
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 1
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 1
- CSMYMGFCEJWALV-WDSKDSINSA-N Gly-Ser-Gln Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O CSMYMGFCEJWALV-WDSKDSINSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- 241000288105 Grus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- BIAKMWKJMQLZOJ-ZKWXMUAHSA-N His-Ala-Ala Chemical compound C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O BIAKMWKJMQLZOJ-ZKWXMUAHSA-N 0.000 description 1
- XINDHUAGVGCNSF-QSFUFRPTSA-N His-Ala-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XINDHUAGVGCNSF-QSFUFRPTSA-N 0.000 description 1
- TTZAWSKKNCEINZ-AVGNSLFASA-N His-Arg-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O TTZAWSKKNCEINZ-AVGNSLFASA-N 0.000 description 1
- JWTKVPMQCCRPQY-SRVKXCTJSA-N His-Asn-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JWTKVPMQCCRPQY-SRVKXCTJSA-N 0.000 description 1
- LMMPTUVWHCFTOT-GARJFASQSA-N His-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O LMMPTUVWHCFTOT-GARJFASQSA-N 0.000 description 1
- BQYZXYCEKYJKAM-VGDYDELISA-N His-Cys-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQYZXYCEKYJKAM-VGDYDELISA-N 0.000 description 1
- VLPMGIJPAWENQB-SRVKXCTJSA-N His-Cys-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O VLPMGIJPAWENQB-SRVKXCTJSA-N 0.000 description 1
- YAALVYQFVJNXIV-KKUMJFAQSA-N His-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 YAALVYQFVJNXIV-KKUMJFAQSA-N 0.000 description 1
- WYSJPCTWSBJFCO-AVGNSLFASA-N His-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CN=CN1)N WYSJPCTWSBJFCO-AVGNSLFASA-N 0.000 description 1
- WCHONUZTYDQMBY-PYJNHQTQSA-N His-Pro-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WCHONUZTYDQMBY-PYJNHQTQSA-N 0.000 description 1
- KAXZXLSXFWSNNZ-XVYDVKMFSA-N His-Ser-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KAXZXLSXFWSNNZ-XVYDVKMFSA-N 0.000 description 1
- JMSONHOUHFDOJH-GUBZILKMSA-N His-Ser-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 JMSONHOUHFDOJH-GUBZILKMSA-N 0.000 description 1
- UOYGZBIPZYKGSH-SRVKXCTJSA-N His-Ser-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N UOYGZBIPZYKGSH-SRVKXCTJSA-N 0.000 description 1
- GGXUJBKENKVYNV-ULQDDVLXSA-N His-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N GGXUJBKENKVYNV-ULQDDVLXSA-N 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108010001160 IgY Proteins 0.000 description 1
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 1
- TZCGZYWNIDZZMR-NAKRPEOUSA-N Ile-Arg-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)O)N TZCGZYWNIDZZMR-NAKRPEOUSA-N 0.000 description 1
- LVQDUPQUJZWKSU-PYJNHQTQSA-N Ile-Arg-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LVQDUPQUJZWKSU-PYJNHQTQSA-N 0.000 description 1
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 description 1
- LDRALPZEVHVXEK-KBIXCLLPSA-N Ile-Cys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N LDRALPZEVHVXEK-KBIXCLLPSA-N 0.000 description 1
- SPQWWEZBHXHUJN-KBIXCLLPSA-N Ile-Glu-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O SPQWWEZBHXHUJN-KBIXCLLPSA-N 0.000 description 1
- KIAOPHMUNPPGEN-PEXQALLHSA-N Ile-Gly-His Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KIAOPHMUNPPGEN-PEXQALLHSA-N 0.000 description 1
- MTONDYJJCIBZTK-PEDHHIEDSA-N Ile-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)O)N MTONDYJJCIBZTK-PEDHHIEDSA-N 0.000 description 1
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 1
- FCWFBHMAJZGWRY-XUXIUFHCSA-N Ile-Leu-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N FCWFBHMAJZGWRY-XUXIUFHCSA-N 0.000 description 1
- PARSHQDZROHERM-NHCYSSNCSA-N Ile-Lys-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)N PARSHQDZROHERM-NHCYSSNCSA-N 0.000 description 1
- IDMNOFVUXYYZPF-DKIMLUQUSA-N Ile-Lys-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N IDMNOFVUXYYZPF-DKIMLUQUSA-N 0.000 description 1
- NPAYJTAXWXJKLO-NAKRPEOUSA-N Ile-Met-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N NPAYJTAXWXJKLO-NAKRPEOUSA-N 0.000 description 1
- FGBRXCZYVRFNKQ-MXAVVETBSA-N Ile-Phe-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N FGBRXCZYVRFNKQ-MXAVVETBSA-N 0.000 description 1
- ZDNNDIJTUHQCAM-MXAVVETBSA-N Ile-Ser-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N ZDNNDIJTUHQCAM-MXAVVETBSA-N 0.000 description 1
- PZWBBXHHUSIGKH-OSUNSFLBSA-N Ile-Thr-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PZWBBXHHUSIGKH-OSUNSFLBSA-N 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- NJGXXYLPDMMFJB-XUXIUFHCSA-N Ile-Val-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N NJGXXYLPDMMFJB-XUXIUFHCSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 1
- WUFYAPWIHCUMLL-CIUDSAMLSA-N Leu-Asn-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O WUFYAPWIHCUMLL-CIUDSAMLSA-N 0.000 description 1
- KKXDHFKZWKLYGB-GUBZILKMSA-N Leu-Asn-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKXDHFKZWKLYGB-GUBZILKMSA-N 0.000 description 1
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 1
- MDVZJYGNAGLPGJ-KKUMJFAQSA-N Leu-Asn-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MDVZJYGNAGLPGJ-KKUMJFAQSA-N 0.000 description 1
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 1
- RVVBWTWPNFDYBE-SRVKXCTJSA-N Leu-Glu-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVVBWTWPNFDYBE-SRVKXCTJSA-N 0.000 description 1
- PRZVBIAOPFGAQF-SRVKXCTJSA-N Leu-Glu-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O PRZVBIAOPFGAQF-SRVKXCTJSA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- LLBQJYDYOLIQAI-JYJNAYRXSA-N Leu-Glu-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LLBQJYDYOLIQAI-JYJNAYRXSA-N 0.000 description 1
- FMEICTQWUKNAGC-YUMQZZPRSA-N Leu-Gly-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O FMEICTQWUKNAGC-YUMQZZPRSA-N 0.000 description 1
- XQXGNBFMAXWIGI-MXAVVETBSA-N Leu-His-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CN=CN1 XQXGNBFMAXWIGI-MXAVVETBSA-N 0.000 description 1
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 1
- PDQDCFBVYXEFSD-SRVKXCTJSA-N Leu-Leu-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PDQDCFBVYXEFSD-SRVKXCTJSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- ZGUMORRUBUCXEH-AVGNSLFASA-N Leu-Lys-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZGUMORRUBUCXEH-AVGNSLFASA-N 0.000 description 1
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 1
- ARRIJPQRBWRNLT-DCAQKATOSA-N Leu-Met-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ARRIJPQRBWRNLT-DCAQKATOSA-N 0.000 description 1
- DDVHDMSBLRAKNV-IHRRRGAJSA-N Leu-Met-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O DDVHDMSBLRAKNV-IHRRRGAJSA-N 0.000 description 1
- PTRKPHUGYULXPU-KKUMJFAQSA-N Leu-Phe-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O PTRKPHUGYULXPU-KKUMJFAQSA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 1
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- LFXSPAIBSZSTEM-PMVMPFDFSA-N Leu-Trp-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N LFXSPAIBSZSTEM-PMVMPFDFSA-N 0.000 description 1
- RIHIGSWBLHSGLV-CQDKDKBSSA-N Leu-Tyr-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O RIHIGSWBLHSGLV-CQDKDKBSSA-N 0.000 description 1
- UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 description 1
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 1
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 1
- ABHIXYDMILIUKV-CIUDSAMLSA-N Lys-Asn-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ABHIXYDMILIUKV-CIUDSAMLSA-N 0.000 description 1
- DEFGUIIUYAUEDU-ZPFDUUQYSA-N Lys-Asn-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DEFGUIIUYAUEDU-ZPFDUUQYSA-N 0.000 description 1
- HKCCVDWHHTVVPN-CIUDSAMLSA-N Lys-Asp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O HKCCVDWHHTVVPN-CIUDSAMLSA-N 0.000 description 1
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 1
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 description 1
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 1
- GKFNXYMAMKJSKD-NHCYSSNCSA-N Lys-Asp-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O GKFNXYMAMKJSKD-NHCYSSNCSA-N 0.000 description 1
- SSYOBDBNBQBSQE-SRVKXCTJSA-N Lys-Cys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O SSYOBDBNBQBSQE-SRVKXCTJSA-N 0.000 description 1
- NNCDAORZCMPZPX-GUBZILKMSA-N Lys-Gln-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N NNCDAORZCMPZPX-GUBZILKMSA-N 0.000 description 1
- HEWWNLVEWBJBKA-WDCWCFNPSA-N Lys-Gln-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN HEWWNLVEWBJBKA-WDCWCFNPSA-N 0.000 description 1
- DRCILAJNUJKAHC-SRVKXCTJSA-N Lys-Glu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DRCILAJNUJKAHC-SRVKXCTJSA-N 0.000 description 1
- LLSUNJYOSCOOEB-GUBZILKMSA-N Lys-Glu-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O LLSUNJYOSCOOEB-GUBZILKMSA-N 0.000 description 1
- CRNNMTHBMRFQNG-GUBZILKMSA-N Lys-Glu-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N CRNNMTHBMRFQNG-GUBZILKMSA-N 0.000 description 1
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 1
- WGLAORUKDGRINI-WDCWCFNPSA-N Lys-Glu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGLAORUKDGRINI-WDCWCFNPSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 1
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 1
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
- QKXZCUCBFPEXNK-KKUMJFAQSA-N Lys-Leu-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QKXZCUCBFPEXNK-KKUMJFAQSA-N 0.000 description 1
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 1
- PFZWARWVRNTPBR-IHPCNDPISA-N Lys-Leu-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N PFZWARWVRNTPBR-IHPCNDPISA-N 0.000 description 1
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 1
- RIJCHEVHFWMDKD-SRVKXCTJSA-N Lys-Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RIJCHEVHFWMDKD-SRVKXCTJSA-N 0.000 description 1
- YUAXTFMFMOIMAM-QWRGUYRKSA-N Lys-Lys-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O YUAXTFMFMOIMAM-QWRGUYRKSA-N 0.000 description 1
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 1
- ATNKHRAIZCMCCN-BZSNNMDCSA-N Lys-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N ATNKHRAIZCMCCN-BZSNNMDCSA-N 0.000 description 1
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
- BXPHMHQHYHILBB-BZSNNMDCSA-N Lys-Lys-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BXPHMHQHYHILBB-BZSNNMDCSA-N 0.000 description 1
- GOVDTWNJCBRRBJ-DCAQKATOSA-N Lys-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N GOVDTWNJCBRRBJ-DCAQKATOSA-N 0.000 description 1
- KFSALEZVQJYHCE-AVGNSLFASA-N Lys-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)N KFSALEZVQJYHCE-AVGNSLFASA-N 0.000 description 1
- LNMKRJJLEFASGA-BZSNNMDCSA-N Lys-Phe-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LNMKRJJLEFASGA-BZSNNMDCSA-N 0.000 description 1
- UDXSLGLHFUBRRM-OEAJRASXSA-N Lys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N)O UDXSLGLHFUBRRM-OEAJRASXSA-N 0.000 description 1
- HYSVGEAWTGPMOA-IHRRRGAJSA-N Lys-Pro-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O HYSVGEAWTGPMOA-IHRRRGAJSA-N 0.000 description 1
- MGKFCQFVPKOWOL-CIUDSAMLSA-N Lys-Ser-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N MGKFCQFVPKOWOL-CIUDSAMLSA-N 0.000 description 1
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 1
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 1
- WZVSHTFTCYOFPL-GARJFASQSA-N Lys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N)C(=O)O WZVSHTFTCYOFPL-GARJFASQSA-N 0.000 description 1
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 1
- BDFHWFUAQLIMJO-KXNHARMFSA-N Lys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N)O BDFHWFUAQLIMJO-KXNHARMFSA-N 0.000 description 1
- RMOKGALPSPOYKE-KATARQTJSA-N Lys-Thr-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMOKGALPSPOYKE-KATARQTJSA-N 0.000 description 1
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 1
- VWJFOUBDZIUXGA-AVGNSLFASA-N Lys-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCCN)N VWJFOUBDZIUXGA-AVGNSLFASA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- QGQGAIBGTUJRBR-NAKRPEOUSA-N Met-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC QGQGAIBGTUJRBR-NAKRPEOUSA-N 0.000 description 1
- BQVJARUIXRXDKN-DCAQKATOSA-N Met-Asn-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 BQVJARUIXRXDKN-DCAQKATOSA-N 0.000 description 1
- QXEVZBXTDTVPCP-GMOBBJLQSA-N Met-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)N QXEVZBXTDTVPCP-GMOBBJLQSA-N 0.000 description 1
- TUSOIZOVPJCMFC-FXQIFTODSA-N Met-Asp-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O TUSOIZOVPJCMFC-FXQIFTODSA-N 0.000 description 1
- HZVXPUHLTZRQEL-UWVGGRQHSA-N Met-Leu-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O HZVXPUHLTZRQEL-UWVGGRQHSA-N 0.000 description 1
- JCMMNFZUKMMECJ-DCAQKATOSA-N Met-Lys-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O JCMMNFZUKMMECJ-DCAQKATOSA-N 0.000 description 1
- XGIQKEAKUSPCBU-SRVKXCTJSA-N Met-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCSC)N XGIQKEAKUSPCBU-SRVKXCTJSA-N 0.000 description 1
- KRLKICLNEICJGV-STQMWFEESA-N Met-Phe-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 KRLKICLNEICJGV-STQMWFEESA-N 0.000 description 1
- RSOMVHWMIAZNLE-HJWJTTGWSA-N Met-Phe-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RSOMVHWMIAZNLE-HJWJTTGWSA-N 0.000 description 1
- MIXPUVSPPOWTCR-FXQIFTODSA-N Met-Ser-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MIXPUVSPPOWTCR-FXQIFTODSA-N 0.000 description 1
- ALTHVGNGGZZSAC-SRVKXCTJSA-N Met-Val-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCNC(N)=N ALTHVGNGGZZSAC-SRVKXCTJSA-N 0.000 description 1
- KPVLLNDCBYXKNV-CYDGBPFRSA-N Met-Val-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KPVLLNDCBYXKNV-CYDGBPFRSA-N 0.000 description 1
- VYDLZDRMOFYOGV-TUAOUCFPSA-N Met-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N VYDLZDRMOFYOGV-TUAOUCFPSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 208000032234 No therapeutic response Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- AJOKKVTWEMXZHC-DRZSPHRISA-N Phe-Ala-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 AJOKKVTWEMXZHC-DRZSPHRISA-N 0.000 description 1
- UHRNIXJAGGLKHP-DLOVCJGASA-N Phe-Ala-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O UHRNIXJAGGLKHP-DLOVCJGASA-N 0.000 description 1
- HXSUFWQYLPKEHF-IHRRRGAJSA-N Phe-Asn-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HXSUFWQYLPKEHF-IHRRRGAJSA-N 0.000 description 1
- MRNRMSDVVSKPGM-AVGNSLFASA-N Phe-Asn-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MRNRMSDVVSKPGM-AVGNSLFASA-N 0.000 description 1
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 1
- CSDMCMITJLKBAH-SOUVJXGZSA-N Phe-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O CSDMCMITJLKBAH-SOUVJXGZSA-N 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- FXPZZKBHNOMLGA-HJWJTTGWSA-N Phe-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FXPZZKBHNOMLGA-HJWJTTGWSA-N 0.000 description 1
- FUAIIFPQELBNJF-ULQDDVLXSA-N Phe-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FUAIIFPQELBNJF-ULQDDVLXSA-N 0.000 description 1
- OHIYMVFLQXTZAW-UFYCRDLUSA-N Phe-Met-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O OHIYMVFLQXTZAW-UFYCRDLUSA-N 0.000 description 1
- OWSLLRKCHLTUND-BZSNNMDCSA-N Phe-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OWSLLRKCHLTUND-BZSNNMDCSA-N 0.000 description 1
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 1
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 1
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- HPXVFFIIGOAQRV-DCAQKATOSA-N Pro-Arg-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O HPXVFFIIGOAQRV-DCAQKATOSA-N 0.000 description 1
- KPDRZQUWJKTMBP-DCAQKATOSA-N Pro-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 KPDRZQUWJKTMBP-DCAQKATOSA-N 0.000 description 1
- XKHCJJPNXFBADI-DCAQKATOSA-N Pro-Asp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O XKHCJJPNXFBADI-DCAQKATOSA-N 0.000 description 1
- QVIZLAUEAMQKGS-GUBZILKMSA-N Pro-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 QVIZLAUEAMQKGS-GUBZILKMSA-N 0.000 description 1
- YFNOUBWUIIJQHF-LPEHRKFASA-N Pro-Asp-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O YFNOUBWUIIJQHF-LPEHRKFASA-N 0.000 description 1
- DEDANIDYQAPTFI-IHRRRGAJSA-N Pro-Asp-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DEDANIDYQAPTFI-IHRRRGAJSA-N 0.000 description 1
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 1
- QGOZJLYCGRYYRW-KKUMJFAQSA-N Pro-Glu-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QGOZJLYCGRYYRW-KKUMJFAQSA-N 0.000 description 1
- DMKWYMWNEKIPFC-IUCAKERBSA-N Pro-Gly-Arg Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O DMKWYMWNEKIPFC-IUCAKERBSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 description 1
- FKYKZHOKDOPHSA-DCAQKATOSA-N Pro-Leu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FKYKZHOKDOPHSA-DCAQKATOSA-N 0.000 description 1
- INDVYIOKMXFQFM-SRVKXCTJSA-N Pro-Lys-Gln Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O INDVYIOKMXFQFM-SRVKXCTJSA-N 0.000 description 1
- ABSSTGUCBCDKMU-UWVGGRQHSA-N Pro-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 ABSSTGUCBCDKMU-UWVGGRQHSA-N 0.000 description 1
- DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- WHNJMTHJGCEKGA-ULQDDVLXSA-N Pro-Phe-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WHNJMTHJGCEKGA-ULQDDVLXSA-N 0.000 description 1
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- WVXQQUWOKUZIEG-VEVYYDQMSA-N Pro-Thr-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O WVXQQUWOKUZIEG-VEVYYDQMSA-N 0.000 description 1
- FYXCBXDAMPEHIQ-FHWLQOOXSA-N Pro-Trp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)O FYXCBXDAMPEHIQ-FHWLQOOXSA-N 0.000 description 1
- BXHRXLMCYSZSIY-STECZYCISA-N Pro-Tyr-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1)C(O)=O BXHRXLMCYSZSIY-STECZYCISA-N 0.000 description 1
- QKWYXRPICJEQAJ-KJEVXHAQSA-N Pro-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2)O QKWYXRPICJEQAJ-KJEVXHAQSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037681 Protein FEV Human genes 0.000 description 1
- 101710198166 Protein FEV Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 1
- RZUOXAKGNHXZTB-GUBZILKMSA-N Ser-Arg-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O RZUOXAKGNHXZTB-GUBZILKMSA-N 0.000 description 1
- RNMRYWZYFHHOEV-CIUDSAMLSA-N Ser-Gln-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RNMRYWZYFHHOEV-CIUDSAMLSA-N 0.000 description 1
- CDVFZMOFNJPUDD-ACZMJKKPSA-N Ser-Gln-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CDVFZMOFNJPUDD-ACZMJKKPSA-N 0.000 description 1
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
- BQWCDDAISCPDQV-XHNCKOQMSA-N Ser-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)C(=O)O BQWCDDAISCPDQV-XHNCKOQMSA-N 0.000 description 1
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 1
- GRSLLFZTTLBOQX-CIUDSAMLSA-N Ser-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N GRSLLFZTTLBOQX-CIUDSAMLSA-N 0.000 description 1
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- FYUIFUJFNCLUIX-XVYDVKMFSA-N Ser-His-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O FYUIFUJFNCLUIX-XVYDVKMFSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- BYCVMHKULKRVPV-GUBZILKMSA-N Ser-Lys-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYCVMHKULKRVPV-GUBZILKMSA-N 0.000 description 1
- GVMUJUPXFQFBBZ-GUBZILKMSA-N Ser-Lys-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GVMUJUPXFQFBBZ-GUBZILKMSA-N 0.000 description 1
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 1
- WOJYIMBIKTWKJO-KKUMJFAQSA-N Ser-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CO)N WOJYIMBIKTWKJO-KKUMJFAQSA-N 0.000 description 1
- FBLNYDYPCLFTSP-IXOXFDKPSA-N Ser-Phe-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FBLNYDYPCLFTSP-IXOXFDKPSA-N 0.000 description 1
- PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 description 1
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 1
- NMZXJDSKEGFDLJ-DCAQKATOSA-N Ser-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)O NMZXJDSKEGFDLJ-DCAQKATOSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 1
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- HAUVENOGHPECML-BPUTZDHNSA-N Ser-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 HAUVENOGHPECML-BPUTZDHNSA-N 0.000 description 1
- PQEQXWRVHQAAKS-SRVKXCTJSA-N Ser-Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=C(O)C=C1 PQEQXWRVHQAAKS-SRVKXCTJSA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- DDPVJPIGACCMEH-XQXXSGGOSA-N Thr-Ala-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DDPVJPIGACCMEH-XQXXSGGOSA-N 0.000 description 1
- JMZKMSTYXHFYAK-VEVYYDQMSA-N Thr-Arg-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O JMZKMSTYXHFYAK-VEVYYDQMSA-N 0.000 description 1
- DCCGCVLVVSAJFK-NUMRIWBASA-N Thr-Asp-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O DCCGCVLVVSAJFK-NUMRIWBASA-N 0.000 description 1
- XXNLGZRRSKPSGF-HTUGSXCWSA-N Thr-Gln-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O XXNLGZRRSKPSGF-HTUGSXCWSA-N 0.000 description 1
- DIPIPFHFLPTCLK-LOKLDPHHSA-N Thr-Gln-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O DIPIPFHFLPTCLK-LOKLDPHHSA-N 0.000 description 1
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 1
- DKDHTRVDOUZZTP-IFFSRLJSSA-N Thr-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DKDHTRVDOUZZTP-IFFSRLJSSA-N 0.000 description 1
- YUOCMLNTUZAGNF-KLHWPWHYSA-N Thr-His-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N)O YUOCMLNTUZAGNF-KLHWPWHYSA-N 0.000 description 1
- RRRRCRYTLZVCEN-HJGDQZAQSA-N Thr-Leu-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O RRRRCRYTLZVCEN-HJGDQZAQSA-N 0.000 description 1
- PRNGXSILMXSWQQ-OEAJRASXSA-N Thr-Leu-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PRNGXSILMXSWQQ-OEAJRASXSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 description 1
- XSEPSRUDSPHMPX-KATARQTJSA-N Thr-Lys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O XSEPSRUDSPHMPX-KATARQTJSA-N 0.000 description 1
- KDGBLMDAPJTQIW-RHYQMDGZSA-N Thr-Met-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N)O KDGBLMDAPJTQIW-RHYQMDGZSA-N 0.000 description 1
- WRUWXBBEFUTJOU-XGEHTFHBSA-N Thr-Met-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N)O WRUWXBBEFUTJOU-XGEHTFHBSA-N 0.000 description 1
- NZRUWPIYECBYRK-HTUGSXCWSA-N Thr-Phe-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O NZRUWPIYECBYRK-HTUGSXCWSA-N 0.000 description 1
- HSQXHRIRJSFDOH-URLPEUOOSA-N Thr-Phe-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HSQXHRIRJSFDOH-URLPEUOOSA-N 0.000 description 1
- LKJCABTUFGTPPY-HJGDQZAQSA-N Thr-Pro-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O LKJCABTUFGTPPY-HJGDQZAQSA-N 0.000 description 1
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 1
- GFRIEEKFXOVPIR-RHYQMDGZSA-N Thr-Pro-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O GFRIEEKFXOVPIR-RHYQMDGZSA-N 0.000 description 1
- YGCDFAJJCRVQKU-RCWTZXSCSA-N Thr-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O YGCDFAJJCRVQKU-RCWTZXSCSA-N 0.000 description 1
- IQPWNQRRAJHOKV-KATARQTJSA-N Thr-Ser-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN IQPWNQRRAJHOKV-KATARQTJSA-N 0.000 description 1
- VUXIQSUQQYNLJP-XAVMHZPKSA-N Thr-Ser-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N)O VUXIQSUQQYNLJP-XAVMHZPKSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- AAZOYLQUEQRUMZ-GSSVUCPTSA-N Thr-Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O AAZOYLQUEQRUMZ-GSSVUCPTSA-N 0.000 description 1
- VBMOVTMNHWPZJR-SUSMZKCASA-N Thr-Thr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VBMOVTMNHWPZJR-SUSMZKCASA-N 0.000 description 1
- QJIODPFLAASXJC-JHYOHUSXSA-N Thr-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O QJIODPFLAASXJC-JHYOHUSXSA-N 0.000 description 1
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 1
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100035559 Transcriptional activator GLI3 Human genes 0.000 description 1
- ICNFHVUVCNWUAB-SZMVWBNQSA-N Trp-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N ICNFHVUVCNWUAB-SZMVWBNQSA-N 0.000 description 1
- NLYCSLWTDMPLSX-QEJZJMRPSA-N Trp-Gln-Cys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N NLYCSLWTDMPLSX-QEJZJMRPSA-N 0.000 description 1
- ILDJYIDXESUBOE-HSCHXYMDSA-N Trp-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N ILDJYIDXESUBOE-HSCHXYMDSA-N 0.000 description 1
- ULHASJWZGUEUNN-XIRDDKMYSA-N Trp-Lys-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O ULHASJWZGUEUNN-XIRDDKMYSA-N 0.000 description 1
- IVBJBFSWJDNQFW-XIRDDKMYSA-N Trp-Pro-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IVBJBFSWJDNQFW-XIRDDKMYSA-N 0.000 description 1
- UGFOSENEZHEQKX-PJODQICGSA-N Trp-Val-Ala Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(O)=O UGFOSENEZHEQKX-PJODQICGSA-N 0.000 description 1
- UOXPLPBMEPLZBW-WDSOQIARSA-N Trp-Val-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 UOXPLPBMEPLZBW-WDSOQIARSA-N 0.000 description 1
- PALLCTDPFINNMM-JQHSSLGASA-N Trp-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N PALLCTDPFINNMM-JQHSSLGASA-N 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- NSOMQRHZMJMZIE-GVARAGBVSA-N Tyr-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NSOMQRHZMJMZIE-GVARAGBVSA-N 0.000 description 1
- NOXKHHXSHQFSGJ-FQPOAREZSA-N Tyr-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NOXKHHXSHQFSGJ-FQPOAREZSA-N 0.000 description 1
- KEHKBBUYZWAMHL-DZKIICNBSA-N Tyr-Gln-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O KEHKBBUYZWAMHL-DZKIICNBSA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 1
- PHKQVWWHRYUCJL-HJOGWXRNSA-N Tyr-Phe-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PHKQVWWHRYUCJL-HJOGWXRNSA-N 0.000 description 1
- NZBSVMQZQMEUHI-WZLNRYEVSA-N Tyr-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NZBSVMQZQMEUHI-WZLNRYEVSA-N 0.000 description 1
- JHDZONWZTCKTJR-KJEVXHAQSA-N Tyr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JHDZONWZTCKTJR-KJEVXHAQSA-N 0.000 description 1
- DJSYPCWZPNHQQE-FHWLQOOXSA-N Tyr-Tyr-Gln Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CC=C(O)C=C1 DJSYPCWZPNHQQE-FHWLQOOXSA-N 0.000 description 1
- HZDQUVQEVVYDDA-ACRUOGEOSA-N Tyr-Tyr-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HZDQUVQEVVYDDA-ACRUOGEOSA-N 0.000 description 1
- 108010064997 VPY tripeptide Proteins 0.000 description 1
- KKHRWGYHBZORMQ-NHCYSSNCSA-N Val-Arg-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKHRWGYHBZORMQ-NHCYSSNCSA-N 0.000 description 1
- CWOSXNKDOACNJN-BZSNNMDCSA-N Val-Arg-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N CWOSXNKDOACNJN-BZSNNMDCSA-N 0.000 description 1
- HLBHFAWNMAQGNO-AVGNSLFASA-N Val-His-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)O)N HLBHFAWNMAQGNO-AVGNSLFASA-N 0.000 description 1
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 1
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 1
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 1
- KTEZUXISLQTDDQ-NHCYSSNCSA-N Val-Lys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KTEZUXISLQTDDQ-NHCYSSNCSA-N 0.000 description 1
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 1
- ZXYPHBKIZLAQTL-QXEWZRGKSA-N Val-Pro-Asp Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N ZXYPHBKIZLAQTL-QXEWZRGKSA-N 0.000 description 1
- VSCIANXXVZOYOC-AVGNSLFASA-N Val-Pro-His Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N VSCIANXXVZOYOC-AVGNSLFASA-N 0.000 description 1
- USLVEJAHTBLSIL-CYDGBPFRSA-N Val-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C USLVEJAHTBLSIL-CYDGBPFRSA-N 0.000 description 1
- MIKHIIQMRFYVOR-RCWTZXSCSA-N Val-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)N)O MIKHIIQMRFYVOR-RCWTZXSCSA-N 0.000 description 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 1
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- JSOXWWFKRJKTMT-WOPDTQHZSA-N Val-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N JSOXWWFKRJKTMT-WOPDTQHZSA-N 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 235000002098 Vicia faba var. major Nutrition 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- DLYSYXOOYVHCJN-UDWGBEOPSA-N [(2r,3s,5r)-2-[[[(4-methoxyphenyl)-diphenylmethyl]amino]methyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphonamidous acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)NC[C@@H]1[C@@H](OP(N)O)C[C@H](N2C(NC(=O)C(C)=C2)=O)O1 DLYSYXOOYVHCJN-UDWGBEOPSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 1
- 108010094001 arginyl-tryptophyl-arginine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 101150036612 gnl gene Proteins 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 108010073093 leucyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010068488 methionylphenylalanine Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000009120 phenotypic response Effects 0.000 description 1
- 108010084572 phenylalanyl-valine Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 229940076376 protein agonist Drugs 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 108091008499 protein kinase binding proteins Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 108010005652 splenotritin Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000003161 three-hybrid assay Methods 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides novel AS3 nucleic acid sequences, AS3 polypeptides, anti-AS3 antibodies, and methods for modulating cell profileration and detecting compounds that modulate cell proliferation. Diagnostic and therapeutic methods utilizing compositions of the invention are also provide d.
Description
ANDROGEN-INDUCED SUPPRESSOR OF CELL PROLIFERATION
AND USES THEREOF
Government Sponsored Research This work was supported in part by PHS NIH grant CA-55574.
Background of the Invention Among men, carcinoma of the prostate is the second most common cancer and the second most common cause of death from cancer in the United States. Each year over 130,000 men are diagnosed with prostate cancer and over 30,000 will die from the disease (( 1992) MMWR 41:459). Typically, 61 % of all deaths from prostate cancer occur within five years of diagnosis and 88% within ten years (Smart (1997) Cancer 80:1835-1844).
Moreover, despite the availability of risk assessment tools, the optimal therapy for treating prostate cancer remains controversial (Small ( 1998) Drugs Aging 13:71-81 ).
For example, although certain markers of prostate cancer progression such as prostate-specific antigen (PSA) have proven valuable in the diagnosis and management of prostate cancer, as currently used, PSA is insufficiently sensitive and specific for early detection or staging of the malignancy (Daher et al. (1998) Clin. Chem. Lab. Med. 36:671-681).
In addition, in some patients with metastatic disease of the prostate, hormone therapy (e.g., antiandrogen, estrogen, etc.) is frequently used. However, many patients on hormone therapy develop hormone resistance and the management of hormone refractory disease is a major clinical problem (Ismail et al. (1997) Tech. Urol. 3:16-24). The death of patients from prostate cancer is related to the development of clones of cells capable of multiplying and metastasizing without androgen stimulation. To date, efforts to suppress these cells have been of limited success (Mewling (1996) Eur. Urol. Suppl. 2:69-74). This is in part due to the fact that the initial events in the development of prostate cancer are not well understood.
Normally, cell numbers in the prostate gland are regulated by androgens through separate pathways that include a) inhibition of cell death (apoptosis), b) induction of cell proliferation (Step-1), and c) inhibition of cell proliferation (Step-2, proliferation shutoff).
In normal tissue, the apoptotic and proliferative activities are minimal and apparently, Step-w0 00/50454 PCT/US00/04732 -2 (inhibition of cell proliferation) maintains the integrity of the tissue.
Prostate cancer cells evolve when this circuitry fails in the initial or early phases in prostate cancer.
Summary of the Invention A hope for managing prostate cancer lies in the earlier detection of the disease using improved diagnostic indicators, and developing markers that will allow for the more efficient and strategic use of hormone therapy, preferably in concert with improvements in the quality of life for patients with prostate cancer.
To this end, a novel androgen-induced tumor suppressor gene termed "Androgen Shutoff Gene 3" (AS3) has 'been discovered. This gene has a role in inhibiting cell proliferation and use as a marker for the efficient diagnosis and treatment of prostate cancer.
The present invention is based, at least in part, on the discovery of a novel androgen-induced tumor suppressor, referred to herein as "Androgen Shutoff Gene 3" or "AS3"
nucleic acid and protein molecules. The AS3 molecules of the present invention are useful as targets for developing modulating agents of cell proliferation, particularly cells of the prostate. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding AS3 proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of AS3-encoding nucleic acids.
In one embodiment, an AS3 nucleic acid molecule of the invention is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or more identical to the nucleotide sequence (e.g., to the entire length of the nucleotide sequence) shown in SEQ
ID NO:1 or 3.
In a preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown SEQ ID NO:1 or 3, or a complement thereof. In another embodiment, the nucleic acid molecule includes SEQ ID N0:3 and nucleotides 66-4238 of SEQ ID NO: l .
In another embodiment, an AS3 nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID N0:2. In a preferred embodiment, an AS3 nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire length of the amino acid sequence ofSEQ ID N0:2. In a related embodiment, the nucleic acid encodes a polypeptide fragment having at least 1391 amino acid residues of the amino acid sequence shown in SEQ ID NO: 2.
In another preferred embodiment, an isolated nucleic acid molecule encodes the amino acid sequence of human AS3. In yet another preferred embodiment, the nucleic acid molecule includes a nucleotide sequence encoding a protein having the 1391 amino acid sequence of SEQ ID N0:2.
Another embodiment of the invention features nucleic acid molecules, preferably AS3 nucleic acid molecules, which specifically detect AS3 nucleic acid molecules relative to nucleic acid molecules encoding non-AS3 proteins. For example, in one embodiment, such a nucleic acid molecule is at least 100-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, or 550-600 or more nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID
NO:1, or a complement thereof. In a related embodiment, the nucleic acid molecule can further contain a nucleotide sequence encoding a heterologous polypeptide.
In a related embodiment, the nucleic acid molecules are at least 15 (e.g., contiguous) nucleotides in length and hybridize under stringent conditions to nucleotides 1-5253 of SEQ
ID NO:1.
In other preferred embodiments, the nucleic acid molecule encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID
N0:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or 3 under stringent conditions.
Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to an AS3 nucleic acid molecule, e.g., the coding strand of an AS3 nucleic acid molecule.
Another aspect of the invention provides a vector comprising an AS3 nucleic acid molecule. In certain embodiments, the vector is a recombinant expression vector. In another embodiment, the invention provides a host cell containing a vector of the invention.
In yet another embodiment, the invention provides a host cell containing a nucleic acid molecule of the invention. The invention also provides a method for producing a protein, preferably an AS3 protein, by culturing in a suitable medium, a host cell, e.g., a mammalian host cell such as a non-human mammalian cell, of the invention containing a recombinant expression vector, such that the protein is produced.
Another aspect of this invention features isolated or recombinant AS3 proteins and polypeptides. In one embodiment, the isolated protein, preferably an AS3 protein has an amino acid sequence at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID N0:2.
In another embodiment, the invention features fragments of the AS3 protein having the amino acid sequence of SEQ ID N0:2, wherein the fragment comprises at least 15 amino acids (e.g., contiguous amino acids) of the amino acid sequence of SEQ
ID N0:2. In another embodiment, the protein, preferably an AS3 protein, has the amino acid sequence of SEQ ID N0:2, respectively.
In another embodiment, the invention features an isolated protein, preferably an AS3 protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to a nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof. This invention further features an isolated protein, preferably an AS3 protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof.
The proteins of the present invention or portions thereof, e.g., biologically active portions thereof, can be operatively linked to a non-AS3 polypeptide (e.g., heterologous amino acid sequences) to form fusion proteins. The invention further features antibodies, such as monoclonal or polyclonal antibodies, that specifically bind proteins of the invention, preferably AS3 proteins.
In another aspect, the present invention provides a method for detecting the presence of an AS3 polypeptide in a biological sample by contacting the biological sample with a compound capable of detecting an AS3 polypeptide. In one embodiment of this invention, the compound is an antibody. In another embodiment of this invention, a kit is featured that contains a compound that selectively binds to the polypeptide and instructions for use.
In another aspect, the present invention features a method for detecting the presence of an AS3 nucleic acid in a biological sample by contacting the biological sample with a nucleic acid probe or primer that selectively hybridizes to an AS3 molecule of the invention and indicating the presence of such a molecule. In other embodiments of this invention, the nucleic acid in the biological sample is RNA. In another embodiment of the invention, a kit is provided comprising at least one reagent that binds a nucleic acid and instructions for use.
In another aspect, the invention provides for a method for identifying a compound that binds to an AS3 polypeptide or fragment by detecting direct binding of the compound, binding using a competition assay, or binding using an AS3 activity.
In yet another aspect, the invention provides a method for identifying a compound that modulates the activity of an AS3 polypeptide or fragment by contacting such a polypeptide or cell expressing such a polypeptide and determining the effect of the test compound on the activity of the polypeptide.
In another aspect, the invention provides a method for modulating AS3 activity comprising contacting a cell capable of expressing AS3 with a compound that modulates AS3 activity such that AS3 activity in the cell is modulated. In one embodiment, the agent inhibits AS3 activity. In another embodiment, the agent stimulates AS3 activity. In one embodiment, the compound modulates expression of AS3 by modulating transcription of an AS3 gene or translation of an AS3 mRNA.
In another aspect, the invention features a transgenic animal generated from a cell genetically engineered to lack nucleic acid encoding an AS3 polypeptide, where the transgenic animal lacks expression of the AS3 polypeptide.
In a related aspect, the invention features a transgenic animal generated from a cell that contains a substantially pure nucleic acid encoding a AS3 polypeptide, where the nucleic acid is expressed in the transgenic animal.
In another aspect, the invention features a method of identifying a compound that modulates cell proliferation. The method includes: (a) providing a cell that has an AS3 gene; (b) contacting the cell with a candidate compound; and (c) monitoring expression of the AS3 gene, where an alteration in the level of expression of the AS3 gene indicates the presence of a compound which modulates cell proliferation. In one preferred embodiment of this aspect, the alteration that is an increase indicates the compound is inhibiting cell proliferation, and the alteration that is a decrease indicates the compound is increasing cell proliferation In a related aspect, the invention features another method of identifying a compound that is able to modulate cell proliferation that includes: (a) providing a cell including a reporter gene operably linked to a promoter from an AS3 gene; (b) contacting the cell with a candidate compound; and (c) measuring expression of the reporter gene, where a change in the expression in response to the candidate compound identifies a compound that is able to modulate cell proliferation. In one preferred embodiment of this aspect, the alteration that is an increase indicates the compound is inhibiting cell proliferation.
In another aspect, the invention features a method of inhibiting the proliferation of a cell by administering an amount of AS3 polypeptide or fragment thereof sufficient to inhibit cell proliferation.
In related aspects, the invention includes methods of decreasing cell proliferation by either providing a transgene encoding a AS3 polypeptide or fragment thereof to a cell of an animal such that the transgene is positioned for expression in the cell; or by administering to the cell a compound which increases AS3 biological activity in a cell. In preferred embodiments, AS3 is from a mammal, the cell being treated is in a mammal, and the mammal has been diagnosed with a condition involving cell proliferation such as cancer (e.g., prostate cancer).
In two other aspects, the invention features methods of diagnosing a mammal for the presence of disease involving altered cell proliferation or an increased likelihood of developing a disease involving altered cell proliferation. The methods include isolating a sample of nucleic acid from the mammal and determining whether the nucleic acid includes a AS3 mutation, where the presence of a mutation is an indication that the animal has a cell proliferation disease or an increased likelihood of developing a disease involving cell proliferation; or measuring AS3 gene expression in a sample from an animal to be diagnosed, where an alteration in the expression or activity relative to a sample from an unaffected mammal is an indication that the mammal has a disease involving cell proliferation or increased likelihood of developing such a disease. In preferred embodiments, AS3 gene expression is measured by assaying the amount of AS3 polypeptide or AS3 biological activity in the sample (e.g., the AS3 polypeptide is measured by immunological methods), or AS3 gene expression is measured by assaying the amount of AS3 RNA in the sample. In other preferred embodiments, the mammal is a human and the method may be performed after or during hormone therapy (e.g., androgen therapy).
In another aspect, the invention features a kit for diagnosing a mammal for the presence of a disease involving altered cell proliferation or an increased likelihood of developing a disease involving altered cell proliferation that includes a substantially pure antibody that specifically binds a AS3 polypeptide. Another such kit includes material for measuring AS3 RNA (e.g., a probe). In a preferred embodiment, the material is a nucleic acid probe.
In a yet another aspect, the invention features a method of obtaining a AS3 polypeptide, including: (a) providing a cell with DNA encoding a AS3 polypeptide, the DNA being positioned for expression in the cell; (b) culturing the cell under conditions for expressing the DNA; and (c) isolating the AS3 polypeptide.
In a related aspect, the invention features a method of isolating an AS3 gene or portion thereof having sequence identity to human AS3. The method includes amplifying by polymerase chain reaction the AS3 gene or portion thereof using oligonucleotide primers wherein the primers (a) are each greater than 15 nucleotides in length; (b) each have regions of complementarity to opposite DNA strands in a region of the nucleotide sequence provided in SEQ ID NO: l; and (c) optionally contain sequences capable of producing restriction endonuclease cut sites in the amplified product; and isolating the AS3 gene or portion thereof.
In another aspect of the invention, the invention features a method for detecting if a subject is at increased risk for developing prostate cancer including the steps of (a) detecting the presence of an AS3 nucleic acid or polypeptide and (b) observing whether or not a subject has reduced or absent AS3 levels as compared to a standard, e.g., normal age matched control, wherein said reduced or absent AS3 levels indicate that the subject is at an increased risk for developing prostate cancer. In a related embodiment, the invention features a kit that contains at least one reagent for detecting the presence of an AS3 molecule.
In another aspect, the invention provides a method of prognosis for prostate cancer by obtaining a biological sample from the subject, measuring AS3 levels, correlating those levels with a control, and determining a prognosis based on whether the subject's AS3 levels _g_ are above average or below average. In related embodiments, the method may be performed during or after hormone therapy (e.g., androgen therapy) and employs an antibody or nucleic acid probe to an AS3 molecule. .
In even another aspect, the invention features a method for the treatment of prostate cancer comprising identifying a subject with prostate cancer or about to have prostate cancer, administering a hormone therapy, and determining if the subject exhibits a change in AS3 levels. In preferred embodiments, the invention provides a method for identifying subjects that exhibit increased AS3 levels after receiving hormone as responsive to hormone therapy and further, as candidates for intermittent hormone therapy. In other preferred embodiments, the hormone therapy is an androgen therapy, the subject is a human, and the method for measuring includes measuring AS3 nucleic acid or polypeptide levels is performed with an antibody or nucleic acid probe or primer.
Other features and advantages of the invention will be apparent from the following detailed description and claims.
Brief Description of the Drawings Figure 1 depicts the cDNA sequence and predicted amino acid sequence of human AS3. The nucleotide sequence corresponds to 1 to 5253 of SEQ ID NO: 1. The amino acid sequence corresponds to amino acids 1 to 1391 of SEQ ID NO: 2. The coding region without the 5' and 3' untranslated regions of the human AS3 gene is shown in SEQ ID NO:
3. Numbers on the left indicate positions in base pairs. The amino acid sequence of the open reading frame is depicted under the coding strand. Numbers on the right indicate amino acid positions. Destabilizing signals found in the untranslated regions of AS3 are underlined and the polyadenylation signal and cleavage site are at base pair positions 5228-5233 and 5249-5253, respectively.
Figure 2 depicts the N-terminal leucine repeat structure of the AS3 polypeptide.
Numbers above the AS3 sequence indicate the positions of the blocks where uninterrupted leucine (or isoleucine, valine) heptades occur.
Figure 3 depicts sequence comparisons of the putative Mg-nucleotide triphosphate binding subdomains of AS3 with corresponding subdomains of various protein kinases. The boxes represent the Hanks' conserved subdomains, as indicated above each box.
The top lines within the boxes show the consensus (3-strand, loop, and a,-helical secondary structure elements. The numbers in the second lines indicate the positions of the corresponding conformations in the AS3 sequence. The actual AS3 motifs are shown in the third line.
Hanks' conserved subdomains from protein kinases of close similarity are represented in the lines below the AS3 sequence. The names of the kinases are indicated in parentheses.
Identical residues are highlighted. In the Mg-ATP binding loop, the "x" and lower case letters indicate non-conserved amino acids.
Figure 4 depicts the genomic, cosmid, and exon maps of the AS3 cDNA. The chromosomal panel represents a 1 megabase (Mb) genomic region around BRCA2.
Boxes with CG numbers are genomic areas where expression of transcripts were detected. The centromer is at the left. The P 1 artificial chromosome (PAC) PAC26H23 (Accession No.:
284467) overlaps with cosmid 267p19 (Accession No .: 275889), which, in turn, overlaps with PAC49J10 (Accession No.: 284572). Numbers below the PAC and cosmid lines indicate positions within the genomic clone. The scale above the exon map indicates the genomic distance in thousands of base pairs. In the exon panel, black boxes represent the exons, while the numbers above them indicate exon numbers. In the mRNA panel, the numbers indicate nucleotide positions.
Figure S depicts the genomic and cDNA positions of exons in the AS3 transcript.
Asterisks represent the exon-intron boundaries. The area between asterisks represents the exons. Exon sequences are in upper case, the numbers represent cDNA positions.
Lower case letters are intron sequences. Numbers of the first exon indicate positions in PAC26H23. Numbers in parenthesis refer to positions on cosmid 267p19, while numbers in brackets refer to PAC49J10 positions.
Figure 6. depicts the cDNA sequence and predicted amino acid sequence of human AS3 having an additional 84 base pairs of untranslated 5' sequence as compared to the sequence presented in Fig. 1. The nucleotide sequence corresponds to 1 to 5337 of SEQ ID
NO: 4. The amino acid sequence shown corresponds to amino acids 1 to 1391 of SEQ ID
NO: 2. The coding region without the 5' and 3' untranslated regions of the human AS3 gene is shown in SEQ ID NO: 3. Numbers on the left indicate positions in base pairs. The amino acid sequence of the open reading frame is depicted under the coding strand.
Numbers on the right indicate amino acid positions. Destabilizing signals found in the untranslated regions of AS3 are underlined and the polyadenylation signal and cleavage signal are at base pair positions 5312-5317 and 5333-5337, respectively.
Detailed Description of the Invention The present invention is based, at least in part, on the discovery of a novel molecule referred to herein as "Androgen Shutoff Gene 3" or "AS3" nucleic acid and protein molecules, which play a role in hormone-induced inhibition of cell proliferation. In one embodiment, the AS3 molecules are capable of modulating cell proliferation, e.g., cancer.
In a preferred embodiment, the AS3 molecules are expressed in cells of the prostate and/or function in the cells of the prostate. In another preferred embodiment, the AS3 molecules are expressed in prostate cells when exposed to a hormone, e.g., an androgen, and inhibit cell proliferation.
The AS3 gene was cloned from a subtracted library made from a human prostate carcinoma cell line induced to undergo growth arrest using androgen.
Androgens regulate prostate cell numbers and cell proliferation by three major mechanisms: a) inhibition of cell death (apoptosis), b) induction of cell proliferation (Step-1), and c) inhibition of cell proliferation (proliferative shutoff, Step-2) (Isaacs (1985) Prostate 5:545-557; Bruchovsky et al. (1975) Vit. & Horm. 33:61-102;
Sonnenschein et al., (1989) Cancer Res. 49:3474-3481). Androgens affect epithelial and stromal cell types which, in turn, interact in the prostate (Hayward et al., (1997) Brit. J.
Urol. Suppl. 2: 18-26).
The human prostate LNCaP-FGC cell line that exhibits hormone responsiveness and is used extensively for endocrine and molecular studies (Sonnenschein et al., (1989) Cancer Res.
49:3474-3481; Horoszewicz et al., (1983) Cancer Res. 43:1809-1818; Soto et al., (1995) Oncology Res. 7: 545-558) was employed herein. Proliferation is inhibited in these cells by sex steroid-stripped (charcoal-dextran treated) human serum (CDHuS) (Sonnenschein et al., (1989) Cancer Res. 49:3474-3481). Low androgen concentrations cancel this inhibition (Step-1) and at higher levels, androgens induce an irreversible proliferative shutoff (Step-2) (Sonnenschein et al., (1989) Cancer Res. 49:3474-3481; Soto et al., (1995) Oncology Res.
AND USES THEREOF
Government Sponsored Research This work was supported in part by PHS NIH grant CA-55574.
Background of the Invention Among men, carcinoma of the prostate is the second most common cancer and the second most common cause of death from cancer in the United States. Each year over 130,000 men are diagnosed with prostate cancer and over 30,000 will die from the disease (( 1992) MMWR 41:459). Typically, 61 % of all deaths from prostate cancer occur within five years of diagnosis and 88% within ten years (Smart (1997) Cancer 80:1835-1844).
Moreover, despite the availability of risk assessment tools, the optimal therapy for treating prostate cancer remains controversial (Small ( 1998) Drugs Aging 13:71-81 ).
For example, although certain markers of prostate cancer progression such as prostate-specific antigen (PSA) have proven valuable in the diagnosis and management of prostate cancer, as currently used, PSA is insufficiently sensitive and specific for early detection or staging of the malignancy (Daher et al. (1998) Clin. Chem. Lab. Med. 36:671-681).
In addition, in some patients with metastatic disease of the prostate, hormone therapy (e.g., antiandrogen, estrogen, etc.) is frequently used. However, many patients on hormone therapy develop hormone resistance and the management of hormone refractory disease is a major clinical problem (Ismail et al. (1997) Tech. Urol. 3:16-24). The death of patients from prostate cancer is related to the development of clones of cells capable of multiplying and metastasizing without androgen stimulation. To date, efforts to suppress these cells have been of limited success (Mewling (1996) Eur. Urol. Suppl. 2:69-74). This is in part due to the fact that the initial events in the development of prostate cancer are not well understood.
Normally, cell numbers in the prostate gland are regulated by androgens through separate pathways that include a) inhibition of cell death (apoptosis), b) induction of cell proliferation (Step-1), and c) inhibition of cell proliferation (Step-2, proliferation shutoff).
In normal tissue, the apoptotic and proliferative activities are minimal and apparently, Step-w0 00/50454 PCT/US00/04732 -2 (inhibition of cell proliferation) maintains the integrity of the tissue.
Prostate cancer cells evolve when this circuitry fails in the initial or early phases in prostate cancer.
Summary of the Invention A hope for managing prostate cancer lies in the earlier detection of the disease using improved diagnostic indicators, and developing markers that will allow for the more efficient and strategic use of hormone therapy, preferably in concert with improvements in the quality of life for patients with prostate cancer.
To this end, a novel androgen-induced tumor suppressor gene termed "Androgen Shutoff Gene 3" (AS3) has 'been discovered. This gene has a role in inhibiting cell proliferation and use as a marker for the efficient diagnosis and treatment of prostate cancer.
The present invention is based, at least in part, on the discovery of a novel androgen-induced tumor suppressor, referred to herein as "Androgen Shutoff Gene 3" or "AS3"
nucleic acid and protein molecules. The AS3 molecules of the present invention are useful as targets for developing modulating agents of cell proliferation, particularly cells of the prostate. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding AS3 proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of AS3-encoding nucleic acids.
In one embodiment, an AS3 nucleic acid molecule of the invention is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or more identical to the nucleotide sequence (e.g., to the entire length of the nucleotide sequence) shown in SEQ
ID NO:1 or 3.
In a preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown SEQ ID NO:1 or 3, or a complement thereof. In another embodiment, the nucleic acid molecule includes SEQ ID N0:3 and nucleotides 66-4238 of SEQ ID NO: l .
In another embodiment, an AS3 nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID N0:2. In a preferred embodiment, an AS3 nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire length of the amino acid sequence ofSEQ ID N0:2. In a related embodiment, the nucleic acid encodes a polypeptide fragment having at least 1391 amino acid residues of the amino acid sequence shown in SEQ ID NO: 2.
In another preferred embodiment, an isolated nucleic acid molecule encodes the amino acid sequence of human AS3. In yet another preferred embodiment, the nucleic acid molecule includes a nucleotide sequence encoding a protein having the 1391 amino acid sequence of SEQ ID N0:2.
Another embodiment of the invention features nucleic acid molecules, preferably AS3 nucleic acid molecules, which specifically detect AS3 nucleic acid molecules relative to nucleic acid molecules encoding non-AS3 proteins. For example, in one embodiment, such a nucleic acid molecule is at least 100-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, or 550-600 or more nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID
NO:1, or a complement thereof. In a related embodiment, the nucleic acid molecule can further contain a nucleotide sequence encoding a heterologous polypeptide.
In a related embodiment, the nucleic acid molecules are at least 15 (e.g., contiguous) nucleotides in length and hybridize under stringent conditions to nucleotides 1-5253 of SEQ
ID NO:1.
In other preferred embodiments, the nucleic acid molecule encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID
N0:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or 3 under stringent conditions.
Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to an AS3 nucleic acid molecule, e.g., the coding strand of an AS3 nucleic acid molecule.
Another aspect of the invention provides a vector comprising an AS3 nucleic acid molecule. In certain embodiments, the vector is a recombinant expression vector. In another embodiment, the invention provides a host cell containing a vector of the invention.
In yet another embodiment, the invention provides a host cell containing a nucleic acid molecule of the invention. The invention also provides a method for producing a protein, preferably an AS3 protein, by culturing in a suitable medium, a host cell, e.g., a mammalian host cell such as a non-human mammalian cell, of the invention containing a recombinant expression vector, such that the protein is produced.
Another aspect of this invention features isolated or recombinant AS3 proteins and polypeptides. In one embodiment, the isolated protein, preferably an AS3 protein has an amino acid sequence at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID N0:2.
In another embodiment, the invention features fragments of the AS3 protein having the amino acid sequence of SEQ ID N0:2, wherein the fragment comprises at least 15 amino acids (e.g., contiguous amino acids) of the amino acid sequence of SEQ
ID N0:2. In another embodiment, the protein, preferably an AS3 protein, has the amino acid sequence of SEQ ID N0:2, respectively.
In another embodiment, the invention features an isolated protein, preferably an AS3 protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to a nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof. This invention further features an isolated protein, preferably an AS3 protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof.
The proteins of the present invention or portions thereof, e.g., biologically active portions thereof, can be operatively linked to a non-AS3 polypeptide (e.g., heterologous amino acid sequences) to form fusion proteins. The invention further features antibodies, such as monoclonal or polyclonal antibodies, that specifically bind proteins of the invention, preferably AS3 proteins.
In another aspect, the present invention provides a method for detecting the presence of an AS3 polypeptide in a biological sample by contacting the biological sample with a compound capable of detecting an AS3 polypeptide. In one embodiment of this invention, the compound is an antibody. In another embodiment of this invention, a kit is featured that contains a compound that selectively binds to the polypeptide and instructions for use.
In another aspect, the present invention features a method for detecting the presence of an AS3 nucleic acid in a biological sample by contacting the biological sample with a nucleic acid probe or primer that selectively hybridizes to an AS3 molecule of the invention and indicating the presence of such a molecule. In other embodiments of this invention, the nucleic acid in the biological sample is RNA. In another embodiment of the invention, a kit is provided comprising at least one reagent that binds a nucleic acid and instructions for use.
In another aspect, the invention provides for a method for identifying a compound that binds to an AS3 polypeptide or fragment by detecting direct binding of the compound, binding using a competition assay, or binding using an AS3 activity.
In yet another aspect, the invention provides a method for identifying a compound that modulates the activity of an AS3 polypeptide or fragment by contacting such a polypeptide or cell expressing such a polypeptide and determining the effect of the test compound on the activity of the polypeptide.
In another aspect, the invention provides a method for modulating AS3 activity comprising contacting a cell capable of expressing AS3 with a compound that modulates AS3 activity such that AS3 activity in the cell is modulated. In one embodiment, the agent inhibits AS3 activity. In another embodiment, the agent stimulates AS3 activity. In one embodiment, the compound modulates expression of AS3 by modulating transcription of an AS3 gene or translation of an AS3 mRNA.
In another aspect, the invention features a transgenic animal generated from a cell genetically engineered to lack nucleic acid encoding an AS3 polypeptide, where the transgenic animal lacks expression of the AS3 polypeptide.
In a related aspect, the invention features a transgenic animal generated from a cell that contains a substantially pure nucleic acid encoding a AS3 polypeptide, where the nucleic acid is expressed in the transgenic animal.
In another aspect, the invention features a method of identifying a compound that modulates cell proliferation. The method includes: (a) providing a cell that has an AS3 gene; (b) contacting the cell with a candidate compound; and (c) monitoring expression of the AS3 gene, where an alteration in the level of expression of the AS3 gene indicates the presence of a compound which modulates cell proliferation. In one preferred embodiment of this aspect, the alteration that is an increase indicates the compound is inhibiting cell proliferation, and the alteration that is a decrease indicates the compound is increasing cell proliferation In a related aspect, the invention features another method of identifying a compound that is able to modulate cell proliferation that includes: (a) providing a cell including a reporter gene operably linked to a promoter from an AS3 gene; (b) contacting the cell with a candidate compound; and (c) measuring expression of the reporter gene, where a change in the expression in response to the candidate compound identifies a compound that is able to modulate cell proliferation. In one preferred embodiment of this aspect, the alteration that is an increase indicates the compound is inhibiting cell proliferation.
In another aspect, the invention features a method of inhibiting the proliferation of a cell by administering an amount of AS3 polypeptide or fragment thereof sufficient to inhibit cell proliferation.
In related aspects, the invention includes methods of decreasing cell proliferation by either providing a transgene encoding a AS3 polypeptide or fragment thereof to a cell of an animal such that the transgene is positioned for expression in the cell; or by administering to the cell a compound which increases AS3 biological activity in a cell. In preferred embodiments, AS3 is from a mammal, the cell being treated is in a mammal, and the mammal has been diagnosed with a condition involving cell proliferation such as cancer (e.g., prostate cancer).
In two other aspects, the invention features methods of diagnosing a mammal for the presence of disease involving altered cell proliferation or an increased likelihood of developing a disease involving altered cell proliferation. The methods include isolating a sample of nucleic acid from the mammal and determining whether the nucleic acid includes a AS3 mutation, where the presence of a mutation is an indication that the animal has a cell proliferation disease or an increased likelihood of developing a disease involving cell proliferation; or measuring AS3 gene expression in a sample from an animal to be diagnosed, where an alteration in the expression or activity relative to a sample from an unaffected mammal is an indication that the mammal has a disease involving cell proliferation or increased likelihood of developing such a disease. In preferred embodiments, AS3 gene expression is measured by assaying the amount of AS3 polypeptide or AS3 biological activity in the sample (e.g., the AS3 polypeptide is measured by immunological methods), or AS3 gene expression is measured by assaying the amount of AS3 RNA in the sample. In other preferred embodiments, the mammal is a human and the method may be performed after or during hormone therapy (e.g., androgen therapy).
In another aspect, the invention features a kit for diagnosing a mammal for the presence of a disease involving altered cell proliferation or an increased likelihood of developing a disease involving altered cell proliferation that includes a substantially pure antibody that specifically binds a AS3 polypeptide. Another such kit includes material for measuring AS3 RNA (e.g., a probe). In a preferred embodiment, the material is a nucleic acid probe.
In a yet another aspect, the invention features a method of obtaining a AS3 polypeptide, including: (a) providing a cell with DNA encoding a AS3 polypeptide, the DNA being positioned for expression in the cell; (b) culturing the cell under conditions for expressing the DNA; and (c) isolating the AS3 polypeptide.
In a related aspect, the invention features a method of isolating an AS3 gene or portion thereof having sequence identity to human AS3. The method includes amplifying by polymerase chain reaction the AS3 gene or portion thereof using oligonucleotide primers wherein the primers (a) are each greater than 15 nucleotides in length; (b) each have regions of complementarity to opposite DNA strands in a region of the nucleotide sequence provided in SEQ ID NO: l; and (c) optionally contain sequences capable of producing restriction endonuclease cut sites in the amplified product; and isolating the AS3 gene or portion thereof.
In another aspect of the invention, the invention features a method for detecting if a subject is at increased risk for developing prostate cancer including the steps of (a) detecting the presence of an AS3 nucleic acid or polypeptide and (b) observing whether or not a subject has reduced or absent AS3 levels as compared to a standard, e.g., normal age matched control, wherein said reduced or absent AS3 levels indicate that the subject is at an increased risk for developing prostate cancer. In a related embodiment, the invention features a kit that contains at least one reagent for detecting the presence of an AS3 molecule.
In another aspect, the invention provides a method of prognosis for prostate cancer by obtaining a biological sample from the subject, measuring AS3 levels, correlating those levels with a control, and determining a prognosis based on whether the subject's AS3 levels _g_ are above average or below average. In related embodiments, the method may be performed during or after hormone therapy (e.g., androgen therapy) and employs an antibody or nucleic acid probe to an AS3 molecule. .
In even another aspect, the invention features a method for the treatment of prostate cancer comprising identifying a subject with prostate cancer or about to have prostate cancer, administering a hormone therapy, and determining if the subject exhibits a change in AS3 levels. In preferred embodiments, the invention provides a method for identifying subjects that exhibit increased AS3 levels after receiving hormone as responsive to hormone therapy and further, as candidates for intermittent hormone therapy. In other preferred embodiments, the hormone therapy is an androgen therapy, the subject is a human, and the method for measuring includes measuring AS3 nucleic acid or polypeptide levels is performed with an antibody or nucleic acid probe or primer.
Other features and advantages of the invention will be apparent from the following detailed description and claims.
Brief Description of the Drawings Figure 1 depicts the cDNA sequence and predicted amino acid sequence of human AS3. The nucleotide sequence corresponds to 1 to 5253 of SEQ ID NO: 1. The amino acid sequence corresponds to amino acids 1 to 1391 of SEQ ID NO: 2. The coding region without the 5' and 3' untranslated regions of the human AS3 gene is shown in SEQ ID NO:
3. Numbers on the left indicate positions in base pairs. The amino acid sequence of the open reading frame is depicted under the coding strand. Numbers on the right indicate amino acid positions. Destabilizing signals found in the untranslated regions of AS3 are underlined and the polyadenylation signal and cleavage site are at base pair positions 5228-5233 and 5249-5253, respectively.
Figure 2 depicts the N-terminal leucine repeat structure of the AS3 polypeptide.
Numbers above the AS3 sequence indicate the positions of the blocks where uninterrupted leucine (or isoleucine, valine) heptades occur.
Figure 3 depicts sequence comparisons of the putative Mg-nucleotide triphosphate binding subdomains of AS3 with corresponding subdomains of various protein kinases. The boxes represent the Hanks' conserved subdomains, as indicated above each box.
The top lines within the boxes show the consensus (3-strand, loop, and a,-helical secondary structure elements. The numbers in the second lines indicate the positions of the corresponding conformations in the AS3 sequence. The actual AS3 motifs are shown in the third line.
Hanks' conserved subdomains from protein kinases of close similarity are represented in the lines below the AS3 sequence. The names of the kinases are indicated in parentheses.
Identical residues are highlighted. In the Mg-ATP binding loop, the "x" and lower case letters indicate non-conserved amino acids.
Figure 4 depicts the genomic, cosmid, and exon maps of the AS3 cDNA. The chromosomal panel represents a 1 megabase (Mb) genomic region around BRCA2.
Boxes with CG numbers are genomic areas where expression of transcripts were detected. The centromer is at the left. The P 1 artificial chromosome (PAC) PAC26H23 (Accession No.:
284467) overlaps with cosmid 267p19 (Accession No .: 275889), which, in turn, overlaps with PAC49J10 (Accession No.: 284572). Numbers below the PAC and cosmid lines indicate positions within the genomic clone. The scale above the exon map indicates the genomic distance in thousands of base pairs. In the exon panel, black boxes represent the exons, while the numbers above them indicate exon numbers. In the mRNA panel, the numbers indicate nucleotide positions.
Figure S depicts the genomic and cDNA positions of exons in the AS3 transcript.
Asterisks represent the exon-intron boundaries. The area between asterisks represents the exons. Exon sequences are in upper case, the numbers represent cDNA positions.
Lower case letters are intron sequences. Numbers of the first exon indicate positions in PAC26H23. Numbers in parenthesis refer to positions on cosmid 267p19, while numbers in brackets refer to PAC49J10 positions.
Figure 6. depicts the cDNA sequence and predicted amino acid sequence of human AS3 having an additional 84 base pairs of untranslated 5' sequence as compared to the sequence presented in Fig. 1. The nucleotide sequence corresponds to 1 to 5337 of SEQ ID
NO: 4. The amino acid sequence shown corresponds to amino acids 1 to 1391 of SEQ ID
NO: 2. The coding region without the 5' and 3' untranslated regions of the human AS3 gene is shown in SEQ ID NO: 3. Numbers on the left indicate positions in base pairs. The amino acid sequence of the open reading frame is depicted under the coding strand.
Numbers on the right indicate amino acid positions. Destabilizing signals found in the untranslated regions of AS3 are underlined and the polyadenylation signal and cleavage signal are at base pair positions 5312-5317 and 5333-5337, respectively.
Detailed Description of the Invention The present invention is based, at least in part, on the discovery of a novel molecule referred to herein as "Androgen Shutoff Gene 3" or "AS3" nucleic acid and protein molecules, which play a role in hormone-induced inhibition of cell proliferation. In one embodiment, the AS3 molecules are capable of modulating cell proliferation, e.g., cancer.
In a preferred embodiment, the AS3 molecules are expressed in cells of the prostate and/or function in the cells of the prostate. In another preferred embodiment, the AS3 molecules are expressed in prostate cells when exposed to a hormone, e.g., an androgen, and inhibit cell proliferation.
The AS3 gene was cloned from a subtracted library made from a human prostate carcinoma cell line induced to undergo growth arrest using androgen.
Androgens regulate prostate cell numbers and cell proliferation by three major mechanisms: a) inhibition of cell death (apoptosis), b) induction of cell proliferation (Step-1), and c) inhibition of cell proliferation (proliferative shutoff, Step-2) (Isaacs (1985) Prostate 5:545-557; Bruchovsky et al. (1975) Vit. & Horm. 33:61-102;
Sonnenschein et al., (1989) Cancer Res. 49:3474-3481). Androgens affect epithelial and stromal cell types which, in turn, interact in the prostate (Hayward et al., (1997) Brit. J.
Urol. Suppl. 2: 18-26).
The human prostate LNCaP-FGC cell line that exhibits hormone responsiveness and is used extensively for endocrine and molecular studies (Sonnenschein et al., (1989) Cancer Res.
49:3474-3481; Horoszewicz et al., (1983) Cancer Res. 43:1809-1818; Soto et al., (1995) Oncology Res. 7: 545-558) was employed herein. Proliferation is inhibited in these cells by sex steroid-stripped (charcoal-dextran treated) human serum (CDHuS) (Sonnenschein et al., (1989) Cancer Res. 49:3474-3481). Low androgen concentrations cancel this inhibition (Step-1) and at higher levels, androgens induce an irreversible proliferative shutoff (Step-2) (Sonnenschein et al., (1989) Cancer Res. 49:3474-3481; Soto et al., (1995) Oncology Res.
7: 545-558). During the shutoff period, these cells remain in the Go/Gl phase of the cell cycle. Prostate specific antigen (PSA) induction, however, is still dependent on androgens in these postmitotic cells (Soto et al., (1995) Oncology Res. 7: 545-558).
To dissect androgen-mediated cell-cycle events, several androgen target cell lines that express only one of the steps of the androgen regulated proliferative response were generated. Two LNCaP variants were isolated: the LNCaP-TAC variant which expresses Step-1 only, and the LNCaP-TJA variant, which is resistant to the inhibitory effect of both CD serum and androgens (Soto et al., (1995) Oncology Res. 7: 545-558). LNCaP-LNO
cells, established by Horoszewicz et al., proliferate maximally in the presence of CDHuS, express an androgen-induced proliferative shutoff, and undergo Go/GI arrest (Step-2) at high androgen concentrations (Horoszewicz et al., (1983) Cancer Res. 43:1809-1818;
Soto et al., (1995) Oncology Res. 7: 545-558). In addition to these human prostate cells, a new model to demonstrate the shutoff effect in another cell type was developed by stable transfection of a wild type androgen-receptor construct into breast carcinoma MCF-7 cells.
These MCF7-AR1 cells are also able to evoke a proliferative shutoff in response to androgens (Szelei et al., (1997) Endocrinology 138: 1406-1412).
Using a differential subtractive amplification procedure, a set of genes induced in the proliferative shutoff response (Step-2) (Wang et al., (1991) Proc. Natl. Acad.
Sci. USA 88:
11505-11509) was identified. In particular, a gene involved in this regulation, AS3 (androgen shutoff gene 3), that shows high expression in the early regulatory phase of androgen-induced proliferative shutoff in cell culture and in the prostates of castrated rats was identified.
The AS3 gene encodes a polypeptide of 1391-residues and has a molecular weight of about 186 kD. It has coiled-coil structures that usually participate in protein-protein interactions, a perfect leucine-zipper that suggests DNA binding, nuclear localization motifs, proline- and serine-rich domains, unique C-terminal acidic-basic repeats, and ATP- and DNA-binding motifs.
The transcript has 34 exons in a 200,000 by region on chromosome 13q12-q13, downstream of the breast cancer susceptibility gene BRCA2, and centromeric to the retinoblastoma (Rbl) locus. This area is subject to frequent allelic losses in cancers, and is believed to carry a number of cryptic suppressor genes.
The AS3 gene is involved in the regulation of androgen-induced proliferative arrest in human prostate cells. Accordingly, the AS3 molecules described below serve as useful diagnostic markers or therapeutic agents to control conditions of aberrant cell proliferation, such as cancer (e.g., cancer of the prostate).
In one embodiment, the present invention is directed at human AS3, however, family members are also intended to be within the scope of the invention. The term "family" when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin, as well as other, distinct proteins of human origin or alternatively, can contain homologues of non-human origin. Members of a family may also have common functional characteristics.
To identify the presence of important domains in a given polypeptide, and make the determination that a protein of interest has a particular profile, the amino acid sequence of the protein can be searched against several databases as described in Example 3. Using these tools, a number of important domains within the AS3 polypeptide have been identified and these results are set forth in Figures 2 and 3 and further described in Example 3.
Isolated proteins of the present invention, preferably AS3 proteins, have an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID N0:2 or are encoded by a nucleotide sequence sufficiently homologous to SEQ ID NO: l or 3. As used herein, the term "sufficiently homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains or motifs and/or a common functional activity. For example, amino acid or nucleotide sequences which share common structural domains have at least 30%, 40%, or 50% homology, preferably 60% homology, more preferably 70%-80%, and even more preferably 90-95% homology across the amino acid sequences of the domains and contain at least one and preferably two structural domains or motifs, are defined herein as sufficiently homologous. Furthermore, amino acid or nucleotide sequences which share at least 30%, 40%, or 50%, preferably 60%, more preferably 70-80%, or 90-95% homology and share a common functional activity are defined herein as sufficiently homologous.
As used interchangeably herein, an "AS3 activity", "biological activity of AS3" or "functional activity of AS3", refers to an activity exerted by an AS3 protein, polypeptide or nucleic acid molecule on an AS3 responsive cell or on an AS3 protein substrate, as determined in vivo, or in vitro, according to standard techniques. In one embodiment, an AS3 activity is a direct activity, such as an association with an AS3-target molecule. As used herein, a "target molecule" or "binding partner" is a molecule with which an AS3 protein binds or interacts in nature, such that AS3-mediated function is achieved. An AS3 target molecule can be a non-AS3 molecule or an AS3 protein or polypeptide of the present invention. Alternatively, an AS3 activity is an indirect activity, such as modulating cell cycle events. Preferably, an AS3 activity is the ability to modulate androgen-mediated cell proliferation.
Accordingly, another embodiment of the invention features isolated AS3 proteins and polypeptides having an AS3 activity. Preferred proteins are AS3 proteins encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or 3.
The nucleotide sequence of the isolated human AS3 cDNA and the predicted amino acid sequence of the human AS3 polypeptide are shown in Figure 1 and in SEQ ID
NOs: l and 2, respectively. A plasmid containing the nucleotide sequence encoding human AS3 was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on and assigned Accession Number This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. ~112.
The human AS3 gene, which is approximately 5253 nucleotides in length, encodes a protein having a molecular weight of approximately 186 kD and which is approximately 1391 amino acid residues in length.
Various aspects of the invention are described in further detail in the following subsections:
I. Isolated Nucleic Acid Molecules One aspect of the invention pertains to isolated nucleic acid molecules that encode AS3 proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify AS3-encoding nucleic acid molecules (e.g., AS3 mRNA) and fragments for use as PCR primers for the amplification or mutation of AS3 nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
The term "isolated nucleic acid molecule" includes nucleic acid molecules which are separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term "isolated"
includes nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.
For example, in various embodiments, the isolated AS3 nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (see Fig. 4). Moreover, an "isolated" nucleic acid molecule, such as a cDNA
molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 or 3, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein.
Using all or portion of the nucleic acid sequence of SEQ ID NO:1 or 3, as a hybridization probe, AS3 nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning. A Laboratory Manual. 2nd, ed , Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). In a related embodiment, the invention features an AS3 nucleic acid molecule having the sequence of SEQ ID
NO: 4 (see Fig. 6) which is identical to the AS3 sequence provided in SEQ ID NO:1 (see Fig. 1) except for an additional 84 base pairs at the 5' end of the molecule. One skilled in the art would recognize that this additional untranslated 5' sequence may indicate that an alternative start site for the beginning of transcription of the AS3 mRNA molecule may exist.
Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:
l or 3 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO:1 or 3.
A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
Furthermore, oligonucleotides corresponding to AS3 nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1. The sequence of SEQ ID
NO:1 corresponds to the human AS3 cDNA. This cDNA comprises sequences encoding the human AS3 protein (i.e., "the coding region", from nucleotides 66-4238), as well as 5' untranslated sequences (nucleotides 1-65) and 3' untranslated sequences (nucleotides 4239-5253). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ
ID NO:1 (e.g., nucleotides 66-4238, corresponding to SEQ ID N0:3).
In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1 or 3, or a portion of any of these nucleotide sequences. A
nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:
l or 3, is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID
NO:l or 3, such that it can hybridize to the nucleotide sequence shown in SEQ
ID NO:1 or 3, thereby forming a stable duplex.
In still another preferred embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire length of the nucleotide sequence shown in SEQ ID NO:1 or 3, or a portion of any of these nucleotide sequences.
Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO:1 or 3, for example, a fragment which can be used as a probe or primer or a fragment encoding a portion of an AS3 protein, e.g., a biologically active portion of an AS3 protein. The nucleotide sequence determined from the cloning of the AS3 gene allows for the generation of probes and primers designed for use in identifying and/or cloning other AS3 family members, as well as AS3 homologues from other species.
The probe/primer typically comprises substantially purified oligonucleotide.
The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense sequence of SEQ ID NO:1 or 3, of an anti-sense sequence of SEQ ID NO:1 or 3, or of a naturally occurring allelic variant or mutant of SEQ ID NO:1 or 3. In an exemplary embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which is greater than 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-1000, or more nucleotides in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO: 1 or 3.
Probes based on the AS3 nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g.; the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress an AS3 protein, such as by measuring a level of an AS3-encoding nucleic acid in a sample of cells from a subject e.g., detecting AS3 mRNA levels or determining whether a genomic AS3 gene has been mutated or deleted.
A nucleic acid fragment encoding a "biologically active portion of an AS3 protein"
can be prepared by isolating a portion of the nucleotide sequence of SEQ ID
NO: 1 or 3, which encodes a polypeptide having an AS3 biological activity (the biological activities of the AS3 proteins are described herein), expressing the encoded portion of the AS3 protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of the AS3 protein.
The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1 or 3, due to degeneracy of the genetic code and thus encode the same AS3 proteins as those encoded by the nucleotide sequence shown in SEQ ID NO:1 or 3. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID N0:2.
In addition to the AS3 nucleotide sequences shown in SEQ ID NO:1 or 3, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the AS3 proteins may exist within a population (e.g., the human population). Such genetic polymorphism in the AS3 genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules which include an open reading frame encoding an AS3 protein, preferably a mammalian AS3 protein, and can further include non-coding regulatory sequences, and introns.
Allelic variants of human AS3 include both functional and non-functional AS3 proteins. Functional allelic variants are naturally occurring amino acid sequence variants of the human AS3 protein that maintain the ability to modulate cell proliferation, e.g., androgen-induced changes in cell proliferation. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID
N0:2 or substitution, deletion or insertion of non-critical residues in non-critical regions of the protein.
Non-functional allelic variants are naturally occurring amino acid sequence variants of the human AS3 protein that do not have the ability to modulate cell proliferation, for example, hormone-induced changes in cell proliferation. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion or premature truncation of the amino acid sequence of SEQ ID N0:2 or a substitution, insertion or deletion in critical residues or critical regions.
The present invention further provides non-human orthologues of the human AS3 protein. Orthologues of the human AS3 protein are proteins that are isolated from non-human organisms and possess the same AS3 ability to modulate cell proliferation, for example, hormone-induced changes in cell proliferation. Orthologues of the human AS3 protein can readily be identified as comprising an amino acid sequence that is substantially homologous to SEQ ID N0:2.
Moreover, nucleic acid molecules encoding other AS3 family members and, thus, which have a nucleotide sequence which differs from the AS3 sequences of SEQ
ID NO:1 or 3, are intended to be within the scope of the invention. For example, another AS3 cDNA
can be identified based on the nucleotide sequence of human AS3. Moreover, nucleic acid molecules encoding AS3 proteins from different species, and which, thus, have a nucleotide sequence which differs from the AS3 sequences of SEQ ID NO:1 or 3, are intended to be within the scope of the invention. For example, a mouse AS3 cDNA can be identified based on the nucleotide sequence of a human AS3.
Nucleic acid molecules corresponding to natural allelic variants and homologues of the AS3 cDNAs of the invention can be isolated based on their homology to the AS3 nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Nucleic acid molecules corresponding to natural allelic variants and homologues of the AS3 cDNAs of the invention can further be isolated by mapping to the same chromosome or locus as the AS3 gene.
Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15, 20, 25, 30 or more nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ
ID NO:1 or 3. In other embodiment, the nucleic acid is at least 30, 50, 100, 150, 200, 250, 253, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, or 950 nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.
Preferably, the conditions are such that sequences at least about 70%, more preferably at least about 80%, even more preferably at least about 85% or 90% homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50°C, preferably at 55°C, more preferably at 60°
C, and even more preferably at 65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID
NO:1 or 3 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).
In addition to naturally-occurring allelic variants of the AS3 sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:1 or 3, thereby leading to changes in the amino acid sequence of the encoded AS3 proteins, without altering the functional ability of the AS3 proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID
NO:1 or 3. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of AS3 (e.g., the sequence of SEQ ID N0:2) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the AS3 proteins of the present invention, e.g., those present in the heptad repeat or kinase domains, are predicted to be particularly recalcitrant to alteration. Furthermore, additional amino acid residues that are conserved between the AS3 proteins of the present invention and other members of the ASIC
family are not likely to be amenable to alteration.
Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding AS3 proteins that contain changes in amino acid residues that are not essential for activity. Such AS3 proteins differ in amino acid sequence from SEQ ID N0:2, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%
or more homologous to SEQ ID N0:2.
An isolated nucleic acid molecule encoding an AS3 protein homologous to the protein of SEQ ID N0:2 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1 or 3, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.
Mutations can be introduced into SEQ ID NO:1 or 3, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A
"conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an AS3 protein is preferably replaced with another amino acid residue from the same side chain family.
Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an AS3 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for AS3 biological activity to identify mutants that retain activity.
Following mutagenesis of SEQ ID NO: 1 or 3, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.
In a preferred embodiment, a mutant AS3 protein can be assayed for the ability to ability to modulate cell proliferation, for example, hormone-induced changes in cell proliferation.
In addition to the nucleic acid molecules encoding AS3 proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA
sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.
The antisense nucleic acid can be complementary to an entire AS3 coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding AS3.
The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the coding region of human AS3 corresponds to SEQ ID N0:3). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding AS3.
The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).
Given the coding strand sequences encoding AS3 disclosed herein (e.g., SEQ ID
N0:3), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of AS3 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of AS3 mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of AS3 mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), ~-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an AS3 protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site.
Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
In yet another embodiment, the antisense nucleic acid molecule of the invention is an a-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual (3-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids.
Res. 15:6625-6641 ). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (moue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA
analogue (moue et al. (1987) FEBSLett. 215:327-330).
In still another embodiment, an antisense nucleic acid of the invention is a ribozyme.
Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave AS3 mRNA transcripts to thereby inhibit translation of AS3 mRNA. A ribozyme having specificity for an AS3-encoding nucleic acid can be designed based upon the nucleotide sequence of an AS3 cDNA disclosed herein (i.e., SEQ ID NO:1 or 3). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an AS3-encoding mRNA. See, e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S.
Patent No. 5,116,742. Alternatively, AS3 mRNA can be used to select a catalytic RNA
having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D.
and Szostak, J.W. (1993) Science 261:1411-1418.
Alternatively, AS3 gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the AS3 (e.g., the AS3 promoter and/or enhancers) to form triple helical structures that prevent transcription of the AS3 gene in target cells. See generally, Helene, C. (1991) Anticancer Drug Des.
6(6):569-84; Helene, C. et al. (1992) Ann. N Y. Acad. Sci. 660:27-36; and Maher, L.J. (1992) Bioassays 14(12):807-15.
In yet another embodiment, the AS3 nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. et al. (1996) Bioorganic & Medicinal Chemistry 4 (1): 5-23).
As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA
under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. et al. (1996) supra; Perry-O'Keefe et al. Proc. Natl. Acad. Sci. 93: 14670-675.
PNAs of AS3 nucleic acid molecules can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of AS3 nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR
clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, (e.g., S1 nucleases (Hyrup B. (1996) supra)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. et al. ( 1996) supra; Perry-O'Keefe supra).
In another embodiment, PNAs of AS3 can be modified, (e.g., to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of AS3 nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA.
Such chimeras allow DNA recognition enzymes, (e.g., RNAse H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup B. (1996) supra and Finn P.J. et al. (1996) Nucleic Acids Res. 24 (17): 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. et al. (1989) Nucleic Acid Res. 17:
5973-88).
PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. et al. (1996) supra).
Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA
segment (Peterser, K.H. et al. (1975) Bioorganic Med. Chem. Lett. 5: 1119-11124).
In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad.
Sci. USA
86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad. Sci. USA 84:648-652;
PCT
Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT
Publication No.
W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, e.g., Krol et al. (1988) Bio-Techniques 6:958-976) or intercalating agents. (See, e.g., Zon (1988) Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).
II. Isolated AS3 Proteins One aspect of the invention pertains to isolated AS3 proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-AS3 antibodies. In one embodiment, native AS3 proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, AS3 proteins are produced by recombinant DNA
techniques. Alternative to recombinant expression, an AS3 protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.
An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the AS3 protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of AS3 protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced.
In one embodiment, the language "substantially free of cellular material"
includes preparations of AS3 protein having less than about 30% (by dry weight) of non-AS3 protein (also referred to herein as a "contaminating protein"), more preferably less than about 20%
of non-AS3 protein, still more preferably less than about 10% of non-AS3 protein, and most preferably less than about 5% non-AS3 protein. When the AS3 protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.
The language "substantially free of chemical precursors or other chemicals"
includes preparations of AS3 protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals"
includes preparations of AS3 protein having less than about 30% (by dry weight) of chemical precursors or non-AS3 chemicals, more preferably less than about 20% chemical precursors or non-AS3 chemicals, still more preferably less than about 10% chemical precursors or non-AS3 chemicals, and most preferably less than about 5% chemical precursors or non-AS3 chemicals.
As used herein, a "biologically active portion" of an AS3 protein includes a fragment of an AS3 protein which participates in an interaction between an AS3 molecule and a non-AS3 molecule. Biologically active portions of an AS3 protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the AS3 protein, e.g., the amino acid sequence shown in SEQ ID N0:2, which include less amino acids than the full length AS3 proteins, and exhibit at least one activity of an AS3 protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the AS3 protein, e.g., the ability to modulate cell proliferation.
A biologically active portion of an AS3 protein can be a polypeptide which is, for example, 10, 25, 50, 100, 200 or more amino acids in length. Biologically active portions of an AS3 protein can be used as targets for developing agents which modulate an AS3 mediated activity, e.g., cell proliferation.
In one embodiment, a biologically active portion of an AS3 protein comprises at least one heptad repeat. It is to be understood that a preferred biologically active portion of an AS3 protein of the present invention may contain two, three, four, or five heptad repeats.
As used herein, the term "heptad repeat" includes a protein domain which contains either a leucine or similar hydrophobic residue (e.g., isoleucine, valine, or tyrosine) in every seventh position over a stretch of at least 20-30 amino acid residues, more preferably at least 20-25 amino acid residues, and most preferably at least 22 amino acid residues.
Typically, the heptad repeat is uninterrupted, and can participate in protein-protein interactions. The leucine-zipper motif of DNA binding proteins is a specific subclass of this general pattern and is encompassed by the above term. Leucine zipper domains are described in, for example, Landschultz et al. (1988) Science 240: 1759-1764, the contents of which are incorporated herein by reference. Amino acid residues 55-161, 196-217, 241-277, 319-355, and 375-404 of the AS3 protein all comprise heptad repeats.
In another embodiment, a biologically active portion of an AS3 protein comprises a least one kinase-related domain. It is understood that a preferred biologically active portion of an AS3 protein of the present invention may contain two, three, four, five, six, seven, eight, or nine kinase-related domains. As used herein, the term "kinase-related domain"
includes a polypeptide consensus motif having high homology to a known protein kinase catalytic domain as described in Hanks et ul. (1988) Meth. Enzymol. 200:38-62 (the contents of which are incorporated herein by reference). In particular, a kinase-related domain is any one of the nine consensus motifs or related sequences set forth in Fig. 3.
In another embodiment, a biologically active portion of an AS3 protein can have kinase activity. As referred to herein, "kinase activity" is an activity associated with a protein or polypeptide which is capable of modulating its own phosphorylation state or the phosphorylation state of another protein or polypeptide. Proteins with kinase activity play a role in signaling pathways associated with cellular growth.
Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native AS3 protein.
In a preferred embodiment, the AS3 protein has an amino acid sequence shown in SEQ ID N0:2: In other embodiments, the AS3 protein is substantially homologous to SEQ
ID N0:2, and retains the functional activity of the protein of SEQ ID N0:2, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the AS3 protein is a protein which comprises an amino acid sequence at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to SEQ ID N0:2.
To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the reference sequence (e.g., when aligning a second sequence to the AS3 amino acid sequence of SEQ ID NO: 2 having 400 amino acid residues, at least 80, preferably at least 100, more preferably at least 120, even more preferably at least 140, and even more preferably at least 150, 200, 300, or 400 amino acid residues are aligned). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP
matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (Comput. Appl.
Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. ( 1990) J. Mol.
Biol.
215:403-10. BLAST nucleotide searches can be performed with the NBLAST
program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to AS3 nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to AS3 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.
See http://www.ncbi.nlm.nih.gov.
The invention also provides AS3 chimeric or fusion proteins. As used herein, an AS3 "chimeric protein" or "fusion protein" comprises an AS3 polypeptide operatively linked to a non-AS3 polypeptide. An "AS3 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to AS3, whereas a "non-AS3 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the AS3 protein, e.g., a protein which is different from the AS3 protein and which is derived from the same or a different organism. Within an AS3 fusion protein the AS3 polypeptide can correspond to all or a portion of an AS3 protein. In a preferred embodiment, an AS3 fusion protein comprises at least one biologically active portion of an AS3 protein. In another preferred embodiment, an AS3 fusion protein comprises at least two biologically active portions of an AS3 protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the AS3 polypeptide and the non-AS3 polypeptide are fused in-frame to each other. The non-AS3 polypeptide can be fused to the N-terminus or C-terminus of the AS3 polypeptide.
For example, in one embodiment, the fusion protein is a GST-AS3 fusion protein in which the AS3 sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant AS3.
In another embodiment, the fusion protein is an AS3 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of AS3 can be increased through use of a heterologous signal sequence.
The AS3 fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject in vivo. The AS3 fusion proteins can be used to affect the bioavailability of an AS3 substrate. Use of AS3 fusion proteins may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding an AS3 protein; (ii) mis-regulation of the AS3 gene; and (iii) aberrant post-translational modification of an AS3 protein.
Moreover, the AS3-fusion proteins of the invention can be used as immunogens to produce anti-AS3 antibodies in a subject, to purify AS3 ligands and in screening assays to identify molecules which inhibit the interaction of AS3 with an AS3 substrate.
Preferably, an AS3 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR
amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons:
1992).
Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An AS3-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the AS3 protein.
The present invention also pertains to variants of the AS3 proteins which function as either AS3 agonists (mimetics) or as AS3 antagonists. Variants of the AS3 proteins can be generated by mutagenesis, e.g., discrete point mutation or truncation of an AS3 protein. An agonist of the AS3 proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of an AS3 protein. An antagonist of an AS3 protein can inhibit one or more of the activities of the naturally occurring form of the AS3 protein by, for example, competitively modulating an AS3-mediated activity of an AS3 protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the AS3 protein.
In one embodiment, variants of an AS3 protein which function as either AS3 agonists (mimetics) or as AS3 antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of an AS3 protein for AS3 protein agonist or antagonist activity. In one embodiment, a variegated library of AS3 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of AS3 variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential AS3 sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of AS3 sequences therein. There are a variety of methods which can be used to produce libraries of potential AS3 variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA
synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential AS3 sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) Tetrahedron 39:3;
Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477.
In addition, libraries of fragments of an AS3 protein coding sequence can be used to generate a variegated population of AS3 fragments for screening and subsequent selection of variants of an AS3 protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an AS3 coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the AS3 protein.
Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA
libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of AS3 proteins.
The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected.
Recrusive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify AS3 variants (Arkin and Yourvan (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al.
(1993) Protein Engineering 6(3):327-331).
In one embodiment, cell based assays can be exploited to analyze a variegated library. For example, a library of expression vectors can be transfected into a cell line, e.g., a neuronal cell line, which ordinarily responds to a particular ligand in an AS3-dependent manner. The transfected cells are then contacted with the ligand and the effect of expression of the mutant on signaling by the ligand can be detected, e.g., by measuring intracellular calcium, potassium, or sodium concentration, neuronal membrane depolarization, or the activity of an AS3-regulated transcription factor. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of signaling by the ligand, and the individual clones further characterized.
III Anti-AS3 Antibodies An isolated AS3 protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind AS3 using standard techniques for polyclonal and monoclonal antibody preparation. A full-length AS3 protein can be used or, alternatively, the invention provides antigenic peptide fragments of AS3 for use as immunogens. The antigenic peptide of AS3 comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID N0:2 and encompasses an epitope of AS3 such that an antibody raised against the peptide forms a specific immune complex with AS3.
Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.
Preferred epitopes encompassed by the antigenic peptide are regions of AS3 that are located on the surface of the protein, e.g., hydrophilic regions, as well as regions with high antigenicity (see, for example, Figure 2).
An AS3 immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed AS3 protein or a chemically synthesized AS3 polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent.
Immunization of a suitable subject with an immunogenic AS3 preparation induces a polyclonal anti-AS3 antibody response.
Accordingly, another aspect of the invention pertains to anti-AS3 antibodies.
The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as AS3.
Examples of immunologically active portions of immunoglobulin molecules include Flab) and F(ab')2 fragments which can be generated by treating the antibody with an enzyme such as pepsin.
The invention provides polyclonal and monoclonal antibodies that bind AS3. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of AS3. A monoclonal antibody composition thus typically displays a single binding affinity for a particular AS3 protein with which it immunoreacts.
Polyclonal anti-AS3 antibodies can be prepared as described above by immunizing a suitable subject with an AS3 immunogen. The anti-AS3 antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized AS3. If desired, the antibody molecules directed against AS3 can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG
fraction. At an appropriate time after immunization, e.g., when the anti-AS3 antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein ( 1975) Nature 256:495-497) (see also, Brown et al. ( 1981 ) J. Immunol. 127:539-46; Brown et al. (1980) J. Biol. Chem .255:4980-83; Yeh et al. (1976) Proc. Natl. Acad. Sci. USA 76:2927-31; and Yeh et al. (1982) Int. J. Cancer 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al. (1983) Immunol Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) Yale J. Biol. Med., 54:387-402; M.
L. Gefter et al. (1977) Somatic Cell Genet. 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an AS3 immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds AS3.
Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-AS3 monoclonal antibody (see, e.g., G. Galfre et al. (1977) Nature 266:55052; Gefter et al.
Somatic Cell Genet., cited supra; Lerner, Yale J. Biol. Med., cited supra; Kenneth, Monoclonal Antibodies, cited supra). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Agl4 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT
medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind AS3, e.g., using a standard ELISA assay.
Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-AS3 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with AS3 to thereby isolate immunoglobulin library members that bind AS3. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-O 1; and the Stratagene SurfZAPTM Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT
International Publication No. WO 92/18619; Dower et al. PCT International Publication No. WO 91/17271;
Winter et al. PCT International Publication WO 92/20791; Markland et al. PCT
International Publication No. WO 92/15679; Breitling et al. PCT International Publication WO
93/01288;
McCafferty et al. PCT International Publication No. WO 92/01047; Garrard et al. PCT
International Publication No. WO 92/09690; Ladner et al. PCT International Publication No.
WO 90/02809; Fuchs et al. (1991) BiolTechnology 9:1370-1372; Hay et al. (1992) Hum.
Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281;
Griffiths et al.
(1993) EMBO J 12:725-734; Hawkins et al. (1992) J. Mol. Biol. 226:889-896;
Clarkson et al. (1991) Nature 352:624-628; Gram et al. (1992) Proc. Natl. Acad Sci. USA
89:3576-3580; Garrad et al. (1991) BiolTechnology 9:1373-1377; Hoogenboom et al.
(1991) Nuc.
Acid Res. 19:4133-4137; Barbas et al. (1991) Proc. Natl. Acad Sci. USA 88:7978-7982; and McCafferty et al. Nature (1990) 348:552-554.
Additionally, recombinant anti-AS3 antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention.
Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA
techniques known in the art, for example using methods described in Robinson et al.
International Application No. PCT/L1S86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al.
European Patent Application 173,494; Neuberger et al. PCT International Publication No.
WO
86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al.
(1987) Proc.
Natl. Acad Sci. USA 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526;
Sun et al.
(1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Canc.
Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl.
Cancer Inst.
80:1553-1559); Morrison, S. L. (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214; Winter U.S. Patent 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J.
Immunol.
141:4053-4060.
An anti-AS3 antibody (e.g., monoclonal antibody) can be used to isolate AS3 by standard techniques, such as affinity chromatography or immunoprecipitation.
An anti-AS3 antibody can facilitate the purification of natural AS3 from cells and of recombinantly produced AS3 expressed in host cells. Moreover, an anti-AS3 antibody can be used to detect AS3 protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the AS3 protein. Anti-AS3 antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen.
Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance.
Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I~ 1311 35S or 3H.
IV. Recombinant Expression Vectors Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an AS3 protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequences) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals).
Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., AS3 proteins, mutant forms of AS3 proteins, fusion proteins, and the like).
The recombinant expression vectors of the invention can be designed for expression of AS3 proteins in prokaryotic or eukaryotic cells. For example, AS3 proteins can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
Expression of proteins in prokaryotes is most often carried out in E. coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.
Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRITS
(Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
Purified fusion proteins can be utilized in AS3 activity assays, (e.g., direct assays or competitive assays described in detail below), or to generate antibodies specific for AS3 proteins, for example. In a preferred embodiment, an AS3 fusion protein expressed in a retroviral expression vector of the present invention can be utilized to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g., six (6) weeks).
Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 1 ld (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California ( 1990) 60-89). Target gene expression from the pTrc vector relies on host RNA
polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET
l ld vector relies on transcription from a T7 gnl0-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gnl gene under the transcriptional control of the lacUV 5 promoter.
One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E.
coli (Wada et al., (1992) Nucleic Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
In another embodiment, the AS3 expression vector is a yeast expression vector.
Examples of vectors for expression in yeast S. cerivisae include pYepSecl (Baldari, et al., (1987) Embo J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and picZ (InVitrogen Corp, San Diego, CA).
Alternatively, AS3 proteins can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) Mol. Cell Biol.
3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC
(Kaufman et al. (1987) EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements.
For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T.
Molecular Cloning.' A Laboratory Manual. 2nd, ed , Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the prostate specific promoter (Gotoh et al. ( 1998) J. Urol. 60:220-229) albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477), pancreas-specific promoters (Edlund et al.
(1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No.
264,166).
Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the a,-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
The invention further provides a recombinant expression vector comprising a DNA
molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA
molecule which is antisense to AS3 mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al:, Antisense RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986.
V. Host Cells Another aspect of the invention pertains to host cells into which an AS3 nucleic acid molecule of the invention is introduced, e.g., an AS3 nucleic acid molecule within a recombinant expression vector or an AS3 nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
A host cell can be any prokaryotic or eukaryotic cell. For example, an AS3 protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.
Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.
For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as 6418, hygromycin and methotrexate.
Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an AS3 protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) an AS3 protein. Accordingly, the invention further provides methods for producing an AS3 protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of the invention (into which a recombinant expression vector encoding an AS3 protein has been introduced) in a suitable medium such that an AS3 protein is produced. In another embodiment, the method further comprises isolating an AS3 protein from the medium or the host cell.
VI. Transgenic Animals The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which AS3-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous AS3 sequences have been introduced into their genome or homologous recombinant animals in which endogenous AS3 sequences have been altered. Such animals are useful for studying the function and/or activity of an AS3 and for identifying and/or evaluating modulators of AS3 activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like.
A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous AS3 gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
A transgenic animal of the invention can be created by introducing an AS3-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The AS3 cDNA sequence of SEQ ID NO:1 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of a human AS3 gene, such as a mouse or rat AS3 gene, can be used as a transgene. Alternatively, an AS3 gene homologue, such as another AS3 family member, can be isolated based on hybridization to the AS3 cDNA sequences of SEQ ID NO:1 or 3 (described further in subsection I
above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequences) can be operably linked to an AS3 transgene to direct expression of an AS3 protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos.
4,736,866 and 4,870,009, both by Leder et al., U.S. Patent No. 4,873,191 by Wagner et al.
and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of an AS3 transgene in its genome and/or expression of AS3 mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding an AS3 protein can further be bred to other transgenic animals carrying other transgenes.
To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an AS3 gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the AS3 gene. The AS3 gene can be a human gene (e.g., the cDNA of SEQ ID N0:3), but more preferably, is a non-human homologue of a human AS3 gene (e.g., a cDNA isolated by stringent hybridization with the nucleotide sequence of SEQ ID NO:1 ). For example, a mouse AS3 gene can be used to construct a homologous recombination nucleic acid molecule, e.g., a vector, suitable for altering an endogenous AS3 gene in the mouse genome. In a preferred embodiment, the homologous recombination nucleic acid molecule is designed such that, upon homologous recombination, the endogenous AS3 gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the homologous recombination nucleic acid molecule can be designed such that, upon homologous recombination, the endogenous AS3 gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous AS3 protein). In the homologous recombination nucleic acid molecule, the altered portion of the AS3 gene is flanked at its 5' and 3' ends by additional nucleic acid sequence of the AS3 gene to allow for homologous recombination to occur between the exogenous AS3 gene carried by the homologous recombination nucleic acid molecule and an endogenous AS3 gene in a cell, e.g., an embryonic stem cell.
The additional flanking AS3 nucleic acid sequence is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the homologous recombination nucleic acid molecule (see, e.g., Thomas, K.R. and Capecchi, M. R. (1987) Cell 51:503 for a description of homologous recombination vectors). The homologous recombination nucleic acid molecule is introduced into a cell, e.g., an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced AS3 gene has homologously recombined with the endogenous AS3 gene are selected (see e.g., Li, E. et al. (1992) Cell 69:915). The selected cells can then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stem Cells:
A Practical Approach, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A
chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination nucleic acid molecules, e.g., vectors, or homologous recombinant animals are described further in Bradley, A. (1991) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos.:
WO
90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.
In another embodiment, transgenic non-humans animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the crelloxP recombinase system of bacteriophage P1. For a description of the c~elloxP recombinase system, see, e.g., Lakso et al. (1992) Proc. Natl.
Acad. Sci. USA 89:6232-6236. Another example of a recombinase system is the FLP
recombinase system of Saccharomyces cerevisiae (O'Gorman et al. ( 1991 ) Science 251:1351-1355. If a crelloxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double"
transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. (1997) Nature 385:810-813 and PCT
International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter Go phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.
VII. Pharmaceutical Compositions The AS3 nucleic acid molecules, fragments of AS3 proteins, and anti-AS3 antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration.
Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for _47_ pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components:
a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugaxs, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a fragment of an AS3 protein or an anti-AS3 antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Oral compositions generally include an inert diluent or an edible carrier.
They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes;
a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin;
or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to.be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers.
These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
Levels in plasma may be measured, for example, by high performance liquid chromatography.
VIII. Gene Therapy The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
Wb 00/50454 PCT/US00/04732 -The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
IX. Uses and Methods of the Invention The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics); and c) methods of treatment (e.g., therapeutic and prophylactic). As described herein, an AS3 protein of the invention modulates the arrest of cell proliferation, preferably hormone-mediated cell proliferation.
Thus, the isolated nucleic acid molecules of the invention can be used, for example, to express AS3 protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect AS3 mRNA (e.g., in a biological sample) or a genetic alteration in an AS3 gene, and to modulate AS3 activity, as described further below. The AS3 nucleic acid molecules can be used to treat disorders characterized by insufficient production of AS3. The AS3 proteins can be used to screen for naturally occurring AS3 substrates, to screen for drugs or compounds which modulate AS3 activity, as well as to treat disorders characterized by insufficient production of AS3 protein or production of AS3 protein forms which have decreased, aberrant or unwanted activity compared to AS3 wild type protein (e.g., excessive cell proliferation). Moreover, the anti-AS3 antibodies of the invention can be used to detect and isolate AS3 proteins, regulate the bioavailability of AS3 proteins, and modulate AS3 activity.
IX, A, Screening Assays The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to AS3 proteins, have a stimulatory or inhibitory effect on, for example, AS3 expression or AS3 activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of AS3 substrate.
In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of an AS3 protein or polypeptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of an AS3 protein or polypeptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) Anticancer Drug Des.
12:145).
Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909;
Erb et al.
(1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Mecl Chem.
37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew.
Chem. Int. Ed.
Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and in Gallop et al. (1994) J. Med. Chem. 37:1233.
Libraries of compounds may be presented in solution (e.g., Houghten (1992) Biotechniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull et al. (1992) Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith (1990) Science 249:386-390); (Devlin (1990) Science 249:404-406);
(Cwirla et al.
(1990) Proc. Natl. Acad. Sci. 87:6378-6382); (Felici (1991) J. Mol. Biol.
222:301-310);
(Ladner supra. ).
In one embodiment, an assay is a cell-based assay in which a cell which expresses an AS3 protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate AS3 activity is determined.
Determining the ability of the test compound to modulate AS3 activity can be determined by monitoring, for example, changes in cell using standard techniques.
In another embodiment, an assay of the present invention is a cell-free assay in which an AS3 protein or biologically active portion thereof is contacted with a test compound and the ability of the.test compound to bind to the AS3 protein or biologically active portion thereof is determined. Preferred biologically active portions of the AS3 proteins to be used in assays of the present invention include fragments which participate in interactions with non-AS3 molecules, e.g., fragments with high surface probability scores (see, for example, Figure 2). Binding of the test compound to the AS3 protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the AS3 protein or biologically active portion thereof with a known compound which binds AS3 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an AS3 protein, wherein determining the ability of the test compound to interact with an AS3 protein comprises determining the ability of the test compound to preferentially bind to AS3 or biologically active portion thereof as compared to the known compound.
In yet another embodiment, the cell-free assay involves contacting an AS3 protein or biologically active portion thereof with a known compound which binds the AS3 protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the AS3 protein, wherein determining the ability of the test compound to interact with the AS3 protein comprises determining the ability of the AS3 protein to preferentially bind to or modulate the activity of an AS3 target molecule.
In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize AS3 to facilitate separation of proteins that interact with AS3, as well as to accommodate automation of the assay. Binding of a test compound to an AS3 protein, or interaction of an AS3 protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/ AS3 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or AS3 protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above.
Alternatively, the complexes can be dissociated from the matrix, and the level of AS3 binding or activity determined using standard techniques.
Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either an AS3 protein or an AS3 target molecule can be immobilized utilizing conjugation of biotin and streptavidin.
Biotinylated AS3 protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
Alternatively, antibodies reactive with AS3 protein or target molecules but which do not interfere with binding of the AS3 protein to its target molecule can be derivatized to the wells of the plate, and unbound target or AS3 protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the AS3 protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the AS3 protein or target molecule.
In another embodiment, modulators of AS3 expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of AS3 mRNA or protein in the cell is determined. The level of expression of AS3 mRNA or protein in the presence of the candidate compound is compared to the level of expression of AS3 mRNA
or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of AS3 expression based on this comparison. For example, when expression of AS3 mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of AS3 mRNA or protein expression. Alternatively, when expression of AS3 mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of AS3 mRNA or protein expression. This assay may be further modified to include the presence of a hormone, e.g., an androgen or an anti-androgen. The level of AS3 mRNA or protein expression in the cells can be determined by methods described herein for detecting AS3 mRNA or protein.
In yet another aspect of the invention, the AS3 proteins can be used as "bait proteins"
in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No.
5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and Brent W094/10300), to identify other proteins, which bind to or interact with AS3 ("AS3-binding proteins" or "AS3-by") and are involved in AS3 activity. Such AS3-binding proteins are also likely to be involved in the propagation of signals by the AS3 proteins or AS3 targets as, for example, downstream elements of an AS3-mediated signaling pathway.
Alternatively, such AS3-binding proteins are likely to be AS3 inhibitors.
The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for an AS3 protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA
sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming an AS3-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor.
Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the AS3 protein.
In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell free assay, and the ability of the agent to modulate the activity of an AS3 protein can be confirmed in vivo, e.g., in an animal such as an animal model for pain.
This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., an AS3 modulating agent, an antisense AS3 nucleic acid molecule, an AS3-specific antibody, or an AS3-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.
IX, B, Detection Assays Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease;
(ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.
IX, B, 1., Chromosome Mapping Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the AS3 nucleotide sequences, described herein, can be used to map the location of the AS3 genes on a chromosome as described in Example 4. The mapping of the AS3 sequences to chromosomes is an important step in correlating these sequences with genes associated with disease.
Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the AS3 gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.
IX, B, 2., Tissue Typing The AS3 sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel.
In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S.
Patent 5,272,057).
Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the AS3 nucleotide sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.
Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The AS3 nucleotide sequences of the invention uniquely represent portions of the human genome.
Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases.
Each of the sequences described herein can,.to some degree, be used as a standard against which DNA
from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO: l can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID N0:3 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.
If a panel of reagents from AS3 nucleotide sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.
IX, B, 3., Use of Partial AS3 Sequences in Forensic Biology DNA-based identification techniques can also be used in forensic biology.
Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample..
The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO:1 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique.
Examples of polynucleotide reagents include.the AS3 nucleotide sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NO:1 having a length of at least 20 bases, preferably at least 30 bases.
The AS3 nucleotide sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such AS3 probes can be used to identify tissue by species and/or by organ type.
In a similar fashion, these reagents, e.g., AS3 primers or probes can be used to screen tissue culture for contamination (i.e. screen for the presence of a mixture of different types of cells in a culture).
IX, C, Predictive Medicine The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically.
Accordingly, one aspect of the present invention.relates to diagnostic assays for determining AS3 protein and/or nucleic acid expression as well as AS3 activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant or reduced AS3 expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with AS3 protein, nucleic acid expression or activity. For example, mutations in an AS3 gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with AS3 protein, nucleic acid expression, or activity.
Another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of AS3 in clinical trials.
These and other agents are described in further detail in the following sections and in Examples 4 and 5.
IX, C, 1., Diagnostic Assays An exemplary method for detecting the presence or absence of AS3 protein or nucleic acid in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting AS3 protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes AS3 protein such that the presence of AS3 protein or nucleic acid is detected in the biological sample.
A preferred agent for detecting AS3 mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to AS3 mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length AS3 nucleic acid, such as the nucleic acid of SEQ ID NO:1 or 3, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to AS3 mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.
A preferred agent for detecting AS3 protein is an antibody capable of binding to AS3 protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')2) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect AS3 mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of AS3 mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of AS3 protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of AS3 genomic DNA
include Southern hybridizations.
In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a tissue or cell sample isolated by conventional means from a subject.
In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting AS3 protein, mRNA, or genomic DNA, such that the presence of AS3 protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of AS3 protein, mRNA or genomic DNA in the control sample with the presence of AS3 protein, mRNA or genomic DNA in the test sample.
The invention also encompasses kits for detecting the presence of AS3 in a biological sample. For example, the kit can comprise a labeled compound or agent capable of detecting AS3 protein or mRNA in a biological sample; means for determining the amount of AS3 in the sample; and means for comparing the amount of AS3 in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect AS3 protein or nucleic acid.
IX, C, 2., Prognostic Assays The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant AS3 expression or activity. As used herein, the term "aberrant" includes an AS3 expression or activity which deviates from the wild type AS3 expression or activity.
Aberrant expression or activity includes increased or decreased expression or activity, as well as expression or activity which does not follow the wild type developmental pattern of expression or the subcellular pattern of expression. For example, aberrant AS3 expression or activity is intended to include the cases in which a mutation in the AS3 gene causes the AS3 gene to be under-expressed or over-expressed and situations in which such mutations result in a non-functional AS3 protein or a protein which does not function in a wild-type fashion, e.g., a protein which does not interact with an AS3 ligand or one which interacts with a non-AS3 ligand.
The assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a malignancy associated with a misregulation in AS3 protein activity or nucleic acid expression, such as a prostate cancer. Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant AS3 expression or activity in which a test sample is obtained from a subject and AS3 protein or nucleic acid (e.g., mRNA or genomic DNA) is detected, wherein the presence of AS3 protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant or unwanted AS3 expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a cell, tissue, or biological fluid containing a cell.
Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate, such as a hormone, e.g., an androgen) to treat a disease or disorder associated with aberrant AS3 expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for aberrant cell proliferation, e.g., cancer of the prostate.
The methods of the invention can also be used to detect genetic alterations in an AS3 gene, thereby determining if a subject with the altered gene is at risk for a disorder characterized by misregulation in AS3 protein activity or nucleic acid expression, such as a proliferative disorder, e.g., cancer. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding an AS3-protein, or the mis-expression of the AS3 gene. For example, such genetic alterations can be detected by ascertaining the existence of at least one of 1 ) a deletion of one or more nucleotides from an AS3 gene; 2) an addition of one or more nucleotides to an AS3 gene; 3) a substitution of one or more nucleotides of an AS3 gene, 4) a chromosomal rearrangement of an AS3 gene; 5) an alteration in the level of a messenger RNA
transcript of an AS3 gene, 6) aberrant modification of an AS3 gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA
transcript of an AS3 gene, 8) a non-wild type level of an AS3-protein, 9) allelic loss of an AS3 gene, and 10) inappropriate post-translational modification of an AS3-protein. As described herein, there are a large number of assays known in the art which can be used for detecting alterations in an AS3 gene. A preferred biological sample is a cell, tissue, or biological fluid containing a cell, isolated by conventional means from a subject.
In certain embodiments, detection of the alteration involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al.
(1994) Proc. Natl.
Acad. Sci. USA 91:360-364), the latter of which can be particularly useful for detecting point mutations in the AS3-gene (see Abravaya et al. (1995) Nucleic Acids Re.s .23:675-682).
This method can include the steps of collecting a sample of cells from a subject. isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample.
contacting the nucleic acid sample with one or more primers which specifically hybridize to an AS3 gene under conditions such that hybridization and amplification of the AS3-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.
Alternative amplification methods include: self sustained sequence replication (Guatelli, J.C. et al., (1990) Proc. Natl. Acad Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh, D.Y. et al., (1989) Proc. Natl. Acad. Sci. USA
86:1173-1177), Q-Beta Replicase (Lizardi, P.M. et al. (1988) Bio-Technology 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
In an alternative embodiment, mutations in an AS3 gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA
indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
In other embodiments, genetic mutations in AS3 can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin, M.T. et al. (1996) Human Mutation 7: 244-255; Kozal, M.J. et al. (1996) Nature Medicine 2: 753-759).
For example, genetic mutations in AS3 can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, M.T. et al. supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.
In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the AS3 gene and detect mutations by comparing the sequence of the sample AS3 with the corresponding wild-type (control) sequence.
Examples of sequencing reactions include those based on techniques developed by Maxam and Gilbert ((1977) Proc. Natl. Acad. Sci. USA 74:560) or Sanger ((1977) Proc.
Natl. Acad.
Sci. USA 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT
International Publication No. WO 94/16101; Cohen et al. (1996) Adv. Chromatogr. 36:127-162;
and Griffin et al. (1993) Appl. Biochem. Biotechnol. 38:147-159).
Other methods for detecting mutations in the AS3 gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA
or RNA/DNA heteroduplexes (Myers et al. (1985) Science 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type AS3 sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNAse and DNNDNA hybrids treated with S 1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton et al.
1S (1988) Proc. Natl Acad Sci USA 85:4397; Saleeba et al. (1992) Methods Enzymol. 217:286 295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.
In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA
mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in AS3 cDNAs obtained from samples of cells. For example, the mutt enzyme of E.
coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662). According to an exemplary embodiment, a probe based on an AS3 sequence, e.g., a wild-type AS3 sequence, is hybridized to a cDNA or other DNA product from a test cell(s).
The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S.
Patent No.
5,459,039.
In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in AS3 genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc Natl. Acad. Sci USA: 86:2766, see also Cotton (1993) Mutat. Res. 285:125-144; and Hayashi (1992) Genet. Anal. Tech. Appl. 9:73-79).
Single-stranded DNA fragments of sample and control AS3 nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA
(rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment; the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet 7:5).
In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 by of high-melting GC-rich DNA
by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA
(Rosenbaum and Reissner (1987) Biophys Chem 265:12753).
Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al.
(1986) Nature 324:163); Saiki et al. (1989) Proc. Natl Acad. Sci USA 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.
Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention.
Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al. ( 1989) W~ 00/50454 PCT/US00/04732 -Nucleic Acids Res. 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 11:238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. ( 1992) Mol.
Cell Probes 6:1 ). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad.
Sci USA
88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.
The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an AS3 gene.
Furthermore, any cell type or tissue in which AS3 is expressed, e.g., prostate tissue, may be utilized in the prognostic assays described herein.
IX, C, 3., Monitoring of Effects During Clinical Trials Monitoring the influence of agents (e.g., hormone therapy) on the expression or activity of an AS3 protein (e.g., the modulation of cell proliferation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase AS3 gene expression, protein levels, or upregulate AS3 activity, can be monitored in clinical trials of subjects exhibiting decreased AS3 gene expression, protein levels, or downregulated AS3 activity.
Alternatively, the effectiveness of an agent determined by a screening assay to decrease AS3 gene expression, protein levels, or downregulate AS3 activity, can be monitored in clinical trials of subjects exhibiting increased AS3 gene expression, protein levels, or upregulated AS3 activity. In such clinical trials, the expression or activity of an AS3 gene, and preferably, other genes (e.g., prostate-specific antigen (PSA)) that have been implicated in, for example, an AS3-associated disorder can be used as a "read out" or markers of the phenotype of a particular cell.
For example, and not by way of limitation, genes, including AS3, that are modulated in cells by treatment with an agent (e.g., compound, drug or hormone) which modulates AS3 activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cell proliferation modulated by AS3, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of AS3 and other genes implicated in the AS3-associated disorder. The levels of gene expression (e.g., a gene expression pattern) can be quantified by northern blot analysis or RT-PCR, as described herein; or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of AS3 or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during treatment of the individual with the agent or may be used to determine when treatment is appropriate.
In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid. small molecule, or other drug candidate, e.g., a hormone, identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an AS3 protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the AS3 protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the AS3 protein, mRNA, or genomic DNA in the pre-administration sample with the AS3 protein, mRNA, or genomic DNA in the post administration sample or samples;
and (vi) altering the administration of the agent to the subject accordingly.
For example, increased administration of the agent may be desirable to increase the expression or activity of AS3 to higher levels than detected, i.e., to increase the effectiveness of the agent.
Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of AS3 to lower levels than detected, i.e. to decrease the effectiveness of the agent. According to such an embodiment, AS3 expression or activity may be used as an indicator of the effectiveness of an agent, even in the absence of an observable phenotypic response.
IX, D., Methods of Treatment The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant AS3 expression or activity. With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. "Pharmacogenomics", as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers to the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype", or "drug response genotype".) Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the AS3 molecules of the present invention or AS3 modulators according to that individual's drug response genotype.
Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.
IX, D., 1., Prophylactic Methods In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant AS3 expression or activity, by administering to the subject an AS3 molecule or an agent which modulates AS3 expression or at least activity. Subjects at risk for a disease (e.g., prostate cancer) which is caused or contributed to by aberrant AS3 expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.
Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the AS3 aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of AS3 aberrancy, for example, an AS3 molecule, AS3 agonist (e.g., hormone therapy), or AS3 antagonist agent can be used for treating the subject.
The appropriate agent can be determined based on screening assays described herein.
IX, D., 2., Therapeutic Methods Another aspect of the invention pertains to methods of modulating AS3 expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell with an AS3 molecule or agent that modulates AS3 protein activity associated with cell (e.g., cell proliferation). An agent that modulates AS3 protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring target molecule of an AS3 protein (e.g., an AS3 substrate), an AS3 antibody, an AS3 agonist or antagonist, a peptidomimetic of an AS3 agonist or antagonist, or other small molecule (e.g., hormone, such as an androgen). In one embodiment, the agent stimulates one or more AS3 activities. Examples of such stimulatory agents include androgen therapy or a nucleic acid molecule encoding AS3 that has been introduced into the cell. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a cell proliferative disease (e.g., prostate cancer) or disorder characterized by aberrant or reduced expression or activity of an AS3 protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay or a hormone such as androgen as described herein), or combination of agents that modulates AS3 expression or activity.
Stimulation of AS3 activity is desirable in situations in which AS3 is abnormally downregulated and/or in which increased AS3 activity is likely to have a beneficial effect.
For example, stimulation of AS3 activity is desirable in a cell proliferative disease such as prostate cancer and increasing AS3 activity is likely to have a beneficial effect. Moreover, the ability to detect androgen-induced AS3 expression in a patient is an indication that the patient is responsive to hormone and therefore a candidate for intermittent hormone therapy.
As used herein, the term "intermittent hormone therapy" or "intermittent hormone treatment" includes a treatment regime wherein a patient is treated with a hormone, such as an androgen, for a period of time and then withdrawn from such treatment for a period of time. This intermittent administration of hormone shall be, at least in part, determined by an analysis of the patients AS3 levels as described herein.
IX, D, 3., Pharmacogenomics The AS3 molecules of the present invention, as well as agents, or modulators which have a stimulatory or inhibitory effect on AS3 activity (e.g., AS3 gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) AS3-associated disorders (e.g., cell proliferation) associated with aberrant or reduced AS3 activity. In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered.
Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant 1 ~ pharmacogenomics studies in determining whether to administer an AS3 molecule or AS3 modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with an AS3 molecule or AS3 modulator.
Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons.
See, for example, Eichelbaum, M. et al. (1996) Clin. Exp. Pharmacol. Physiol.
23(10-11) :983-985 and Linder, M.W. et al. (1997) Clin. Chem. 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.
One pharmacogenomics approach to identifying genes that predict drug response, known as "a genome-wide association", relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers (e.g., a "bi-allelic" gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two.variants.) Such a high-resolution genetic map can be compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a "SNP" is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be disease-associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.
Alternatively, a method termed the "candidate gene approach", can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drugs target is known (e.g., an AS3 protein of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.
As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT
2) and cytochrome P450 enzymes CYP2D6 and CYP2C 19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6.
Poor metabolizers of CYP2D6 and CYP2C 19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.
Alternatively, a method termed the "gene expression profiling", can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug (e.g., an AS3 molecule or AS3 modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.
Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an AS3 molecule or AS3 modulator, such as a modulator identified by one of the exemplary screening assays described herein.
This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.
EXAMPLE 1.
In this example, the isolation and cloning of the gene encoding human AS3 is described.
To isolate a cDNA encoding an inhibitor of prostate cancer progression, the LNCaP-FGC cell line established from a metastatic lymph node from a patient with prostate adenocarcinoma (Horoszewicz et al., (1983) Cancer Res. 43:1809-1818) was utilized. This cell line and related cell lines derived therefrom were cultured as previously described (Soto et al., (1995) Oncology Res. 7: 545-558; Soto et al., (1991) J. Steroid Biochem. 23: 87-94).
In addition, to isolate a gene expressed at the proliferative shutoff point (i.e., Step 2), a subtractive strategy was used whereby the proliferation of LNCaP-FGC cells was arrested using two different treatments, namely, CD serum (i.e., androgen free serum) and high androgen concentrations. This selective approach takes advantage of the fact that the cells were equally arrested at the G1 stage of the cell cycle by different mechanisms (Soto et al., (1995) Oncology Res. 7: 545-558).
Moreover, since regulatory mRNAs are frequently expressed at low copy numbers, a protocol was adopted using repeated PCR cycles to selectively amplify these sequences.
The final subtracted pool, therefore, was enriched to represent high ranking regulatory elements in the androgen-induced proliferative shutoff (Step-2).
Briefly, androgen-specific, low-abundance regulatory mRNA sequences expressed during the proliferative shutoff, were selected using the Wang-Brown approach (Wang et al., (1991) Proc. Natl. Acad. Sci. USA 88: 11505-11509). Short fragments of cDNAs were amplified first: then three cycles of subtractions and amplifications between the control and proliferation arrested cDNAs resulted in sequence pools that were differentially expressed (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218). LNCaP-FGC
cells were treated with 30 nM 81881 to generate proliferative shutoff. 81881 (methyltrienolone) is a synthetic, non-metabolized androgen (Roussell-UCLAF, Romainville, France).
Exposure to androgen for 24 hours was required to commit LNCaP-FGC cells to an irreversible proliferative shutoff (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63:
211-218). It was concluded that at this point, the genes responsible for the shutoff were highly induced.
LNCaP-FGC cells reversibly arrested by CDHuS were considered as the shutoff negative control; they were harvested after three days of CDHuS treatment. Total RNA
was prepared by the acidic guanidinium-thiocyanate method and polyA+ RNA was purified by using the FastTrack kit (Invitrogen, San Diego, CA) (Chomczinsky et al., (1987) Anal.
Biochem. 162:
156-159).
Double-stranded cDNA pools from 81881-treated cells (R cDNA) and CDHuS-treated cells (CD cDNA) were synthesized using the Copy Kit (Invitrogen), with oligo-dT
priming. After Alul and Rsal digestions and adaptor ligations, the constructs were PCR-amplified (GeneAmp Kit, Perkin Elmer, Foster City, CA). The amplified CD cDNA
were digested with Eco RI, photobiotinylated (driver cDNA) and hybridized at 20-fold molar excess to an aliquot of non-biotinylated R cDNA. The hybridized non-specific sequences were eliminated by subsequent Streptavidin chromatography. After 3 cycles of selection, the amplified expressed sequence tag (EST) pool of the androgen-induced shutoff AS (R
cDNA pool minus CD cDNA pool) sequences was digested with EcoRl, cloned into the BlueScript SK vector (Stratagene, La Jolla, CA) and transformed into E. coli (OneShot strain, Invitrogen).
Isolation of unique cDNAs from the differentially expressed sequence pool was performed as follows. Recombinants were collected randomly from the shutoff positive AS
pool of the Wang-Brown differential library and were plated. Using the labeled CD- and R-subtracted (CD cDNA pool minus R cDNA pool), PCR-amplified DNA master mixes as S
probes, double hybridizations revealed 11 and 14 clones that were present exclusively in the CD and R clone sets, respectively (Geck et al., (1997) J. Steroid Biochem.
Mol. Biol. 63:
211-218). Multiple cross-hybridizations identified ten unique inserts.
To sequence the identified EST fragments, PCR sequencing reactions were performed using the dsDNA Sequencing System (Life Technologies, Gaithersburg, MD).
The EST DNA sequences were tested for homology to known DNA sequences using the PASTA and BLAST (National Center for Biotechnology Information, Bethesda, MD) programs. Five inserts were found with no match in GenBank (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218;. For further analysis, the mRNA with the highest induction in shutoff positive LNCaP-FGC cells (AS3, >5-6-fold of the 5.3 kb mRNA, and >3-4-fold of the 8 kb isoform) was selected.
To isolate the full length AS3 cDNA sequence, a 262 by AS3 tag sequence was utilized to design nested primer pairs to amplify the full length cDNA
sequence from a cDNA library. The cDNA libraries were generated by Human Genome Sciences (Rockville, MD), using polyA+ mRNA preparations from androgen-treated or CDHuS-treated proliferation-arrested LNCaP-FGC cells. The Lambda ZAPII (UniZAP) phage was used as vector carrying EcoRl and Xhol cloning sites. The PCR reaction was designed to amplify the cloned unknown cDNA segments between the known tag sequence and the flanking vector sequences. Since the orientation of the tag sequence was not known, both ends of the insert were amplified in both directions. The vector primers used were commercially available sequencing primers: M 13 Reverse and T3 primers at the EcoRl site, and M 13-20 and T7 primers at the Xhol site.
For the PCR reaction, the Expand High Fidelity kit was used and a 1 ~l phage suspension as template (Boehringer-Mannheim). A 40 cycle amplification in a Perkin-Elmer 9600 thermocycler resulted in the production of a 1370 by 5' fragment and a 3250 by 3' fragment. These PCR products were purified using Qiagen columns, and sequenced by automatic sequencing using a primer walking strategy. The sequencing data showed that the open reading frame in the 5'end fragment did not have an authentic AUG codon.
To search for the missing 5' end of the transcript, the Prostate Specific Marathon Ready cDNA preparation from Clontech was used. Amplifications with the Clontech anchored primer and a set of AS3 specific primers resulted in a 419 by fragment. The DNA
was cloned and sequencing data showed that it carried the N-terminal 118 amino acids of the open reading frame. The nucleotide sequence reported herein has been submitted to GenBank under the accession number U95825 (see also Geck et al., (1999) J.
Steriod Biochem. ~.Tol. Biol., 68:41-50).
EXAMPLE 2.
CHARACTERIZATION OF THE AS3 cDNA SEQUENCE
In this example, the features of the AS3 mRNA and cDNA sequences are described.
Computer analysis of the sequenced 5253 by AS3 cDNA identified a long open reading frame (Figure 1 ). The initiator methionine is at position 66, the stop codon was found at position 4239, and the region codes for a polypeptide of 1391 residues. 'the initiator is the first AUG codon downstream from the 5' end of the sequence, and appears in a strong Kozak-context (Kozak, (1991) J. Biol. Chem. 266:19867-19870; Kozak, (1991) J.
Cell Biol. 115:887-903). The Northern blot size of the transcript is between 5.3 and 5.5 kb (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218) and since the sequence reported here has 5253 nucleotides plus the poly-A tail, the 5' end of our sequence is at or within a few nucleotides of the 5' physical end, further suggesting that the initiator is authentic. The 5' non-coding region is high in GC nucleotides (63.3 %), but it has no recognizable secondary structure elements or other sequence features. The 3' noncoding region has several destabilizing AT-rich elements (underlined in Figure 1 ), typical of transcripts claimed to play a role in cell proliferation (Shaw et al., (1986) Cell 46:659-667, Chen et al., (1995) Trends Biochem. Sci. 20:465-470). The polyadenylation signal of the transcript is 25 by upstream of the consensus GT-rich cleavage site (indicated in a larger font in Figure 1 ).
EXAMPLE 3.
In this example, various structural and functional features of the AS3 polypeptide are described.
Computer analysis of the AS3 open reading frame was performed using the Translate program of the Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wisconsin. (3-strand and a-helix structures were calculated by the Chou-Fasman 1 S method using PepStructure and PepPlot programs. Motif and profile predictions were calculated using various programs of the Wisconsin Package, or by using remote servers offering sequence analyses of protein functional domains through the Internet.
The following remote servers were used: PROWEB (http://www.proweb.org); BLOCKS
(http://www.blocks.fhcrc.org); PRODOM (http://www.toulouse.inra.fr/prodom/);
PRINTS
(http://www.biochem.ucl.ac.uk/cgi-bin/attwood/) and the Protein Kinase Resource (http://www.sdsc.edu/Kinases/).
Employing the above programs, the expected molecular weight of the AS3 polypeptide is determined as 186 kD. In addition, it's noted that the N-terminal 400 amino acid domain is characterized by a unique arrangement of 31 aliphatic residues (21 of them are leucines). Every seventh position (with minor variations) is occupied by a leucine or similar hydrophobic residues and in the five subdomains shown in Figure 2, the pattern is uninterrupted. The arrangement is typical for coiled-coil structures where one side of the long a,-helices is hydrophobic and usually participates in protein-protein interactions (Lupas, (1996) Trends Biochem. Sci. 22:375-382; Beavil et al., (1992) Proc. Natl.
Acad. Sci. USA
89:753-757). The leucine-zipper motif of DNA binding proteins is a specific subclass of _78_ this general pattern and the subdomain between positions 196 and 217 in the AS3 sequence is a perfect leucine-zipper.
The AS3 polypeptide sequence between positions 400 and 600 has elements of a conserved Mg-ATP binding domain of various nucleotide triphosphate binding proteins including protein kinases. In Figure 3, the AS3 sequence is shown in the conserved subdomain arrangements established by Hanks (Hanks et al. , ( 1991 ) Methods Enzymol.
200:38-62). The conserved (3-strand, a,-helix structures and highly conserved critical residues are also indicated, together with the corresponding sequences of various protein kinases (Taylor et al., (1992) Annu. Rev. Cell Biol. 8:429-462). Although the complete AS3 sequence did not appear to be related to any particular protein kinase or ATP binding protein, partial homology within the subdomains was maintained, and probably indicates that the domain is functional. Indeed, one feature of the AS3 polypeptide is the presence of several relatively well conserved kinase -related domains such as an Mg-nucleotide triphosphate binding pocket, as well as elements of the catalytic domain of several protein kinases (see Figure 3). Functional analysis of this domain using GST-fusion constructs indicates that the fusion construct polypeptide can form a complex resulting in the phosphorylation of at least two substrate proteins found in LNCaP-FGC cell extracts.
In addition to the above-mentioned motifs, the AS3 polypeptide also has a functional protein kinase domain located at amino acid residues 474-680 (encoded by nucleic acids 1420-2040; see SEQ ID NO: 3). To demonstrate that this region of the AS3 polypeptide has kinase activity, and is, e.g., capable of phosphorylating cellular substrates, the nucleic acid encoding this region was PCR amplified (using a corresponding upstream primer with a BamHI site and a corresponding downstream primer with a EcoRI site), digested, purified, and cloned into BamHI sites of the bacterial GST-fusion vector pGEX-T2 thereby fusing the AS3 domain to the C-terminus of GST (thus, the fusion protein is referred to as GST-AS3).
The resultant construct, encoding a GST-AS3 fusion protein, was then transferred into bacteria (BL21 protease minus host) which were then induced to express the GST-AS3 fusion protein.
Bacterial extracts containing the GST/AS3 fusion protein were incubated with MCF7-AR1 cell extracts in the presence of 32P-ATP and chromatographed through glutathione-Sepharose.
Proteins which specifically bound to the GST-AS3 fusion protein were resolved by SDS-PAGE and autoradiography using standard conditions. Two polypeptides (40 and 120 kDa) were specifically purified and phosphorylated by the AS3-GST fusion protein demonstrating the functional kinase activity of this protein kinase domain of AS3. There was no 32P-labelled band observed at 90 kDa (the mass of the AS3-GTS fusion protein) suggesting that the AS3 kinase domain does not auto-phosphorylate but phosphorylates other proteins through, e.g., a docking mechanism.
Furthermore, a putative nuclear localization sequence (NLS) (KKFTQVLEDDEKIRK) resembling that of the androgen receptor and DNA polymerase-a was localized at position 547( Zhou et al., (1994) J. Biol. Chem. 269:13115-13123;
Bouvier et al., (1995 Mol. Biol. Cell 6:1697-1705). Further, the C-terminal region of the putative AS3 polypeptide contains several sequence elements that show similarities to DNA
binding proteins. Motifs and ProfileScan searches in the Wisconsin Package indicated helix-loop-helix and Homeo-box signature sequences in the area, and a remote search on the BLOCKS server also identified DNA binding block elements in the C-terminal sequences.
Still further, it is noted a serine-rich domain at position 1139, and a proline/glycine-rich domain at the 1284 position were also found. The C-terminal domain (about 200 amino acids) is highly charged and arranged in unique repeats of seven alternating acidic and basic domains.
A BLASTP search performed on the GenBank database resulted in a single high score similarity with the bimD gene of the eukaryotic organism Aspergillus nidulans, where 50% of the amino acid sequence was functionally similar in portions of the coiled-coil domain and the putative DNA binding domain at the C-terminus. The bimD protein has a basic leucine-zipper and a C-terminal charged (acidic) domain, similar to AS3, and appears to function as a DNA binding protein (benison et al., (1992) Genetics, 134:1085-1096).
Both the AS3 and the bimD proteins also have nuclear localization consensus sequences.
Finally, to confirm that the AS3 polypeptide is capable of binding to DNA and moreover, to elucidate a DNA motif that binds to the DNA recognition sequence of AS3, an AS3-GST fusion polypeptide containing the DNA recognition sequence of AS3 was produced using a similar approach as used above to assay AS3 kinase activity.
Briefly, an expression vector was engineered to encode the DNA binding domain of AS3 fused to the N-terminus of GST (thus, the fusion protein is referred to as AS3-GST) which, when expressed in bacteria, allowed for the production of an AS3-GST
fusion protein for DNA binding studies. The AS3-GST protein was then purified by affinity chromatography as described above. Next, the resultant, purified AS3-GST protein was incubated with a mixture of oligonucleotides comprising constant 5' (25 bp) and 3' (25 bp) ends and randomly generated middle segments (18 bp) and chromatographed through a glutathione-Sepharose the column. To avoid non-specific binding, double stranded poly(dI-dC) (average length 1800 bp) was added to the mixture. The AS3-GST fusion protein, together with bound oligonucleotides, was eluted with glutathione and the bound oligonucleotides were amplified by PCR, purified, and subjected to a second round of column chromatography using AS3-GST
before being PCR amplified and cloned into a TA vector.
Thirty clones were sequenced to assess whether a specific nucleotide sequence was recognized by the AS3-GST fusion product. The sequences were compared and analyzed by the PILE-UP program of the GCG package. The co-alignment of the sequences revealed a pattern of the following putative consensus sequence:
5' C, T, A, [T/A], [T/A], A, G, [C/G], C, C, C, [C/G], G, C, [C/G]), C, A, [A/T], 3' (SEQ ID
NU: 5) Interestingly, sequence similarities were found between the putative AS3 DNA
recognition sequence and the NF-kappaB and the Mbpl recognition motifs. In addition, similarities within the p27~'" promoter at positions -270, -383, -427, and -586 were also found indicating that important gene regulatory elements exist in the cell in which the AS3 protein may interact with (Zhang et al., (1997) Biochem. Biophys. Acta., 1353:307-317). Interestingly, the transcription factor NF-kappaB, which is involved in the control of apoptosis, and Mbpl which is involved in the Gl-S cell cycle transition in yeast, also interact with similar DNA
motifs (Waddick et al., (1999) Biochem. Pharmacol., 57:9-17; Koch et al., (1993) Science, 261:1551-1557).
Accordingly, it was concluded that AS3 is capable of binding to DNA in a sequence specific manner and therefore, may function as a transcriptional regulator of genes involved in cell growth control.
EXAMPLE 4.
MARKERS FOR DISEASE
In this example, aspects of the AS3 genomic locus and the use of AS3 related molecules as markers for disease are described.
A computer homology search in GenBank was performed and identified the AS3 genomic region as residing on chromosome 13q12-q13. This area is represented by cosmid 267p 19, and on P 1 artificial chromosomes PAC26H23 and PAC49J 10. Consensus splicing donor and acceptor sites were identified and the entire exon-intron structure of the AS3 gene was resolved comparing the cDNA sequence and the genomic sequence using the BLAST
program (see Figure 4) (Shapiro et al., (1987) Nucl. Acids Res. 15:7155-7174).
The actual cosmid and cDNA positions are listed in Figure 4, and the arrangement of exons is depicted in Figure 5. The area covers nearly 200,000 by and the average size of the exons is 100-150 bp.
Interestingly, the AS3 genomic area is centromeric to the RB 1 locus, and telomeric to BRCA2. The AS3 gene is transcribed in the same direction as BRCA2, and the coding strand is downstream from the breast cancer gene (Couch et al., (1997]
Genomics 36:86-99). On the opposite strand upstream of AS3, three regions were assigned to cDNAs of unknown functions. An expressed sequence (CG008) has been assigned to this area, and represents a portion of the AS3 transcript (Couch et al., (1997) Genomics 36:86-99). The N
terminal 354 amino acids of the open reading frame are missing in the CG008 sequence in GenBank. The CG008 open reading frame terminates at amino acid 738 of the AS3 sequence. The sequencing data reported herein and the published genomic sequence are identical, confirming the correct sequence of AS3. The extra C at nucleotide position 1,109 in the CG008 sequence suggests a possible sequencing error that results in a frame shift and a stop codon at position 1,152 of the CG008 sequence.
With the above information in hand, it was observed that several epidemiological studies support a link between breast and prostate cancers implying shared genetic suppressor elements in both disease states (Thiessen, (1974) Cancer 34:1102-1107;
Tulinius et al., (1992) Br. Med. J. 305:855-857). For example, studies of breast cancer families with high loss of heterogenicity (LOH) in the BRCA2 area showed that high W~ 00/50454 PCT/US00/04732 -prostate cancer incidence also occurred in 4 out of 5 families examined (Gudmundsson et al., (1995) Cancer Res. 55:4830-4832). Further, in the majority of the male relatives with prostate cancer in these families (86%), allelic losses in the BRCA2 area were also detected with some of these mutations occurring in the region immediately downstream of the BRCA2 gene (Gudmundsson et al., (1995) Cancer Res. 55:4830-4832; Van den Berg et al., (1996) Br. J. Cancer 74:1615-1619; Cleton-Jansen et al., (1995) Br. J. Cancer 72:1241-1244).
Moreover, it was noted that putative suppressors in the immediate vicinity of BRCA2 are not only limited to sex hormone-related cancers. For example, recent studies on chronic lymphoid leukemia detected a 1 Mb allelic loss in this region, with no mutations in the BRCA2 gene, pointing to a cryptic suppressor next to this gene (Garcia-Marco et al., (1996) Blood 88:1568-1575; Caldas et al., (1997) Proc. Am. Assoc. Cancer Res.
38:191).
As indicated herein, the coding sequence of AS3 lies within this area. Thus, AS3 (or AS3-related molecules) may be associated with a number of diseases and conditions at several different levels involving, e.g., genomic alterations (including deletions and/or mutations at the chromosomal level), altered transcription or transcript production, and/or altered protein or protein expression levels. Thus, "AS3 related molecules" include, nucleic acid fragments or probes derived from the AS3 genomic locus (or an AS3 cDNA), and AS3 or AS3 related proteins or protein fragments.
In addition to foregoing, the ability to determine AS3 protein expression levels, altered AS3 proteins, and/or AS3 protein expression patterns in, for example, different tissue samples (such a biopsy sample from, e.g., the prostate) may be desired. To this end, several antibodies have been developed that specifically bind the AS3 polypeptide. Briefly, computer aided sequence analysis of the AS3 protein was performed in order to identify several antigenic areas of the AS3 protein that were suitable for use as an immunogen. Accordingly, oligopeptides corresponding to amino acid residues 711-727 and 1,369-1387 of SEQ ID NO: 4 were synthesized and used to raise antibodies in, respectively, rabbits and chickens (egg yolk immunoglobulin Y). The resultant antibodies were both tested against cellular extracts derived from either LNCaP-FGC or MCF7-ARl cells induced with androgen to express AS3 protein and both antibody preparations recognized a protein band of the expected size for AS3 protein.
Thus, these antibodies can be used for performing, for example, immunocytochemistry on various cell samples (e.g., biopsies of the prostate) for various prognostic and diagnostic determinations:
Accordingly, it was concluded that the AS3-related molecules and AS3-specific antibodies disclosed herein are useful prognostic/diagnostic probes for evaluating diseases (e.g., the aforementioned cancers) that are associated with, or map to, the AS3 locus or are associated with altered AS3 protein expression.
EXAMPLE 5.
In this example, the use of AS3 as a marker in guiding the appropriate administration of hormone therapy for prostate cancer is discussed.
It was determined that expression analysis of the AS3 transcript demonstrated proliferation arrest-specific induction patterns, starting soon (4-6 h) after androgen exposure (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218). AS3 levels peaked at 18-20 h, about 4 h before the commitment for proliferative shutoff was detected, suggesting that this gene is a candidate for a shutoff mediator. Furthermore, expression of the AS3 transcript positively correlated with proliferation arrest as this gene was expressed only in shutoff positive cell lines and variants. In addition, LNCaP-FGC cells proliferated maximally in CDHuS supplemented with 30 pM R1881 and under these conditions AS3 was not expressed. When AS3 was strongly induced in the presence of hormone (i.e., 0.3-30 nM of R1881), the cells were inhibited from proliferating. An additional observation that indicates the AS3 gene codes for an inhibitor of the proliferation of prostate cells is the increase of AS3 mRNA levels in the rat prostate when proliferation was arrested by prolonged androgen administration. In addition, comparable effects in MCF7-AR1 cells have been observed. Finally, significant homology between the fungal gene bimD
and AS3 was found. Importantly, it was noted that overexpression of bimD in Aspergillus nidulans results in a cell cycle arrest in G1/S phase and observe a similar cell cycle arrest and concordant peak expression of AS3 in mammalian cells induced to undergo androgen-induced proliferative shutoff (benison et al., (1992) Genetics, 134:1085-1096;
Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218).
Based on these observations, it was concluded that AS3 expression is a useful marker of responsiveness of prostate cancer cells to the inhibitory effect of androgens. In order to make the tumor regress, avoid reoccurrence, and maintain an acceptable quality of life, patients presenting this response may be treated with alternate cycles of antiandrogens and androgens. Androgens have a biphasic effect on the normal prostate: an initial phase of increased proliferation (Step 1 ) followed by a phase of inhibition (Step 2).
Prior to the invention, prostate cancer has been treated by hormone ablation (castration, antiandrogens) to take advantage of Step I. Usually after a significant regression, the remaining tumor cells become resistant and the tumor and/or metastases relapse. The invention avoids this problem by allowing the clinician to subject patients to an intermittent therapy. This is based on a classification of patients who have an increased chance to be responsive to the intermittent hormone therapy. Patients not showing AS3 positive cancer cells would then be subjected to alternative therapies (chemotherapy, radiation, etc.). In contrast, the protocol for AS3 positive patients would be to first administer antiandrogens, to block the proliferative effect and return PSA
levels to normal, and then to treat the patient with physiological but high doses of androgen to elicit Step 2.
The invention allows the clinician to confidently assess the initial hormone dependence of the tumor (i.e., whether tumor cells express AS3 in response to hormone) and determine when to re-expose the patient to hormone. Importantly, the use of intermittent hormone therapy allows the clinician to determine exactly when cells are no longer responding to hormone such that hormone treatment can be withdrawn before the cells become refractory to hormone treatment and untreatable. If the patient develops metastases capable of being biopsied, assaying AS3 levels as described herein would allow a renewed attempt to reduce the proliferation of those cancer cell by increasing the androgen concentration of the treatment. This important aspect of the invention should allow the clinician to lower the rate at which clones of cells develop hormone resistance and become capable of multiplying and metastasizing without androgen stimulation. Moreover, this new treatment regime affords a better quality of life for the patient because, unlike with constant hormone treatment, sexual drive and potency are recovered.
EXAMPLE 6.
INDUCED SUPPRESSOR OF CELL PROLIFERATION
In this example, an inducible antisense assay is provided for demonstrating that AS3 is an androgen-inducible suppressor of cell proliferation.
To demonstrate androgen-inducible AS3 suppressor activity in a proliferating cell (i.e., proliferative shut off activity), clonal cell lines were derived in which the presence or absence of AS3 could be controlled using an inducible AS3 antisense gene. The prediction was that cells incubated in the presence of androgen would have reduced levels of proliferation as compared to the same cells in the absence of androgen or cells in the presence of androgen but in which levels of AS3 had been experimentally ablated. Thus, cells incubated in the presence of androgen, but also induced to express antisense AS3 gene transcript which removes cellular levels of the AS3, would be predicted to grow like wild type cells because, even though the cells were being exposed to androgen, there would be insufficient AS3 to mediate the androgen signal reducing cell growth. This is precisely what was observed (see, e.g., Table 1 ), thereby demonstrating that AS3 is an androgen-induced suppressor of cell proliferation.
In order to develop the foregoing novel cell lines in which to demonstrate that AS3 mediates the androgen-induced shutoff effect, an inducible transgene encoding an AS3 antisense transcript (or empty vector as a negative control) was genetically engineered into a retroviral vector backbone for efficient, stable, integration into cells. In particular, the AS3 antisense gene was cloned into the Clontech pRevTRE retroviral vector under the control of a tetracycline sensitive promoter. The promoter has seven repeats of the bacterial tet0 operator sequence upstream of the minimal CMV promoter which can be bound by the tetracycline transactivator (tTA). The tTA is a fusion protein between the bacterial tetracycline repressor and the V 16 herpes virus transactivator. The tetracycline transactivator is sensitive for tetracycline such that, in the presence of tetracycline, the transactivator cannot bind the tetracycline promoter so the transgene is "off ' and conversely, in the absence of tetracycline, the gene is "on" (i.e., the Tet-Off system;
see, e.g., Clontech pRevTRE manual for further details).
To stably introduce the foregoing inducible vectors into cells, the vectors were first transfected into a packaging cell line (PT67) under drug selection (hygromycin). After 2-3 weeks of selection, the surviving packaging cells were used as a source of supernatants containing infectious virions containing the inducible transgene.
The supernatants containing the highest amounts of virions were then used to infect the STFX1 cell line, a derivative of the MCF7-AR1 that has a tetracycline transactivator gene stably integrated. During the cloning and selection procedures, cells were maintained in 1 ~g/mL of tetracycline to suppress the expression of the inducible transgenes.
In order to characterize the cell lines expressing AS3 antisense and the "control" cell lines having vector without insert, cells were incubated in the presence (i.e., the transgene is off) and absence of tetracycline (i.e., the transgene is on) and, after 36 hours, assayed for transcript expression using RT-PCR under standard conditions, To determine the affect of androgen induced AS3 suppression of cellular growth, cells lines showing high levels of inducible AS3 antisense expression were chosen for further study. Cells were seeded onto coverslips in standard growth medium and allowed to grow for 5 days in the presence of 10 ~g/ml tetracycline (hereafter "tet").
Then, the medium was changed to i) 10 ~g/ml tet, or ii) no tet for 36 hours as indicated in Table 1. Then, vehicle or 10 nM of the androgen 81881 was added. Finally, 24 hours later, the cells were treated with 10 ~g/ml of bromodeoxyuridine (BrdU) for several hours to measure the percent of cells actively proliferating as a function of BrdU incorporation during DNA
replication. The cells were then fixed, Hoechst stained, and the percent number of BrdU-labeled cells was determined using immunocytochemistry (using standard BrdU
labeling regents and protocols from Boheringer).
As clearly indicated in Table 1, administration of the androgen 81881 results in a significant decrease in the number of proliferating cells in S phase (compare to sample 1 where cells are not treated with androgen) when cellular levels of AS3 are unaffected because the transgene vector is empty and uninduced (sample 2), empty and induced (sample 4), or encoding AS3 but uninduced (sample 6). In stark contrast, when AS3 levels are reduced by antisense expression in the absence of tetracycline, the androgen Rl 881 no longer induces a proliferative shutoff (compare sample 8 with sample 6).
WO 00/50454 PCT/tJS00/04732 _87_ Table 1. Analysis of the effect of tetracycline and androgen on the percent BrdU-labeled nuclei of STFXl cells containing vector only or AS3 antisense constructs Sample Treatment % Proliferating Cells (Mean +I- S.E.) 1 vector, +tet, -A 35.0 +I-1.7 2 vector, +tet, +A 9.4 +I-1.7 3 vector, -tet, -A 36.6 +/-2.7 4 vector, -tet, +A 10.7 +~-0.9 Antisense, +tet, -A 34.7 +~-1.0 6 Antisense, +tet, +A 9.7 +I-0.6 7 Antisense, -tet, -A 32.2 +/-1.5 8 Antisense, -tet, +A 29.1 +I-1.6 5 Vector denotes STFX1 cells expressing empty vector under tetracycline control. Tetracycline is abbreviated tet; A denotes 10 nM R1881. Antisense denotes STFX1 cells expressing AS3-antisense under tetracycline control. Tetracycline represses the expression of the vector and the AS3 antisense. Each data point represents the mean of 8-9 low power fields containing about 150-200 cells/field. Data were analyzed using the Mann-Whitney test; significance was measured at p<0.001.
This experiment further shows that the expression of the empty vector neither interferes with the androgen-mediated shutoff, nor results in toxic effects.
Accordingly, it is concluded that androgen induced suppression of cell proliferation (or proliferative shutoff) is modulated by AS3 because expression of an AS3 antisense that reduces cellular levels of AS3 results in the unlinking of androgen-induced AS3-mediated suppression of cell growth.
_gg_ Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
What is claimed:
SEQUENCE LISTING
<110> Soto, Ana, et al.
<120> A NOVEL ANDROGEN-INDUCED SUPPRESSOR OF CELL PROLIFERATION AND USES
THEREOF
<130> MBI-008-1 <140>
<141>
<160> 5 <170> PatentIn Ver. 2.0 <210> 1 <211> 5271 <212> DNA
<213> Homo Sapiens <220>
<221> CDS
<222> (66)..(4238) <400> 1 ccggagagcc ccggagtgag cggagtagcg agtcggcaac ccggaggggt agaaatattt 60 ctgtc atg get cat tca aag act agg acc aat gat gga aaa att aca tat 110 Met Ala His Ser Lys Thr Arg Thr Asn Asp Gly Lys Ile Thr Tyr ccg cct ggg gtc aag gaa ata tca gat aaa ata tct aaa gag gag atg 158 Pro Pro Gly Val Lys Glu Ile Ser Asp Lys Ile Ser Lys Glu Glu Met gtg aga cga tta aag atg gtt gtg aaa act ttt atg gat atg gac cag 206 Val Arg Arg Leu Lys Met Val Val Lys Thr Phe Met Asp Met Asp Gln gac tct gaa gaa gaa aag gag ctt tat tta aac cta get tta cat ctt 254 Asp Ser Glu Glu Glu Lys Glu Leu Tyr Leu Asn Leu Ala Leu His Leu get tca gat ttt ttt ctc aag cat cct ggt aaa gat gtt cgc tta ctg 302 Ala Ser Asp Phe Phe Leu Lys His Pro Gly Lys Asp Val Arg Leu Leu gta gcc tgc tgc ctt get gat att ttc agg att tat get cct gaa get 350 Val Ala Cys Cys Leu Ala Asp Ile Phe Arg Ile Tyr Ala Pro Glu Ala cct tac aca tcc cct gat aaa cta aag gat ata ttt atg ttt ata aca 398 Pro Tyr Thr Ser Pro Asp Lys Leu Lys Asp Ile Phe Met Phe Ile Thr aga cag ttg aag ggg cta gag gat aca aag agc cca caa ttc aat agg 446 Arg Gln Leu Lys Gly Leu Glu Asp Thr Lys Ser Pro Gln Phe Asn Arg tat ttt tat tta ctt gag aac att get tgg gtc aag tca tat aac ata 494 Tyr Phe Tyr Leu Leu Glu Asn Ile Ala Trp Val Lys Ser Tyr Asn Ile tgc ttt gag tta gaa gat agc aat gaa att ttc acc cag cta tac aga 542 Cys Phe Glu Leu Glu Asp Ser Asn Glu Ile Phe Thr Gln Leu Tyr Arg acc tta ttt tca gtt ata aac aat ggc cac aat cag aaa gtc cat atg 590 Thr Leu Phe Ser Val Ile Asn Asn Gly His Asn Gln Lys Val His Met cac atg gta gac ctt atg agc tct att att tgt gaa ggt gat aca gtg 638 His Met Val Asp Leu Met Ser Ser Ile Ile Cys Glu Gly Asp Thr Val tctcaggagcttttggatacggttttagtaaatctggtacctgetcat 686 SerGlnGluLeuLeuAspThrValLeuValAsnLeuValProAlaHis aagaatttaaacaagcaagcatatgattt.ggcaaaggetttactgaag 734 LysAsnLeuAsnLysGlnAlaTyrAspLeuAlaLysAlaLeuLeuLys aggacagetcaagetattgagccatatattaccactttttttaatcag 782 ArgThrAlaGlnAlaIleGluProTyrIleThrThrPhePheAsnGln gttctgatgcttgggaaaacatctatcagcgatttgtcagagcatgtc 830 ValLeuMetLeuGlyLysThrSerIleSerAspLeuSerGluHisVal tttgacttaattttggagctctacaatattgatagtcatttgctgctc 878 PheAspLeuIleLeuGluLeuTyrAsnIleAspSerHisLeuLeuLeu tctgttttaccccagcttgaatttaaattaaagagcaatgataatgag 926 SerValLeuProGlnLeuGluPheLysLeuLysSerAsnAspAsnGlu gagcgcctacaagttgttaaactactggcaaaaatgtttggggcaaag 974 GluArgLeuGlnValValLysLeuLeuAlaLysMetPheGlyAlaLys gattcagaattggettctcaaaacaagccactttggcagtgctacttg 1022 AspSerGluLeuAlaSerGlnAsnLysProLeuTrpGlnCysTyrLeu ggcaggtttaatgatatccatgtaccaatccgcctggaatgtgtgaaa 1070 GlyArgPheAsnAspIleHisValProIleArgLeuGluCysValLys tttgetagccattgtctcatgaaccatcctgatttagcaaaagactta 1118 PheAlaSerHisCysLeuMetAsnHisProAspLeuAlaLysAspLeu acagagtatcttaaagtgaggtcacatgaccctgaggaagetattaga 1166 ThrGluTyrLeuLysValArgSerHisAspProGluGluAlaIleArg catgatgttattgtgtcaatagttacagetgetaaaaaggatattctt 1214 HisAspValIleValSerIleValThrAlaAlaLysLysAspIleLeu ctggtcaatgatcacttacttaattttgtgagagagagaacattagac 1262 LeuValAsnAspHisLeuLeuAsnPheValArgGluArgThrLeuAsp aaacgatggagagtacgcaaagaagccatgatgggacttgcccaaatt 1310 LysArgTrpArgValArgLysGluAlaMetMetGlyLeuAlaGlnIle tataagaaatatgetttacagtcagcagetggaaaagatgetgcaaaa 1358 TyrLysLysTyrAlaLeuGlnSerAlaAlaGlyLysAspAlaAlaLys cagatagcatggatcaaagacaaattgctacatatatattatcaaaat 1406 GlnIleAlaTrpIleLysAspLysLeuLeuHisIleTyrTyrGlnAsn agtattgatgatcgactacttgttgaacggatctttgetcaatacatg 1454 SerIleAspAspArgLeuLeuValGluArgIlePheAlaGlnTyrMet gtt cct cac aat tta gaa act aca gaa cgg atg aaa tgc tta tat tac 1502 Val Pro His Asn Leu Glu Thr Thr Glu Arg Met Lys Cys Leu Tyr Tyr ttg tat gcc aca ctg gat tta aat get gtg aaa gca ttg aat gaa atg 1550 Leu Tyr Ala Thr Leu Asp Leu Asn Ala Val Lys Ala Leu Asn Glu Met tgg aaa tgt caa aat ctg ctc cga cat caa gta aag gat ttg ctt gac 1598 Trp Lys Cys Gln Asn Leu Leu Arg His Gln Val Lys Asp Leu Leu Asp ttg att aag caa ccc aaa aca gat gcc agt gtc aag gcc ata ttt tca 1646 Leu Ile Lys Gln Pro Lys Thr Asp Ala Ser Val Lys Ala Ile Phe Ser aaa gtg atg gtt att aca aga aat tta cct gat cct ggt aag get cag 1694 Lys Val Met Val Ile Thr Arg Asn Leu Pro Asp Pro Gly Lys Ala Gln gat ttc atg aag aaa ttc aca cag gtg tta gaa gat gat gag aaa ata 1742 Asp Phe Met Lys Lys Phe Thr Gln Val Leu Glu Asp Asp Glu Lys Ile aga aag cag tta gaa gta ctt gtt agt cca aca tgc tcc tgc aag cag 1790 Arg Lys Gln Leu Glu Val Leu Val Ser Pro Thr Cys Ser Cys Lys Gln get gaa ggt tgt gtg cgt gaa ata act aag aag ttg ggc aac ccc aaa 1838 Ala Glu Gly Cys Val Arg Glu Ile Thr Lys Lys Leu Gly Asn Pro Lys cag cct aca aat cct ttc ctg gaa atg atc aag ttt ctc ttg gag agg 1886 Gln Pro Thr Asn Pro Phe Leu Glu Met Ile Lys Phe Leu Leu Glu Arg ata gca cct gtg cac ata gat acc gaa tct atc agt get ctt att aaa 1934 Ile Ala Pro Val His Ile Asp Thr Glu Ser Ile Ser Ala Leu Ile Lys caa gtg aac aaa tca ata gat gga aca gca gat gat gaa gat gag ggt 1982 Gln Val Asn Lys Ser Ile Asp Gly Thr Ala Asp Asp Glu Asp Glu Gly gtt cca act gat caa gcc atc aga gca ggt ctt gaa ctg ctt aag gta 2030 Val Pro Thr Asp Gln Ala Ile Arg Ala Gly Leu Glu Leu Leu Lys Val ctc tca ttt aca cat ccc atc tca ttt cat tct get gaa aca ttt gaa 2078 Leu Ser Phe Thr His Pro Ile Ser Phe His Ser Ala Glu Thr Phe Glu tca tta ctg get tgt ctg aaa atg gat gat gaa aaa gta gca gaa get 2126 Ser Leu Leu Ala Cys Leu Lys Met Asp Asp Glu Lys Val Ala Glu Ala gca cta caa att ttc aaa aac aca gga agc aaa att gaa gag gat ttt 2174 Ala Leu Gln Ile Phe Lys Asn Thr Gly Ser Lys Ile Glu Glu Asp Phe cca cac atc aga tca gcc ttg ctt cct gtt tta cat cac aaa tct aaa 2222 Pro His Ile Arg Ser Ala Leu Leu Pro Val Leu His His Lys Ser Lys aaa gga ccc ccc cgt caa gcc aaa tat gcc att cat tgt atc cat gcg 2270 Lys Gly Pro Pro Arg Gln Ala Lys Tyr Ala Ile His Cys Ile His Ala ata ttt tct agt aaa gag acc cag ttt gca cag ata ttt gag cct ctg 2318 Ile Phe Ser Ser Lys Glu Thr Gln Phe Ala Gln Ile Phe Glu Pro Leu cat aag agc cta gat cca agc aac ctg gaa cat ctc ata aca cca ttg 2366 His Lys Ser Leu Asp Pro Ser Asn Leu Glu His Leu Ile Thr Pro Leu gtt act att ggt cat att get ctc ctt gca cct gat caa ttt get get 2414 Val Thr Ile Gly His Ile Ala Leu Leu Ala Pro Asp Gln Phe Ala Ala cct tgg aaa tct tgg gta get act ttc att gtg aaa gat ctt ctc atg 2462 Pro Trp Lys Ser Trp Val Ala Thr Phe Ile Val Lys Asp Leu Leu Met aat gat cgg ctt cca ggg aaa aag aca act aaa ctt tgg gtt cca gat 2510 Asn Asp Arg Leu Pro Gly Lys Lys Thr Thr Lys Leu Trp Val Pro Asp gaa gaa gta tct cct gag aca atg gtc aaa att cag get att aaa atg 2558 Glu Glu Val Ser Pro Glu Thr Met Val Lys Ile Gln Ala Ile Lys Met atg gtt cga tgg cta ctt gga atg aaa aat aat cac agt aaa tca gga 2606 Met Val Arg Trp Leu Leu Gly Met Lys Asn Asn His Ser Lys Ser Gly act tct acc tta aga ttg cta aca aca ata ttg cat agt gat gga gac 2654 Thr Ser Thr Leu Arg Leu Leu Thr Thr Ile Leu His Ser Asp Gly Asp 850 855 g60 ttg aca gaa cag ggg aaa att agt aaa cca gat atg tca cgt ctg aga 2702 Leu Thr Glu Gln Gly Lys Ile Ser Lys Pro Asp Met Ser Arg Leu Arg 865 870 g75 ctt get get ggg agt get att gtg aag ctg gca caa gaa ccc tgt tac 2750 Leu Ala Ala Gly Ser Ala Ile Val Lys Leu Ala Gln Glu Pro Cys Tyr cat gaa atc atc aca tta gaa caa tat cag cta tgt gca tta get atc 2798 His Glu Ile Ile Thr Leu Glu Gln Tyr Gln Leu Cys Ala Leu Ala Ile aacgatgaatgctatcaagtaagacaagtgtttgcccagaaacttcac 2846 AsnAspGluCysTyrGlnValArgGlnValPheAlaGlnLysLeuHis aaaggcctttcccgtttacggcttccacttgagtatatggcaatctgt 2894 LysGlyLeuSerArgLeuArgLeuProLeuGluTyrMetAlaIleCys gccctttgtgcaaaagatcctgtaaaggagagaagagetcatgetagg 2942 AlaLeuCysAlaLysAspProValLysGluArgArgAlaHisAlaArg caatgtttggtgaaaaatataaatgtaaggcgggagtatctgaagcag 2990 GlnCysLeuValLysAsnIleAsnValArgArgGluTyrLeuLysGln catgcagetgttagtgaaaaattattgtctcttctaccagagtatgtt 3038 HisAlaAlaValSerGluLysLeuLeuSerLeuLeuProGluTyrVal gttccatatacaattcaccttttggcacatgacccagattatgtcaaa 3086 ValProTyrThrIleHisLeuLeuAlaHisAspProAspTyrValLys gtacaggatattgaacaacttaaagatgttaaagaatgtctttggttt 3134 ValGlnAspIleGluGlnLeuLysAspValLysGluCysLeuTrpPhe gttctggaaatattaatggetaaaaatgaaaataacagtcacgetttt 3182 ValLeuGluIleLeuMetAlaLysAsnGluAsnAsnSerHisAlaPhe atcagaaagatggtagaaaatattaaacaaacaaaagatgcccaagga 3230 IleArgLysMetValGluAsnIleLysGlnThrLysAspAlaGlnGly ccagatgatgcaaaaatgaatgaaaaactgtacactgtgtgtgatgtt 3278 ProAspAspAlaLysMetAsnGluLysLeuTyrThrValCysAspVal gccatgaatatcatcatgtcaaagagtactacatacagtttggaatct 3326 AlaMetAsnIleIleMetSerLysSerThrThrTyrSerLeuGluSer cctaaagacccggtactaccagetcgtttcttcactcaacctgacaag 3374 ProLysAspProValLeuProAlaArgPhePheThrGlnProAspLys aatttcagtaacaccaaaaattatctgcctcctgaaatgaaatcattt 3422 AsnPheSerAsnThrLysAsnTyrLeuProProGluMetLysSerPhe ttcactcctggaaaacctaaaacaaccaatgttctaggagetgttaac 3470 PheThrProGlyLysProLysThrThrAsnValLeuGlyAlaValAsn aagccactttcatcagcaggcaagcaatctcagaccaaatcatcacga 3518 LysProLeuSerSerAlaGlyLysGlnSerGlnThrLysSerSerArg atggaaactgtaagcaatgcaagcagcagctcaaatccaagctctcct 3566 MetGluThrValSerAsnAlaSerSerSerSerAsnProSerSerPro ggaagaataaaggggagg cttgatagttctgaa atggatcacagtgaa 3614 GlyArgIleLysGlyArg LeuAspSerSerGlu MetAspHisSerGlu aatgaagattacacaatg tcttcacctttgccg gggaaaaaaagtgac 3662 AsnGluAspTyrThrMet SerSerProLeuPro GlyLysLysSerAsp aagagagacgactctgat cttgtaaggtctgaa ttggagaagcctaga 3710 LysArgAspAspSerAsp LeuValArgSerGlu LeuGluLysProArg ggcaggaaaaaaacgccc gtcacagaacaggag gagaaattaggtatg 3758 GlyArgLysLysThrPro ValThrGluGlnGlu GluLysLeuGlyMet gatgacttgactaagttg gtacaggaacagaaa cctaaaggcagtcag 3806 AspAspLeuThrLysLeu ValGlnGluGlnLys ProLysGlySerGln cgaagtcggaaaagaggc catacggettcagaa tctgatgaacagcag 3854 ArgSerArgLysArgGly HisThrAlaSerGlu SerAspGluGlnGln tggcctgaggaaaagagg ctcaaagaagatata ttagaaaatgaagat 3902 TrpProGluGluLysArg LeuLysGluAspIle LeuGluAsnGluAsp gaacagaatagtccgcca aaaaagggtaaaaga ggccgaccaccaaaa 3950 GluGlnAsnSerProPro LysLysGlyLysArg GlyArgProProLys cctcttggtggaggtaca ccaaaagaagagcca acaatgaaaacttct 3998 ProLeuGlyGlyGlyThr ProLysGluGluPro ThrMetLysThrSer aaaaaaggaagcaaaaaa aaatctggacctcca gcaccagaggaggag 4046 LysLysGlySerLysLys LysSerGlyProPro AlaProGluGluGlu gaagaagaagaaagacaa agtggaaatacggaa cagaagtccaaaagc 4094 GluGluGluGluArgGln SerGlyAsnThrGlu GlnLysSerLysSer aaacagcaccgagtgtca aggagagcacagcag agagcagaatctcct 4142 LysGlnHisArgValSer ArgArgAlaGlnGln ArgAlaGluSerPro gaatctagtgcaattgaa tccacacagtccaca ccacagaaaggacga 4190 GluSerSerAlaIleGlu SerThrGlnSerThr ProGlnLysGlyArg ggaagaccatcaaaaacg ccatcaccatcacaa ccaaaaaaaaatgtg 4238 GlyArgProSerLysThr ProSerProSerGln ProLysLysAsnVal taagttgtaa atattacatt tcaaaccaat ttcaaattat tttgcaaaag ttcctaaatt 4298 tgtaaacata catattgctg tatttaaatt ccatatattt agccccatta cactaggtac 4358 ggcggcgaag tgctaaaagg gaacggcgat gaacaaatgt aattaataac tttctctgtg 4418 aaagctttgg aaaaatcttt tttttttttt tttttttttg gtcaagcttg aggctgaata 4478 aagcctttga tgcacaaaat gggactgctg aagagtggac agttggacct tactttggtg 4538 accccataca tttgtggtca catgctttag ccatacacat ggtaacattg actatggagt 4598 cttgtgaaag tgtaatgtgc gatggctatg tagacataaa gaagaaactt gtaaatatct 4658 tttttctttt ttttaatgtt tctgatttct gaagtgcttg tatagctttt atctgcggct 4718 ttaaactgac agtacccgac tgtttattgg atctattgat ttgaaaagaa tttgttagga 4778 tagatcttaa gcagtaatct gtcagtgttt gtatttgtat tttctgcaat tttactgtga 4838 aaaaaaattt gttttcaaca attggtgtca ttttcttgat gtcactattt gttggagagt 4898 taaatggtct cttccctttg tgtatcttac ctagtgttta ctcctgggca cccttaatct 4958 tcagaggtgc taaattgtct gccattacac cagaaggatg cctctgatag gaggacaacc 5018 atgcaaattg tgaaatagtc ctgaagttct tggattactt tacacctcag tattgatttg 5078 tcccagaatt ttctggcctt tcatggcaat gaaaatttta agaagaaaga tttaaagtat 5138 tttaatttta aagagtgtgt tataaaataa tgtactgaat tctttatccc attttatcat 5198 cctttcagtt tttattaatc tactgtatca ataaaattct gtaatttgaa tgagtaaaaa 5258 aaaaaaaaaa aaa 5271 <210> 2 <211> 1391 <212> PRT
<213> Homo Sapiens <400> 2 Met Ala His Ser Lys Thr Arg Thr Asn Asp Gly Lys Ile Thr Tyr Pro Pro Gly Val Lys Glu Ile Ser Asp Lys Ile Ser Lys Glu Glu Met Val Arg Arg Leu Lys Met Val Val Lys Thr Phe Met Asp Met Asp Gln Asp Ser Glu Glu Glu Lys Glu Leu Tyr Leu Asn Leu Ala Leu His Leu Ala Ser Asp Phe Phe Leu Lys His Pro Gly Lys Asp Val Arg Leu Leu Val Ala Cys Cys Leu Ala Asp Ile Phe Arg Ile Tyr Ala Pro Glu Ala Pro Tyr Thr Ser Pro Asp Lys Leu Lys Asp Ile Phe Met Phe Ile Thr Arg Gln Leu Lys Gly Leu Glu Asp Thr Lys Ser Pro Gln Phe.Asn Arg Tyr Phe Tyr Leu Leu Glu Asn Ile Ala Trp Val Lys Ser Tyr Asn Ile Cys Phe Glu Leu Glu Asp Ser Asn Glu Ile Phe Thr Gln Leu Tyr Arg Thr Leu Phe Ser Val Ile Asn Asn Gly His Asn Gln Lys Val His Met His Met Val Asp Leu Met Ser Ser Ile Ile Cys Glu Gly Asp Thr Val Ser Gln Glu Leu Leu Asp Thr Val Leu Val Asn Leu Val Pro Ala His Lys Asn Leu Asn Lys Gln Ala Tyr Asp Leu Ala Lys Ala Leu Leu Lys Arg Thr Ala Gln Ala Ile Glu Pro Tyr Ile Thr Thr Phe Phe Asn Gln Val Leu Met Leu Gly Lys Thr Ser Ile Ser Asp Leu Ser Glu His Val Phe Asp Leu Ile Leu Glu Leu Tyr Asn Ile Asp Ser His Leu Leu Leu Ser Val Leu Pro Gln Leu Glu Phe Lys Leu Lys Ser Asn Asp Asn Glu Glu Arg Leu Gln Val Val Lys Leu Leu Ala Lys Met Phe Gly Ala Lys Asp Ser Glu Leu Ala Ser Gln Asn Lys Pro Leu Trp Gln Cys Tyr Leu Gly Arg Phe Asn Asp Ile His Val Pro Ile Arg Leu Glu Cys Val Lys Phe Ala Ser His Cys Leu Met Asn His Pro Asp Leu Ala Lys Asp Leu Thr Glu Tyr Leu Lys Val Arg Ser His Asp Pro Glu Glu Ala Ile Arg His Asp Val Ile Val Ser Ile Val Thr Ala Ala Lys Lys Asp Ile Leu Leu Val Asn Asp His Leu Leu Asn Phe Val Arg Glu Arg Thr Leu Asp Lys Arg Trp Arg Val Arg Lys Glu Ala Met Met Gly Leu Ala Gln Ile Tyr Lys Lys Tyr Ala Leu Gln Ser Ala Ala Gly Lys Asp Ala Ala Lys Gln Ile Ala Trp Ile Lys Asp Lys Leu Leu His Ile Tyr Tyr Gln Asn Ser Ile Asp Asp Arg Leu Leu Val Glu Arg Ile Phe Ala Gln Tyr Met Val Pro His Asn Leu Glu Thr Thr Glu Arg Met Lys Cys Leu Tyr Tyr Leu Tyr Ala Thr Leu Asp Leu Asn Ala Val Lys Ala Leu Asn Glu Met Trp Lys Cys Gln Asn Leu Leu Arg His Gln Val Lys Asp Leu Leu Asp Leu Ile Lys Gln Pro Lys Thr Asp Ala Ser Val Lys Ala Ile Phe Ser Lys Val Met Val Ile Thr Arg Asn Leu Pro Asp Pro Gly Lys Ala Gln Asp Phe Met Lys Lys Phe Thr Gln Val Leu Glu Asp Asp Glu Lys Ile Arg Lys Gln Leu Glu Val Leu Val Ser Pro Thr Cys Ser Cys Lys Gln Ala Glu Gly Cys Val Arg Glu Ile Thr Lys Lys Leu Gly Asn Pro Lys Gln Pro Thr Asn Pro Phe Leu Glu Met Ile Lys Phe Leu Leu Glu Arg Ile Ala Pro Val His Ile Asp Thr Glu Ser Ile Ser Ala Leu Ile Lys Gln Val Asn Lys Ser Ile Asp Gly Thr Ala Asp Asp Glu Asp Glu Gly Val Pro Thr Asp Gln Ala Ile Arg Ala Gly Leu Glu Leu Leu Lys Val Leu Ser Phe Thr His Pro Ile Ser Phe His Ser Ala Glu Thr Phe Glu Ser Leu Leu Ala Cys Leu Lys Met Asp Asp Glu Lys Val Ala Glu Ala Ala Leu Gln Ile Phe Lys Asn Thr Gly Ser Lys Ile Glu Glu Asp Phe Pro His Ile Arg Ser Ala Leu Leu Pro Val Leu His His Lys Ser Lys Lys Gly Pro Pro Arg Gln Ala Lys Tyr Ala Ile His Cys Ile His Ala Ile Phe Ser Ser Lys Glu Thr Gln Phe Ala Gln Ile Phe Glu Pro Leu His Lys Ser Leu Asp Pro Ser Asn Leu Glu His Leu Ile Thr Pro Leu Val Thr Ile Gly His Ile Ala Leu Leu Ala Pro Asp Gln Phe Ala Ala Pro Trp Lys Ser Trp Val Ala Thr Phe Ile Val Lys Asp Leu Leu Met Asn Asp Arg Leu Pro Gly Lys Lys Thr Thr Lys Leu Trp Val Pro Asp Glu Glu Val Ser Pro Glu Thr Met Val Lys Ile Gln Ala Ile Lys Met Met Val Arg Trp Leu Leu Gly Met Lys Asn Asn His Ser Lys Ser Gly Thr Ser Thr Leu Arg Leu Leu Thr Thr Ile Leu His Ser Asp Gly Asp Leu Thr Glu Gln Gly Lys Ile Ser Lys Pro Asp Met Ser Arg Leu Arg Leu Ala Ala Gly Ser Ala Ile Val Lys Leu Ala Gln Glu Pro Cys Tyr His Glu Ile Ile Thr Leu Glu Gln Tyr Gln Leu Cys Ala Leu Ala Ile Asn Asp Glu Cys Tyr Gln Val Arg Gln Val Phe Ala Gln Lys Leu His Lys Gly Leu Ser Arg Leu Arg Leu Pro Leu Glu Tyr Met Ala Ile Cys Ala Leu Cys Ala Lys Asp Pro Val Lys Glu Arg Arg Ala His Ala Arg Gln Cys Leu Val Lys Asn Ile Asn Val Arg Arg Glu Tyr Leu Lys Gln His Ala Ala Val Ser Glu Lys Leu Leu Ser Leu Leu Pro Glu Tyr Val Val Pro Tyr Thr Ile His Leu Leu Ala His Asp Pro Asp Tyr Val Lys Val Gln Asp Ile Glu Gln Leu Lys Asp Val Lys Glu Cys Leu Trp Phe Val Leu Glu Ile Leu Met Ala Lys Asn Glu Asn Asn Ser His Ala Phe Ile Arg Lys Met Val Glu Asn Ile Lys Gln Thr Lys Asp Ala Gln Gly Pro Asp Asp Ala Lys Met Asn Glu Lys Leu Tyr Thr Val Cys Asp Val Ala Met Asn Ile Ile Met Ser Lys Ser Thr Thr Tyr Ser Leu Glu Ser Pro Lys Asp Pro Val Leu Pro Ala Arg Phe Phe Thr Gln Pro Asp Lys Asn Phe Ser Asn Thr Lys Asn Tyr Leu Pro Pro Glu Met Lys Ser Phe Phe Thr Pro Gly Lys Pro Lys Thr Thr Asn Val Leu Gly Ala Val Asn Lys Pro Leu Ser Ser Ala Gly Lys Gln Ser Gln Thr Lys Ser.Ser Arg Met Glu Thr Val Ser Asn Ala Ser Ser Ser Ser Asn Pro Ser Ser Pro Gly Arg Ile Lys Gly Arg Leu Asp Ser Ser Glu Met Asp His Ser Glu Asn Glu Asp Tyr Thr Met Ser Ser Pro Leu Pro Gly Lys Lys Ser Asp Lys Arg Asp Asp Ser Asp Leu Val Arg Ser Glu Leu Glu Lys Pro Arg Gly Arg Lys Lys Thr Pro Val Thr Glu Gln Glu Glu Lys Leu Gly Met Asp Asp Leu Thr Lys Leu Val Gln Glu Gln Lys Pro Lys Gly Ser Gln Arg Ser Arg Lys Arg Gly His Thr Ala Ser Glu Ser Asp Glu Gln Gln Trp Pro Glu Glu Lys Arg Leu Lys Glu Asp Ile Leu Glu Asn Glu Asp Glu Gln Asn Ser Pro Pro Lys Lys Gly Lys Arg Gly Arg Pro Pro Lys Pro Leu Gly Gly Gly Thr Pro Lys Glu Glu Pro Thr Met Lys Thr Ser Lys Lys Gly Ser Lys Lys Lys Ser Gly Pro Pro Ala Pro Glu Glu Glu Glu Glu Glu Glu Arg Gln Ser Gly Asn Thr Glu Gln Lys Ser Lys Ser Lys Gln His Arg Val Ser Arg Arg Ala Gln Gln Arg Ala Glu Ser Pro Glu Ser Ser Ala Ile Glu Ser Thr Gln Ser Thr Pro Gln Lys Gly Arg Gly Arg Pro Ser Lys Thr Pro Ser Pro Ser Gln Pro Lys Lys Asn Val <210> 3 c211> 4173 <212> DNA
<213> Homo sapiens c220>
<221> CDS
<222> (1)..(4173) <400> 3 atg get cat tca aag act agg acc aat gat gga aaa att aca tat ccg 48 Met Ala His Ser Lys Thr Arg Thr Asn Asp Gly Lys Ile Thr Tyr Pro cct ggg gtc aag gaa ata tca gat aaa ata tct aaa gag gag atg gtg 96 Pro Gly Val Lys Glu Ile Ser Asp Lys Ile Ser Lys Glu Glu Met Val aga cga tta aag atg gtt gtg aaa act ttt atg gat atg gac cag gac 144 Arg Arg Leu Lys Met Val Val Lys Thr Phe Met Asp Met Asp Gln Asp tctgaagaagaaaaggagctttatttaaacctagetttacatcttget192 SerGluGluGluLysGluLeuTyrLeuAsnLeuAlaLeuHisLeuAla tcagatttttttctcaagcatcctggtaaagatgttcgcttactggta240 SerAspPhePheLeuLysHisProGlyLysAspValArgLeuLeuVal gcctgctgccttgetgatattttcaggatttatgetcctgaagetcct288 AlaCysCysLeuAlaAspIlePheArgIleTyrAlaProGluAlaPro tacacatcccctgataaactaaaggatatatttatgtttataacaaga336 TyrThrSerProAspLysLeuLysAspIlePheMetPheIleThrArg cag ttg aag ggg cta gag gat aca aag agc cca caa ttc aat agg tat 384 Gln Leu Lys Gly Leu Glu Asp Thr Lys Ser Pro Gln Phe Asn Arg Tyr ttt tat tta ctt gag aac att get tgg gtc aag tca tat aac ata tgc 432 Phe Tyr Leu Leu Glu Asn Ile Ala Trp Val Lys Ser Tyr Asn Ile Cys ttt gag tta gaa gat agc aat gaa att ttc acc cag cta tac aga acc 480 Phe Glu Leu Glu Asp Ser Asn Glu Ile Phe Thr Gln Leu Tyr Arg Thr tta ttt tca gtt ata aac aat ggc cac aat cag aaa gtc cat atg cac 528 Leu Phe Ser Val Ile Asn Asn Gly His Asn Gln Lys Val His Met His atg gta gac ctt atg agc tct att att tgt gaa ggt gat aca gtg tct 576 Met Val Asp Leu Met Ser Ser Ile Ile Cys Glu Gly Asp Thr Val Ser cag gag ctt ttg gat acg gtt tta gta aat ctg gta cct get cat aag 624 Gln Glu Leu Leu Asp Thr Val Leu Val Asn Leu Val Pro Ala His Lys aat tta aac aag caa gca tat gat ttg gca aag get tta ctg aag agg 672 Asn Leu Asn Lys Gln Ala Tyr Asp Leu Ala Lys Ala Leu Leu Lys Arg aca get caa get att gag cca tat att acc act ttt ttt aat cag gtt 720 Thr Ala Gln Ala Ile Glu Pro Tyr Ile Thr Thr Phe Phe Asn Gln Val ctg atg ctt ggg aaa aca tct atc agc gat ttg tca gag cat gtc ttt 768 Leu Met Leu Gly Lys Thr Ser Ile Ser Asp Leu Ser Glu His Val Phe gac tta att ttg gag ctc tac aat att gat agt cat ttg ctg ctc tct 816 Asp Leu Ile Leu Glu Leu Tyr Asn Ile Asp Ser His Leu Leu Leu Ser gtt tta ccc cag ctt gaa ttt aaa tta aag agc aat gat aat gag gag 864 Val Leu Pro Gln Leu Glu Phe Lys Leu Lys Ser Asn Asp Asn Glu Glu cgc cta caa gtt gtt aaa cta ctg gca aaa atg ttt ggg gca aag gat 912 Arg Leu Gln Val Val Lys Leu Leu Ala Lys Met Phe Gly Ala Lys Asp tcagaattggettctcaaaacaagccactttggcagtgctacttgggc 960 SerGluLeuAlaSerGlnAsnLysProLeuTrpGlnCysTyrLeuGly aggtttaatgatatccatgtaccaatccgcctggaatgtgtgaaattt 1008 ArgPheAsnAspIleHisValProIleArgLeuGluCysValLysPhe getagccattgtctcatgaaccatcctgatttagcaaaagacttaaca 1056 AlaSerHisCysLeuMetAsnHisProAspLeuAlaLysAspLeuThr gagtatcttaaagtgaggtcacatgaccctgaggaagetattagacat 1104 GluTyrLeuLysValArgSerHisAspProGluGluAlaIleArgHis gatgttattgtgtcaatagttacagetgetaaaaaggatattcttctg 1152 AspValIleValSerIleValThrAlaAlaLysLysAspIleLeuLeu gtcaatgatcacttacttaattttgtgagagagagaacattagacaaa 1200 ValAsnAspHisLeuLeuAsnPheValArgGluArgThrLeuAspLys cgatggagagtacgcaaagaagccatgatgggacttgcccaaatttat 1248 ArgTrpArgValArgLysGluAlaMetMetGlyLeuAlaGlnIleTyr aagaaatatgetttacagtcagcagetggaaaagatgetgcaaaacag 1296 LysLysTyrAlaLeuGlnSerAlaAlaGlyLysAspAlaAlaLysGln atagcatggatcaaagacaaattgctacatatatattatcaaaatagt 1344 IleAlaTrpIleLysAspLysLeuLeuHisIleTyrTyrGlnAsnSer attgatgatcgactacttgttgaacggatctttgetcaatacatggtt 1392 IleAspAspArgLeuLeuValGluArgIlePheAlaGlnTyrMetVal cctcacaatttagaaactacagaacggatgaaatgcttatattacttg 1440 ProHisAsnLeuGluThrThrGluArgMetLysCysLeuTyrTyrLeu tatgccacactggatttaaatgetgtgaaagcattgaatgaaatgtgg 1488 TyrAlaThrLeuAspLeuAsnAlaValLysAlaLeuAsnGluMetTrp aaatgtcaaaatctgctccgacatcaagtaaaggatttgcttgacttg 1536 LysCysGlnAsnLeuLeuArgHisGlnValLysAspLeuLeuAspLeu attaagcaacccaaaacagatgccagtgtcaaggccatattttcaaaa 1584 IleLysGlnProLysThrAspAlaSerValLysAlaIlePheSerLys gtgatggttattacaagaaatttacctgatcctggtaaggetcaggat 1632 ValMetValIleThrArgAsnLeuProAspProGlyLys.AlaGlnAsp ttcatgaagaaattcacacaggtgttagaagatgatgagaaaataaga 1680 PheMetLysLysPheThrGlnValLeuGluAspAspGluLysIleArg aagcagttagaagtacttgttagtccaacatgctcctgcaagcagget1728 LysGlnLeuGluValLeuValSerProThrCysSerCysLysGlnAla gaaggttgtgtgcgtgaaataactaagaagttgggcaaccccaaacag1776 GluGlyCysValArgGluIleThrLysLysLeuGlyAsnProLysGln cctacaaatcctttcctggaaatgatcaagtttctcttggagaggata1824 ProThrAsnProPheLeuGluMetIleLysPheLeuLeuGluArgIle gcacctgtgcacatagataccgaatctatcagtgetcttattaaacaa1872 AlaProValHisIleAspThrGluSerIleSerAlaLeuIleLysGln gtgaacaaatcaatagatggaacagcagatgatgaagatgagggtgtt1920 ValAsnLysSerIleAspGlyThrAlaAspAspGluAspGluGlyVal ccaactgatcaagccatcagagcaggtcttgaactgcttaaggtactc1968 ProThrAspGlnAlaIleArgAlaGlyLeuGluLeuLeuLysValLeu tcatttacacatcccatctcatttcattctgetgaaacatttgaatca2016 SerPheThrHisProIleSerPheHisSerAlaGluThrPheGluSer ttactggettgtctgaaaatggatgatgaaaaagtagcagaagetgca2064 LeuLeuAlaCysLeuLysMetAspAspGluLysValAlaGluAlaAla ctacaaattttcaaaaacacaggaagcaaaattgaagaggattttcca2112 LeuGlnIlePheLysAsnThrGlySerLysIleGluGluAspPhePro cacatcagatcagccttgcttcctgttttacatcacaaatctaaaaaa2160 HisIleArgSerAlaLeuLeuProValLeuHisHisLysSerLysLys ggacccccccgtcaagccaaatatgccattcattgtatccatgcgata2208 GlyProProArgGlnAlaLysTyrAlaIleHisCysIleHisAlaIle ttttctagtaaagagacccagtttgcacagatatttgagcctctgcat2256 PheSerSerLysGluThrGlnPheAlaGlnIlePheGluProLeuHis 740 745' 750 aagagcctagatccaagcaacctggaacatctcataacaccattggtt2304 LysSerLeuAspProSerAsnLeuGluHisLeuIleThrProLeuVal actattggtcatattgetctccttgcacctgatcaatttgetgetcct2352 ThrIleGlyHisIleAlaLeuLeuAlaProAspGlnPheAlaAlaPro tggaaatcttgggtagetactttcattgtgaaagatcttctcatgaat2400 TrpLysSerTrpValAlaThrPheIleValLysAspLeuLeuMetAsn gatcggcttccagggaaaaagacaactaaactttgggttccagatgaa2448 AspArgLeuProGlyLysLysThrThrLysLeuTrpValProAspGlu gaagtatctcctgag acaatggtcaaaattcaggetattaaaatgatg 2496 GluValSerProGlu ThrMetValLysIleGlnAlaIleLysMetMet gttcgatggctactt ggaatgaaaaataatcacagtaaatcaggaact 2544 ValArgTrpLeuLeu GlyMetLysAsnAsnHisSerLysSerGlyThr tctaccttaagattg ctaacaacaatattgcatagtgatggagacttg 2592 SerThrLeuArgLeu LeuThrThrIleLeuHisSerAspGlyAspLeu acagaacaggggaaa attagtaaaccagatatgtcacgtctgagactt 2640 ThrGluGlnGlyLys IleSerLysProAspMetSerArgLeuArgLeu getgetgggagtget attgtgaagctggcacaagaaccctgttaccat 2688 AlaAlaGlySerAla IleValLysLeuAlaGlnGluProCysTyrHis gaaatcatcacatta gaacaatatcagctatgtgcattagetatcaac 2736 GluIleIleThrLeu GluGlnTyrGlnLeuCysAlaLeuAlaIleAsn gatgaatgctatcaa gtaagacaagtgtttgcccagaaacttcacaaa 2784 AspGluCysTyrGln ValArgGlnValPheAlaGlnLysLeuHisLys ggcctttcccgttta cggcttccacttgagtatatggcaatctgtgcc 2832 GlyLeuSerArgLeu ArgLeuProLeuGluTyrMetAlaIleCysAla ctttgtgcaaaagat cctgtaaaggagagaagagetcatgetaggcaa 2880 LeuCysAlaLysAsp ProValLysGluArgArgAlaHisAlaArgGln tgtttggtgaaaaat ataaatgtaaggcgggagtatctgaagcagcat 2928 CysLeuValLysAsn IleAsnValArgArgGluTyrLeuLysGlnHis gcagetgttagtgaa aaattattgtctcttctaccagagtatgttgtt 2976 AlaAlaValSerGlu LysLeuLeuSerLeuLeuProGluTyrValVal ccatatacaattcac cttttggcacatgacccagattatgtcaaagta 3024 ProTyrThrIleHis LeuLeuAlaHisAspProAspTyrValLysVal caggatattgaacaa cttaaagatgttaaagaatgtctttggtttgtt 3072 GlnAspIleGluGln LeuLysAspValLysGluCysLeuTrpPheVal ctggaaatattaatg getaaaaatgaaaataacagtcacgettttatc 3120 LeuGluIleLeuMet AlaLysAsnGluAsnAsnSerHisAlaPheIle agaaagatggtagaa aatattaaacaaacaaaagatgcccaaggacca 3168 ArgLysMetValGlu AsnIleLysGlnThrLysAspAlaGlnGlyPro gatgatgcaaaaatg aatgaaaaactgtacactgtgtgtgatgttgcc 3216 AspAspAlaLysMet AsnGluLysLeuTyrThrValCysAspValAla atg aat atc atc atg tca aag agt act aca tac agt ttg gaa tct cct 3264 Met Asn Ile Ile Met Ser Lys Ser Thr Thr Tyr Ser Leu Glu Ser Pro aaa gac ccg gta cta cca get cgt ttc ttc act caa cct gac aag aat 3312 Lys Asp Pro Val Leu Pro Ala Arg Phe Phe Thr Gln Pro Asp Lys Asn ttc agt aac acc aaa aat tat ctg cct cct gaa atg aaa tca ttt ttc 3360 Phe Ser Asn Thr Lys Asn Tyr Leu Pro Pro Glu Met Lys Ser Phe Phe act cct gga aaa cct aaa aca acc aat gtt cta gga get gtt aac aag 3408 Thr Pro Gly Lys Pro Lys Thr Thr Asn Val Leu Gly Ala Val Asn Lys cca ctt tca tca gca ggc aag caa tct cag acc aaa tca tca cga atg 3456 Pro Leu Ser Ser Ala Gly Lys Gln Ser Gln Thr Lys Ser Ser Arg Met gaa act gta agc aat gca agc agc agc tca aat cca agc tct cct gga 3504 Glu Thr Val Ser Asn Ala Ser Ser Ser Ser Asn Pro Ser Ser Pro Gly aga ata aag ggg agg ctt gat agt tct gaa atg gat cac agt gaa aat 3552 Arg Ile Lys Gly Arg Leu Asp Ser Ser Glu Met Asp His Ser Glu Asn gaa gat tac aca atg tct tca cct ttg ccg ggg aaa aaa agt gac aag 3600 Glu Asp Tyr Thr Met Ser Ser Pro Leu Pro Gly Lys Lys Ser Asp Lys aga gac gac tct gat ctt gta agg tct gaa ttg gag aag cct aga ggc 3648 Arg Asp Asp Ser Asp Leu Val Arg Ser Glu Leu Glu Lys Pro Arg Gly agg aaa aaa acg ccc gtc aca gaa cag gag gag aaa tta ggt atg gat 3696 Arg Lys Lys Thr Pro Val Thr Glu Gln Glu Glu Lys Leu Gly Met Asp gac ttg act aag ttg gta cag gaa cag aaa cct aaa ggc agt cag cga 3744 Asp Leu Thr Lys Leu Val Gln Glu Gln Lys Pro Lys Gly Ser Gln Arg agt cgg aaa aga ggc cat acg get tca gaa tct gat gaa cag cag tgg 3792 Ser Arg Lys Arg Gly His Thr Ala Ser Glu Ser Asp Glu Gln Gln Trp cct gag gaa aag agg ctc aaa gaa gat ata tta gaa aat gaa gat gaa 3840 Pro Glu Glu Lys Arg Leu Lys Glu Asp Ile Leu Glu Asn Glu Asp Glu cag aat agt ccg cca aaa aag ggt aaa aga ggc cga cca cca aaa cct 3888 Gln Asn Ser Pro Pro Lys Lys Gly Lys Arg Gly Arg Pro Pro Lys Pro ctt ggt gga ggt aca cca aaa gaa gag cca aca atg aaa act tct aaa 3936 Leu Gly Gly Gly Thr Pro Lys Glu Glu Pro Thr Met Lys.Thr Ser Lys aaa gga agc aaa aaa aaa tct gga cct cca gca cca gag gag gag gaa 3984 Lys Gly Ser Lys Lys Lys Ser Gly Pro Pro Ala Pro Glu Glu Glu Glu Wb 00/50454 PCT/US00/04732 gaagaagaaagacaaagtggaaatacggaacagaag tccaaa agcaaa4032 GluGluGluArgGlnSerGlyAsnThrGluGlnLys SerLys SerLys cagcaccgagtgtcaaggagagcacagcagagagca gaatct cctgaa4080 GlnHisArgValSerArgArgAlaGlnGlnArgAla GluSer ProGlu tctagtgcaattgaatccacacagtccacaccacag aaagga cgagga4128 SerSerAlaIleGluSerThrGlnSerThrProGln LysGly ArgGly agaccatcaaaaacgccatcaccatcacaaccaaaa aaaaat gtg 4173 ArgProSerLysThrProSerProSerGlnProLys LysAsn Val <210> 4 <211> 5355 <212> DNA
<213> Homo sapiens <220>
<221> CDS
<222> (150)..(4322) <400> 4 cggagaggag gaggaacggc agggctggct gcggaagggg aggggggggg agaaggcgat 60 tggatgcggc ggcggcggcg gatcccggag agccccggag tgagcggagt agcgagtcgg 120 caacccggag gggtagaaat atttctgtc atg get cat tca aag act agg acc 173 Met Ala His Ser Lys Thr Arg Thr aat gat gga aaa att aca tat ccg cct ggg gtc aag gaa ata tca gat 221 Asn Asp Gly Lys Ile Thr Tyr Pro Pro Gly Val Lys Glu Ile Ser Asp aaa ata tct aaa gag gag atg gtg aga cga tta aag atg gtt gtg aaa 269 Lys Ile Ser Lys Glu Glu Met Val Arg Arg Leu Lys Met Val Val Lys act ttt atg gat atg gac cag gac tct gaa gaa gaa aag gag ctt tat 317 Thr Phe Met Asp Met Asp Gln Asp Ser Glu Glu Glu Lys Glu Leu Tyr tta aac cta get tta cat ctt get tca gat ttt ttt ctc aag cat cct 365 Leu Asn Leu Ala Leu His Leu Ala Ser Asp Phe Phe Leu Lys His Pro ggt aaa gat gtt cgc tta ctg gta gcc tgc tgc ctt get gat att ttc 413 Gly Lys Asp Val Arg Leu Leu Val Ala Cys Cys Leu Ala Asp Ile Phe agg att tat get cct gaa get cct tac aca tcc cct gat aaa cta aag 461 Arg Ile Tyr Ala Pro Glu Ala Pro Tyr Thr Ser Pro Asp Lys Leu Lys gat ata ttt atg ttt ata aca aga cag ttg aag ggg cta gag gat aca 509 Asp Ile Phe Met Phe Ile Thr Arg Gln Leu Lys Gly Leu Glu Asp Thr aag agc cca caa ttc aat agg tat ttt tat tta ctt gag aac att get 557 LysSerProGlnPheAsnArg PheTyrLeuLeuGluAsnIleAla Tyr tgggtoaagtcatataacatatgctttgagttagaagatagcaatgaa605 TrpValLysSerTyrAsnIleCysPheGluLeuGluAspSerAsnGlu attttcacccagctatacagaaccttattttcagttataaacaatggc653 IlePheThrGlnLeuTyrArgThrLeuPheSerValIleAsnAsnGly cacaatcagaaagtccatatgcacatggtagaccttatgagctctatt701 HisAsnGlnLysValHisMetHisMetValAspLeuMetSerSerIle atttgtgaaggtgatacagtgtctcaggagcttttggatacggtttta749 IleCysGluGlyAspThrValSerGlnGluLeuLeuAspThrValLeu gtaaatctggtacctgetcataagaatttaaacaagcaagcatatgat797 ValAsnLeuValProAlaHisLysAsnLeuAsnLysGlnAlaTyrAsp ttggcaaaggetttactgaagaggacagetcaagetattgagccatat845 LeuAlaLysAlaLeuLeuLysArgThrAlaGlnAlaIleGluProTyr attaccactttttttaatcaggttctgatgcttgggaaaacatctatc893 IleThrThrPhePheAsnGlnValLeuMetLeuGlyLysThrSerIle agcgatttgtcagagcatgtctttgacttaattttggagctctacaat941 SerAspLeuSerGluHisValPheAspLeuIleLeuGluLeuTyrAsn attgatagtcatttgctgctctctgttttaccccagcttgaatttaaa989 IleAspSerHisLeuLeuLeuSerValLeuProGlnLeuGluPheLys ttaaagagcaatgataatgaggagcgcctacaagttgttaaactactg1037 LeuLysSerAsnAspAsnGluGluArgLeuGlnValValLysLeuLeu gcaaaaatgtttggggcaaaggattcagaattggettctcaaaacaag1085 AlaLysMetPheGlyAlaLysAspSerGluLeuAlaSerGlnAsnLys ccactttggcagtgctacttgggcaggtttaatgatatccatgtacca1133 ProLeuTrpGlnCysTyrLeuGlyArgPheAsnAspIleHisValPro atccgcctggaatgtgtgaaatttgetagccattgtctcatgaaccat1181 IleArgLeuGluCysValLysPheAlaSerHisCysLeuMetAsnHis cctgatttagcaaaagacttaacagagtatcttaaagtgaggtcacat1229 ProAspLeuAlaLysAspLeuThrGluTyrLeuLysValArgSerHis gaccctgaggaagetattagacatgatgttattgtgtcaatagttaca1277 AspProGluGluAlaIleArgHisAspValIleValSerIleValThr 365 370 3'75 getgetaaaaaggatattcttctggtcaatgatcacttacttaatttt1325 WO 00/50454 PC'T/US00/04732 -AlaAlaLysLysAspIleLeuLeuValAsnAspHisLeuLeuAsnPhe gtgagagagagaacattagacaaacgatggagagtacgcaaagaagcc 1373 ValArgGluArgThrLeuAspLysArgTrpArgValArgLysGluAla atgatgggacttgcccaaatttataagaaatatgetttacagtcagca 1421 MetMetGlyLeuAlaGlnIleTyrLysLysTyrAlaLeuGlnSerAla getggaaaagatgetgcaaaacagatagcatggatcaaagacaaattg 1469 AlaGlyLysAspAlaAlaLysGlnIleAlaTrpIleLysAspLysLeu ctacatatatattatcaaaatagtattgatgatcgactacttgttgaa 1517 LeuHisIleTyrTyrGlnAsnSerIleAspAspArgLeuLeuValGlu cggatctttgetcaatacatggttcctcacaatttagaaactacagaa 1565 ArgIlePheAlaGlnTyrMetValProHisAsnLeuGluThrThrGlu cggatgaaatgcttatattacttgtatgccacactggatttaaatget 1613 ArgMetLysCysLeuTyrTyrLeuTyrAlaThrLeuAspLeuAsnAla gtgaaagcattgaatgaaatgtggaaatgtcaaaatctgctccgacat 1661 ValLysAlaLeuAsnGluMetTrpLysCysGlnAsnLeuLeuArgHis caagtaaaggatttgcttgacttgattaagcaacccaaaacagatgcc 1709 GlnValLysAspLeuLeuAspLeuIleLysGlnProLysThrAspAla agtgtcaaggccatattttcaaaagtgatggttattacaagaaattta 1757 SerValLysAlaIlePheSerLysValMetValIleThrArgAsnLeu cctgatcctggtaaggetcaggatttcatgaagaaattcacacaggtg 1805 ProAspProGlyLysAlaGlnAspPheMetLysLysPheThrGlnVal ttagaagatgatgagaaaataagaaagcagttagaagtacttgttagt 1853 LeuGluAspAspGluLysIleArgLysGlnLeuGluValLeuValSer ccaacatgctcctgcaagcaggetgaaggttgtgtgcgtgaaataact 1901 ProThrCysSerCysLysGlnAlaGluGlyCysValArgGluIleThr aagaagttgggcaaccccaaacagcctacaaatcctttcctggaaatg 1949 LysLysLeuGlyAsnProLysGlnProThrAsnProPheLeuGluMet atcaagtttctcttggagaggatagcacctgtgcacatagataccgaa 1997 IleLysPheLeuLeuGluArgIleAlaProValHisIleAspThrGlu tctatcagtgetcttattaaacaagtgaacaaatcaatagatggaaca 2045 SerIleSerAlaLeuIleLysGlnValAsnLysSerIleAspGlyThr gcagatgatgaagatgagggtgttccaactgatcaagccatcagagca 2093 AlaAspAspGluAspGluGlyValProThrAspGlnAlaIleArgAla ggtcttgaactgcttaaggtactctcatttacacatcccatctcattt 2141 GlyLeuGluLeuLeuLysValLeuSerPheThrHisProIleSerPhe cattctgetgaaacatttgaatcattactggettgtctgaaaatggat 2189 HisSerAlaGluThrPheGluSerLeuLeuAlaCysLeuLysMetAsp gatgaaaaagtagcagaagetgcactacaaattttcaaaaacacagga 2237 AspGluLysValAlaGluAlaAlaLeuGlnIlePheLysAsnThrGly agcaaaattgaagaggattttccacacatcagatcagccttgcttcct 2285 SerLysIleGluGluAspPheProHisIleArgSerAlaLeuLeuPro gttttacatcacaaatctaaaaaaggacccccccgtcaagccaaatat 2333 ValLeuHisHisLysSerLysLysGlyProProArgGlnAlaLysTyr gccattcattgtatccatgcgatattttctagtaaagagacccagttt 2381 AlaIleHisCysIleHisAlaIlePheSerSerLysGluThrGlnPhe gcacagatatttgagcctctgcataagagcctagatccaagcaacctg 2429 AlaGlnIlePheGluProLeuHisLysSerLeuAspProSerAsnLeu gaacatctcataacaccattggttactattggtcatattgetctcctt 2477 GluHisLeuIleThrProLeuValThrIleGlyHisIleAlaLeuLeu gcacctgatcaatttgetgetccttggaaatcttgggtagetactttc 2525 AlaProAspGlnPheAlaAlaProTrpLysSerTrpValAlaThrPhe attgtgaaagatcttctcatgaatgatcggcttccagggaaaaagaca 2573 IleValLysAspLeuLeuMetAsnAspArgLeuProGlyLysLysThr actaaactttgggttccagatgaagaagtatctcctgagacaatggtc 2621 ThrLysLeuTrpValProAspGluGluValSerProGluThrMetVal aaaattcaggetattaaaatgatggttcgatggctacttggaatgaaa 2669 LysIleGlnAlaIleLysMetMetValArgTrpLeuLeuGlyMetLys aataatcacagtaaatcaggaacttctaccttaagattgctaacaaca 2717 AsnAsnHisSerLysSerGlyThrSerThrLeuArgLeuLeuThrThr atattgcatagtgatggagacttgacagaacaggggaaaattagtaaa 2765 IleLeuHisSerAspGlyAspLeuThrGluGlnGlyLysIleSerLys ccagatatgtcacgtctgagacttgetgetgggagtgetattgtgaag 2813 ProAspMetSerArgLeuArgLeuAlaAlaGlySerAlaIleValLys 875 880 gg5 ctggcacaagaaccctgttaccatgaaatcatcacattagaacaatat 2861 LeuAlaGlnGluProCysTyrHisGluIleIleThrLeuGluGlnTyr cagctatgtgcattagetatcaacgatgaatgctatcaagtaagacaa 2909 GlnLeuCysAlaLeuAlaIleAsnAspGluCysTyrGlnValArgGln gtgtttgcccagaaacttcacaaaggcctttcccgtttacggcttcca 2957 ValPheAlaGlnLysLeuHisLysGlyLeuSerArgLeuArgLeuPro cttgagtatatggcaatctgtgccctttgtgcaaaagatcctgtaaag 3005 LeuGluTyrMetAlaIleCysAlaLeuCysAlaLysAspProValLys gagagaagagetcatgetaggcaatgtttggtgaaaaatataaatgta 3053 GluArgArgAlaHisAlaArgGlnCysLeuValLysAsnIleAsnVal aggcgggagtatctgaagcagcatgcagetgttagtgaaaaattattg 3101 ArgArgGluTyrLeuLysGlnHisAlaAlaValSerGluLysLeuLeu tctcttctaccagagtatgttgttccatatacaattcaccttttggca 3149 SerLeuLeuProGluTyrValValProTyrThrIleHisLeuLeuAla catgacccagattatgtcaaagtacaggatattgaacaacttaaagat 3197 HisAspProAspTyrValLysValGlnAspIleGluGlnLeuLysAsp gttaaagaatgtctttggtttgttctggaaatattaatggetaaaaat 3245 ValLysGluCysLeuTrpPheValLeuGluIleLeuMetAlaLysAsn gaaaataacagtcacgettttatcagaaagatggtagaaaatattaaa 3293 GluAsnAsnSerHisAlaPheIleArgLysMetValGluAsnIleLys caaacaaaagatgcccaaggaccagatgatgcaaaaatgaatgaaaaa 3341 GlnThrLysAspAlaGlnGlyProAspAspAlaLysMetAsnGluLys ctgtacactgtgtgtgatgttgccatgaatatcatcatgtcaaagagt 3389 LeuTyrThrValCysAspValAlaMetAsnIleIleMetSerLysSer actacatacagtttggaatctcctaaagacccggtactaccagetcgt 3437 ThrThrTyrSerLeuGluSerProLysAspProValLeuProAlaArg ttcttcactcaacctgacaagaatttcagtaacaccaaaaattatctg 3485 PhePheThrGlnProAspLysAsnPheSerAsnThrLysAsnTyrLeu cctcctgaaatgaaatcatttttcactcctggaaaacctaaaacaacc 3533 ProProGluMetLysSerPhePheThrProGlyLysProLysThrThr aatgttctaggagetgttaacaagccactttcatcagcaggcaagcaa 3581 AsnValLeuGlyAlaValAsnLysProLeuSerSerAlaGlyLysGln tctcagaccaaatcatcacgaatggaaactgtaagcaatgcaagcagc 3629 Ser Gln Thr Lys Ser Ser Arg Met Glu Thr Val Ser Asn Ala Ser Ser agc tca aat cca agc tct cct gga aga ata aag ggg agg ctt gat agt 3677 Ser Ser Asn Pro Ser Ser Pro Gly Arg Ile Lys Gly Arg Leu Asp Ser tct gaa atg gat cac agt gaa aat gaa gat tac aca atg tct tca cct 3725 Ser Glu Met Asp His Ser Glu Asn Glu Asp Tyr Thr Met Ser Ser Pro ttg ccg ggg aaa aaa agt gac aag aga gac gac tct gat ctt gta agg 3773 Leu Pro Gly Lys Lys Ser Asp Lys Arg Asp Asp Ser Asp Leu Val Arg tct gaa ttg gag aag cct aga ggc agg aaa aaa acg ccc gtc aca gaa 3821 Ser Glu Leu Glu Lys Pro Arg Gly Arg Lys Lys Thr Pro Val Thr Glu cag gag gag aaa tta ggt atg gat gac ttg act aag ttg gta cag gaa 3869 Gln Glu Glu Lys Leu Gly Met Asp Asp Leu Thr Lys Leu Val Gln Glu cag aaa cct aaa ggc agt cag cga agt cgg aaa aga ggc cat acg get 3917 Gln Lys Pro Lys Gly Ser Gln Arg Ser Arg Lys Arg Gly His Thr Ala tca gaa tct gat gaa cag cag tgg cct gag gaa aag agg ctc aaa gaa 3965 Ser Glu Ser Asp Glu Gln Gln Trp Pro Glu Glu Lys Arg Leu Lys Glu gat ata tta gaa aat gaa gat gaa cag aat agt ccg cca aaa aag ggt 4013 Asp Ile Leu Glu Asn Glu Asp Glu Gln Asn Ser Pro Pro Lys Lys Gly aaa aga ggc cga cca cca aaa cct ctt ggt gga ggt aca cca aaa gaa 4061 Lys Arg Gly Arg Pro Pro Lys Pro Leu Gly Gly Gly Thr Pro Lys Glu gag cca aca atg aaa act tct aaa aaa gga agc aaa aaa aaa tct gga 4109 Glu Pro Thr Met Lys Thr Ser Lys Lys Gly Ser Lys Lys Lys Ser Gly cct cca gca cca gag gag gag gaa gaa gaa gaa aga caa agt gga aat 4157 Pro Pro Ala Pro Glu Glu Glu Glu Glu Glu Glu Arg Gln Ser Gly Asn acg gaa cag aag tcc aaa agc aaa cag cac cga gtg tca agg aga gca 4205 Thr Glu Gln Lys Ser Lys Ser Lys Gln His Arg Val Ser Arg Arg Ala cag cag aga gca gaa tct cct gaa tct agt gca att gaa tcc aca cag 4253 Gln Gln Arg Ala Glu Ser Pro Glu Ser Ser Ala Ile Glu Ser Thr Gln tcc aca cca cag aaa gga cga gga aga cca tca aaa acg cca tca cca 4301 Ser Thr Pro Gln Lys Gly Arg Gly Arg Pro Ser Lys Thr Pro Ser Pro tca caa cca aaa aaa aat gtg taagttgtaa atattacatt tcaaaccaat 4352 Ser Gln Pro Lys Lys Asn Val ttcaaattat tttgcaaaag ttcctaaatt tgtaaacata catattgctg tatttaaatt 4412 ccatatattt agccccatta cactaggtac ggcggcgaag tgctaaaagg gaacggcgat 4472 gaacaaatgt aattaataac tttctctgtg aaagctttgg aaaaatcttt tttttttttt 4532 tttttttttg gtcaagcttg aggctgaata aagcctttga tgcacaaaat gggactgctg 4592 aagagtggac agttggacct tactttggtg accccataca tttgtggtca catgctttag 4652 ccatacacat ggtaacattg actatggagt cttgtgaaag tgtaatgtgc gatggctatg 4712 tagacataaa gaagaaactt gtaaatatct tttttctttt ttttaatgtt tctgatttct 4772 gaagtgcttg tatagctttt atctgcggct ttaaactgac agtacccgac tgtttattgg 4832 atctattgat ttgaaaagaa tttgttagga tagatcttaa gcagtaatct gtcagtgttt 4892 gtatttgtat tttctgcaat tttactgtga aaaaaaattt gttttcaaca attggtgtca 4952 ttttcttgat gtcactattt gttggagagt taaatggtct cttccctttg tgtatcttac 5012 ctagtgttta ctcctgggca cccttaatct tcagaggtgc taaattgtct gccattacac 5072 cagaaggatg cctctgatag gaggacaacc atgcaaattg tgaaatagtc ctgaagttct 5132 tggattactt tacacctcag tattgatttg tcccagaatt ttctggcctt tcatggcaat 5192 gaaaatttta agaagaaaga tttaaagtat tttaatttta aagagtgtgt tataaaataa 5252 tgtactgaat tctttatccc attttatcat cctttcagtt tttattaatc tactgtatca 5312 ataaaattct gtaatttgaa tgagtaaaaa aaaaaaaaaa aaa 5355 <210> 5 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Consensus Sequence <400> 5 ctawwagscc csgcscaw lg
To dissect androgen-mediated cell-cycle events, several androgen target cell lines that express only one of the steps of the androgen regulated proliferative response were generated. Two LNCaP variants were isolated: the LNCaP-TAC variant which expresses Step-1 only, and the LNCaP-TJA variant, which is resistant to the inhibitory effect of both CD serum and androgens (Soto et al., (1995) Oncology Res. 7: 545-558). LNCaP-LNO
cells, established by Horoszewicz et al., proliferate maximally in the presence of CDHuS, express an androgen-induced proliferative shutoff, and undergo Go/GI arrest (Step-2) at high androgen concentrations (Horoszewicz et al., (1983) Cancer Res. 43:1809-1818;
Soto et al., (1995) Oncology Res. 7: 545-558). In addition to these human prostate cells, a new model to demonstrate the shutoff effect in another cell type was developed by stable transfection of a wild type androgen-receptor construct into breast carcinoma MCF-7 cells.
These MCF7-AR1 cells are also able to evoke a proliferative shutoff in response to androgens (Szelei et al., (1997) Endocrinology 138: 1406-1412).
Using a differential subtractive amplification procedure, a set of genes induced in the proliferative shutoff response (Step-2) (Wang et al., (1991) Proc. Natl. Acad.
Sci. USA 88:
11505-11509) was identified. In particular, a gene involved in this regulation, AS3 (androgen shutoff gene 3), that shows high expression in the early regulatory phase of androgen-induced proliferative shutoff in cell culture and in the prostates of castrated rats was identified.
The AS3 gene encodes a polypeptide of 1391-residues and has a molecular weight of about 186 kD. It has coiled-coil structures that usually participate in protein-protein interactions, a perfect leucine-zipper that suggests DNA binding, nuclear localization motifs, proline- and serine-rich domains, unique C-terminal acidic-basic repeats, and ATP- and DNA-binding motifs.
The transcript has 34 exons in a 200,000 by region on chromosome 13q12-q13, downstream of the breast cancer susceptibility gene BRCA2, and centromeric to the retinoblastoma (Rbl) locus. This area is subject to frequent allelic losses in cancers, and is believed to carry a number of cryptic suppressor genes.
The AS3 gene is involved in the regulation of androgen-induced proliferative arrest in human prostate cells. Accordingly, the AS3 molecules described below serve as useful diagnostic markers or therapeutic agents to control conditions of aberrant cell proliferation, such as cancer (e.g., cancer of the prostate).
In one embodiment, the present invention is directed at human AS3, however, family members are also intended to be within the scope of the invention. The term "family" when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin, as well as other, distinct proteins of human origin or alternatively, can contain homologues of non-human origin. Members of a family may also have common functional characteristics.
To identify the presence of important domains in a given polypeptide, and make the determination that a protein of interest has a particular profile, the amino acid sequence of the protein can be searched against several databases as described in Example 3. Using these tools, a number of important domains within the AS3 polypeptide have been identified and these results are set forth in Figures 2 and 3 and further described in Example 3.
Isolated proteins of the present invention, preferably AS3 proteins, have an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID N0:2 or are encoded by a nucleotide sequence sufficiently homologous to SEQ ID NO: l or 3. As used herein, the term "sufficiently homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains or motifs and/or a common functional activity. For example, amino acid or nucleotide sequences which share common structural domains have at least 30%, 40%, or 50% homology, preferably 60% homology, more preferably 70%-80%, and even more preferably 90-95% homology across the amino acid sequences of the domains and contain at least one and preferably two structural domains or motifs, are defined herein as sufficiently homologous. Furthermore, amino acid or nucleotide sequences which share at least 30%, 40%, or 50%, preferably 60%, more preferably 70-80%, or 90-95% homology and share a common functional activity are defined herein as sufficiently homologous.
As used interchangeably herein, an "AS3 activity", "biological activity of AS3" or "functional activity of AS3", refers to an activity exerted by an AS3 protein, polypeptide or nucleic acid molecule on an AS3 responsive cell or on an AS3 protein substrate, as determined in vivo, or in vitro, according to standard techniques. In one embodiment, an AS3 activity is a direct activity, such as an association with an AS3-target molecule. As used herein, a "target molecule" or "binding partner" is a molecule with which an AS3 protein binds or interacts in nature, such that AS3-mediated function is achieved. An AS3 target molecule can be a non-AS3 molecule or an AS3 protein or polypeptide of the present invention. Alternatively, an AS3 activity is an indirect activity, such as modulating cell cycle events. Preferably, an AS3 activity is the ability to modulate androgen-mediated cell proliferation.
Accordingly, another embodiment of the invention features isolated AS3 proteins and polypeptides having an AS3 activity. Preferred proteins are AS3 proteins encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or 3.
The nucleotide sequence of the isolated human AS3 cDNA and the predicted amino acid sequence of the human AS3 polypeptide are shown in Figure 1 and in SEQ ID
NOs: l and 2, respectively. A plasmid containing the nucleotide sequence encoding human AS3 was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on and assigned Accession Number This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. ~112.
The human AS3 gene, which is approximately 5253 nucleotides in length, encodes a protein having a molecular weight of approximately 186 kD and which is approximately 1391 amino acid residues in length.
Various aspects of the invention are described in further detail in the following subsections:
I. Isolated Nucleic Acid Molecules One aspect of the invention pertains to isolated nucleic acid molecules that encode AS3 proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify AS3-encoding nucleic acid molecules (e.g., AS3 mRNA) and fragments for use as PCR primers for the amplification or mutation of AS3 nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
The term "isolated nucleic acid molecule" includes nucleic acid molecules which are separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term "isolated"
includes nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.
For example, in various embodiments, the isolated AS3 nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (see Fig. 4). Moreover, an "isolated" nucleic acid molecule, such as a cDNA
molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 or 3, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein.
Using all or portion of the nucleic acid sequence of SEQ ID NO:1 or 3, as a hybridization probe, AS3 nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning. A Laboratory Manual. 2nd, ed , Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). In a related embodiment, the invention features an AS3 nucleic acid molecule having the sequence of SEQ ID
NO: 4 (see Fig. 6) which is identical to the AS3 sequence provided in SEQ ID NO:1 (see Fig. 1) except for an additional 84 base pairs at the 5' end of the molecule. One skilled in the art would recognize that this additional untranslated 5' sequence may indicate that an alternative start site for the beginning of transcription of the AS3 mRNA molecule may exist.
Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:
l or 3 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO:1 or 3.
A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
Furthermore, oligonucleotides corresponding to AS3 nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1. The sequence of SEQ ID
NO:1 corresponds to the human AS3 cDNA. This cDNA comprises sequences encoding the human AS3 protein (i.e., "the coding region", from nucleotides 66-4238), as well as 5' untranslated sequences (nucleotides 1-65) and 3' untranslated sequences (nucleotides 4239-5253). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ
ID NO:1 (e.g., nucleotides 66-4238, corresponding to SEQ ID N0:3).
In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1 or 3, or a portion of any of these nucleotide sequences. A
nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:
l or 3, is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID
NO:l or 3, such that it can hybridize to the nucleotide sequence shown in SEQ
ID NO:1 or 3, thereby forming a stable duplex.
In still another preferred embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire length of the nucleotide sequence shown in SEQ ID NO:1 or 3, or a portion of any of these nucleotide sequences.
Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO:1 or 3, for example, a fragment which can be used as a probe or primer or a fragment encoding a portion of an AS3 protein, e.g., a biologically active portion of an AS3 protein. The nucleotide sequence determined from the cloning of the AS3 gene allows for the generation of probes and primers designed for use in identifying and/or cloning other AS3 family members, as well as AS3 homologues from other species.
The probe/primer typically comprises substantially purified oligonucleotide.
The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense sequence of SEQ ID NO:1 or 3, of an anti-sense sequence of SEQ ID NO:1 or 3, or of a naturally occurring allelic variant or mutant of SEQ ID NO:1 or 3. In an exemplary embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which is greater than 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-1000, or more nucleotides in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO: 1 or 3.
Probes based on the AS3 nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g.; the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress an AS3 protein, such as by measuring a level of an AS3-encoding nucleic acid in a sample of cells from a subject e.g., detecting AS3 mRNA levels or determining whether a genomic AS3 gene has been mutated or deleted.
A nucleic acid fragment encoding a "biologically active portion of an AS3 protein"
can be prepared by isolating a portion of the nucleotide sequence of SEQ ID
NO: 1 or 3, which encodes a polypeptide having an AS3 biological activity (the biological activities of the AS3 proteins are described herein), expressing the encoded portion of the AS3 protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of the AS3 protein.
The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1 or 3, due to degeneracy of the genetic code and thus encode the same AS3 proteins as those encoded by the nucleotide sequence shown in SEQ ID NO:1 or 3. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID N0:2.
In addition to the AS3 nucleotide sequences shown in SEQ ID NO:1 or 3, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the AS3 proteins may exist within a population (e.g., the human population). Such genetic polymorphism in the AS3 genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules which include an open reading frame encoding an AS3 protein, preferably a mammalian AS3 protein, and can further include non-coding regulatory sequences, and introns.
Allelic variants of human AS3 include both functional and non-functional AS3 proteins. Functional allelic variants are naturally occurring amino acid sequence variants of the human AS3 protein that maintain the ability to modulate cell proliferation, e.g., androgen-induced changes in cell proliferation. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID
N0:2 or substitution, deletion or insertion of non-critical residues in non-critical regions of the protein.
Non-functional allelic variants are naturally occurring amino acid sequence variants of the human AS3 protein that do not have the ability to modulate cell proliferation, for example, hormone-induced changes in cell proliferation. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion or premature truncation of the amino acid sequence of SEQ ID N0:2 or a substitution, insertion or deletion in critical residues or critical regions.
The present invention further provides non-human orthologues of the human AS3 protein. Orthologues of the human AS3 protein are proteins that are isolated from non-human organisms and possess the same AS3 ability to modulate cell proliferation, for example, hormone-induced changes in cell proliferation. Orthologues of the human AS3 protein can readily be identified as comprising an amino acid sequence that is substantially homologous to SEQ ID N0:2.
Moreover, nucleic acid molecules encoding other AS3 family members and, thus, which have a nucleotide sequence which differs from the AS3 sequences of SEQ
ID NO:1 or 3, are intended to be within the scope of the invention. For example, another AS3 cDNA
can be identified based on the nucleotide sequence of human AS3. Moreover, nucleic acid molecules encoding AS3 proteins from different species, and which, thus, have a nucleotide sequence which differs from the AS3 sequences of SEQ ID NO:1 or 3, are intended to be within the scope of the invention. For example, a mouse AS3 cDNA can be identified based on the nucleotide sequence of a human AS3.
Nucleic acid molecules corresponding to natural allelic variants and homologues of the AS3 cDNAs of the invention can be isolated based on their homology to the AS3 nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Nucleic acid molecules corresponding to natural allelic variants and homologues of the AS3 cDNAs of the invention can further be isolated by mapping to the same chromosome or locus as the AS3 gene.
Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15, 20, 25, 30 or more nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ
ID NO:1 or 3. In other embodiment, the nucleic acid is at least 30, 50, 100, 150, 200, 250, 253, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, or 950 nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.
Preferably, the conditions are such that sequences at least about 70%, more preferably at least about 80%, even more preferably at least about 85% or 90% homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50°C, preferably at 55°C, more preferably at 60°
C, and even more preferably at 65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID
NO:1 or 3 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).
In addition to naturally-occurring allelic variants of the AS3 sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:1 or 3, thereby leading to changes in the amino acid sequence of the encoded AS3 proteins, without altering the functional ability of the AS3 proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID
NO:1 or 3. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of AS3 (e.g., the sequence of SEQ ID N0:2) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the AS3 proteins of the present invention, e.g., those present in the heptad repeat or kinase domains, are predicted to be particularly recalcitrant to alteration. Furthermore, additional amino acid residues that are conserved between the AS3 proteins of the present invention and other members of the ASIC
family are not likely to be amenable to alteration.
Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding AS3 proteins that contain changes in amino acid residues that are not essential for activity. Such AS3 proteins differ in amino acid sequence from SEQ ID N0:2, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%
or more homologous to SEQ ID N0:2.
An isolated nucleic acid molecule encoding an AS3 protein homologous to the protein of SEQ ID N0:2 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1 or 3, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.
Mutations can be introduced into SEQ ID NO:1 or 3, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A
"conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an AS3 protein is preferably replaced with another amino acid residue from the same side chain family.
Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an AS3 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for AS3 biological activity to identify mutants that retain activity.
Following mutagenesis of SEQ ID NO: 1 or 3, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.
In a preferred embodiment, a mutant AS3 protein can be assayed for the ability to ability to modulate cell proliferation, for example, hormone-induced changes in cell proliferation.
In addition to the nucleic acid molecules encoding AS3 proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA
sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.
The antisense nucleic acid can be complementary to an entire AS3 coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding AS3.
The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the coding region of human AS3 corresponds to SEQ ID N0:3). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding AS3.
The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).
Given the coding strand sequences encoding AS3 disclosed herein (e.g., SEQ ID
N0:3), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of AS3 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of AS3 mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of AS3 mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), ~-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an AS3 protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site.
Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
In yet another embodiment, the antisense nucleic acid molecule of the invention is an a-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual (3-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids.
Res. 15:6625-6641 ). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (moue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA
analogue (moue et al. (1987) FEBSLett. 215:327-330).
In still another embodiment, an antisense nucleic acid of the invention is a ribozyme.
Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave AS3 mRNA transcripts to thereby inhibit translation of AS3 mRNA. A ribozyme having specificity for an AS3-encoding nucleic acid can be designed based upon the nucleotide sequence of an AS3 cDNA disclosed herein (i.e., SEQ ID NO:1 or 3). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an AS3-encoding mRNA. See, e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S.
Patent No. 5,116,742. Alternatively, AS3 mRNA can be used to select a catalytic RNA
having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D.
and Szostak, J.W. (1993) Science 261:1411-1418.
Alternatively, AS3 gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the AS3 (e.g., the AS3 promoter and/or enhancers) to form triple helical structures that prevent transcription of the AS3 gene in target cells. See generally, Helene, C. (1991) Anticancer Drug Des.
6(6):569-84; Helene, C. et al. (1992) Ann. N Y. Acad. Sci. 660:27-36; and Maher, L.J. (1992) Bioassays 14(12):807-15.
In yet another embodiment, the AS3 nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. et al. (1996) Bioorganic & Medicinal Chemistry 4 (1): 5-23).
As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA
under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. et al. (1996) supra; Perry-O'Keefe et al. Proc. Natl. Acad. Sci. 93: 14670-675.
PNAs of AS3 nucleic acid molecules can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of AS3 nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR
clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, (e.g., S1 nucleases (Hyrup B. (1996) supra)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. et al. ( 1996) supra; Perry-O'Keefe supra).
In another embodiment, PNAs of AS3 can be modified, (e.g., to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of AS3 nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA.
Such chimeras allow DNA recognition enzymes, (e.g., RNAse H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup B. (1996) supra and Finn P.J. et al. (1996) Nucleic Acids Res. 24 (17): 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. et al. (1989) Nucleic Acid Res. 17:
5973-88).
PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. et al. (1996) supra).
Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA
segment (Peterser, K.H. et al. (1975) Bioorganic Med. Chem. Lett. 5: 1119-11124).
In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad.
Sci. USA
86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad. Sci. USA 84:648-652;
PCT
Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT
Publication No.
W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, e.g., Krol et al. (1988) Bio-Techniques 6:958-976) or intercalating agents. (See, e.g., Zon (1988) Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).
II. Isolated AS3 Proteins One aspect of the invention pertains to isolated AS3 proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-AS3 antibodies. In one embodiment, native AS3 proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, AS3 proteins are produced by recombinant DNA
techniques. Alternative to recombinant expression, an AS3 protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.
An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the AS3 protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of AS3 protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced.
In one embodiment, the language "substantially free of cellular material"
includes preparations of AS3 protein having less than about 30% (by dry weight) of non-AS3 protein (also referred to herein as a "contaminating protein"), more preferably less than about 20%
of non-AS3 protein, still more preferably less than about 10% of non-AS3 protein, and most preferably less than about 5% non-AS3 protein. When the AS3 protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.
The language "substantially free of chemical precursors or other chemicals"
includes preparations of AS3 protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals"
includes preparations of AS3 protein having less than about 30% (by dry weight) of chemical precursors or non-AS3 chemicals, more preferably less than about 20% chemical precursors or non-AS3 chemicals, still more preferably less than about 10% chemical precursors or non-AS3 chemicals, and most preferably less than about 5% chemical precursors or non-AS3 chemicals.
As used herein, a "biologically active portion" of an AS3 protein includes a fragment of an AS3 protein which participates in an interaction between an AS3 molecule and a non-AS3 molecule. Biologically active portions of an AS3 protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the AS3 protein, e.g., the amino acid sequence shown in SEQ ID N0:2, which include less amino acids than the full length AS3 proteins, and exhibit at least one activity of an AS3 protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the AS3 protein, e.g., the ability to modulate cell proliferation.
A biologically active portion of an AS3 protein can be a polypeptide which is, for example, 10, 25, 50, 100, 200 or more amino acids in length. Biologically active portions of an AS3 protein can be used as targets for developing agents which modulate an AS3 mediated activity, e.g., cell proliferation.
In one embodiment, a biologically active portion of an AS3 protein comprises at least one heptad repeat. It is to be understood that a preferred biologically active portion of an AS3 protein of the present invention may contain two, three, four, or five heptad repeats.
As used herein, the term "heptad repeat" includes a protein domain which contains either a leucine or similar hydrophobic residue (e.g., isoleucine, valine, or tyrosine) in every seventh position over a stretch of at least 20-30 amino acid residues, more preferably at least 20-25 amino acid residues, and most preferably at least 22 amino acid residues.
Typically, the heptad repeat is uninterrupted, and can participate in protein-protein interactions. The leucine-zipper motif of DNA binding proteins is a specific subclass of this general pattern and is encompassed by the above term. Leucine zipper domains are described in, for example, Landschultz et al. (1988) Science 240: 1759-1764, the contents of which are incorporated herein by reference. Amino acid residues 55-161, 196-217, 241-277, 319-355, and 375-404 of the AS3 protein all comprise heptad repeats.
In another embodiment, a biologically active portion of an AS3 protein comprises a least one kinase-related domain. It is understood that a preferred biologically active portion of an AS3 protein of the present invention may contain two, three, four, five, six, seven, eight, or nine kinase-related domains. As used herein, the term "kinase-related domain"
includes a polypeptide consensus motif having high homology to a known protein kinase catalytic domain as described in Hanks et ul. (1988) Meth. Enzymol. 200:38-62 (the contents of which are incorporated herein by reference). In particular, a kinase-related domain is any one of the nine consensus motifs or related sequences set forth in Fig. 3.
In another embodiment, a biologically active portion of an AS3 protein can have kinase activity. As referred to herein, "kinase activity" is an activity associated with a protein or polypeptide which is capable of modulating its own phosphorylation state or the phosphorylation state of another protein or polypeptide. Proteins with kinase activity play a role in signaling pathways associated with cellular growth.
Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native AS3 protein.
In a preferred embodiment, the AS3 protein has an amino acid sequence shown in SEQ ID N0:2: In other embodiments, the AS3 protein is substantially homologous to SEQ
ID N0:2, and retains the functional activity of the protein of SEQ ID N0:2, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the AS3 protein is a protein which comprises an amino acid sequence at least about 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to SEQ ID N0:2.
To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the reference sequence (e.g., when aligning a second sequence to the AS3 amino acid sequence of SEQ ID NO: 2 having 400 amino acid residues, at least 80, preferably at least 100, more preferably at least 120, even more preferably at least 140, and even more preferably at least 150, 200, 300, or 400 amino acid residues are aligned). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP
matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (Comput. Appl.
Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. ( 1990) J. Mol.
Biol.
215:403-10. BLAST nucleotide searches can be performed with the NBLAST
program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to AS3 nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to AS3 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.
See http://www.ncbi.nlm.nih.gov.
The invention also provides AS3 chimeric or fusion proteins. As used herein, an AS3 "chimeric protein" or "fusion protein" comprises an AS3 polypeptide operatively linked to a non-AS3 polypeptide. An "AS3 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to AS3, whereas a "non-AS3 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the AS3 protein, e.g., a protein which is different from the AS3 protein and which is derived from the same or a different organism. Within an AS3 fusion protein the AS3 polypeptide can correspond to all or a portion of an AS3 protein. In a preferred embodiment, an AS3 fusion protein comprises at least one biologically active portion of an AS3 protein. In another preferred embodiment, an AS3 fusion protein comprises at least two biologically active portions of an AS3 protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the AS3 polypeptide and the non-AS3 polypeptide are fused in-frame to each other. The non-AS3 polypeptide can be fused to the N-terminus or C-terminus of the AS3 polypeptide.
For example, in one embodiment, the fusion protein is a GST-AS3 fusion protein in which the AS3 sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant AS3.
In another embodiment, the fusion protein is an AS3 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of AS3 can be increased through use of a heterologous signal sequence.
The AS3 fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject in vivo. The AS3 fusion proteins can be used to affect the bioavailability of an AS3 substrate. Use of AS3 fusion proteins may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding an AS3 protein; (ii) mis-regulation of the AS3 gene; and (iii) aberrant post-translational modification of an AS3 protein.
Moreover, the AS3-fusion proteins of the invention can be used as immunogens to produce anti-AS3 antibodies in a subject, to purify AS3 ligands and in screening assays to identify molecules which inhibit the interaction of AS3 with an AS3 substrate.
Preferably, an AS3 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR
amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons:
1992).
Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An AS3-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the AS3 protein.
The present invention also pertains to variants of the AS3 proteins which function as either AS3 agonists (mimetics) or as AS3 antagonists. Variants of the AS3 proteins can be generated by mutagenesis, e.g., discrete point mutation or truncation of an AS3 protein. An agonist of the AS3 proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of an AS3 protein. An antagonist of an AS3 protein can inhibit one or more of the activities of the naturally occurring form of the AS3 protein by, for example, competitively modulating an AS3-mediated activity of an AS3 protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the AS3 protein.
In one embodiment, variants of an AS3 protein which function as either AS3 agonists (mimetics) or as AS3 antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of an AS3 protein for AS3 protein agonist or antagonist activity. In one embodiment, a variegated library of AS3 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of AS3 variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential AS3 sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of AS3 sequences therein. There are a variety of methods which can be used to produce libraries of potential AS3 variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA
synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential AS3 sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) Tetrahedron 39:3;
Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477.
In addition, libraries of fragments of an AS3 protein coding sequence can be used to generate a variegated population of AS3 fragments for screening and subsequent selection of variants of an AS3 protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an AS3 coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the AS3 protein.
Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA
libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of AS3 proteins.
The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected.
Recrusive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify AS3 variants (Arkin and Yourvan (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al.
(1993) Protein Engineering 6(3):327-331).
In one embodiment, cell based assays can be exploited to analyze a variegated library. For example, a library of expression vectors can be transfected into a cell line, e.g., a neuronal cell line, which ordinarily responds to a particular ligand in an AS3-dependent manner. The transfected cells are then contacted with the ligand and the effect of expression of the mutant on signaling by the ligand can be detected, e.g., by measuring intracellular calcium, potassium, or sodium concentration, neuronal membrane depolarization, or the activity of an AS3-regulated transcription factor. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of signaling by the ligand, and the individual clones further characterized.
III Anti-AS3 Antibodies An isolated AS3 protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind AS3 using standard techniques for polyclonal and monoclonal antibody preparation. A full-length AS3 protein can be used or, alternatively, the invention provides antigenic peptide fragments of AS3 for use as immunogens. The antigenic peptide of AS3 comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID N0:2 and encompasses an epitope of AS3 such that an antibody raised against the peptide forms a specific immune complex with AS3.
Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.
Preferred epitopes encompassed by the antigenic peptide are regions of AS3 that are located on the surface of the protein, e.g., hydrophilic regions, as well as regions with high antigenicity (see, for example, Figure 2).
An AS3 immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed AS3 protein or a chemically synthesized AS3 polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent.
Immunization of a suitable subject with an immunogenic AS3 preparation induces a polyclonal anti-AS3 antibody response.
Accordingly, another aspect of the invention pertains to anti-AS3 antibodies.
The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as AS3.
Examples of immunologically active portions of immunoglobulin molecules include Flab) and F(ab')2 fragments which can be generated by treating the antibody with an enzyme such as pepsin.
The invention provides polyclonal and monoclonal antibodies that bind AS3. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of AS3. A monoclonal antibody composition thus typically displays a single binding affinity for a particular AS3 protein with which it immunoreacts.
Polyclonal anti-AS3 antibodies can be prepared as described above by immunizing a suitable subject with an AS3 immunogen. The anti-AS3 antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized AS3. If desired, the antibody molecules directed against AS3 can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG
fraction. At an appropriate time after immunization, e.g., when the anti-AS3 antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein ( 1975) Nature 256:495-497) (see also, Brown et al. ( 1981 ) J. Immunol. 127:539-46; Brown et al. (1980) J. Biol. Chem .255:4980-83; Yeh et al. (1976) Proc. Natl. Acad. Sci. USA 76:2927-31; and Yeh et al. (1982) Int. J. Cancer 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al. (1983) Immunol Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) Yale J. Biol. Med., 54:387-402; M.
L. Gefter et al. (1977) Somatic Cell Genet. 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an AS3 immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds AS3.
Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-AS3 monoclonal antibody (see, e.g., G. Galfre et al. (1977) Nature 266:55052; Gefter et al.
Somatic Cell Genet., cited supra; Lerner, Yale J. Biol. Med., cited supra; Kenneth, Monoclonal Antibodies, cited supra). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Agl4 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT
medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind AS3, e.g., using a standard ELISA assay.
Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-AS3 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with AS3 to thereby isolate immunoglobulin library members that bind AS3. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-O 1; and the Stratagene SurfZAPTM Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT
International Publication No. WO 92/18619; Dower et al. PCT International Publication No. WO 91/17271;
Winter et al. PCT International Publication WO 92/20791; Markland et al. PCT
International Publication No. WO 92/15679; Breitling et al. PCT International Publication WO
93/01288;
McCafferty et al. PCT International Publication No. WO 92/01047; Garrard et al. PCT
International Publication No. WO 92/09690; Ladner et al. PCT International Publication No.
WO 90/02809; Fuchs et al. (1991) BiolTechnology 9:1370-1372; Hay et al. (1992) Hum.
Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281;
Griffiths et al.
(1993) EMBO J 12:725-734; Hawkins et al. (1992) J. Mol. Biol. 226:889-896;
Clarkson et al. (1991) Nature 352:624-628; Gram et al. (1992) Proc. Natl. Acad Sci. USA
89:3576-3580; Garrad et al. (1991) BiolTechnology 9:1373-1377; Hoogenboom et al.
(1991) Nuc.
Acid Res. 19:4133-4137; Barbas et al. (1991) Proc. Natl. Acad Sci. USA 88:7978-7982; and McCafferty et al. Nature (1990) 348:552-554.
Additionally, recombinant anti-AS3 antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention.
Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA
techniques known in the art, for example using methods described in Robinson et al.
International Application No. PCT/L1S86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al.
European Patent Application 173,494; Neuberger et al. PCT International Publication No.
WO
86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al.
(1987) Proc.
Natl. Acad Sci. USA 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526;
Sun et al.
(1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Canc.
Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl.
Cancer Inst.
80:1553-1559); Morrison, S. L. (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214; Winter U.S. Patent 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J.
Immunol.
141:4053-4060.
An anti-AS3 antibody (e.g., monoclonal antibody) can be used to isolate AS3 by standard techniques, such as affinity chromatography or immunoprecipitation.
An anti-AS3 antibody can facilitate the purification of natural AS3 from cells and of recombinantly produced AS3 expressed in host cells. Moreover, an anti-AS3 antibody can be used to detect AS3 protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the AS3 protein. Anti-AS3 antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen.
Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance.
Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I~ 1311 35S or 3H.
IV. Recombinant Expression Vectors Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an AS3 protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequences) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals).
Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., AS3 proteins, mutant forms of AS3 proteins, fusion proteins, and the like).
The recombinant expression vectors of the invention can be designed for expression of AS3 proteins in prokaryotic or eukaryotic cells. For example, AS3 proteins can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
Expression of proteins in prokaryotes is most often carried out in E. coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.
Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRITS
(Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
Purified fusion proteins can be utilized in AS3 activity assays, (e.g., direct assays or competitive assays described in detail below), or to generate antibodies specific for AS3 proteins, for example. In a preferred embodiment, an AS3 fusion protein expressed in a retroviral expression vector of the present invention can be utilized to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g., six (6) weeks).
Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 1 ld (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California ( 1990) 60-89). Target gene expression from the pTrc vector relies on host RNA
polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET
l ld vector relies on transcription from a T7 gnl0-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gnl gene under the transcriptional control of the lacUV 5 promoter.
One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E.
coli (Wada et al., (1992) Nucleic Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
In another embodiment, the AS3 expression vector is a yeast expression vector.
Examples of vectors for expression in yeast S. cerivisae include pYepSecl (Baldari, et al., (1987) Embo J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and picZ (InVitrogen Corp, San Diego, CA).
Alternatively, AS3 proteins can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) Mol. Cell Biol.
3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC
(Kaufman et al. (1987) EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements.
For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T.
Molecular Cloning.' A Laboratory Manual. 2nd, ed , Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the prostate specific promoter (Gotoh et al. ( 1998) J. Urol. 60:220-229) albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477), pancreas-specific promoters (Edlund et al.
(1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No.
264,166).
Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the a,-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
The invention further provides a recombinant expression vector comprising a DNA
molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA
molecule which is antisense to AS3 mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al:, Antisense RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986.
V. Host Cells Another aspect of the invention pertains to host cells into which an AS3 nucleic acid molecule of the invention is introduced, e.g., an AS3 nucleic acid molecule within a recombinant expression vector or an AS3 nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
A host cell can be any prokaryotic or eukaryotic cell. For example, an AS3 protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.
Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.
For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as 6418, hygromycin and methotrexate.
Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an AS3 protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) an AS3 protein. Accordingly, the invention further provides methods for producing an AS3 protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of the invention (into which a recombinant expression vector encoding an AS3 protein has been introduced) in a suitable medium such that an AS3 protein is produced. In another embodiment, the method further comprises isolating an AS3 protein from the medium or the host cell.
VI. Transgenic Animals The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which AS3-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous AS3 sequences have been introduced into their genome or homologous recombinant animals in which endogenous AS3 sequences have been altered. Such animals are useful for studying the function and/or activity of an AS3 and for identifying and/or evaluating modulators of AS3 activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like.
A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous AS3 gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
A transgenic animal of the invention can be created by introducing an AS3-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The AS3 cDNA sequence of SEQ ID NO:1 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of a human AS3 gene, such as a mouse or rat AS3 gene, can be used as a transgene. Alternatively, an AS3 gene homologue, such as another AS3 family member, can be isolated based on hybridization to the AS3 cDNA sequences of SEQ ID NO:1 or 3 (described further in subsection I
above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequences) can be operably linked to an AS3 transgene to direct expression of an AS3 protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos.
4,736,866 and 4,870,009, both by Leder et al., U.S. Patent No. 4,873,191 by Wagner et al.
and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of an AS3 transgene in its genome and/or expression of AS3 mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding an AS3 protein can further be bred to other transgenic animals carrying other transgenes.
To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an AS3 gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the AS3 gene. The AS3 gene can be a human gene (e.g., the cDNA of SEQ ID N0:3), but more preferably, is a non-human homologue of a human AS3 gene (e.g., a cDNA isolated by stringent hybridization with the nucleotide sequence of SEQ ID NO:1 ). For example, a mouse AS3 gene can be used to construct a homologous recombination nucleic acid molecule, e.g., a vector, suitable for altering an endogenous AS3 gene in the mouse genome. In a preferred embodiment, the homologous recombination nucleic acid molecule is designed such that, upon homologous recombination, the endogenous AS3 gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the homologous recombination nucleic acid molecule can be designed such that, upon homologous recombination, the endogenous AS3 gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous AS3 protein). In the homologous recombination nucleic acid molecule, the altered portion of the AS3 gene is flanked at its 5' and 3' ends by additional nucleic acid sequence of the AS3 gene to allow for homologous recombination to occur between the exogenous AS3 gene carried by the homologous recombination nucleic acid molecule and an endogenous AS3 gene in a cell, e.g., an embryonic stem cell.
The additional flanking AS3 nucleic acid sequence is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the homologous recombination nucleic acid molecule (see, e.g., Thomas, K.R. and Capecchi, M. R. (1987) Cell 51:503 for a description of homologous recombination vectors). The homologous recombination nucleic acid molecule is introduced into a cell, e.g., an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced AS3 gene has homologously recombined with the endogenous AS3 gene are selected (see e.g., Li, E. et al. (1992) Cell 69:915). The selected cells can then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stem Cells:
A Practical Approach, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A
chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination nucleic acid molecules, e.g., vectors, or homologous recombinant animals are described further in Bradley, A. (1991) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos.:
WO
90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al.
In another embodiment, transgenic non-humans animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the crelloxP recombinase system of bacteriophage P1. For a description of the c~elloxP recombinase system, see, e.g., Lakso et al. (1992) Proc. Natl.
Acad. Sci. USA 89:6232-6236. Another example of a recombinase system is the FLP
recombinase system of Saccharomyces cerevisiae (O'Gorman et al. ( 1991 ) Science 251:1351-1355. If a crelloxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double"
transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. (1997) Nature 385:810-813 and PCT
International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter Go phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.
VII. Pharmaceutical Compositions The AS3 nucleic acid molecules, fragments of AS3 proteins, and anti-AS3 antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration.
Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for _47_ pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components:
a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugaxs, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a fragment of an AS3 protein or an anti-AS3 antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Oral compositions generally include an inert diluent or an edible carrier.
They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes;
a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin;
or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to.be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers.
These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
Levels in plasma may be measured, for example, by high performance liquid chromatography.
VIII. Gene Therapy The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
Wb 00/50454 PCT/US00/04732 -The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
IX. Uses and Methods of the Invention The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics); and c) methods of treatment (e.g., therapeutic and prophylactic). As described herein, an AS3 protein of the invention modulates the arrest of cell proliferation, preferably hormone-mediated cell proliferation.
Thus, the isolated nucleic acid molecules of the invention can be used, for example, to express AS3 protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect AS3 mRNA (e.g., in a biological sample) or a genetic alteration in an AS3 gene, and to modulate AS3 activity, as described further below. The AS3 nucleic acid molecules can be used to treat disorders characterized by insufficient production of AS3. The AS3 proteins can be used to screen for naturally occurring AS3 substrates, to screen for drugs or compounds which modulate AS3 activity, as well as to treat disorders characterized by insufficient production of AS3 protein or production of AS3 protein forms which have decreased, aberrant or unwanted activity compared to AS3 wild type protein (e.g., excessive cell proliferation). Moreover, the anti-AS3 antibodies of the invention can be used to detect and isolate AS3 proteins, regulate the bioavailability of AS3 proteins, and modulate AS3 activity.
IX, A, Screening Assays The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to AS3 proteins, have a stimulatory or inhibitory effect on, for example, AS3 expression or AS3 activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of AS3 substrate.
In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of an AS3 protein or polypeptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of an AS3 protein or polypeptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) Anticancer Drug Des.
12:145).
Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909;
Erb et al.
(1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Mecl Chem.
37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew.
Chem. Int. Ed.
Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and in Gallop et al. (1994) J. Med. Chem. 37:1233.
Libraries of compounds may be presented in solution (e.g., Houghten (1992) Biotechniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull et al. (1992) Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith (1990) Science 249:386-390); (Devlin (1990) Science 249:404-406);
(Cwirla et al.
(1990) Proc. Natl. Acad. Sci. 87:6378-6382); (Felici (1991) J. Mol. Biol.
222:301-310);
(Ladner supra. ).
In one embodiment, an assay is a cell-based assay in which a cell which expresses an AS3 protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate AS3 activity is determined.
Determining the ability of the test compound to modulate AS3 activity can be determined by monitoring, for example, changes in cell using standard techniques.
In another embodiment, an assay of the present invention is a cell-free assay in which an AS3 protein or biologically active portion thereof is contacted with a test compound and the ability of the.test compound to bind to the AS3 protein or biologically active portion thereof is determined. Preferred biologically active portions of the AS3 proteins to be used in assays of the present invention include fragments which participate in interactions with non-AS3 molecules, e.g., fragments with high surface probability scores (see, for example, Figure 2). Binding of the test compound to the AS3 protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the AS3 protein or biologically active portion thereof with a known compound which binds AS3 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an AS3 protein, wherein determining the ability of the test compound to interact with an AS3 protein comprises determining the ability of the test compound to preferentially bind to AS3 or biologically active portion thereof as compared to the known compound.
In yet another embodiment, the cell-free assay involves contacting an AS3 protein or biologically active portion thereof with a known compound which binds the AS3 protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the AS3 protein, wherein determining the ability of the test compound to interact with the AS3 protein comprises determining the ability of the AS3 protein to preferentially bind to or modulate the activity of an AS3 target molecule.
In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize AS3 to facilitate separation of proteins that interact with AS3, as well as to accommodate automation of the assay. Binding of a test compound to an AS3 protein, or interaction of an AS3 protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/ AS3 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or AS3 protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above.
Alternatively, the complexes can be dissociated from the matrix, and the level of AS3 binding or activity determined using standard techniques.
Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either an AS3 protein or an AS3 target molecule can be immobilized utilizing conjugation of biotin and streptavidin.
Biotinylated AS3 protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
Alternatively, antibodies reactive with AS3 protein or target molecules but which do not interfere with binding of the AS3 protein to its target molecule can be derivatized to the wells of the plate, and unbound target or AS3 protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the AS3 protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the AS3 protein or target molecule.
In another embodiment, modulators of AS3 expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of AS3 mRNA or protein in the cell is determined. The level of expression of AS3 mRNA or protein in the presence of the candidate compound is compared to the level of expression of AS3 mRNA
or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of AS3 expression based on this comparison. For example, when expression of AS3 mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of AS3 mRNA or protein expression. Alternatively, when expression of AS3 mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of AS3 mRNA or protein expression. This assay may be further modified to include the presence of a hormone, e.g., an androgen or an anti-androgen. The level of AS3 mRNA or protein expression in the cells can be determined by methods described herein for detecting AS3 mRNA or protein.
In yet another aspect of the invention, the AS3 proteins can be used as "bait proteins"
in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No.
5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and Brent W094/10300), to identify other proteins, which bind to or interact with AS3 ("AS3-binding proteins" or "AS3-by") and are involved in AS3 activity. Such AS3-binding proteins are also likely to be involved in the propagation of signals by the AS3 proteins or AS3 targets as, for example, downstream elements of an AS3-mediated signaling pathway.
Alternatively, such AS3-binding proteins are likely to be AS3 inhibitors.
The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for an AS3 protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA
sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming an AS3-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor.
Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the AS3 protein.
In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell free assay, and the ability of the agent to modulate the activity of an AS3 protein can be confirmed in vivo, e.g., in an animal such as an animal model for pain.
This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., an AS3 modulating agent, an antisense AS3 nucleic acid molecule, an AS3-specific antibody, or an AS3-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.
IX, B, Detection Assays Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease;
(ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.
IX, B, 1., Chromosome Mapping Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the AS3 nucleotide sequences, described herein, can be used to map the location of the AS3 genes on a chromosome as described in Example 4. The mapping of the AS3 sequences to chromosomes is an important step in correlating these sequences with genes associated with disease.
Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the AS3 gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.
IX, B, 2., Tissue Typing The AS3 sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel.
In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S.
Patent 5,272,057).
Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the AS3 nucleotide sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.
Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The AS3 nucleotide sequences of the invention uniquely represent portions of the human genome.
Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases.
Each of the sequences described herein can,.to some degree, be used as a standard against which DNA
from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO: l can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID N0:3 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.
If a panel of reagents from AS3 nucleotide sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.
IX, B, 3., Use of Partial AS3 Sequences in Forensic Biology DNA-based identification techniques can also be used in forensic biology.
Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample..
The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO:1 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique.
Examples of polynucleotide reagents include.the AS3 nucleotide sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NO:1 having a length of at least 20 bases, preferably at least 30 bases.
The AS3 nucleotide sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such AS3 probes can be used to identify tissue by species and/or by organ type.
In a similar fashion, these reagents, e.g., AS3 primers or probes can be used to screen tissue culture for contamination (i.e. screen for the presence of a mixture of different types of cells in a culture).
IX, C, Predictive Medicine The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically.
Accordingly, one aspect of the present invention.relates to diagnostic assays for determining AS3 protein and/or nucleic acid expression as well as AS3 activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant or reduced AS3 expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with AS3 protein, nucleic acid expression or activity. For example, mutations in an AS3 gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with AS3 protein, nucleic acid expression, or activity.
Another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of AS3 in clinical trials.
These and other agents are described in further detail in the following sections and in Examples 4 and 5.
IX, C, 1., Diagnostic Assays An exemplary method for detecting the presence or absence of AS3 protein or nucleic acid in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting AS3 protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes AS3 protein such that the presence of AS3 protein or nucleic acid is detected in the biological sample.
A preferred agent for detecting AS3 mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to AS3 mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length AS3 nucleic acid, such as the nucleic acid of SEQ ID NO:1 or 3, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to AS3 mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.
A preferred agent for detecting AS3 protein is an antibody capable of binding to AS3 protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')2) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect AS3 mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of AS3 mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of AS3 protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of AS3 genomic DNA
include Southern hybridizations.
In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a tissue or cell sample isolated by conventional means from a subject.
In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting AS3 protein, mRNA, or genomic DNA, such that the presence of AS3 protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of AS3 protein, mRNA or genomic DNA in the control sample with the presence of AS3 protein, mRNA or genomic DNA in the test sample.
The invention also encompasses kits for detecting the presence of AS3 in a biological sample. For example, the kit can comprise a labeled compound or agent capable of detecting AS3 protein or mRNA in a biological sample; means for determining the amount of AS3 in the sample; and means for comparing the amount of AS3 in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect AS3 protein or nucleic acid.
IX, C, 2., Prognostic Assays The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant AS3 expression or activity. As used herein, the term "aberrant" includes an AS3 expression or activity which deviates from the wild type AS3 expression or activity.
Aberrant expression or activity includes increased or decreased expression or activity, as well as expression or activity which does not follow the wild type developmental pattern of expression or the subcellular pattern of expression. For example, aberrant AS3 expression or activity is intended to include the cases in which a mutation in the AS3 gene causes the AS3 gene to be under-expressed or over-expressed and situations in which such mutations result in a non-functional AS3 protein or a protein which does not function in a wild-type fashion, e.g., a protein which does not interact with an AS3 ligand or one which interacts with a non-AS3 ligand.
The assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a malignancy associated with a misregulation in AS3 protein activity or nucleic acid expression, such as a prostate cancer. Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant AS3 expression or activity in which a test sample is obtained from a subject and AS3 protein or nucleic acid (e.g., mRNA or genomic DNA) is detected, wherein the presence of AS3 protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant or unwanted AS3 expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a cell, tissue, or biological fluid containing a cell.
Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate, such as a hormone, e.g., an androgen) to treat a disease or disorder associated with aberrant AS3 expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for aberrant cell proliferation, e.g., cancer of the prostate.
The methods of the invention can also be used to detect genetic alterations in an AS3 gene, thereby determining if a subject with the altered gene is at risk for a disorder characterized by misregulation in AS3 protein activity or nucleic acid expression, such as a proliferative disorder, e.g., cancer. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding an AS3-protein, or the mis-expression of the AS3 gene. For example, such genetic alterations can be detected by ascertaining the existence of at least one of 1 ) a deletion of one or more nucleotides from an AS3 gene; 2) an addition of one or more nucleotides to an AS3 gene; 3) a substitution of one or more nucleotides of an AS3 gene, 4) a chromosomal rearrangement of an AS3 gene; 5) an alteration in the level of a messenger RNA
transcript of an AS3 gene, 6) aberrant modification of an AS3 gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA
transcript of an AS3 gene, 8) a non-wild type level of an AS3-protein, 9) allelic loss of an AS3 gene, and 10) inappropriate post-translational modification of an AS3-protein. As described herein, there are a large number of assays known in the art which can be used for detecting alterations in an AS3 gene. A preferred biological sample is a cell, tissue, or biological fluid containing a cell, isolated by conventional means from a subject.
In certain embodiments, detection of the alteration involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al.
(1994) Proc. Natl.
Acad. Sci. USA 91:360-364), the latter of which can be particularly useful for detecting point mutations in the AS3-gene (see Abravaya et al. (1995) Nucleic Acids Re.s .23:675-682).
This method can include the steps of collecting a sample of cells from a subject. isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample.
contacting the nucleic acid sample with one or more primers which specifically hybridize to an AS3 gene under conditions such that hybridization and amplification of the AS3-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.
Alternative amplification methods include: self sustained sequence replication (Guatelli, J.C. et al., (1990) Proc. Natl. Acad Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh, D.Y. et al., (1989) Proc. Natl. Acad. Sci. USA
86:1173-1177), Q-Beta Replicase (Lizardi, P.M. et al. (1988) Bio-Technology 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
In an alternative embodiment, mutations in an AS3 gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA
indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
In other embodiments, genetic mutations in AS3 can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin, M.T. et al. (1996) Human Mutation 7: 244-255; Kozal, M.J. et al. (1996) Nature Medicine 2: 753-759).
For example, genetic mutations in AS3 can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, M.T. et al. supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.
In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the AS3 gene and detect mutations by comparing the sequence of the sample AS3 with the corresponding wild-type (control) sequence.
Examples of sequencing reactions include those based on techniques developed by Maxam and Gilbert ((1977) Proc. Natl. Acad. Sci. USA 74:560) or Sanger ((1977) Proc.
Natl. Acad.
Sci. USA 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT
International Publication No. WO 94/16101; Cohen et al. (1996) Adv. Chromatogr. 36:127-162;
and Griffin et al. (1993) Appl. Biochem. Biotechnol. 38:147-159).
Other methods for detecting mutations in the AS3 gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA
or RNA/DNA heteroduplexes (Myers et al. (1985) Science 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type AS3 sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNAse and DNNDNA hybrids treated with S 1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton et al.
1S (1988) Proc. Natl Acad Sci USA 85:4397; Saleeba et al. (1992) Methods Enzymol. 217:286 295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.
In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA
mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in AS3 cDNAs obtained from samples of cells. For example, the mutt enzyme of E.
coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662). According to an exemplary embodiment, a probe based on an AS3 sequence, e.g., a wild-type AS3 sequence, is hybridized to a cDNA or other DNA product from a test cell(s).
The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S.
Patent No.
5,459,039.
In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in AS3 genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc Natl. Acad. Sci USA: 86:2766, see also Cotton (1993) Mutat. Res. 285:125-144; and Hayashi (1992) Genet. Anal. Tech. Appl. 9:73-79).
Single-stranded DNA fragments of sample and control AS3 nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA
(rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment; the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet 7:5).
In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 by of high-melting GC-rich DNA
by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA
(Rosenbaum and Reissner (1987) Biophys Chem 265:12753).
Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al.
(1986) Nature 324:163); Saiki et al. (1989) Proc. Natl Acad. Sci USA 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.
Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention.
Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al. ( 1989) W~ 00/50454 PCT/US00/04732 -Nucleic Acids Res. 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 11:238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. ( 1992) Mol.
Cell Probes 6:1 ). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad.
Sci USA
88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.
The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an AS3 gene.
Furthermore, any cell type or tissue in which AS3 is expressed, e.g., prostate tissue, may be utilized in the prognostic assays described herein.
IX, C, 3., Monitoring of Effects During Clinical Trials Monitoring the influence of agents (e.g., hormone therapy) on the expression or activity of an AS3 protein (e.g., the modulation of cell proliferation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase AS3 gene expression, protein levels, or upregulate AS3 activity, can be monitored in clinical trials of subjects exhibiting decreased AS3 gene expression, protein levels, or downregulated AS3 activity.
Alternatively, the effectiveness of an agent determined by a screening assay to decrease AS3 gene expression, protein levels, or downregulate AS3 activity, can be monitored in clinical trials of subjects exhibiting increased AS3 gene expression, protein levels, or upregulated AS3 activity. In such clinical trials, the expression or activity of an AS3 gene, and preferably, other genes (e.g., prostate-specific antigen (PSA)) that have been implicated in, for example, an AS3-associated disorder can be used as a "read out" or markers of the phenotype of a particular cell.
For example, and not by way of limitation, genes, including AS3, that are modulated in cells by treatment with an agent (e.g., compound, drug or hormone) which modulates AS3 activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cell proliferation modulated by AS3, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of AS3 and other genes implicated in the AS3-associated disorder. The levels of gene expression (e.g., a gene expression pattern) can be quantified by northern blot analysis or RT-PCR, as described herein; or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of AS3 or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during treatment of the individual with the agent or may be used to determine when treatment is appropriate.
In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid. small molecule, or other drug candidate, e.g., a hormone, identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an AS3 protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the AS3 protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the AS3 protein, mRNA, or genomic DNA in the pre-administration sample with the AS3 protein, mRNA, or genomic DNA in the post administration sample or samples;
and (vi) altering the administration of the agent to the subject accordingly.
For example, increased administration of the agent may be desirable to increase the expression or activity of AS3 to higher levels than detected, i.e., to increase the effectiveness of the agent.
Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of AS3 to lower levels than detected, i.e. to decrease the effectiveness of the agent. According to such an embodiment, AS3 expression or activity may be used as an indicator of the effectiveness of an agent, even in the absence of an observable phenotypic response.
IX, D., Methods of Treatment The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant AS3 expression or activity. With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. "Pharmacogenomics", as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers to the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype", or "drug response genotype".) Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the AS3 molecules of the present invention or AS3 modulators according to that individual's drug response genotype.
Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.
IX, D., 1., Prophylactic Methods In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant AS3 expression or activity, by administering to the subject an AS3 molecule or an agent which modulates AS3 expression or at least activity. Subjects at risk for a disease (e.g., prostate cancer) which is caused or contributed to by aberrant AS3 expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.
Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the AS3 aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of AS3 aberrancy, for example, an AS3 molecule, AS3 agonist (e.g., hormone therapy), or AS3 antagonist agent can be used for treating the subject.
The appropriate agent can be determined based on screening assays described herein.
IX, D., 2., Therapeutic Methods Another aspect of the invention pertains to methods of modulating AS3 expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell with an AS3 molecule or agent that modulates AS3 protein activity associated with cell (e.g., cell proliferation). An agent that modulates AS3 protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring target molecule of an AS3 protein (e.g., an AS3 substrate), an AS3 antibody, an AS3 agonist or antagonist, a peptidomimetic of an AS3 agonist or antagonist, or other small molecule (e.g., hormone, such as an androgen). In one embodiment, the agent stimulates one or more AS3 activities. Examples of such stimulatory agents include androgen therapy or a nucleic acid molecule encoding AS3 that has been introduced into the cell. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a cell proliferative disease (e.g., prostate cancer) or disorder characterized by aberrant or reduced expression or activity of an AS3 protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay or a hormone such as androgen as described herein), or combination of agents that modulates AS3 expression or activity.
Stimulation of AS3 activity is desirable in situations in which AS3 is abnormally downregulated and/or in which increased AS3 activity is likely to have a beneficial effect.
For example, stimulation of AS3 activity is desirable in a cell proliferative disease such as prostate cancer and increasing AS3 activity is likely to have a beneficial effect. Moreover, the ability to detect androgen-induced AS3 expression in a patient is an indication that the patient is responsive to hormone and therefore a candidate for intermittent hormone therapy.
As used herein, the term "intermittent hormone therapy" or "intermittent hormone treatment" includes a treatment regime wherein a patient is treated with a hormone, such as an androgen, for a period of time and then withdrawn from such treatment for a period of time. This intermittent administration of hormone shall be, at least in part, determined by an analysis of the patients AS3 levels as described herein.
IX, D, 3., Pharmacogenomics The AS3 molecules of the present invention, as well as agents, or modulators which have a stimulatory or inhibitory effect on AS3 activity (e.g., AS3 gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) AS3-associated disorders (e.g., cell proliferation) associated with aberrant or reduced AS3 activity. In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered.
Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant 1 ~ pharmacogenomics studies in determining whether to administer an AS3 molecule or AS3 modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with an AS3 molecule or AS3 modulator.
Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons.
See, for example, Eichelbaum, M. et al. (1996) Clin. Exp. Pharmacol. Physiol.
23(10-11) :983-985 and Linder, M.W. et al. (1997) Clin. Chem. 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.
One pharmacogenomics approach to identifying genes that predict drug response, known as "a genome-wide association", relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers (e.g., a "bi-allelic" gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two.variants.) Such a high-resolution genetic map can be compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a "SNP" is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be disease-associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.
Alternatively, a method termed the "candidate gene approach", can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drugs target is known (e.g., an AS3 protein of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.
As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT
2) and cytochrome P450 enzymes CYP2D6 and CYP2C 19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6.
Poor metabolizers of CYP2D6 and CYP2C 19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.
Alternatively, a method termed the "gene expression profiling", can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug (e.g., an AS3 molecule or AS3 modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.
Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an AS3 molecule or AS3 modulator, such as a modulator identified by one of the exemplary screening assays described herein.
This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.
EXAMPLE 1.
In this example, the isolation and cloning of the gene encoding human AS3 is described.
To isolate a cDNA encoding an inhibitor of prostate cancer progression, the LNCaP-FGC cell line established from a metastatic lymph node from a patient with prostate adenocarcinoma (Horoszewicz et al., (1983) Cancer Res. 43:1809-1818) was utilized. This cell line and related cell lines derived therefrom were cultured as previously described (Soto et al., (1995) Oncology Res. 7: 545-558; Soto et al., (1991) J. Steroid Biochem. 23: 87-94).
In addition, to isolate a gene expressed at the proliferative shutoff point (i.e., Step 2), a subtractive strategy was used whereby the proliferation of LNCaP-FGC cells was arrested using two different treatments, namely, CD serum (i.e., androgen free serum) and high androgen concentrations. This selective approach takes advantage of the fact that the cells were equally arrested at the G1 stage of the cell cycle by different mechanisms (Soto et al., (1995) Oncology Res. 7: 545-558).
Moreover, since regulatory mRNAs are frequently expressed at low copy numbers, a protocol was adopted using repeated PCR cycles to selectively amplify these sequences.
The final subtracted pool, therefore, was enriched to represent high ranking regulatory elements in the androgen-induced proliferative shutoff (Step-2).
Briefly, androgen-specific, low-abundance regulatory mRNA sequences expressed during the proliferative shutoff, were selected using the Wang-Brown approach (Wang et al., (1991) Proc. Natl. Acad. Sci. USA 88: 11505-11509). Short fragments of cDNAs were amplified first: then three cycles of subtractions and amplifications between the control and proliferation arrested cDNAs resulted in sequence pools that were differentially expressed (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218). LNCaP-FGC
cells were treated with 30 nM 81881 to generate proliferative shutoff. 81881 (methyltrienolone) is a synthetic, non-metabolized androgen (Roussell-UCLAF, Romainville, France).
Exposure to androgen for 24 hours was required to commit LNCaP-FGC cells to an irreversible proliferative shutoff (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63:
211-218). It was concluded that at this point, the genes responsible for the shutoff were highly induced.
LNCaP-FGC cells reversibly arrested by CDHuS were considered as the shutoff negative control; they were harvested after three days of CDHuS treatment. Total RNA
was prepared by the acidic guanidinium-thiocyanate method and polyA+ RNA was purified by using the FastTrack kit (Invitrogen, San Diego, CA) (Chomczinsky et al., (1987) Anal.
Biochem. 162:
156-159).
Double-stranded cDNA pools from 81881-treated cells (R cDNA) and CDHuS-treated cells (CD cDNA) were synthesized using the Copy Kit (Invitrogen), with oligo-dT
priming. After Alul and Rsal digestions and adaptor ligations, the constructs were PCR-amplified (GeneAmp Kit, Perkin Elmer, Foster City, CA). The amplified CD cDNA
were digested with Eco RI, photobiotinylated (driver cDNA) and hybridized at 20-fold molar excess to an aliquot of non-biotinylated R cDNA. The hybridized non-specific sequences were eliminated by subsequent Streptavidin chromatography. After 3 cycles of selection, the amplified expressed sequence tag (EST) pool of the androgen-induced shutoff AS (R
cDNA pool minus CD cDNA pool) sequences was digested with EcoRl, cloned into the BlueScript SK vector (Stratagene, La Jolla, CA) and transformed into E. coli (OneShot strain, Invitrogen).
Isolation of unique cDNAs from the differentially expressed sequence pool was performed as follows. Recombinants were collected randomly from the shutoff positive AS
pool of the Wang-Brown differential library and were plated. Using the labeled CD- and R-subtracted (CD cDNA pool minus R cDNA pool), PCR-amplified DNA master mixes as S
probes, double hybridizations revealed 11 and 14 clones that were present exclusively in the CD and R clone sets, respectively (Geck et al., (1997) J. Steroid Biochem.
Mol. Biol. 63:
211-218). Multiple cross-hybridizations identified ten unique inserts.
To sequence the identified EST fragments, PCR sequencing reactions were performed using the dsDNA Sequencing System (Life Technologies, Gaithersburg, MD).
The EST DNA sequences were tested for homology to known DNA sequences using the PASTA and BLAST (National Center for Biotechnology Information, Bethesda, MD) programs. Five inserts were found with no match in GenBank (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218;. For further analysis, the mRNA with the highest induction in shutoff positive LNCaP-FGC cells (AS3, >5-6-fold of the 5.3 kb mRNA, and >3-4-fold of the 8 kb isoform) was selected.
To isolate the full length AS3 cDNA sequence, a 262 by AS3 tag sequence was utilized to design nested primer pairs to amplify the full length cDNA
sequence from a cDNA library. The cDNA libraries were generated by Human Genome Sciences (Rockville, MD), using polyA+ mRNA preparations from androgen-treated or CDHuS-treated proliferation-arrested LNCaP-FGC cells. The Lambda ZAPII (UniZAP) phage was used as vector carrying EcoRl and Xhol cloning sites. The PCR reaction was designed to amplify the cloned unknown cDNA segments between the known tag sequence and the flanking vector sequences. Since the orientation of the tag sequence was not known, both ends of the insert were amplified in both directions. The vector primers used were commercially available sequencing primers: M 13 Reverse and T3 primers at the EcoRl site, and M 13-20 and T7 primers at the Xhol site.
For the PCR reaction, the Expand High Fidelity kit was used and a 1 ~l phage suspension as template (Boehringer-Mannheim). A 40 cycle amplification in a Perkin-Elmer 9600 thermocycler resulted in the production of a 1370 by 5' fragment and a 3250 by 3' fragment. These PCR products were purified using Qiagen columns, and sequenced by automatic sequencing using a primer walking strategy. The sequencing data showed that the open reading frame in the 5'end fragment did not have an authentic AUG codon.
To search for the missing 5' end of the transcript, the Prostate Specific Marathon Ready cDNA preparation from Clontech was used. Amplifications with the Clontech anchored primer and a set of AS3 specific primers resulted in a 419 by fragment. The DNA
was cloned and sequencing data showed that it carried the N-terminal 118 amino acids of the open reading frame. The nucleotide sequence reported herein has been submitted to GenBank under the accession number U95825 (see also Geck et al., (1999) J.
Steriod Biochem. ~.Tol. Biol., 68:41-50).
EXAMPLE 2.
CHARACTERIZATION OF THE AS3 cDNA SEQUENCE
In this example, the features of the AS3 mRNA and cDNA sequences are described.
Computer analysis of the sequenced 5253 by AS3 cDNA identified a long open reading frame (Figure 1 ). The initiator methionine is at position 66, the stop codon was found at position 4239, and the region codes for a polypeptide of 1391 residues. 'the initiator is the first AUG codon downstream from the 5' end of the sequence, and appears in a strong Kozak-context (Kozak, (1991) J. Biol. Chem. 266:19867-19870; Kozak, (1991) J.
Cell Biol. 115:887-903). The Northern blot size of the transcript is between 5.3 and 5.5 kb (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218) and since the sequence reported here has 5253 nucleotides plus the poly-A tail, the 5' end of our sequence is at or within a few nucleotides of the 5' physical end, further suggesting that the initiator is authentic. The 5' non-coding region is high in GC nucleotides (63.3 %), but it has no recognizable secondary structure elements or other sequence features. The 3' noncoding region has several destabilizing AT-rich elements (underlined in Figure 1 ), typical of transcripts claimed to play a role in cell proliferation (Shaw et al., (1986) Cell 46:659-667, Chen et al., (1995) Trends Biochem. Sci. 20:465-470). The polyadenylation signal of the transcript is 25 by upstream of the consensus GT-rich cleavage site (indicated in a larger font in Figure 1 ).
EXAMPLE 3.
In this example, various structural and functional features of the AS3 polypeptide are described.
Computer analysis of the AS3 open reading frame was performed using the Translate program of the Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wisconsin. (3-strand and a-helix structures were calculated by the Chou-Fasman 1 S method using PepStructure and PepPlot programs. Motif and profile predictions were calculated using various programs of the Wisconsin Package, or by using remote servers offering sequence analyses of protein functional domains through the Internet.
The following remote servers were used: PROWEB (http://www.proweb.org); BLOCKS
(http://www.blocks.fhcrc.org); PRODOM (http://www.toulouse.inra.fr/prodom/);
PRINTS
(http://www.biochem.ucl.ac.uk/cgi-bin/attwood/) and the Protein Kinase Resource (http://www.sdsc.edu/Kinases/).
Employing the above programs, the expected molecular weight of the AS3 polypeptide is determined as 186 kD. In addition, it's noted that the N-terminal 400 amino acid domain is characterized by a unique arrangement of 31 aliphatic residues (21 of them are leucines). Every seventh position (with minor variations) is occupied by a leucine or similar hydrophobic residues and in the five subdomains shown in Figure 2, the pattern is uninterrupted. The arrangement is typical for coiled-coil structures where one side of the long a,-helices is hydrophobic and usually participates in protein-protein interactions (Lupas, (1996) Trends Biochem. Sci. 22:375-382; Beavil et al., (1992) Proc. Natl.
Acad. Sci. USA
89:753-757). The leucine-zipper motif of DNA binding proteins is a specific subclass of _78_ this general pattern and the subdomain between positions 196 and 217 in the AS3 sequence is a perfect leucine-zipper.
The AS3 polypeptide sequence between positions 400 and 600 has elements of a conserved Mg-ATP binding domain of various nucleotide triphosphate binding proteins including protein kinases. In Figure 3, the AS3 sequence is shown in the conserved subdomain arrangements established by Hanks (Hanks et al. , ( 1991 ) Methods Enzymol.
200:38-62). The conserved (3-strand, a,-helix structures and highly conserved critical residues are also indicated, together with the corresponding sequences of various protein kinases (Taylor et al., (1992) Annu. Rev. Cell Biol. 8:429-462). Although the complete AS3 sequence did not appear to be related to any particular protein kinase or ATP binding protein, partial homology within the subdomains was maintained, and probably indicates that the domain is functional. Indeed, one feature of the AS3 polypeptide is the presence of several relatively well conserved kinase -related domains such as an Mg-nucleotide triphosphate binding pocket, as well as elements of the catalytic domain of several protein kinases (see Figure 3). Functional analysis of this domain using GST-fusion constructs indicates that the fusion construct polypeptide can form a complex resulting in the phosphorylation of at least two substrate proteins found in LNCaP-FGC cell extracts.
In addition to the above-mentioned motifs, the AS3 polypeptide also has a functional protein kinase domain located at amino acid residues 474-680 (encoded by nucleic acids 1420-2040; see SEQ ID NO: 3). To demonstrate that this region of the AS3 polypeptide has kinase activity, and is, e.g., capable of phosphorylating cellular substrates, the nucleic acid encoding this region was PCR amplified (using a corresponding upstream primer with a BamHI site and a corresponding downstream primer with a EcoRI site), digested, purified, and cloned into BamHI sites of the bacterial GST-fusion vector pGEX-T2 thereby fusing the AS3 domain to the C-terminus of GST (thus, the fusion protein is referred to as GST-AS3).
The resultant construct, encoding a GST-AS3 fusion protein, was then transferred into bacteria (BL21 protease minus host) which were then induced to express the GST-AS3 fusion protein.
Bacterial extracts containing the GST/AS3 fusion protein were incubated with MCF7-AR1 cell extracts in the presence of 32P-ATP and chromatographed through glutathione-Sepharose.
Proteins which specifically bound to the GST-AS3 fusion protein were resolved by SDS-PAGE and autoradiography using standard conditions. Two polypeptides (40 and 120 kDa) were specifically purified and phosphorylated by the AS3-GST fusion protein demonstrating the functional kinase activity of this protein kinase domain of AS3. There was no 32P-labelled band observed at 90 kDa (the mass of the AS3-GTS fusion protein) suggesting that the AS3 kinase domain does not auto-phosphorylate but phosphorylates other proteins through, e.g., a docking mechanism.
Furthermore, a putative nuclear localization sequence (NLS) (KKFTQVLEDDEKIRK) resembling that of the androgen receptor and DNA polymerase-a was localized at position 547( Zhou et al., (1994) J. Biol. Chem. 269:13115-13123;
Bouvier et al., (1995 Mol. Biol. Cell 6:1697-1705). Further, the C-terminal region of the putative AS3 polypeptide contains several sequence elements that show similarities to DNA
binding proteins. Motifs and ProfileScan searches in the Wisconsin Package indicated helix-loop-helix and Homeo-box signature sequences in the area, and a remote search on the BLOCKS server also identified DNA binding block elements in the C-terminal sequences.
Still further, it is noted a serine-rich domain at position 1139, and a proline/glycine-rich domain at the 1284 position were also found. The C-terminal domain (about 200 amino acids) is highly charged and arranged in unique repeats of seven alternating acidic and basic domains.
A BLASTP search performed on the GenBank database resulted in a single high score similarity with the bimD gene of the eukaryotic organism Aspergillus nidulans, where 50% of the amino acid sequence was functionally similar in portions of the coiled-coil domain and the putative DNA binding domain at the C-terminus. The bimD protein has a basic leucine-zipper and a C-terminal charged (acidic) domain, similar to AS3, and appears to function as a DNA binding protein (benison et al., (1992) Genetics, 134:1085-1096).
Both the AS3 and the bimD proteins also have nuclear localization consensus sequences.
Finally, to confirm that the AS3 polypeptide is capable of binding to DNA and moreover, to elucidate a DNA motif that binds to the DNA recognition sequence of AS3, an AS3-GST fusion polypeptide containing the DNA recognition sequence of AS3 was produced using a similar approach as used above to assay AS3 kinase activity.
Briefly, an expression vector was engineered to encode the DNA binding domain of AS3 fused to the N-terminus of GST (thus, the fusion protein is referred to as AS3-GST) which, when expressed in bacteria, allowed for the production of an AS3-GST
fusion protein for DNA binding studies. The AS3-GST protein was then purified by affinity chromatography as described above. Next, the resultant, purified AS3-GST protein was incubated with a mixture of oligonucleotides comprising constant 5' (25 bp) and 3' (25 bp) ends and randomly generated middle segments (18 bp) and chromatographed through a glutathione-Sepharose the column. To avoid non-specific binding, double stranded poly(dI-dC) (average length 1800 bp) was added to the mixture. The AS3-GST fusion protein, together with bound oligonucleotides, was eluted with glutathione and the bound oligonucleotides were amplified by PCR, purified, and subjected to a second round of column chromatography using AS3-GST
before being PCR amplified and cloned into a TA vector.
Thirty clones were sequenced to assess whether a specific nucleotide sequence was recognized by the AS3-GST fusion product. The sequences were compared and analyzed by the PILE-UP program of the GCG package. The co-alignment of the sequences revealed a pattern of the following putative consensus sequence:
5' C, T, A, [T/A], [T/A], A, G, [C/G], C, C, C, [C/G], G, C, [C/G]), C, A, [A/T], 3' (SEQ ID
NU: 5) Interestingly, sequence similarities were found between the putative AS3 DNA
recognition sequence and the NF-kappaB and the Mbpl recognition motifs. In addition, similarities within the p27~'" promoter at positions -270, -383, -427, and -586 were also found indicating that important gene regulatory elements exist in the cell in which the AS3 protein may interact with (Zhang et al., (1997) Biochem. Biophys. Acta., 1353:307-317). Interestingly, the transcription factor NF-kappaB, which is involved in the control of apoptosis, and Mbpl which is involved in the Gl-S cell cycle transition in yeast, also interact with similar DNA
motifs (Waddick et al., (1999) Biochem. Pharmacol., 57:9-17; Koch et al., (1993) Science, 261:1551-1557).
Accordingly, it was concluded that AS3 is capable of binding to DNA in a sequence specific manner and therefore, may function as a transcriptional regulator of genes involved in cell growth control.
EXAMPLE 4.
MARKERS FOR DISEASE
In this example, aspects of the AS3 genomic locus and the use of AS3 related molecules as markers for disease are described.
A computer homology search in GenBank was performed and identified the AS3 genomic region as residing on chromosome 13q12-q13. This area is represented by cosmid 267p 19, and on P 1 artificial chromosomes PAC26H23 and PAC49J 10. Consensus splicing donor and acceptor sites were identified and the entire exon-intron structure of the AS3 gene was resolved comparing the cDNA sequence and the genomic sequence using the BLAST
program (see Figure 4) (Shapiro et al., (1987) Nucl. Acids Res. 15:7155-7174).
The actual cosmid and cDNA positions are listed in Figure 4, and the arrangement of exons is depicted in Figure 5. The area covers nearly 200,000 by and the average size of the exons is 100-150 bp.
Interestingly, the AS3 genomic area is centromeric to the RB 1 locus, and telomeric to BRCA2. The AS3 gene is transcribed in the same direction as BRCA2, and the coding strand is downstream from the breast cancer gene (Couch et al., (1997]
Genomics 36:86-99). On the opposite strand upstream of AS3, three regions were assigned to cDNAs of unknown functions. An expressed sequence (CG008) has been assigned to this area, and represents a portion of the AS3 transcript (Couch et al., (1997) Genomics 36:86-99). The N
terminal 354 amino acids of the open reading frame are missing in the CG008 sequence in GenBank. The CG008 open reading frame terminates at amino acid 738 of the AS3 sequence. The sequencing data reported herein and the published genomic sequence are identical, confirming the correct sequence of AS3. The extra C at nucleotide position 1,109 in the CG008 sequence suggests a possible sequencing error that results in a frame shift and a stop codon at position 1,152 of the CG008 sequence.
With the above information in hand, it was observed that several epidemiological studies support a link between breast and prostate cancers implying shared genetic suppressor elements in both disease states (Thiessen, (1974) Cancer 34:1102-1107;
Tulinius et al., (1992) Br. Med. J. 305:855-857). For example, studies of breast cancer families with high loss of heterogenicity (LOH) in the BRCA2 area showed that high W~ 00/50454 PCT/US00/04732 -prostate cancer incidence also occurred in 4 out of 5 families examined (Gudmundsson et al., (1995) Cancer Res. 55:4830-4832). Further, in the majority of the male relatives with prostate cancer in these families (86%), allelic losses in the BRCA2 area were also detected with some of these mutations occurring in the region immediately downstream of the BRCA2 gene (Gudmundsson et al., (1995) Cancer Res. 55:4830-4832; Van den Berg et al., (1996) Br. J. Cancer 74:1615-1619; Cleton-Jansen et al., (1995) Br. J. Cancer 72:1241-1244).
Moreover, it was noted that putative suppressors in the immediate vicinity of BRCA2 are not only limited to sex hormone-related cancers. For example, recent studies on chronic lymphoid leukemia detected a 1 Mb allelic loss in this region, with no mutations in the BRCA2 gene, pointing to a cryptic suppressor next to this gene (Garcia-Marco et al., (1996) Blood 88:1568-1575; Caldas et al., (1997) Proc. Am. Assoc. Cancer Res.
38:191).
As indicated herein, the coding sequence of AS3 lies within this area. Thus, AS3 (or AS3-related molecules) may be associated with a number of diseases and conditions at several different levels involving, e.g., genomic alterations (including deletions and/or mutations at the chromosomal level), altered transcription or transcript production, and/or altered protein or protein expression levels. Thus, "AS3 related molecules" include, nucleic acid fragments or probes derived from the AS3 genomic locus (or an AS3 cDNA), and AS3 or AS3 related proteins or protein fragments.
In addition to foregoing, the ability to determine AS3 protein expression levels, altered AS3 proteins, and/or AS3 protein expression patterns in, for example, different tissue samples (such a biopsy sample from, e.g., the prostate) may be desired. To this end, several antibodies have been developed that specifically bind the AS3 polypeptide. Briefly, computer aided sequence analysis of the AS3 protein was performed in order to identify several antigenic areas of the AS3 protein that were suitable for use as an immunogen. Accordingly, oligopeptides corresponding to amino acid residues 711-727 and 1,369-1387 of SEQ ID NO: 4 were synthesized and used to raise antibodies in, respectively, rabbits and chickens (egg yolk immunoglobulin Y). The resultant antibodies were both tested against cellular extracts derived from either LNCaP-FGC or MCF7-ARl cells induced with androgen to express AS3 protein and both antibody preparations recognized a protein band of the expected size for AS3 protein.
Thus, these antibodies can be used for performing, for example, immunocytochemistry on various cell samples (e.g., biopsies of the prostate) for various prognostic and diagnostic determinations:
Accordingly, it was concluded that the AS3-related molecules and AS3-specific antibodies disclosed herein are useful prognostic/diagnostic probes for evaluating diseases (e.g., the aforementioned cancers) that are associated with, or map to, the AS3 locus or are associated with altered AS3 protein expression.
EXAMPLE 5.
In this example, the use of AS3 as a marker in guiding the appropriate administration of hormone therapy for prostate cancer is discussed.
It was determined that expression analysis of the AS3 transcript demonstrated proliferation arrest-specific induction patterns, starting soon (4-6 h) after androgen exposure (Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218). AS3 levels peaked at 18-20 h, about 4 h before the commitment for proliferative shutoff was detected, suggesting that this gene is a candidate for a shutoff mediator. Furthermore, expression of the AS3 transcript positively correlated with proliferation arrest as this gene was expressed only in shutoff positive cell lines and variants. In addition, LNCaP-FGC cells proliferated maximally in CDHuS supplemented with 30 pM R1881 and under these conditions AS3 was not expressed. When AS3 was strongly induced in the presence of hormone (i.e., 0.3-30 nM of R1881), the cells were inhibited from proliferating. An additional observation that indicates the AS3 gene codes for an inhibitor of the proliferation of prostate cells is the increase of AS3 mRNA levels in the rat prostate when proliferation was arrested by prolonged androgen administration. In addition, comparable effects in MCF7-AR1 cells have been observed. Finally, significant homology between the fungal gene bimD
and AS3 was found. Importantly, it was noted that overexpression of bimD in Aspergillus nidulans results in a cell cycle arrest in G1/S phase and observe a similar cell cycle arrest and concordant peak expression of AS3 in mammalian cells induced to undergo androgen-induced proliferative shutoff (benison et al., (1992) Genetics, 134:1085-1096;
Geck et al., (1997) J. Steroid Biochem. Mol. Biol. 63: 211-218).
Based on these observations, it was concluded that AS3 expression is a useful marker of responsiveness of prostate cancer cells to the inhibitory effect of androgens. In order to make the tumor regress, avoid reoccurrence, and maintain an acceptable quality of life, patients presenting this response may be treated with alternate cycles of antiandrogens and androgens. Androgens have a biphasic effect on the normal prostate: an initial phase of increased proliferation (Step 1 ) followed by a phase of inhibition (Step 2).
Prior to the invention, prostate cancer has been treated by hormone ablation (castration, antiandrogens) to take advantage of Step I. Usually after a significant regression, the remaining tumor cells become resistant and the tumor and/or metastases relapse. The invention avoids this problem by allowing the clinician to subject patients to an intermittent therapy. This is based on a classification of patients who have an increased chance to be responsive to the intermittent hormone therapy. Patients not showing AS3 positive cancer cells would then be subjected to alternative therapies (chemotherapy, radiation, etc.). In contrast, the protocol for AS3 positive patients would be to first administer antiandrogens, to block the proliferative effect and return PSA
levels to normal, and then to treat the patient with physiological but high doses of androgen to elicit Step 2.
The invention allows the clinician to confidently assess the initial hormone dependence of the tumor (i.e., whether tumor cells express AS3 in response to hormone) and determine when to re-expose the patient to hormone. Importantly, the use of intermittent hormone therapy allows the clinician to determine exactly when cells are no longer responding to hormone such that hormone treatment can be withdrawn before the cells become refractory to hormone treatment and untreatable. If the patient develops metastases capable of being biopsied, assaying AS3 levels as described herein would allow a renewed attempt to reduce the proliferation of those cancer cell by increasing the androgen concentration of the treatment. This important aspect of the invention should allow the clinician to lower the rate at which clones of cells develop hormone resistance and become capable of multiplying and metastasizing without androgen stimulation. Moreover, this new treatment regime affords a better quality of life for the patient because, unlike with constant hormone treatment, sexual drive and potency are recovered.
EXAMPLE 6.
INDUCED SUPPRESSOR OF CELL PROLIFERATION
In this example, an inducible antisense assay is provided for demonstrating that AS3 is an androgen-inducible suppressor of cell proliferation.
To demonstrate androgen-inducible AS3 suppressor activity in a proliferating cell (i.e., proliferative shut off activity), clonal cell lines were derived in which the presence or absence of AS3 could be controlled using an inducible AS3 antisense gene. The prediction was that cells incubated in the presence of androgen would have reduced levels of proliferation as compared to the same cells in the absence of androgen or cells in the presence of androgen but in which levels of AS3 had been experimentally ablated. Thus, cells incubated in the presence of androgen, but also induced to express antisense AS3 gene transcript which removes cellular levels of the AS3, would be predicted to grow like wild type cells because, even though the cells were being exposed to androgen, there would be insufficient AS3 to mediate the androgen signal reducing cell growth. This is precisely what was observed (see, e.g., Table 1 ), thereby demonstrating that AS3 is an androgen-induced suppressor of cell proliferation.
In order to develop the foregoing novel cell lines in which to demonstrate that AS3 mediates the androgen-induced shutoff effect, an inducible transgene encoding an AS3 antisense transcript (or empty vector as a negative control) was genetically engineered into a retroviral vector backbone for efficient, stable, integration into cells. In particular, the AS3 antisense gene was cloned into the Clontech pRevTRE retroviral vector under the control of a tetracycline sensitive promoter. The promoter has seven repeats of the bacterial tet0 operator sequence upstream of the minimal CMV promoter which can be bound by the tetracycline transactivator (tTA). The tTA is a fusion protein between the bacterial tetracycline repressor and the V 16 herpes virus transactivator. The tetracycline transactivator is sensitive for tetracycline such that, in the presence of tetracycline, the transactivator cannot bind the tetracycline promoter so the transgene is "off ' and conversely, in the absence of tetracycline, the gene is "on" (i.e., the Tet-Off system;
see, e.g., Clontech pRevTRE manual for further details).
To stably introduce the foregoing inducible vectors into cells, the vectors were first transfected into a packaging cell line (PT67) under drug selection (hygromycin). After 2-3 weeks of selection, the surviving packaging cells were used as a source of supernatants containing infectious virions containing the inducible transgene.
The supernatants containing the highest amounts of virions were then used to infect the STFX1 cell line, a derivative of the MCF7-AR1 that has a tetracycline transactivator gene stably integrated. During the cloning and selection procedures, cells were maintained in 1 ~g/mL of tetracycline to suppress the expression of the inducible transgenes.
In order to characterize the cell lines expressing AS3 antisense and the "control" cell lines having vector without insert, cells were incubated in the presence (i.e., the transgene is off) and absence of tetracycline (i.e., the transgene is on) and, after 36 hours, assayed for transcript expression using RT-PCR under standard conditions, To determine the affect of androgen induced AS3 suppression of cellular growth, cells lines showing high levels of inducible AS3 antisense expression were chosen for further study. Cells were seeded onto coverslips in standard growth medium and allowed to grow for 5 days in the presence of 10 ~g/ml tetracycline (hereafter "tet").
Then, the medium was changed to i) 10 ~g/ml tet, or ii) no tet for 36 hours as indicated in Table 1. Then, vehicle or 10 nM of the androgen 81881 was added. Finally, 24 hours later, the cells were treated with 10 ~g/ml of bromodeoxyuridine (BrdU) for several hours to measure the percent of cells actively proliferating as a function of BrdU incorporation during DNA
replication. The cells were then fixed, Hoechst stained, and the percent number of BrdU-labeled cells was determined using immunocytochemistry (using standard BrdU
labeling regents and protocols from Boheringer).
As clearly indicated in Table 1, administration of the androgen 81881 results in a significant decrease in the number of proliferating cells in S phase (compare to sample 1 where cells are not treated with androgen) when cellular levels of AS3 are unaffected because the transgene vector is empty and uninduced (sample 2), empty and induced (sample 4), or encoding AS3 but uninduced (sample 6). In stark contrast, when AS3 levels are reduced by antisense expression in the absence of tetracycline, the androgen Rl 881 no longer induces a proliferative shutoff (compare sample 8 with sample 6).
WO 00/50454 PCT/tJS00/04732 _87_ Table 1. Analysis of the effect of tetracycline and androgen on the percent BrdU-labeled nuclei of STFXl cells containing vector only or AS3 antisense constructs Sample Treatment % Proliferating Cells (Mean +I- S.E.) 1 vector, +tet, -A 35.0 +I-1.7 2 vector, +tet, +A 9.4 +I-1.7 3 vector, -tet, -A 36.6 +/-2.7 4 vector, -tet, +A 10.7 +~-0.9 Antisense, +tet, -A 34.7 +~-1.0 6 Antisense, +tet, +A 9.7 +I-0.6 7 Antisense, -tet, -A 32.2 +/-1.5 8 Antisense, -tet, +A 29.1 +I-1.6 5 Vector denotes STFX1 cells expressing empty vector under tetracycline control. Tetracycline is abbreviated tet; A denotes 10 nM R1881. Antisense denotes STFX1 cells expressing AS3-antisense under tetracycline control. Tetracycline represses the expression of the vector and the AS3 antisense. Each data point represents the mean of 8-9 low power fields containing about 150-200 cells/field. Data were analyzed using the Mann-Whitney test; significance was measured at p<0.001.
This experiment further shows that the expression of the empty vector neither interferes with the androgen-mediated shutoff, nor results in toxic effects.
Accordingly, it is concluded that androgen induced suppression of cell proliferation (or proliferative shutoff) is modulated by AS3 because expression of an AS3 antisense that reduces cellular levels of AS3 results in the unlinking of androgen-induced AS3-mediated suppression of cell growth.
_gg_ Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
What is claimed:
SEQUENCE LISTING
<110> Soto, Ana, et al.
<120> A NOVEL ANDROGEN-INDUCED SUPPRESSOR OF CELL PROLIFERATION AND USES
THEREOF
<130> MBI-008-1 <140>
<141>
<160> 5 <170> PatentIn Ver. 2.0 <210> 1 <211> 5271 <212> DNA
<213> Homo Sapiens <220>
<221> CDS
<222> (66)..(4238) <400> 1 ccggagagcc ccggagtgag cggagtagcg agtcggcaac ccggaggggt agaaatattt 60 ctgtc atg get cat tca aag act agg acc aat gat gga aaa att aca tat 110 Met Ala His Ser Lys Thr Arg Thr Asn Asp Gly Lys Ile Thr Tyr ccg cct ggg gtc aag gaa ata tca gat aaa ata tct aaa gag gag atg 158 Pro Pro Gly Val Lys Glu Ile Ser Asp Lys Ile Ser Lys Glu Glu Met gtg aga cga tta aag atg gtt gtg aaa act ttt atg gat atg gac cag 206 Val Arg Arg Leu Lys Met Val Val Lys Thr Phe Met Asp Met Asp Gln gac tct gaa gaa gaa aag gag ctt tat tta aac cta get tta cat ctt 254 Asp Ser Glu Glu Glu Lys Glu Leu Tyr Leu Asn Leu Ala Leu His Leu get tca gat ttt ttt ctc aag cat cct ggt aaa gat gtt cgc tta ctg 302 Ala Ser Asp Phe Phe Leu Lys His Pro Gly Lys Asp Val Arg Leu Leu gta gcc tgc tgc ctt get gat att ttc agg att tat get cct gaa get 350 Val Ala Cys Cys Leu Ala Asp Ile Phe Arg Ile Tyr Ala Pro Glu Ala cct tac aca tcc cct gat aaa cta aag gat ata ttt atg ttt ata aca 398 Pro Tyr Thr Ser Pro Asp Lys Leu Lys Asp Ile Phe Met Phe Ile Thr aga cag ttg aag ggg cta gag gat aca aag agc cca caa ttc aat agg 446 Arg Gln Leu Lys Gly Leu Glu Asp Thr Lys Ser Pro Gln Phe Asn Arg tat ttt tat tta ctt gag aac att get tgg gtc aag tca tat aac ata 494 Tyr Phe Tyr Leu Leu Glu Asn Ile Ala Trp Val Lys Ser Tyr Asn Ile tgc ttt gag tta gaa gat agc aat gaa att ttc acc cag cta tac aga 542 Cys Phe Glu Leu Glu Asp Ser Asn Glu Ile Phe Thr Gln Leu Tyr Arg acc tta ttt tca gtt ata aac aat ggc cac aat cag aaa gtc cat atg 590 Thr Leu Phe Ser Val Ile Asn Asn Gly His Asn Gln Lys Val His Met cac atg gta gac ctt atg agc tct att att tgt gaa ggt gat aca gtg 638 His Met Val Asp Leu Met Ser Ser Ile Ile Cys Glu Gly Asp Thr Val tctcaggagcttttggatacggttttagtaaatctggtacctgetcat 686 SerGlnGluLeuLeuAspThrValLeuValAsnLeuValProAlaHis aagaatttaaacaagcaagcatatgattt.ggcaaaggetttactgaag 734 LysAsnLeuAsnLysGlnAlaTyrAspLeuAlaLysAlaLeuLeuLys aggacagetcaagetattgagccatatattaccactttttttaatcag 782 ArgThrAlaGlnAlaIleGluProTyrIleThrThrPhePheAsnGln gttctgatgcttgggaaaacatctatcagcgatttgtcagagcatgtc 830 ValLeuMetLeuGlyLysThrSerIleSerAspLeuSerGluHisVal tttgacttaattttggagctctacaatattgatagtcatttgctgctc 878 PheAspLeuIleLeuGluLeuTyrAsnIleAspSerHisLeuLeuLeu tctgttttaccccagcttgaatttaaattaaagagcaatgataatgag 926 SerValLeuProGlnLeuGluPheLysLeuLysSerAsnAspAsnGlu gagcgcctacaagttgttaaactactggcaaaaatgtttggggcaaag 974 GluArgLeuGlnValValLysLeuLeuAlaLysMetPheGlyAlaLys gattcagaattggettctcaaaacaagccactttggcagtgctacttg 1022 AspSerGluLeuAlaSerGlnAsnLysProLeuTrpGlnCysTyrLeu ggcaggtttaatgatatccatgtaccaatccgcctggaatgtgtgaaa 1070 GlyArgPheAsnAspIleHisValProIleArgLeuGluCysValLys tttgetagccattgtctcatgaaccatcctgatttagcaaaagactta 1118 PheAlaSerHisCysLeuMetAsnHisProAspLeuAlaLysAspLeu acagagtatcttaaagtgaggtcacatgaccctgaggaagetattaga 1166 ThrGluTyrLeuLysValArgSerHisAspProGluGluAlaIleArg catgatgttattgtgtcaatagttacagetgetaaaaaggatattctt 1214 HisAspValIleValSerIleValThrAlaAlaLysLysAspIleLeu ctggtcaatgatcacttacttaattttgtgagagagagaacattagac 1262 LeuValAsnAspHisLeuLeuAsnPheValArgGluArgThrLeuAsp aaacgatggagagtacgcaaagaagccatgatgggacttgcccaaatt 1310 LysArgTrpArgValArgLysGluAlaMetMetGlyLeuAlaGlnIle tataagaaatatgetttacagtcagcagetggaaaagatgetgcaaaa 1358 TyrLysLysTyrAlaLeuGlnSerAlaAlaGlyLysAspAlaAlaLys cagatagcatggatcaaagacaaattgctacatatatattatcaaaat 1406 GlnIleAlaTrpIleLysAspLysLeuLeuHisIleTyrTyrGlnAsn agtattgatgatcgactacttgttgaacggatctttgetcaatacatg 1454 SerIleAspAspArgLeuLeuValGluArgIlePheAlaGlnTyrMet gtt cct cac aat tta gaa act aca gaa cgg atg aaa tgc tta tat tac 1502 Val Pro His Asn Leu Glu Thr Thr Glu Arg Met Lys Cys Leu Tyr Tyr ttg tat gcc aca ctg gat tta aat get gtg aaa gca ttg aat gaa atg 1550 Leu Tyr Ala Thr Leu Asp Leu Asn Ala Val Lys Ala Leu Asn Glu Met tgg aaa tgt caa aat ctg ctc cga cat caa gta aag gat ttg ctt gac 1598 Trp Lys Cys Gln Asn Leu Leu Arg His Gln Val Lys Asp Leu Leu Asp ttg att aag caa ccc aaa aca gat gcc agt gtc aag gcc ata ttt tca 1646 Leu Ile Lys Gln Pro Lys Thr Asp Ala Ser Val Lys Ala Ile Phe Ser aaa gtg atg gtt att aca aga aat tta cct gat cct ggt aag get cag 1694 Lys Val Met Val Ile Thr Arg Asn Leu Pro Asp Pro Gly Lys Ala Gln gat ttc atg aag aaa ttc aca cag gtg tta gaa gat gat gag aaa ata 1742 Asp Phe Met Lys Lys Phe Thr Gln Val Leu Glu Asp Asp Glu Lys Ile aga aag cag tta gaa gta ctt gtt agt cca aca tgc tcc tgc aag cag 1790 Arg Lys Gln Leu Glu Val Leu Val Ser Pro Thr Cys Ser Cys Lys Gln get gaa ggt tgt gtg cgt gaa ata act aag aag ttg ggc aac ccc aaa 1838 Ala Glu Gly Cys Val Arg Glu Ile Thr Lys Lys Leu Gly Asn Pro Lys cag cct aca aat cct ttc ctg gaa atg atc aag ttt ctc ttg gag agg 1886 Gln Pro Thr Asn Pro Phe Leu Glu Met Ile Lys Phe Leu Leu Glu Arg ata gca cct gtg cac ata gat acc gaa tct atc agt get ctt att aaa 1934 Ile Ala Pro Val His Ile Asp Thr Glu Ser Ile Ser Ala Leu Ile Lys caa gtg aac aaa tca ata gat gga aca gca gat gat gaa gat gag ggt 1982 Gln Val Asn Lys Ser Ile Asp Gly Thr Ala Asp Asp Glu Asp Glu Gly gtt cca act gat caa gcc atc aga gca ggt ctt gaa ctg ctt aag gta 2030 Val Pro Thr Asp Gln Ala Ile Arg Ala Gly Leu Glu Leu Leu Lys Val ctc tca ttt aca cat ccc atc tca ttt cat tct get gaa aca ttt gaa 2078 Leu Ser Phe Thr His Pro Ile Ser Phe His Ser Ala Glu Thr Phe Glu tca tta ctg get tgt ctg aaa atg gat gat gaa aaa gta gca gaa get 2126 Ser Leu Leu Ala Cys Leu Lys Met Asp Asp Glu Lys Val Ala Glu Ala gca cta caa att ttc aaa aac aca gga agc aaa att gaa gag gat ttt 2174 Ala Leu Gln Ile Phe Lys Asn Thr Gly Ser Lys Ile Glu Glu Asp Phe cca cac atc aga tca gcc ttg ctt cct gtt tta cat cac aaa tct aaa 2222 Pro His Ile Arg Ser Ala Leu Leu Pro Val Leu His His Lys Ser Lys aaa gga ccc ccc cgt caa gcc aaa tat gcc att cat tgt atc cat gcg 2270 Lys Gly Pro Pro Arg Gln Ala Lys Tyr Ala Ile His Cys Ile His Ala ata ttt tct agt aaa gag acc cag ttt gca cag ata ttt gag cct ctg 2318 Ile Phe Ser Ser Lys Glu Thr Gln Phe Ala Gln Ile Phe Glu Pro Leu cat aag agc cta gat cca agc aac ctg gaa cat ctc ata aca cca ttg 2366 His Lys Ser Leu Asp Pro Ser Asn Leu Glu His Leu Ile Thr Pro Leu gtt act att ggt cat att get ctc ctt gca cct gat caa ttt get get 2414 Val Thr Ile Gly His Ile Ala Leu Leu Ala Pro Asp Gln Phe Ala Ala cct tgg aaa tct tgg gta get act ttc att gtg aaa gat ctt ctc atg 2462 Pro Trp Lys Ser Trp Val Ala Thr Phe Ile Val Lys Asp Leu Leu Met aat gat cgg ctt cca ggg aaa aag aca act aaa ctt tgg gtt cca gat 2510 Asn Asp Arg Leu Pro Gly Lys Lys Thr Thr Lys Leu Trp Val Pro Asp gaa gaa gta tct cct gag aca atg gtc aaa att cag get att aaa atg 2558 Glu Glu Val Ser Pro Glu Thr Met Val Lys Ile Gln Ala Ile Lys Met atg gtt cga tgg cta ctt gga atg aaa aat aat cac agt aaa tca gga 2606 Met Val Arg Trp Leu Leu Gly Met Lys Asn Asn His Ser Lys Ser Gly act tct acc tta aga ttg cta aca aca ata ttg cat agt gat gga gac 2654 Thr Ser Thr Leu Arg Leu Leu Thr Thr Ile Leu His Ser Asp Gly Asp 850 855 g60 ttg aca gaa cag ggg aaa att agt aaa cca gat atg tca cgt ctg aga 2702 Leu Thr Glu Gln Gly Lys Ile Ser Lys Pro Asp Met Ser Arg Leu Arg 865 870 g75 ctt get get ggg agt get att gtg aag ctg gca caa gaa ccc tgt tac 2750 Leu Ala Ala Gly Ser Ala Ile Val Lys Leu Ala Gln Glu Pro Cys Tyr cat gaa atc atc aca tta gaa caa tat cag cta tgt gca tta get atc 2798 His Glu Ile Ile Thr Leu Glu Gln Tyr Gln Leu Cys Ala Leu Ala Ile aacgatgaatgctatcaagtaagacaagtgtttgcccagaaacttcac 2846 AsnAspGluCysTyrGlnValArgGlnValPheAlaGlnLysLeuHis aaaggcctttcccgtttacggcttccacttgagtatatggcaatctgt 2894 LysGlyLeuSerArgLeuArgLeuProLeuGluTyrMetAlaIleCys gccctttgtgcaaaagatcctgtaaaggagagaagagetcatgetagg 2942 AlaLeuCysAlaLysAspProValLysGluArgArgAlaHisAlaArg caatgtttggtgaaaaatataaatgtaaggcgggagtatctgaagcag 2990 GlnCysLeuValLysAsnIleAsnValArgArgGluTyrLeuLysGln catgcagetgttagtgaaaaattattgtctcttctaccagagtatgtt 3038 HisAlaAlaValSerGluLysLeuLeuSerLeuLeuProGluTyrVal gttccatatacaattcaccttttggcacatgacccagattatgtcaaa 3086 ValProTyrThrIleHisLeuLeuAlaHisAspProAspTyrValLys gtacaggatattgaacaacttaaagatgttaaagaatgtctttggttt 3134 ValGlnAspIleGluGlnLeuLysAspValLysGluCysLeuTrpPhe gttctggaaatattaatggetaaaaatgaaaataacagtcacgetttt 3182 ValLeuGluIleLeuMetAlaLysAsnGluAsnAsnSerHisAlaPhe atcagaaagatggtagaaaatattaaacaaacaaaagatgcccaagga 3230 IleArgLysMetValGluAsnIleLysGlnThrLysAspAlaGlnGly ccagatgatgcaaaaatgaatgaaaaactgtacactgtgtgtgatgtt 3278 ProAspAspAlaLysMetAsnGluLysLeuTyrThrValCysAspVal gccatgaatatcatcatgtcaaagagtactacatacagtttggaatct 3326 AlaMetAsnIleIleMetSerLysSerThrThrTyrSerLeuGluSer cctaaagacccggtactaccagetcgtttcttcactcaacctgacaag 3374 ProLysAspProValLeuProAlaArgPhePheThrGlnProAspLys aatttcagtaacaccaaaaattatctgcctcctgaaatgaaatcattt 3422 AsnPheSerAsnThrLysAsnTyrLeuProProGluMetLysSerPhe ttcactcctggaaaacctaaaacaaccaatgttctaggagetgttaac 3470 PheThrProGlyLysProLysThrThrAsnValLeuGlyAlaValAsn aagccactttcatcagcaggcaagcaatctcagaccaaatcatcacga 3518 LysProLeuSerSerAlaGlyLysGlnSerGlnThrLysSerSerArg atggaaactgtaagcaatgcaagcagcagctcaaatccaagctctcct 3566 MetGluThrValSerAsnAlaSerSerSerSerAsnProSerSerPro ggaagaataaaggggagg cttgatagttctgaa atggatcacagtgaa 3614 GlyArgIleLysGlyArg LeuAspSerSerGlu MetAspHisSerGlu aatgaagattacacaatg tcttcacctttgccg gggaaaaaaagtgac 3662 AsnGluAspTyrThrMet SerSerProLeuPro GlyLysLysSerAsp aagagagacgactctgat cttgtaaggtctgaa ttggagaagcctaga 3710 LysArgAspAspSerAsp LeuValArgSerGlu LeuGluLysProArg ggcaggaaaaaaacgccc gtcacagaacaggag gagaaattaggtatg 3758 GlyArgLysLysThrPro ValThrGluGlnGlu GluLysLeuGlyMet gatgacttgactaagttg gtacaggaacagaaa cctaaaggcagtcag 3806 AspAspLeuThrLysLeu ValGlnGluGlnLys ProLysGlySerGln cgaagtcggaaaagaggc catacggettcagaa tctgatgaacagcag 3854 ArgSerArgLysArgGly HisThrAlaSerGlu SerAspGluGlnGln tggcctgaggaaaagagg ctcaaagaagatata ttagaaaatgaagat 3902 TrpProGluGluLysArg LeuLysGluAspIle LeuGluAsnGluAsp gaacagaatagtccgcca aaaaagggtaaaaga ggccgaccaccaaaa 3950 GluGlnAsnSerProPro LysLysGlyLysArg GlyArgProProLys cctcttggtggaggtaca ccaaaagaagagcca acaatgaaaacttct 3998 ProLeuGlyGlyGlyThr ProLysGluGluPro ThrMetLysThrSer aaaaaaggaagcaaaaaa aaatctggacctcca gcaccagaggaggag 4046 LysLysGlySerLysLys LysSerGlyProPro AlaProGluGluGlu gaagaagaagaaagacaa agtggaaatacggaa cagaagtccaaaagc 4094 GluGluGluGluArgGln SerGlyAsnThrGlu GlnLysSerLysSer aaacagcaccgagtgtca aggagagcacagcag agagcagaatctcct 4142 LysGlnHisArgValSer ArgArgAlaGlnGln ArgAlaGluSerPro gaatctagtgcaattgaa tccacacagtccaca ccacagaaaggacga 4190 GluSerSerAlaIleGlu SerThrGlnSerThr ProGlnLysGlyArg ggaagaccatcaaaaacg ccatcaccatcacaa ccaaaaaaaaatgtg 4238 GlyArgProSerLysThr ProSerProSerGln ProLysLysAsnVal taagttgtaa atattacatt tcaaaccaat ttcaaattat tttgcaaaag ttcctaaatt 4298 tgtaaacata catattgctg tatttaaatt ccatatattt agccccatta cactaggtac 4358 ggcggcgaag tgctaaaagg gaacggcgat gaacaaatgt aattaataac tttctctgtg 4418 aaagctttgg aaaaatcttt tttttttttt tttttttttg gtcaagcttg aggctgaata 4478 aagcctttga tgcacaaaat gggactgctg aagagtggac agttggacct tactttggtg 4538 accccataca tttgtggtca catgctttag ccatacacat ggtaacattg actatggagt 4598 cttgtgaaag tgtaatgtgc gatggctatg tagacataaa gaagaaactt gtaaatatct 4658 tttttctttt ttttaatgtt tctgatttct gaagtgcttg tatagctttt atctgcggct 4718 ttaaactgac agtacccgac tgtttattgg atctattgat ttgaaaagaa tttgttagga 4778 tagatcttaa gcagtaatct gtcagtgttt gtatttgtat tttctgcaat tttactgtga 4838 aaaaaaattt gttttcaaca attggtgtca ttttcttgat gtcactattt gttggagagt 4898 taaatggtct cttccctttg tgtatcttac ctagtgttta ctcctgggca cccttaatct 4958 tcagaggtgc taaattgtct gccattacac cagaaggatg cctctgatag gaggacaacc 5018 atgcaaattg tgaaatagtc ctgaagttct tggattactt tacacctcag tattgatttg 5078 tcccagaatt ttctggcctt tcatggcaat gaaaatttta agaagaaaga tttaaagtat 5138 tttaatttta aagagtgtgt tataaaataa tgtactgaat tctttatccc attttatcat 5198 cctttcagtt tttattaatc tactgtatca ataaaattct gtaatttgaa tgagtaaaaa 5258 aaaaaaaaaa aaa 5271 <210> 2 <211> 1391 <212> PRT
<213> Homo Sapiens <400> 2 Met Ala His Ser Lys Thr Arg Thr Asn Asp Gly Lys Ile Thr Tyr Pro Pro Gly Val Lys Glu Ile Ser Asp Lys Ile Ser Lys Glu Glu Met Val Arg Arg Leu Lys Met Val Val Lys Thr Phe Met Asp Met Asp Gln Asp Ser Glu Glu Glu Lys Glu Leu Tyr Leu Asn Leu Ala Leu His Leu Ala Ser Asp Phe Phe Leu Lys His Pro Gly Lys Asp Val Arg Leu Leu Val Ala Cys Cys Leu Ala Asp Ile Phe Arg Ile Tyr Ala Pro Glu Ala Pro Tyr Thr Ser Pro Asp Lys Leu Lys Asp Ile Phe Met Phe Ile Thr Arg Gln Leu Lys Gly Leu Glu Asp Thr Lys Ser Pro Gln Phe.Asn Arg Tyr Phe Tyr Leu Leu Glu Asn Ile Ala Trp Val Lys Ser Tyr Asn Ile Cys Phe Glu Leu Glu Asp Ser Asn Glu Ile Phe Thr Gln Leu Tyr Arg Thr Leu Phe Ser Val Ile Asn Asn Gly His Asn Gln Lys Val His Met His Met Val Asp Leu Met Ser Ser Ile Ile Cys Glu Gly Asp Thr Val Ser Gln Glu Leu Leu Asp Thr Val Leu Val Asn Leu Val Pro Ala His Lys Asn Leu Asn Lys Gln Ala Tyr Asp Leu Ala Lys Ala Leu Leu Lys Arg Thr Ala Gln Ala Ile Glu Pro Tyr Ile Thr Thr Phe Phe Asn Gln Val Leu Met Leu Gly Lys Thr Ser Ile Ser Asp Leu Ser Glu His Val Phe Asp Leu Ile Leu Glu Leu Tyr Asn Ile Asp Ser His Leu Leu Leu Ser Val Leu Pro Gln Leu Glu Phe Lys Leu Lys Ser Asn Asp Asn Glu Glu Arg Leu Gln Val Val Lys Leu Leu Ala Lys Met Phe Gly Ala Lys Asp Ser Glu Leu Ala Ser Gln Asn Lys Pro Leu Trp Gln Cys Tyr Leu Gly Arg Phe Asn Asp Ile His Val Pro Ile Arg Leu Glu Cys Val Lys Phe Ala Ser His Cys Leu Met Asn His Pro Asp Leu Ala Lys Asp Leu Thr Glu Tyr Leu Lys Val Arg Ser His Asp Pro Glu Glu Ala Ile Arg His Asp Val Ile Val Ser Ile Val Thr Ala Ala Lys Lys Asp Ile Leu Leu Val Asn Asp His Leu Leu Asn Phe Val Arg Glu Arg Thr Leu Asp Lys Arg Trp Arg Val Arg Lys Glu Ala Met Met Gly Leu Ala Gln Ile Tyr Lys Lys Tyr Ala Leu Gln Ser Ala Ala Gly Lys Asp Ala Ala Lys Gln Ile Ala Trp Ile Lys Asp Lys Leu Leu His Ile Tyr Tyr Gln Asn Ser Ile Asp Asp Arg Leu Leu Val Glu Arg Ile Phe Ala Gln Tyr Met Val Pro His Asn Leu Glu Thr Thr Glu Arg Met Lys Cys Leu Tyr Tyr Leu Tyr Ala Thr Leu Asp Leu Asn Ala Val Lys Ala Leu Asn Glu Met Trp Lys Cys Gln Asn Leu Leu Arg His Gln Val Lys Asp Leu Leu Asp Leu Ile Lys Gln Pro Lys Thr Asp Ala Ser Val Lys Ala Ile Phe Ser Lys Val Met Val Ile Thr Arg Asn Leu Pro Asp Pro Gly Lys Ala Gln Asp Phe Met Lys Lys Phe Thr Gln Val Leu Glu Asp Asp Glu Lys Ile Arg Lys Gln Leu Glu Val Leu Val Ser Pro Thr Cys Ser Cys Lys Gln Ala Glu Gly Cys Val Arg Glu Ile Thr Lys Lys Leu Gly Asn Pro Lys Gln Pro Thr Asn Pro Phe Leu Glu Met Ile Lys Phe Leu Leu Glu Arg Ile Ala Pro Val His Ile Asp Thr Glu Ser Ile Ser Ala Leu Ile Lys Gln Val Asn Lys Ser Ile Asp Gly Thr Ala Asp Asp Glu Asp Glu Gly Val Pro Thr Asp Gln Ala Ile Arg Ala Gly Leu Glu Leu Leu Lys Val Leu Ser Phe Thr His Pro Ile Ser Phe His Ser Ala Glu Thr Phe Glu Ser Leu Leu Ala Cys Leu Lys Met Asp Asp Glu Lys Val Ala Glu Ala Ala Leu Gln Ile Phe Lys Asn Thr Gly Ser Lys Ile Glu Glu Asp Phe Pro His Ile Arg Ser Ala Leu Leu Pro Val Leu His His Lys Ser Lys Lys Gly Pro Pro Arg Gln Ala Lys Tyr Ala Ile His Cys Ile His Ala Ile Phe Ser Ser Lys Glu Thr Gln Phe Ala Gln Ile Phe Glu Pro Leu His Lys Ser Leu Asp Pro Ser Asn Leu Glu His Leu Ile Thr Pro Leu Val Thr Ile Gly His Ile Ala Leu Leu Ala Pro Asp Gln Phe Ala Ala Pro Trp Lys Ser Trp Val Ala Thr Phe Ile Val Lys Asp Leu Leu Met Asn Asp Arg Leu Pro Gly Lys Lys Thr Thr Lys Leu Trp Val Pro Asp Glu Glu Val Ser Pro Glu Thr Met Val Lys Ile Gln Ala Ile Lys Met Met Val Arg Trp Leu Leu Gly Met Lys Asn Asn His Ser Lys Ser Gly Thr Ser Thr Leu Arg Leu Leu Thr Thr Ile Leu His Ser Asp Gly Asp Leu Thr Glu Gln Gly Lys Ile Ser Lys Pro Asp Met Ser Arg Leu Arg Leu Ala Ala Gly Ser Ala Ile Val Lys Leu Ala Gln Glu Pro Cys Tyr His Glu Ile Ile Thr Leu Glu Gln Tyr Gln Leu Cys Ala Leu Ala Ile Asn Asp Glu Cys Tyr Gln Val Arg Gln Val Phe Ala Gln Lys Leu His Lys Gly Leu Ser Arg Leu Arg Leu Pro Leu Glu Tyr Met Ala Ile Cys Ala Leu Cys Ala Lys Asp Pro Val Lys Glu Arg Arg Ala His Ala Arg Gln Cys Leu Val Lys Asn Ile Asn Val Arg Arg Glu Tyr Leu Lys Gln His Ala Ala Val Ser Glu Lys Leu Leu Ser Leu Leu Pro Glu Tyr Val Val Pro Tyr Thr Ile His Leu Leu Ala His Asp Pro Asp Tyr Val Lys Val Gln Asp Ile Glu Gln Leu Lys Asp Val Lys Glu Cys Leu Trp Phe Val Leu Glu Ile Leu Met Ala Lys Asn Glu Asn Asn Ser His Ala Phe Ile Arg Lys Met Val Glu Asn Ile Lys Gln Thr Lys Asp Ala Gln Gly Pro Asp Asp Ala Lys Met Asn Glu Lys Leu Tyr Thr Val Cys Asp Val Ala Met Asn Ile Ile Met Ser Lys Ser Thr Thr Tyr Ser Leu Glu Ser Pro Lys Asp Pro Val Leu Pro Ala Arg Phe Phe Thr Gln Pro Asp Lys Asn Phe Ser Asn Thr Lys Asn Tyr Leu Pro Pro Glu Met Lys Ser Phe Phe Thr Pro Gly Lys Pro Lys Thr Thr Asn Val Leu Gly Ala Val Asn Lys Pro Leu Ser Ser Ala Gly Lys Gln Ser Gln Thr Lys Ser.Ser Arg Met Glu Thr Val Ser Asn Ala Ser Ser Ser Ser Asn Pro Ser Ser Pro Gly Arg Ile Lys Gly Arg Leu Asp Ser Ser Glu Met Asp His Ser Glu Asn Glu Asp Tyr Thr Met Ser Ser Pro Leu Pro Gly Lys Lys Ser Asp Lys Arg Asp Asp Ser Asp Leu Val Arg Ser Glu Leu Glu Lys Pro Arg Gly Arg Lys Lys Thr Pro Val Thr Glu Gln Glu Glu Lys Leu Gly Met Asp Asp Leu Thr Lys Leu Val Gln Glu Gln Lys Pro Lys Gly Ser Gln Arg Ser Arg Lys Arg Gly His Thr Ala Ser Glu Ser Asp Glu Gln Gln Trp Pro Glu Glu Lys Arg Leu Lys Glu Asp Ile Leu Glu Asn Glu Asp Glu Gln Asn Ser Pro Pro Lys Lys Gly Lys Arg Gly Arg Pro Pro Lys Pro Leu Gly Gly Gly Thr Pro Lys Glu Glu Pro Thr Met Lys Thr Ser Lys Lys Gly Ser Lys Lys Lys Ser Gly Pro Pro Ala Pro Glu Glu Glu Glu Glu Glu Glu Arg Gln Ser Gly Asn Thr Glu Gln Lys Ser Lys Ser Lys Gln His Arg Val Ser Arg Arg Ala Gln Gln Arg Ala Glu Ser Pro Glu Ser Ser Ala Ile Glu Ser Thr Gln Ser Thr Pro Gln Lys Gly Arg Gly Arg Pro Ser Lys Thr Pro Ser Pro Ser Gln Pro Lys Lys Asn Val <210> 3 c211> 4173 <212> DNA
<213> Homo sapiens c220>
<221> CDS
<222> (1)..(4173) <400> 3 atg get cat tca aag act agg acc aat gat gga aaa att aca tat ccg 48 Met Ala His Ser Lys Thr Arg Thr Asn Asp Gly Lys Ile Thr Tyr Pro cct ggg gtc aag gaa ata tca gat aaa ata tct aaa gag gag atg gtg 96 Pro Gly Val Lys Glu Ile Ser Asp Lys Ile Ser Lys Glu Glu Met Val aga cga tta aag atg gtt gtg aaa act ttt atg gat atg gac cag gac 144 Arg Arg Leu Lys Met Val Val Lys Thr Phe Met Asp Met Asp Gln Asp tctgaagaagaaaaggagctttatttaaacctagetttacatcttget192 SerGluGluGluLysGluLeuTyrLeuAsnLeuAlaLeuHisLeuAla tcagatttttttctcaagcatcctggtaaagatgttcgcttactggta240 SerAspPhePheLeuLysHisProGlyLysAspValArgLeuLeuVal gcctgctgccttgetgatattttcaggatttatgetcctgaagetcct288 AlaCysCysLeuAlaAspIlePheArgIleTyrAlaProGluAlaPro tacacatcccctgataaactaaaggatatatttatgtttataacaaga336 TyrThrSerProAspLysLeuLysAspIlePheMetPheIleThrArg cag ttg aag ggg cta gag gat aca aag agc cca caa ttc aat agg tat 384 Gln Leu Lys Gly Leu Glu Asp Thr Lys Ser Pro Gln Phe Asn Arg Tyr ttt tat tta ctt gag aac att get tgg gtc aag tca tat aac ata tgc 432 Phe Tyr Leu Leu Glu Asn Ile Ala Trp Val Lys Ser Tyr Asn Ile Cys ttt gag tta gaa gat agc aat gaa att ttc acc cag cta tac aga acc 480 Phe Glu Leu Glu Asp Ser Asn Glu Ile Phe Thr Gln Leu Tyr Arg Thr tta ttt tca gtt ata aac aat ggc cac aat cag aaa gtc cat atg cac 528 Leu Phe Ser Val Ile Asn Asn Gly His Asn Gln Lys Val His Met His atg gta gac ctt atg agc tct att att tgt gaa ggt gat aca gtg tct 576 Met Val Asp Leu Met Ser Ser Ile Ile Cys Glu Gly Asp Thr Val Ser cag gag ctt ttg gat acg gtt tta gta aat ctg gta cct get cat aag 624 Gln Glu Leu Leu Asp Thr Val Leu Val Asn Leu Val Pro Ala His Lys aat tta aac aag caa gca tat gat ttg gca aag get tta ctg aag agg 672 Asn Leu Asn Lys Gln Ala Tyr Asp Leu Ala Lys Ala Leu Leu Lys Arg aca get caa get att gag cca tat att acc act ttt ttt aat cag gtt 720 Thr Ala Gln Ala Ile Glu Pro Tyr Ile Thr Thr Phe Phe Asn Gln Val ctg atg ctt ggg aaa aca tct atc agc gat ttg tca gag cat gtc ttt 768 Leu Met Leu Gly Lys Thr Ser Ile Ser Asp Leu Ser Glu His Val Phe gac tta att ttg gag ctc tac aat att gat agt cat ttg ctg ctc tct 816 Asp Leu Ile Leu Glu Leu Tyr Asn Ile Asp Ser His Leu Leu Leu Ser gtt tta ccc cag ctt gaa ttt aaa tta aag agc aat gat aat gag gag 864 Val Leu Pro Gln Leu Glu Phe Lys Leu Lys Ser Asn Asp Asn Glu Glu cgc cta caa gtt gtt aaa cta ctg gca aaa atg ttt ggg gca aag gat 912 Arg Leu Gln Val Val Lys Leu Leu Ala Lys Met Phe Gly Ala Lys Asp tcagaattggettctcaaaacaagccactttggcagtgctacttgggc 960 SerGluLeuAlaSerGlnAsnLysProLeuTrpGlnCysTyrLeuGly aggtttaatgatatccatgtaccaatccgcctggaatgtgtgaaattt 1008 ArgPheAsnAspIleHisValProIleArgLeuGluCysValLysPhe getagccattgtctcatgaaccatcctgatttagcaaaagacttaaca 1056 AlaSerHisCysLeuMetAsnHisProAspLeuAlaLysAspLeuThr gagtatcttaaagtgaggtcacatgaccctgaggaagetattagacat 1104 GluTyrLeuLysValArgSerHisAspProGluGluAlaIleArgHis gatgttattgtgtcaatagttacagetgetaaaaaggatattcttctg 1152 AspValIleValSerIleValThrAlaAlaLysLysAspIleLeuLeu gtcaatgatcacttacttaattttgtgagagagagaacattagacaaa 1200 ValAsnAspHisLeuLeuAsnPheValArgGluArgThrLeuAspLys cgatggagagtacgcaaagaagccatgatgggacttgcccaaatttat 1248 ArgTrpArgValArgLysGluAlaMetMetGlyLeuAlaGlnIleTyr aagaaatatgetttacagtcagcagetggaaaagatgetgcaaaacag 1296 LysLysTyrAlaLeuGlnSerAlaAlaGlyLysAspAlaAlaLysGln atagcatggatcaaagacaaattgctacatatatattatcaaaatagt 1344 IleAlaTrpIleLysAspLysLeuLeuHisIleTyrTyrGlnAsnSer attgatgatcgactacttgttgaacggatctttgetcaatacatggtt 1392 IleAspAspArgLeuLeuValGluArgIlePheAlaGlnTyrMetVal cctcacaatttagaaactacagaacggatgaaatgcttatattacttg 1440 ProHisAsnLeuGluThrThrGluArgMetLysCysLeuTyrTyrLeu tatgccacactggatttaaatgetgtgaaagcattgaatgaaatgtgg 1488 TyrAlaThrLeuAspLeuAsnAlaValLysAlaLeuAsnGluMetTrp aaatgtcaaaatctgctccgacatcaagtaaaggatttgcttgacttg 1536 LysCysGlnAsnLeuLeuArgHisGlnValLysAspLeuLeuAspLeu attaagcaacccaaaacagatgccagtgtcaaggccatattttcaaaa 1584 IleLysGlnProLysThrAspAlaSerValLysAlaIlePheSerLys gtgatggttattacaagaaatttacctgatcctggtaaggetcaggat 1632 ValMetValIleThrArgAsnLeuProAspProGlyLys.AlaGlnAsp ttcatgaagaaattcacacaggtgttagaagatgatgagaaaataaga 1680 PheMetLysLysPheThrGlnValLeuGluAspAspGluLysIleArg aagcagttagaagtacttgttagtccaacatgctcctgcaagcagget1728 LysGlnLeuGluValLeuValSerProThrCysSerCysLysGlnAla gaaggttgtgtgcgtgaaataactaagaagttgggcaaccccaaacag1776 GluGlyCysValArgGluIleThrLysLysLeuGlyAsnProLysGln cctacaaatcctttcctggaaatgatcaagtttctcttggagaggata1824 ProThrAsnProPheLeuGluMetIleLysPheLeuLeuGluArgIle gcacctgtgcacatagataccgaatctatcagtgetcttattaaacaa1872 AlaProValHisIleAspThrGluSerIleSerAlaLeuIleLysGln gtgaacaaatcaatagatggaacagcagatgatgaagatgagggtgtt1920 ValAsnLysSerIleAspGlyThrAlaAspAspGluAspGluGlyVal ccaactgatcaagccatcagagcaggtcttgaactgcttaaggtactc1968 ProThrAspGlnAlaIleArgAlaGlyLeuGluLeuLeuLysValLeu tcatttacacatcccatctcatttcattctgetgaaacatttgaatca2016 SerPheThrHisProIleSerPheHisSerAlaGluThrPheGluSer ttactggettgtctgaaaatggatgatgaaaaagtagcagaagetgca2064 LeuLeuAlaCysLeuLysMetAspAspGluLysValAlaGluAlaAla ctacaaattttcaaaaacacaggaagcaaaattgaagaggattttcca2112 LeuGlnIlePheLysAsnThrGlySerLysIleGluGluAspPhePro cacatcagatcagccttgcttcctgttttacatcacaaatctaaaaaa2160 HisIleArgSerAlaLeuLeuProValLeuHisHisLysSerLysLys ggacccccccgtcaagccaaatatgccattcattgtatccatgcgata2208 GlyProProArgGlnAlaLysTyrAlaIleHisCysIleHisAlaIle ttttctagtaaagagacccagtttgcacagatatttgagcctctgcat2256 PheSerSerLysGluThrGlnPheAlaGlnIlePheGluProLeuHis 740 745' 750 aagagcctagatccaagcaacctggaacatctcataacaccattggtt2304 LysSerLeuAspProSerAsnLeuGluHisLeuIleThrProLeuVal actattggtcatattgetctccttgcacctgatcaatttgetgetcct2352 ThrIleGlyHisIleAlaLeuLeuAlaProAspGlnPheAlaAlaPro tggaaatcttgggtagetactttcattgtgaaagatcttctcatgaat2400 TrpLysSerTrpValAlaThrPheIleValLysAspLeuLeuMetAsn gatcggcttccagggaaaaagacaactaaactttgggttccagatgaa2448 AspArgLeuProGlyLysLysThrThrLysLeuTrpValProAspGlu gaagtatctcctgag acaatggtcaaaattcaggetattaaaatgatg 2496 GluValSerProGlu ThrMetValLysIleGlnAlaIleLysMetMet gttcgatggctactt ggaatgaaaaataatcacagtaaatcaggaact 2544 ValArgTrpLeuLeu GlyMetLysAsnAsnHisSerLysSerGlyThr tctaccttaagattg ctaacaacaatattgcatagtgatggagacttg 2592 SerThrLeuArgLeu LeuThrThrIleLeuHisSerAspGlyAspLeu acagaacaggggaaa attagtaaaccagatatgtcacgtctgagactt 2640 ThrGluGlnGlyLys IleSerLysProAspMetSerArgLeuArgLeu getgetgggagtget attgtgaagctggcacaagaaccctgttaccat 2688 AlaAlaGlySerAla IleValLysLeuAlaGlnGluProCysTyrHis gaaatcatcacatta gaacaatatcagctatgtgcattagetatcaac 2736 GluIleIleThrLeu GluGlnTyrGlnLeuCysAlaLeuAlaIleAsn gatgaatgctatcaa gtaagacaagtgtttgcccagaaacttcacaaa 2784 AspGluCysTyrGln ValArgGlnValPheAlaGlnLysLeuHisLys ggcctttcccgttta cggcttccacttgagtatatggcaatctgtgcc 2832 GlyLeuSerArgLeu ArgLeuProLeuGluTyrMetAlaIleCysAla ctttgtgcaaaagat cctgtaaaggagagaagagetcatgetaggcaa 2880 LeuCysAlaLysAsp ProValLysGluArgArgAlaHisAlaArgGln tgtttggtgaaaaat ataaatgtaaggcgggagtatctgaagcagcat 2928 CysLeuValLysAsn IleAsnValArgArgGluTyrLeuLysGlnHis gcagetgttagtgaa aaattattgtctcttctaccagagtatgttgtt 2976 AlaAlaValSerGlu LysLeuLeuSerLeuLeuProGluTyrValVal ccatatacaattcac cttttggcacatgacccagattatgtcaaagta 3024 ProTyrThrIleHis LeuLeuAlaHisAspProAspTyrValLysVal caggatattgaacaa cttaaagatgttaaagaatgtctttggtttgtt 3072 GlnAspIleGluGln LeuLysAspValLysGluCysLeuTrpPheVal ctggaaatattaatg getaaaaatgaaaataacagtcacgettttatc 3120 LeuGluIleLeuMet AlaLysAsnGluAsnAsnSerHisAlaPheIle agaaagatggtagaa aatattaaacaaacaaaagatgcccaaggacca 3168 ArgLysMetValGlu AsnIleLysGlnThrLysAspAlaGlnGlyPro gatgatgcaaaaatg aatgaaaaactgtacactgtgtgtgatgttgcc 3216 AspAspAlaLysMet AsnGluLysLeuTyrThrValCysAspValAla atg aat atc atc atg tca aag agt act aca tac agt ttg gaa tct cct 3264 Met Asn Ile Ile Met Ser Lys Ser Thr Thr Tyr Ser Leu Glu Ser Pro aaa gac ccg gta cta cca get cgt ttc ttc act caa cct gac aag aat 3312 Lys Asp Pro Val Leu Pro Ala Arg Phe Phe Thr Gln Pro Asp Lys Asn ttc agt aac acc aaa aat tat ctg cct cct gaa atg aaa tca ttt ttc 3360 Phe Ser Asn Thr Lys Asn Tyr Leu Pro Pro Glu Met Lys Ser Phe Phe act cct gga aaa cct aaa aca acc aat gtt cta gga get gtt aac aag 3408 Thr Pro Gly Lys Pro Lys Thr Thr Asn Val Leu Gly Ala Val Asn Lys cca ctt tca tca gca ggc aag caa tct cag acc aaa tca tca cga atg 3456 Pro Leu Ser Ser Ala Gly Lys Gln Ser Gln Thr Lys Ser Ser Arg Met gaa act gta agc aat gca agc agc agc tca aat cca agc tct cct gga 3504 Glu Thr Val Ser Asn Ala Ser Ser Ser Ser Asn Pro Ser Ser Pro Gly aga ata aag ggg agg ctt gat agt tct gaa atg gat cac agt gaa aat 3552 Arg Ile Lys Gly Arg Leu Asp Ser Ser Glu Met Asp His Ser Glu Asn gaa gat tac aca atg tct tca cct ttg ccg ggg aaa aaa agt gac aag 3600 Glu Asp Tyr Thr Met Ser Ser Pro Leu Pro Gly Lys Lys Ser Asp Lys aga gac gac tct gat ctt gta agg tct gaa ttg gag aag cct aga ggc 3648 Arg Asp Asp Ser Asp Leu Val Arg Ser Glu Leu Glu Lys Pro Arg Gly agg aaa aaa acg ccc gtc aca gaa cag gag gag aaa tta ggt atg gat 3696 Arg Lys Lys Thr Pro Val Thr Glu Gln Glu Glu Lys Leu Gly Met Asp gac ttg act aag ttg gta cag gaa cag aaa cct aaa ggc agt cag cga 3744 Asp Leu Thr Lys Leu Val Gln Glu Gln Lys Pro Lys Gly Ser Gln Arg agt cgg aaa aga ggc cat acg get tca gaa tct gat gaa cag cag tgg 3792 Ser Arg Lys Arg Gly His Thr Ala Ser Glu Ser Asp Glu Gln Gln Trp cct gag gaa aag agg ctc aaa gaa gat ata tta gaa aat gaa gat gaa 3840 Pro Glu Glu Lys Arg Leu Lys Glu Asp Ile Leu Glu Asn Glu Asp Glu cag aat agt ccg cca aaa aag ggt aaa aga ggc cga cca cca aaa cct 3888 Gln Asn Ser Pro Pro Lys Lys Gly Lys Arg Gly Arg Pro Pro Lys Pro ctt ggt gga ggt aca cca aaa gaa gag cca aca atg aaa act tct aaa 3936 Leu Gly Gly Gly Thr Pro Lys Glu Glu Pro Thr Met Lys.Thr Ser Lys aaa gga agc aaa aaa aaa tct gga cct cca gca cca gag gag gag gaa 3984 Lys Gly Ser Lys Lys Lys Ser Gly Pro Pro Ala Pro Glu Glu Glu Glu Wb 00/50454 PCT/US00/04732 gaagaagaaagacaaagtggaaatacggaacagaag tccaaa agcaaa4032 GluGluGluArgGlnSerGlyAsnThrGluGlnLys SerLys SerLys cagcaccgagtgtcaaggagagcacagcagagagca gaatct cctgaa4080 GlnHisArgValSerArgArgAlaGlnGlnArgAla GluSer ProGlu tctagtgcaattgaatccacacagtccacaccacag aaagga cgagga4128 SerSerAlaIleGluSerThrGlnSerThrProGln LysGly ArgGly agaccatcaaaaacgccatcaccatcacaaccaaaa aaaaat gtg 4173 ArgProSerLysThrProSerProSerGlnProLys LysAsn Val <210> 4 <211> 5355 <212> DNA
<213> Homo sapiens <220>
<221> CDS
<222> (150)..(4322) <400> 4 cggagaggag gaggaacggc agggctggct gcggaagggg aggggggggg agaaggcgat 60 tggatgcggc ggcggcggcg gatcccggag agccccggag tgagcggagt agcgagtcgg 120 caacccggag gggtagaaat atttctgtc atg get cat tca aag act agg acc 173 Met Ala His Ser Lys Thr Arg Thr aat gat gga aaa att aca tat ccg cct ggg gtc aag gaa ata tca gat 221 Asn Asp Gly Lys Ile Thr Tyr Pro Pro Gly Val Lys Glu Ile Ser Asp aaa ata tct aaa gag gag atg gtg aga cga tta aag atg gtt gtg aaa 269 Lys Ile Ser Lys Glu Glu Met Val Arg Arg Leu Lys Met Val Val Lys act ttt atg gat atg gac cag gac tct gaa gaa gaa aag gag ctt tat 317 Thr Phe Met Asp Met Asp Gln Asp Ser Glu Glu Glu Lys Glu Leu Tyr tta aac cta get tta cat ctt get tca gat ttt ttt ctc aag cat cct 365 Leu Asn Leu Ala Leu His Leu Ala Ser Asp Phe Phe Leu Lys His Pro ggt aaa gat gtt cgc tta ctg gta gcc tgc tgc ctt get gat att ttc 413 Gly Lys Asp Val Arg Leu Leu Val Ala Cys Cys Leu Ala Asp Ile Phe agg att tat get cct gaa get cct tac aca tcc cct gat aaa cta aag 461 Arg Ile Tyr Ala Pro Glu Ala Pro Tyr Thr Ser Pro Asp Lys Leu Lys gat ata ttt atg ttt ata aca aga cag ttg aag ggg cta gag gat aca 509 Asp Ile Phe Met Phe Ile Thr Arg Gln Leu Lys Gly Leu Glu Asp Thr aag agc cca caa ttc aat agg tat ttt tat tta ctt gag aac att get 557 LysSerProGlnPheAsnArg PheTyrLeuLeuGluAsnIleAla Tyr tgggtoaagtcatataacatatgctttgagttagaagatagcaatgaa605 TrpValLysSerTyrAsnIleCysPheGluLeuGluAspSerAsnGlu attttcacccagctatacagaaccttattttcagttataaacaatggc653 IlePheThrGlnLeuTyrArgThrLeuPheSerValIleAsnAsnGly cacaatcagaaagtccatatgcacatggtagaccttatgagctctatt701 HisAsnGlnLysValHisMetHisMetValAspLeuMetSerSerIle atttgtgaaggtgatacagtgtctcaggagcttttggatacggtttta749 IleCysGluGlyAspThrValSerGlnGluLeuLeuAspThrValLeu gtaaatctggtacctgetcataagaatttaaacaagcaagcatatgat797 ValAsnLeuValProAlaHisLysAsnLeuAsnLysGlnAlaTyrAsp ttggcaaaggetttactgaagaggacagetcaagetattgagccatat845 LeuAlaLysAlaLeuLeuLysArgThrAlaGlnAlaIleGluProTyr attaccactttttttaatcaggttctgatgcttgggaaaacatctatc893 IleThrThrPhePheAsnGlnValLeuMetLeuGlyLysThrSerIle agcgatttgtcagagcatgtctttgacttaattttggagctctacaat941 SerAspLeuSerGluHisValPheAspLeuIleLeuGluLeuTyrAsn attgatagtcatttgctgctctctgttttaccccagcttgaatttaaa989 IleAspSerHisLeuLeuLeuSerValLeuProGlnLeuGluPheLys ttaaagagcaatgataatgaggagcgcctacaagttgttaaactactg1037 LeuLysSerAsnAspAsnGluGluArgLeuGlnValValLysLeuLeu gcaaaaatgtttggggcaaaggattcagaattggettctcaaaacaag1085 AlaLysMetPheGlyAlaLysAspSerGluLeuAlaSerGlnAsnLys ccactttggcagtgctacttgggcaggtttaatgatatccatgtacca1133 ProLeuTrpGlnCysTyrLeuGlyArgPheAsnAspIleHisValPro atccgcctggaatgtgtgaaatttgetagccattgtctcatgaaccat1181 IleArgLeuGluCysValLysPheAlaSerHisCysLeuMetAsnHis cctgatttagcaaaagacttaacagagtatcttaaagtgaggtcacat1229 ProAspLeuAlaLysAspLeuThrGluTyrLeuLysValArgSerHis gaccctgaggaagetattagacatgatgttattgtgtcaatagttaca1277 AspProGluGluAlaIleArgHisAspValIleValSerIleValThr 365 370 3'75 getgetaaaaaggatattcttctggtcaatgatcacttacttaatttt1325 WO 00/50454 PC'T/US00/04732 -AlaAlaLysLysAspIleLeuLeuValAsnAspHisLeuLeuAsnPhe gtgagagagagaacattagacaaacgatggagagtacgcaaagaagcc 1373 ValArgGluArgThrLeuAspLysArgTrpArgValArgLysGluAla atgatgggacttgcccaaatttataagaaatatgetttacagtcagca 1421 MetMetGlyLeuAlaGlnIleTyrLysLysTyrAlaLeuGlnSerAla getggaaaagatgetgcaaaacagatagcatggatcaaagacaaattg 1469 AlaGlyLysAspAlaAlaLysGlnIleAlaTrpIleLysAspLysLeu ctacatatatattatcaaaatagtattgatgatcgactacttgttgaa 1517 LeuHisIleTyrTyrGlnAsnSerIleAspAspArgLeuLeuValGlu cggatctttgetcaatacatggttcctcacaatttagaaactacagaa 1565 ArgIlePheAlaGlnTyrMetValProHisAsnLeuGluThrThrGlu cggatgaaatgcttatattacttgtatgccacactggatttaaatget 1613 ArgMetLysCysLeuTyrTyrLeuTyrAlaThrLeuAspLeuAsnAla gtgaaagcattgaatgaaatgtggaaatgtcaaaatctgctccgacat 1661 ValLysAlaLeuAsnGluMetTrpLysCysGlnAsnLeuLeuArgHis caagtaaaggatttgcttgacttgattaagcaacccaaaacagatgcc 1709 GlnValLysAspLeuLeuAspLeuIleLysGlnProLysThrAspAla agtgtcaaggccatattttcaaaagtgatggttattacaagaaattta 1757 SerValLysAlaIlePheSerLysValMetValIleThrArgAsnLeu cctgatcctggtaaggetcaggatttcatgaagaaattcacacaggtg 1805 ProAspProGlyLysAlaGlnAspPheMetLysLysPheThrGlnVal ttagaagatgatgagaaaataagaaagcagttagaagtacttgttagt 1853 LeuGluAspAspGluLysIleArgLysGlnLeuGluValLeuValSer ccaacatgctcctgcaagcaggetgaaggttgtgtgcgtgaaataact 1901 ProThrCysSerCysLysGlnAlaGluGlyCysValArgGluIleThr aagaagttgggcaaccccaaacagcctacaaatcctttcctggaaatg 1949 LysLysLeuGlyAsnProLysGlnProThrAsnProPheLeuGluMet atcaagtttctcttggagaggatagcacctgtgcacatagataccgaa 1997 IleLysPheLeuLeuGluArgIleAlaProValHisIleAspThrGlu tctatcagtgetcttattaaacaagtgaacaaatcaatagatggaaca 2045 SerIleSerAlaLeuIleLysGlnValAsnLysSerIleAspGlyThr gcagatgatgaagatgagggtgttccaactgatcaagccatcagagca 2093 AlaAspAspGluAspGluGlyValProThrAspGlnAlaIleArgAla ggtcttgaactgcttaaggtactctcatttacacatcccatctcattt 2141 GlyLeuGluLeuLeuLysValLeuSerPheThrHisProIleSerPhe cattctgetgaaacatttgaatcattactggettgtctgaaaatggat 2189 HisSerAlaGluThrPheGluSerLeuLeuAlaCysLeuLysMetAsp gatgaaaaagtagcagaagetgcactacaaattttcaaaaacacagga 2237 AspGluLysValAlaGluAlaAlaLeuGlnIlePheLysAsnThrGly agcaaaattgaagaggattttccacacatcagatcagccttgcttcct 2285 SerLysIleGluGluAspPheProHisIleArgSerAlaLeuLeuPro gttttacatcacaaatctaaaaaaggacccccccgtcaagccaaatat 2333 ValLeuHisHisLysSerLysLysGlyProProArgGlnAlaLysTyr gccattcattgtatccatgcgatattttctagtaaagagacccagttt 2381 AlaIleHisCysIleHisAlaIlePheSerSerLysGluThrGlnPhe gcacagatatttgagcctctgcataagagcctagatccaagcaacctg 2429 AlaGlnIlePheGluProLeuHisLysSerLeuAspProSerAsnLeu gaacatctcataacaccattggttactattggtcatattgetctcctt 2477 GluHisLeuIleThrProLeuValThrIleGlyHisIleAlaLeuLeu gcacctgatcaatttgetgetccttggaaatcttgggtagetactttc 2525 AlaProAspGlnPheAlaAlaProTrpLysSerTrpValAlaThrPhe attgtgaaagatcttctcatgaatgatcggcttccagggaaaaagaca 2573 IleValLysAspLeuLeuMetAsnAspArgLeuProGlyLysLysThr actaaactttgggttccagatgaagaagtatctcctgagacaatggtc 2621 ThrLysLeuTrpValProAspGluGluValSerProGluThrMetVal aaaattcaggetattaaaatgatggttcgatggctacttggaatgaaa 2669 LysIleGlnAlaIleLysMetMetValArgTrpLeuLeuGlyMetLys aataatcacagtaaatcaggaacttctaccttaagattgctaacaaca 2717 AsnAsnHisSerLysSerGlyThrSerThrLeuArgLeuLeuThrThr atattgcatagtgatggagacttgacagaacaggggaaaattagtaaa 2765 IleLeuHisSerAspGlyAspLeuThrGluGlnGlyLysIleSerLys ccagatatgtcacgtctgagacttgetgetgggagtgetattgtgaag 2813 ProAspMetSerArgLeuArgLeuAlaAlaGlySerAlaIleValLys 875 880 gg5 ctggcacaagaaccctgttaccatgaaatcatcacattagaacaatat 2861 LeuAlaGlnGluProCysTyrHisGluIleIleThrLeuGluGlnTyr cagctatgtgcattagetatcaacgatgaatgctatcaagtaagacaa 2909 GlnLeuCysAlaLeuAlaIleAsnAspGluCysTyrGlnValArgGln gtgtttgcccagaaacttcacaaaggcctttcccgtttacggcttcca 2957 ValPheAlaGlnLysLeuHisLysGlyLeuSerArgLeuArgLeuPro cttgagtatatggcaatctgtgccctttgtgcaaaagatcctgtaaag 3005 LeuGluTyrMetAlaIleCysAlaLeuCysAlaLysAspProValLys gagagaagagetcatgetaggcaatgtttggtgaaaaatataaatgta 3053 GluArgArgAlaHisAlaArgGlnCysLeuValLysAsnIleAsnVal aggcgggagtatctgaagcagcatgcagetgttagtgaaaaattattg 3101 ArgArgGluTyrLeuLysGlnHisAlaAlaValSerGluLysLeuLeu tctcttctaccagagtatgttgttccatatacaattcaccttttggca 3149 SerLeuLeuProGluTyrValValProTyrThrIleHisLeuLeuAla catgacccagattatgtcaaagtacaggatattgaacaacttaaagat 3197 HisAspProAspTyrValLysValGlnAspIleGluGlnLeuLysAsp gttaaagaatgtctttggtttgttctggaaatattaatggetaaaaat 3245 ValLysGluCysLeuTrpPheValLeuGluIleLeuMetAlaLysAsn gaaaataacagtcacgettttatcagaaagatggtagaaaatattaaa 3293 GluAsnAsnSerHisAlaPheIleArgLysMetValGluAsnIleLys caaacaaaagatgcccaaggaccagatgatgcaaaaatgaatgaaaaa 3341 GlnThrLysAspAlaGlnGlyProAspAspAlaLysMetAsnGluLys ctgtacactgtgtgtgatgttgccatgaatatcatcatgtcaaagagt 3389 LeuTyrThrValCysAspValAlaMetAsnIleIleMetSerLysSer actacatacagtttggaatctcctaaagacccggtactaccagetcgt 3437 ThrThrTyrSerLeuGluSerProLysAspProValLeuProAlaArg ttcttcactcaacctgacaagaatttcagtaacaccaaaaattatctg 3485 PhePheThrGlnProAspLysAsnPheSerAsnThrLysAsnTyrLeu cctcctgaaatgaaatcatttttcactcctggaaaacctaaaacaacc 3533 ProProGluMetLysSerPhePheThrProGlyLysProLysThrThr aatgttctaggagetgttaacaagccactttcatcagcaggcaagcaa 3581 AsnValLeuGlyAlaValAsnLysProLeuSerSerAlaGlyLysGln tctcagaccaaatcatcacgaatggaaactgtaagcaatgcaagcagc 3629 Ser Gln Thr Lys Ser Ser Arg Met Glu Thr Val Ser Asn Ala Ser Ser agc tca aat cca agc tct cct gga aga ata aag ggg agg ctt gat agt 3677 Ser Ser Asn Pro Ser Ser Pro Gly Arg Ile Lys Gly Arg Leu Asp Ser tct gaa atg gat cac agt gaa aat gaa gat tac aca atg tct tca cct 3725 Ser Glu Met Asp His Ser Glu Asn Glu Asp Tyr Thr Met Ser Ser Pro ttg ccg ggg aaa aaa agt gac aag aga gac gac tct gat ctt gta agg 3773 Leu Pro Gly Lys Lys Ser Asp Lys Arg Asp Asp Ser Asp Leu Val Arg tct gaa ttg gag aag cct aga ggc agg aaa aaa acg ccc gtc aca gaa 3821 Ser Glu Leu Glu Lys Pro Arg Gly Arg Lys Lys Thr Pro Val Thr Glu cag gag gag aaa tta ggt atg gat gac ttg act aag ttg gta cag gaa 3869 Gln Glu Glu Lys Leu Gly Met Asp Asp Leu Thr Lys Leu Val Gln Glu cag aaa cct aaa ggc agt cag cga agt cgg aaa aga ggc cat acg get 3917 Gln Lys Pro Lys Gly Ser Gln Arg Ser Arg Lys Arg Gly His Thr Ala tca gaa tct gat gaa cag cag tgg cct gag gaa aag agg ctc aaa gaa 3965 Ser Glu Ser Asp Glu Gln Gln Trp Pro Glu Glu Lys Arg Leu Lys Glu gat ata tta gaa aat gaa gat gaa cag aat agt ccg cca aaa aag ggt 4013 Asp Ile Leu Glu Asn Glu Asp Glu Gln Asn Ser Pro Pro Lys Lys Gly aaa aga ggc cga cca cca aaa cct ctt ggt gga ggt aca cca aaa gaa 4061 Lys Arg Gly Arg Pro Pro Lys Pro Leu Gly Gly Gly Thr Pro Lys Glu gag cca aca atg aaa act tct aaa aaa gga agc aaa aaa aaa tct gga 4109 Glu Pro Thr Met Lys Thr Ser Lys Lys Gly Ser Lys Lys Lys Ser Gly cct cca gca cca gag gag gag gaa gaa gaa gaa aga caa agt gga aat 4157 Pro Pro Ala Pro Glu Glu Glu Glu Glu Glu Glu Arg Gln Ser Gly Asn acg gaa cag aag tcc aaa agc aaa cag cac cga gtg tca agg aga gca 4205 Thr Glu Gln Lys Ser Lys Ser Lys Gln His Arg Val Ser Arg Arg Ala cag cag aga gca gaa tct cct gaa tct agt gca att gaa tcc aca cag 4253 Gln Gln Arg Ala Glu Ser Pro Glu Ser Ser Ala Ile Glu Ser Thr Gln tcc aca cca cag aaa gga cga gga aga cca tca aaa acg cca tca cca 4301 Ser Thr Pro Gln Lys Gly Arg Gly Arg Pro Ser Lys Thr Pro Ser Pro tca caa cca aaa aaa aat gtg taagttgtaa atattacatt tcaaaccaat 4352 Ser Gln Pro Lys Lys Asn Val ttcaaattat tttgcaaaag ttcctaaatt tgtaaacata catattgctg tatttaaatt 4412 ccatatattt agccccatta cactaggtac ggcggcgaag tgctaaaagg gaacggcgat 4472 gaacaaatgt aattaataac tttctctgtg aaagctttgg aaaaatcttt tttttttttt 4532 tttttttttg gtcaagcttg aggctgaata aagcctttga tgcacaaaat gggactgctg 4592 aagagtggac agttggacct tactttggtg accccataca tttgtggtca catgctttag 4652 ccatacacat ggtaacattg actatggagt cttgtgaaag tgtaatgtgc gatggctatg 4712 tagacataaa gaagaaactt gtaaatatct tttttctttt ttttaatgtt tctgatttct 4772 gaagtgcttg tatagctttt atctgcggct ttaaactgac agtacccgac tgtttattgg 4832 atctattgat ttgaaaagaa tttgttagga tagatcttaa gcagtaatct gtcagtgttt 4892 gtatttgtat tttctgcaat tttactgtga aaaaaaattt gttttcaaca attggtgtca 4952 ttttcttgat gtcactattt gttggagagt taaatggtct cttccctttg tgtatcttac 5012 ctagtgttta ctcctgggca cccttaatct tcagaggtgc taaattgtct gccattacac 5072 cagaaggatg cctctgatag gaggacaacc atgcaaattg tgaaatagtc ctgaagttct 5132 tggattactt tacacctcag tattgatttg tcccagaatt ttctggcctt tcatggcaat 5192 gaaaatttta agaagaaaga tttaaagtat tttaatttta aagagtgtgt tataaaataa 5252 tgtactgaat tctttatccc attttatcat cctttcagtt tttattaatc tactgtatca 5312 ataaaattct gtaatttgaa tgagtaaaaa aaaaaaaaaa aaa 5355 <210> 5 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Consensus Sequence <400> 5 ctawwagscc csgcscaw lg
Claims (66)
1. An isolated nucleic acid molecule selected from the group consisting of:
(a) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1; and (b) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:3.
(a) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1; and (b) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:3.
2. An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2.
3. An isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence set forth in SEQ
ID NO: 2.
ID NO: 2.
4. An isolated nucleic acid molecule selected from the group consisting of:
(a) a nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to the nucleotide sequence of SEQ ID NO: 1 or 3, or a complement thereof;
(b) a nucleic acid molecule comprising a fragment of at least 250 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1 or 3, or a complement thereof;
(c) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID
NO:2; and (d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acid residues of the amino acid sequence of SEQ ID
NO:2.
(a) a nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to the nucleotide sequence of SEQ ID NO: 1 or 3, or a complement thereof;
(b) a nucleic acid molecule comprising a fragment of at least 250 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1 or 3, or a complement thereof;
(c) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID
NO:2; and (d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acid residues of the amino acid sequence of SEQ ID
NO:2.
5. An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of any one of claims 1, 2, 3, or 4 under stringent conditions.
6. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of the nucleic acid molecule of any one of claims 1, 2, 3, or 4.
7. An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 1, 2, 3, or 4, and a nucleotide sequence encoding a heterologous polypeptide.
8. A vector comprising the nucleic acid molecule of any one of claims 1, 2, 3, or 4.
9. The vector of claim 8, which is an expression vector.
10. A host cell transfected with the expression vector of claim 9.
11. A method of producing a polypeptide comprising culturing the host cell of claim in an appropriate culture medium to, thereby, produce the polypeptide.
12. An isolated polypeptide selected from the group consisting of:
(a) a fragment of a polypeptide comprising the amino acid sequence of SEQ
ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID
NO:2;
(b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of SEQ ID NO:1 or 3 under stringent conditions;
(c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 50 % homologous to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or 3;
(d) a polypeptide comprising an amino acid sequence which is at least 45%
homologous to the amino acid sequence of SEQ ID NO:2.
(a) a fragment of a polypeptide comprising the amino acid sequence of SEQ
ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID
NO:2;
(b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of SEQ ID NO:1 or 3 under stringent conditions;
(c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 50 % homologous to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or 3;
(d) a polypeptide comprising an amino acid sequence which is at least 45%
homologous to the amino acid sequence of SEQ ID NO:2.
13. The isolated polypeptide of claim 12 comprising the amino acid sequence of SEQ ID NO:2.
14. The polypeptide of claim 12, further comprising heterologous amino acid sequences.
15. An antibody which selectively binds to a polypeptide of claim 12.
16. A method for detecting the presence of a polypeptide of claim 12 in a sample comprising:
(a) contacting the sample with a compound which selectively binds to the polypeptide; and (b) determining whether the compound binds to the polypeptide in the sample to thereby detect the presence of a polypeptide of claim 12 in the sample.
(a) contacting the sample with a compound which selectively binds to the polypeptide; and (b) determining whether the compound binds to the polypeptide in the sample to thereby detect the presence of a polypeptide of claim 12 in the sample.
17. The method of claim 16, wherein the compound which binds to the polypeptide is an antibody.
18. A kit comprising a compound which selectively binds to a polypeptide of claim 12 and instructions for use.
19. A method for detecting the presence of a nucleic acid molecule of any one of claims 1, 2, 3, or 4 in a sample comprising:
(a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and (b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample to thereby detect the presence of a nucleic acid molecule of any one of claims 1, 2, 3, or 4 in the sample.
(a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and (b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample to thereby detect the presence of a nucleic acid molecule of any one of claims 1, 2, 3, or 4 in the sample.
20. The method of claim 19, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
21. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of any one of claims 1, 2, 3, or 4 and instructions for use.
22. A method for identifying a compound which binds to a polypeptide of claim comprising:
(a) contacting the polypeptide, or a cell expressing the polypeptide with a test compound; and (b) determining whether the polypeptide binds to the test compound.
(a) contacting the polypeptide, or a cell expressing the polypeptide with a test compound; and (b) determining whether the polypeptide binds to the test compound.
23. A method for identifying a compound which modulates the activity of a polypeptide of claim 12 comprising:
(a) contacting a polypeptide of claim 12 with a test compound; and (b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.
(a) contacting a polypeptide of claim 12 with a test compound; and (b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.
24. A method for modulating the activity of a polypeptide of claim 12 comprising contacting the polypeptide or a cell expressing the polypeptide with a compound in a sufficient concentration to modulate the activity of the polypeptide.
25. A transgenic animal generated from a cell genetically engineered to lack nucleic acid encoding a AS3 polypeptide, said transgenic animal lacking expression of said AS3 polypeptide.~
26. A transgenic animal generated from a cell that contains a substantially pure nucleic acid replacing DNA encoding a AS3 polypeptide, wherein said nucleic acid is expressed in said transgenic animal.
27. A method of identifying a compound that modulates cell proliferation, said method comprising:
(a) providing a cell comprising a AS3 gene; and (b) contacting said cell with a candidate compound; and (c) monitoring expression of said AS3 gene, wherein an alteration in the level of expression of said gene indicates a compound which modulates cell proliferation.
(a) providing a cell comprising a AS3 gene; and (b) contacting said cell with a candidate compound; and (c) monitoring expression of said AS3 gene, wherein an alteration in the level of expression of said gene indicates a compound which modulates cell proliferation.
28. A method of identifying a compound that modulates cell proliferation, said method comprising:
(a) providing a cell comprising a reporter gene operably linked to a promoter from a AS3 gene;
(b) contacting said cell with a candidate compound; and (c) measuring expression of said reporter gene, an alteration in said expression in response to said candidate compound identifying a compound that is able to modulate cell proliferation.
(a) providing a cell comprising a reporter gene operably linked to a promoter from a AS3 gene;
(b) contacting said cell with a candidate compound; and (c) measuring expression of said reporter gene, an alteration in said expression in response to said candidate compound identifying a compound that is able to modulate cell proliferation.
29. The method of claim 27 or 28, wherein said alteration is an increase indicating said compound is an inhibitor of cell proliferation.
30. A method of inhibiting the proliferation of a cell, said method comprising administering to said cell an amount of AS3 polypeptide or fragment thereof sufficient to inhibit cell proliferation.
31. A method of inhibiting cell proliferation in a mammal, said method comprising providing a transgene encoding a AS3 polypeptide or fragment thereof to a cell of said mammal, said transgene being positioned for expression in said cell.
32. A method of inhibiting cell proliferation in a cell, said method comprising administering a compound which increases AS3 activity.
33. The method of claim 30, 31, or 32, wherein said AS3 is from a mammal.
34. The method of claim 30, 31, or 32, wherein said cell is in a mammal.
35. The method of claim 30, 31, or 32, wherein said cell is in a mammal diagnosed as having a condition involving cell proliferation.
36. The method of claim 35, wherein said condition is cancer.
37. The method of claim 36, wherein said cancer is prostate cancer.
38. A method of diagnosing a mammal for the presence of disease involving altered cell proliferation or an increased likelihood of developing a disease involving altered cell proliferation, said method comprising isolating a sample of nucleic acid from said mammal and determining whether said nucleic acid comprises a AS3 mutation, said mutation being an indication that said mammal has a cell proliferative disease or an increased likelihood of developing a disease involving cell proliferation.
39. A method of diagnosing a mammal for the presence of a disease involving altered cell proliferation or an increased likelihood of developing a disease involving altered cell proliferation, said method comprising measuring AS3 gene expression in a sample from said mammal, an alteration in said expression relative to a sample from an unaffected mammal being an indication that said mammal has a cell proliferative disease or increased likelihood of developing an cell proliferative disease.
40. The method of claim 39, wherein said gene expression is measured by assaying the amount of AS3 polypeptide or AS3 biological activity in said sample.
41. The method of claim 40 wherein said AS3 polypeptide is measured by immunological methods or by assaying the amount of AS3 RNA in said sample.
42. The method of claim 39 or 40, wherein said mammal is a human.
43. The method of claim 39, wherein said measuring is performed after or concurrent with the administration of a hormone to said mammal.
44. The method of claim 43, wherein said hormone as an androgen.
45. A kit for diagnosing a mammal for the presence of a disease involving altered cell proliferation or an increased likelihood of developing a disease involving altered cell proliferation, said kit comprising a substantially pure antibody that specifically binds a AS3 polypeptide.
46. A kit for diagnosing a mammal for the presence of a disease involving altered cell proliferation or an increased likelihood of developing a disease involving altered cell proliferation, said kit comprising a material for measuring AS3 RNA.
47. A method of obtaining a AS3 polypeptide, said method comprising:
(a) providing a cell with DNA encoding a AS3 polypeptide, said DNA being positioned for expression in said cell;
(b) culturing said cell under conditions for expressing said DNA; and (c) isolating said AS3 polypeptide.
(a) providing a cell with DNA encoding a AS3 polypeptide, said DNA being positioned for expression in said cell;
(b) culturing said cell under conditions for expressing said DNA; and (c) isolating said AS3 polypeptide.
48. A method of isolating a AS3 gene or portion thereof having sequence identity to human AS3, said method comprising amplifying by polymerase chain reaction said gene or portion thereof using oligonucleotide primers wherein said primers (a) are each greater than 15 nucleotides in length;
(b) each have regions of complementarity to opposite DNA strands in a region of the nucleotide sequence of SEQ ID NO: 1; and (c) optionally contain sequences capable of producing restriction endonuclease cut sites in the amplified product; and isolating said AS3 gene or portion thereof.
(b) each have regions of complementarity to opposite DNA strands in a region of the nucleotide sequence of SEQ ID NO: 1; and (c) optionally contain sequences capable of producing restriction endonuclease cut sites in the amplified product; and isolating said AS3 gene or portion thereof.
49. A method of detecting if a subject is at increased risk of developing prostate cancer comprising directly or indirectly:
(a) detecting levels of AS3 nucleic acid or polypeptide; and (b) observing if the subject has AS3 levels that are reduced as compared to a standard wherein said reduced AS3 levels indicate said subject is at increased risk of developing prostate cancer.
(a) detecting levels of AS3 nucleic acid or polypeptide; and (b) observing if the subject has AS3 levels that are reduced as compared to a standard wherein said reduced AS3 levels indicate said subject is at increased risk of developing prostate cancer.
50. A kit for determining if a subject is at increased risk of developing prostate cancer comprising:
(a) at least one reagent that specifically detects an AS3 molecule, wherein said reagent is selected from the group consisting of antibodies that selectively bind AS3, and oligonucleotide probes that selectively bind to DNA encoding AS3; and (b) instructions for determining that the subject is at increased risk of developing prostate cancer by (c) detecting the presence or absence of AS3 in said subject with at least one reagent;
and (d) observing whether or not the subject is at increased risk of developing prostate cancer by observing if the presence of AS3 is or is not detected with said at least one reagent, wherein reduced or absent levels of AS3 indicates said subject is at increased risk of developing prostate cancer.
(a) at least one reagent that specifically detects an AS3 molecule, wherein said reagent is selected from the group consisting of antibodies that selectively bind AS3, and oligonucleotide probes that selectively bind to DNA encoding AS3; and (b) instructions for determining that the subject is at increased risk of developing prostate cancer by (c) detecting the presence or absence of AS3 in said subject with at least one reagent;
and (d) observing whether or not the subject is at increased risk of developing prostate cancer by observing if the presence of AS3 is or is not detected with said at least one reagent, wherein reduced or absent levels of AS3 indicates said subject is at increased risk of developing prostate cancer.
51. A method of prognosis for prostate cancer comprising:
(a) obtaining a biological sample from a subject;
(b) measuring AS3 nucleic acid or polypeptide levels in said sample;
(c) correlating said AS3 level with a baseline level, wherein the baseline level is determined by measuring levels of AS3 in disease free subjects;
(d) correlating levels of AS3 at baseline or below, which is a negative result, with a poorer prognosis than a positive result, wherein the level of AS3 is above the baseline level.
(a) obtaining a biological sample from a subject;
(b) measuring AS3 nucleic acid or polypeptide levels in said sample;
(c) correlating said AS3 level with a baseline level, wherein the baseline level is determined by measuring levels of AS3 in disease free subjects;
(d) correlating levels of AS3 at baseline or below, which is a negative result, with a poorer prognosis than a positive result, wherein the level of AS3 is above the baseline level.
52. The method of claim 51, wherein said measuring is performed after or concurrent with the administration of a hormone to said mammal.
53. The method of claim 51, wherein said hormone as an androgen.
54. The method of claim 51, wherein the level of AS3 is measured with an antibody or antibody fragment thereof that selectively binds AS3.
55. The method of claim 51, wherein the level of AS3 is measured with an nucleic acid probe or primer that selectively binds AS3.
56. A method of treating prostate cancer comprising, (a) identifying a subject having or about to have prostate cancer;
(b) administering a hormone to said subject; and (c) determining if said subject exhibits an increase in AS3 levels.
(b) administering a hormone to said subject; and (c) determining if said subject exhibits an increase in AS3 levels.
57. The method of claim 56, wherein the method further includes determining that said subject exhibiting an increase in AS3 levels is likely to be responsive to the inhibitory effect of androgens as compared to a subject not exhibiting an increase in AS3 levels.
58. The method of claim 56, wherein said subject showing an increase in AS3 levels is a candidate for hormone treatment.
59. The method of claim 58, wherein said subject showing an increase in AS3 levels is indicated as being a candidate for intermittent hormone treatment.
60. The method of claim 56, wherein the hormone is an androgen.
61. The method of claim 56, wherein the subject is a human.
62. The method of claim 56, wherein said AS3 levels are nucleic acid levels or polypeptide levels.
63. The method of claim 56, wherein the level of AS3 is measured with an antibody or antibody fragment thereof that selectively binds AS3.
64. The method of claim 56, wherein the level of AS3 is measured with an nucleic acid probe or primer that selectively binds AS3.
65. A method of diagnosing a mammal for the presence of disease associated with AS3 or an AS3 related molecule or an increased likelihood of developing a disease associated with an AS3 or an AS3 related molecule, said method comprising isolating a sample of nucleic acid from said mammal and determining whether said nucleic acid comprises a mutation in an AS3 or AS3 related molecule, said mutation being an indication that said mammal has a disease associated with AS3 or an AS3 related molecule or an increased likelihood of developing a disease associated with an AS3 or an AS3 related molecule.
66. A method of diagnosing a mammal for the presence of a disease associated with AS3 or an AS3 related molecule or an increased likelihood of developing a disease associated with an AS3 or an AS3 related molecule, said method comprising measuring expression levels of AS3 or an AS3 related molecule in a sample from said mammal, an alteration in said expression relative to a sample from an unaffected mammal being an indication that said mammal has a disease or increased likelihood of a disease associated with AS3 or an AS3 related molecule.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12146199P | 1999-02-24 | 1999-02-24 | |
US60/121,461 | 1999-02-24 | ||
PCT/US2000/004732 WO2000050454A1 (en) | 1999-02-24 | 2000-02-24 | Androgen-induced suppressor of cell proliferation and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2363605A1 true CA2363605A1 (en) | 2000-08-31 |
Family
ID=22396883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002363605A Abandoned CA2363605A1 (en) | 1999-02-24 | 2000-02-24 | Androgen-induced suppressor of cell proliferation and uses thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1165605A1 (en) |
AU (1) | AU2884200A (en) |
CA (1) | CA2363605A1 (en) |
HK (1) | HK1042905A1 (en) |
WO (1) | WO2000050454A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090176722A9 (en) | 2000-01-28 | 2009-07-09 | Shiv Srivastava | Androgen-regulated PMEPA1 gene and polypeptides |
AU2003231196C1 (en) * | 2002-05-10 | 2009-05-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Androgen-regulated PMEPA1 and cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997031531A1 (en) * | 1996-03-01 | 1997-09-04 | Merck & Co., Inc. | Antiandrogenic agents and methods of identification thereof |
-
2000
- 2000-02-24 WO PCT/US2000/004732 patent/WO2000050454A1/en not_active Application Discontinuation
- 2000-02-24 CA CA002363605A patent/CA2363605A1/en not_active Abandoned
- 2000-02-24 AU AU28842/00A patent/AU2884200A/en not_active Abandoned
- 2000-02-24 EP EP00907320A patent/EP1165605A1/en not_active Withdrawn
-
2002
- 2002-06-27 HK HK02104777.9A patent/HK1042905A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1165605A1 (en) | 2002-01-02 |
AU2884200A (en) | 2000-09-14 |
HK1042905A1 (en) | 2002-08-30 |
WO2000050454A1 (en) | 2000-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006166917A (en) | Crsp protein, nucleic acid molecule encoding the same and use thereof | |
JP2002531069A (en) | Novel members of the capsaicin / vanilloid receptor family of proteins and their uses | |
US7268218B2 (en) | Cardiovascular system associated protein kinase 3 (CSAPK-3) antibodies | |
US6423494B1 (en) | DR6 and uses thereof | |
US6225085B1 (en) | LRSG protein and nucleic acid molecules and uses therefor | |
US6872811B1 (en) | HRPCa9 and HRPCa10 nucleic acids and polypeptides | |
WO1999041412A1 (en) | A novel npg-1 gene that is differentially expressed in prostate tumors | |
JP2002516079A (en) | Novel secreted and membrane-associated proteins and uses therefor | |
WO2002038767A2 (en) | G protein-coupled receptor protein and nucleic acid molecules and uses therefor | |
US6994992B1 (en) | Androgen-induced suppressor of cell proliferation and uses thereof | |
CA2363605A1 (en) | Androgen-induced suppressor of cell proliferation and uses thereof | |
US6756212B1 (en) | Isolated proteins and nucleic acid molecules having homology to the NIP2 protein and uses thereof | |
US7632660B2 (en) | Lymphoma associated molecules and uses therefor | |
WO2001000878A9 (en) | A novel vascular endothelial growth factor family member and uses thereof | |
US20020004193A1 (en) | Novel MP-7 protein and nucleic acid molecules and uses therefor | |
US6485921B1 (en) | UBCLP and uses thereof | |
US6870040B1 (en) | Nucleic acid sequence encoding lymphoma associated molecule BAL | |
US20020065223A1 (en) | 33358, a novel human ankyrin family member and uses thereof | |
US20020123094A1 (en) | 57250, a novel human sugar transporter family member and uses thereof | |
CA2348758A1 (en) | Lymphoma associated molecules and uses therefor | |
US20020115185A1 (en) | Neuronal cell death associated molecules and uses therefor | |
US20020086982A1 (en) | Novel EBI-3-ALT protein and nucleic acid molecules and uses therefor | |
WO2000017236A2 (en) | Apoptosis related protein and uses therefor | |
WO2000039277A2 (en) | Ndsp nucleic acids and polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |